6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O another/O section/O of/O the/O label/O :/O New/O Primary/B-AdverseReaction Malignancies/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Tumor/B-AdverseReaction Promotion/I-AdverseReaction in/I-AdverseReaction BRAF/I-AdverseReaction Wild/I-AdverseReaction -/I-AdverseReaction Type/O Melanoma/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hemorrhage/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Venous/B-AdverseReaction Thromboembolism/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Cardiomyopathy/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Ocular/B-AdverseReaction Toxicities/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Serious/B-Severity Febrile/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Serious/B-Severity Skin/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.8/O )/O ]/O Hyperglycemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.9/O )/O ]/O Glucose-6-Phosphate/B-AdverseReaction Dehydrogenase/I-AdverseReaction Deficiency/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.10/O )/O ]/O Most/O common/O adverse/O reactions/O (/O 20/O %/O )/O for/O TAFINLAR/O as/O a/O single/O agent/O are/O hyperkeratosis/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O papilloma/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O and/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O ./O
(/O 6.1/O )/O Most/O common/O adverse/O reactions/O (/O 20/O %/O )/O for/O TAFINLAR/O in/O combination/O with/O trametinib/O are/O pyrexia/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O night/B-AdverseReaction sweats/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O and/O myalgia/B-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 888/O -/O 825/O -/O 5249/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O data/O described/O in/O the/O Warnings/O and/O Precautions/O section/O and/O below/O reflect/O exposure/O to/O TAFINLAR/O as/O a/O single/O agent/O and/O in/O combination/O with/O trametinib/O ./O
BRAF/O V600E/O Unresectable/O or/O Metastatic/O Melanoma/O :/O The/O safety/O of/O TAFINLAR/O as/O a/O single/O agent/O was/O evaluated/O in/O 586/O patients/O with/O BRAF/O V600/O mutation/O -/O positive/O unresectable/O or/O metastatic/O melanoma/O ,/O previously/O treated/O or/O untreated/O ,/O who/O received/O TAFINLAR/O 150/O mg/O orally/O twice/O daily/O until/O disease/O progression/O or/O unacceptable/O toxicity/O ,/O including/O 181/O patients/O treated/O for/O at/O least/O 6/O months/O and/O 86/O additional/O patients/O treated/O for/O more/O than/O 12/O months/O ./O
TAFINLAR/O was/O studied/O in/O open/O -/O label/O ,/O single/O -/O arm/O trials/O and/O in/O an/O open/O -/O label/O ,/O randomized/O ,/O active/O -/O controlled/O trial/O ./O
The/O median/O daily/O dose/O of/O TAFINLAR/O was/O 300/O mg/O (/O range/O :/O 118/O to/O 300/O mg/O )/O ./O
Table/O 3/O and/O Table/O 4/O present/O adverse/O drug/O reactions/O and/O laboratory/O abnormalities/O identified/O from/O analyses/O of/O Trial/O 1/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
Trial/O 1/O ,/O a/O multicenter/O ,/O international/O ,/O open/O -/O label/O ,/O randomized/O (/O 3:1/O )/O ,/O controlled/O trial/O allocated/O 250/O patients/O with/O unresectable/O or/O metastatic/O BRAF/O V600E/O mutation/O -/O positive/O melanoma/O to/O receive/O TAFINLAR/O 150/O mg/O orally/O twice/O daily/O (/O n/O 187/O )/O or/O dacarbazine/O 1,000/O mg/O m/O 2/O intravenously/O every/O 3/O weeks/O (/O n/O 63/O )/O ./O
The/O trial/O excluded/O patients/O with/O abnormal/O left/O ventricular/O ejection/O fraction/O or/O cardiac/O valve/O morphology/O (/O Grade/O 2/O )/O ,/O corrected/O QT/O interval/O 480/O milliseconds/O on/O electrocardiogram/O ,/O or/O a/O known/O history/O of/O glucose-6-phosphate/O dehydrogenase/O deficiency/O ./O
The/O median/O duration/O on/O treatment/O was/O 4.9/O months/O for/O patients/O treated/O with/O TAFINLAR/O and/O 2.8/O months/O for/O dacarbazine/O -/O treated/O patients/O ./O
The/O population/O exposed/O to/O TAFINLAR/O was/O 60/O %/O male/O ,/O 99/O %/O white/O ,/O and/O had/O a/O median/O age/O of/O 53/O years/O ./O
The/O most/O commonly/O occurring/O adverse/O reactions/O (/O 20/O %/O )/O in/O patients/O treated/O with/O TAFINLAR/O were/O ,/O in/O order/O of/O decreasing/O frequency/O :/O hyperkeratosis/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O papilloma/B-AdverseReaction ,/O alopecia/B-AdverseReaction ,/O and/O palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O (/O PPES/B-AdverseReaction )/O ./O
The/O incidence/O of/O adverse/O events/O resulting/O in/O permanent/O discontinuation/O of/O study/O medication/O in/O Trial/O 1/O was/O 3/O %/O for/O patients/O treated/O with/O TAFINLAR/O and/O 3/O %/O for/O patients/O treated/O with/O dacarbazine/O ./O
The/O most/O frequent/O (/O 2/O %/O )/O adverse/O reactions/O leading/O to/O dose/O reduction/O of/O TAFINLAR/O were/O pyrexia/B-AdverseReaction (/O 9/O %/O )/O ,/O PPES/B-AdverseReaction (/O 3/O %/O )/O ,/O chills/B-AdverseReaction (/O 3/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O headache/B-AdverseReaction (/O 2/O %/O )/O ./O
Table/O 3/O ./O
Selected/O Common/O Adverse/O Reactions/O Occurring/O in/O 10/O %/O (/O All/O Grades/O )/O or/O 2/O %/O (/O Grades/O 3/O or/O 4/O )/O of/O Patients/O Treated/O With/O TAFINLARa/O TAFINLARN/O 187/O Dacarbazine/O N/O 59/O Primary/O System/O Organ/O Class/O Preferred/O Term/O All/O Grades/O (/O %/O )/O Grades/O 3/O and/O 4b/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grades/O 3/O and/O 4/O (/O %/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Hyperkeratosis/B-AdverseReaction 37/O 1/O 0/O 0/O Alopecia/B-AdverseReaction 22/O NAf/O 2/O NAf/O Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O 20/O 2/O 2/O 0/O Rash/B-AdverseReaction 17/O 0/O 0/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 32/O 0/O 8/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 28/O 3/O 10/O 0/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Arthralgia/B-AdverseReaction 27/O 1/O 2/O 0/O Back/B-AdverseReaction pain/I-AdverseReaction 12/O 3/O 7/O 0/O Myalgia/B-AdverseReaction 11/O 0/O 0/O 0/O Neoplasms/O benign/O ,/O malignant/O ,/O and/O unspecified/O (/O including/O cysts/O and/O polyps/O )/O Papilloma/B-AdverseReaction c/O 27/O 0/O 2/O 0/O cuSCC/B-AdverseReaction d/O ,/O e/O 7/O 4/O 0/O 0/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 12/O 0/O 5/O 0/O Gastrointestinal/O disorders/O Constipation/B-AdverseReaction 11/O 2/O 14/O 0/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 10/O 0/O 3/O 0/O a/O Adverse/O drug/O reactions/O ,/O reported/O using/O MedDRA/O and/O graded/O using/O CTCAE/O version/O 4.0/O for/O assessment/O of/O toxicity/O ./O
b/O Grade/B-Severity 4/I-Severity adverse/O reactions/O limited/O to/O hyperkeratosis/B-AdverseReaction (/O n/O 1/O )/O and/O constipation/B-AdverseReaction (/O n/O 1/O )/O ./O
c/O Includes/O skin/B-AdverseReaction papilloma/I-AdverseReaction and/O papilloma/B-AdverseReaction ./O
d/O Includes/O squamous/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction skin/I-AdverseReaction and/O keratoacanthoma/B-AdverseReaction ./O
e/O Cases/O of/O cutaneous/B-AdverseReaction squamous/I-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction were/O required/O to/O be/O reported/O as/O Grade/B-Severity 3/I-Severity per/O protocol/O ./O
f/O NA/O not/O applicable/O ./O
Table/O 4/O ./O
Incidence/O of/O Laboratory/O Abnormalities/O Increased/O From/O Baseline/O Occurring/O at/O a/O Higher/O Incidence/O in/O Patients/O Treated/O With/O TAFINLAR/O in/O Trial/O 1/O [/O Between/O -/O Arm/O Difference/O of/O 5/O %/O (/O All/O Grades/O )/O or/O 2/O %/O (/O Grades/O 3/O or/O 4/O )/O ]/O Test/O TAFINLAR/O N/O 187/O DTIC/O N/O 59/O All/O Grades/O (/O %/O )/O Grades/O 3/O and/O 4/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grades/O 3/O and/O 4/O (/O %/O )/O Hyperglycemia/B-AdverseReaction 50/O 6/O 43/O 0/O Hypophosphatemia/B-AdverseReaction 37/O 6a/O 14/O 2/O Increased/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction 19/O 0/O 14/O 2/O Hyponatremia/B-AdverseReaction 8/O 2/O 3/O 0/O a/O Grade/B-Severity 4/I-Severity laboratory/O abnormality/O limited/O to/O hypophosphatemia/B-AdverseReaction (/O n/O 1/O )/O ./O
Other/O clinically/O important/O adverse/O reactions/O observed/O in/O 10/O %/O of/O patients/O (/O N/O 586/O )/O treated/O with/O TAFINLAR/O were/O :/O Gastrointestinal/O Disorders/O :/O Pancreatitis/B-AdverseReaction ./O
Immune/O System/O Disorders/O :/O Hypersensitivity/B-AdverseReaction manifesting/O as/O bullous/B-AdverseReaction rash/I-AdverseReaction ./O
Renal/O and/O Urinary/O Disorders/O :/O Interstitial/B-AdverseReaction nephritis/I-AdverseReaction ./O
BRAF/O V600E/O or/O V600/O K/O Unresectable/O or/O Metastatic/O Melanoma/O :/O The/O safety/O of/O TAFINLAR/O in/O combination/O with/O trametinib/O was/O evaluated/O in/O Trial/O 2/O and/O other/O trials/O consisting/O of/O a/O total/O of/O 202/O patients/O with/O BRAF/O V600/O mutation/O -/O positive/O unresectable/O or/O metastatic/O melanoma/O who/O received/O TAFINLAR/O 150/O mg/O orally/O twice/O daily/O in/O combination/O with/O trametinib/O 2/O mg/O orally/O once/O daily/O until/O disease/O progression/O or/O unacceptable/O toxicity/O ./O
Among/O these/O 202/O patients/O ,/O 66/O (/O 33/O %/O )/O were/O exposed/O to/O TAFINLAR/O and/O 68/O (/O 34/O %/O )/O were/O exposed/O to/O trametinib/O for/O greater/O than/O 6/O to/O 12/O months/O while/O 40/O (/O 20/O %/O )/O were/O exposed/O to/O TAFINLAR/O and/O 36/O (/O 18/O %/O )/O were/O exposed/O to/O trametinib/O for/O greater/O than/O one/O year/O ./O
The/O median/O age/O was/O 54/O years/O ,/O 57/O %/O were/O male/O ,/O and/O 99/O %/O were/O white/O ./O
Table/O 5/O presents/O adverse/O reactions/O from/O Trial/O 2/O ,/O a/O multicenter/O ,/O open/O -/O label/O ,/O randomized/O trial/O of/O 162/O patients/O with/O BRAF/O V600E/O or/O V600/O K/O mutation/O -/O positive/O melanoma/O receiving/O TAFINLAR/O 150/O mg/O twice/O daily/O in/O combination/O with/O trametinib/O 2/O mg/O orally/O once/O daily/O (/O n/O 55/O )/O ,/O TAFINLAR/O 150/O mg/O orally/O twice/O daily/O in/O combination/O with/O trametinib/O 1/O mg/O once/O daily/O (/O n/O 54/O )/O ,/O and/O TAFINLAR/O as/O a/O single/O agent/O 150/O mg/O orally/O twice/O daily/O (/O n/O 53/O )/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
Patients/O with/O abnormal/O LVEF/O ,/O history/O of/O acute/O coronary/O syndrome/O within/O 6/O months/O ,/O current/O evidence/O of/O Class/O II/O or/O greater/O congestive/O heart/O failure/O (/O New/O York/O Heart/O Association/O )/O ,/O history/O RVO/O or/O RPED/O ,/O QTc/O interval/O 480/O msec/O ,/O treatment/O refractory/O hypertension/O ,/O uncontrolled/O arrhythmias/O ,/O history/O of/O pneumonitis/O or/O interstitial/O lung/O disease/O ,/O or/O a/O known/O history/O of/O G6PD/O deficiency/O were/O excluded/O ./O
The/O median/O duration/O of/O treatment/O was/O 10.9/O months/O for/O both/O TAFINLAR/O and/O trametinib/O (/O 2-mg/O orally/O once/O -/O daily/O treatment/O group/O )/O when/O used/O in/O combination/O ,/O 10.6/O months/O for/O both/O TAFINLAR/O and/O trametinib/O (/O 1-mg/O orally/O once/O -/O daily/O treatment/O group/O )/O when/O used/O in/O combination/O ,/O and/O 6.1/O months/O for/O TAFINLAR/O as/O a/O single/O agent/O ./O
In/O Trial/O 2/O ,/O 13/O %/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O experienced/O adverse/O reactions/O resulting/O in/O permanent/O discontinuation/O of/O trial/O medication(s/O )/O ./O
The/O most/O common/O adverse/O reaction/O resulting/O in/O permanent/O discontinuation/O was/O pyrexia/B-AdverseReaction (/O 4/O %/O )/O ./O
Adverse/O reactions/O led/O to/O dose/O reductions/O in/O 49/O %/O and/O dose/O interruptions/O in/O 67/O %/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Pyrexia/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction were/O the/O most/O common/O reasons/O cited/O for/O dose/O reductions/O and/O pyrexia/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O and/O decreased/B-AdverseReaction ejection/I-AdverseReaction fraction/I-AdverseReaction were/O the/O most/O common/O reasons/O cited/O for/O dose/O interruptions/O of/O TAFINLAR/O and/O trametinib/O when/O used/O in/O combination/O ./O
Table/O 5/O ./O
Common/O Adverse/O Drug/O Reactions/O Occurring/O in/O 10/O %/O at/O (/O All/O Grades/O )/O or/O 5/O %/O (/O Grades/O 3/O or/O 4/O )/O of/O Patients/O Treated/O With/O TAFINLAR/O in/O Combination/O With/O Trametinib/O in/O Trial/O 2/O Adverse/O Reactions/O TAFINLAR/O plus/O Trametinib/O 2/O mg/O N/O 55/O TAFINLAR/O plus/O Trametinib/O 1/O mg/O N/O 54/O TAFINLAR/O N/O 53/O All/O Gradesa/O Grades/O 3/O and/O 4/O All/O Gradesa/O Grades/O 3/O and/O 4/O All/O Gradesa/O Grades/O 3/O and/O 4/O General/O disorders/O and/O administrative/O site/O conditions/O Pyrexia/B-AdverseReaction 71/O 5/O 69/O 9/O 26/O 0/O Chills/B-AdverseReaction 58/O 2/O 50/O 2/O 17/O 0/O Fatigue/B-AdverseReaction 53/O 4/O 57/O 2/O 40/O 6/O Edema/B-AdverseReaction peripheral/I-AdverseReaction b/O 31/O 0/O 28/O 0/O 17/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction c/O 45/O 0/O 43/O 2/O 53/O 0/O Night/B-AdverseReaction Sweats/I-AdverseReaction 24/O 0/O 15/O 0/O 6/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 18/O 0/O 9/O 0/O 6/O 0/O Dermatitis/B-AdverseReaction acneiform/I-AdverseReaction 16/O 0/O 11/O 0/O 4/O 0/O Actinic/B-AdverseReaction keratosis/I-AdverseReaction 15/O 0/O 7/O 0/O 9/O 0/O Erythema/B-AdverseReaction 15/O 0/O 6/O 0/O 2/O 0/O Pruritus/B-AdverseReaction 11/O 0/O 11/O 0/O 13/O 0/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 44/O 2/O 46/O 6/O 21/O 0/O Vomiting/B-AdverseReaction 40/O 2/O 43/O 4/O 15/O 0/O Diarrhea/B-AdverseReaction 36/O 2/O 26/O 0/O 28/O 0/O Abdominal/B-AdverseReaction pain/I-AdverseReaction d/O 33/O 2/O 24/O 2/O 21/O 2/O Constipation/B-AdverseReaction 22/O 0/O 17/O 2/O 11/O 0/O Dry/B-AdverseReaction mouth/I-AdverseReaction 11/O 0/O 11/O 0/O 6/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 29/O 0/O 37/O 2/O 28/O 0/O Dizziness/B-AdverseReaction 16/O 0/O 13/O 0/O 9/O 0/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 29/O 0/O 11/O 0/O 21/O 0/O Oropharyngeal/B-AdverseReaction pain/I-AdverseReaction 13/O 0/O 7/O 0/O 0/O 0/O Musculoskeletal/O ,/O connective/O tissue/O ,/O and/O bone/O disorders/O Arthralgia/B-AdverseReaction 27/O 0/O 44/O 0/O 34/O 0/O Myalgia/B-AdverseReaction 22/O 2/O 24/O 0/O 23/O 2/O Back/B-AdverseReaction pain/I-AdverseReaction 18/O 5/O 11/O 0/O 11/O 2/O Muscle/B-AdverseReaction spasms/I-AdverseReaction 16/O 0/O 2/O 0/O 4/O 0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 16/O 0/O 11/O 2/O 19/O 0/O Metabolism/O and/O nutritional/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 22/O 0/O 30/O 0/O 19/O 0/O Dehydration/B-AdverseReaction 11/O 0/O 6/O 2/O 2/O 0/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 18/O 0/O 11/O 0/O 8/O 2/O Vascular/O disorders/O Hemorrhage/B-AdverseReaction e/O 16/O 5/O 11/O 0/O 2/O 0/O Infections/O and/O infestations/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 13/O 2/O 6/O 0/O 9/O 2/O Renal/O and/O urinary/O disorders/O Renal/B-AdverseReaction failure/I-AdverseReaction f/O 7/O 7/O 2/O 0/O 0/O 0/O a/O National/O Cancer/O Institute/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O ,/O version/O 4/O ./O
b/O Includes/O the/O following/O terms/O :/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O edema/B-AdverseReaction ,/O and/O lymphedema/B-AdverseReaction ./O
c/O Includes/O the/O following/O terms/O :/O rash/B-AdverseReaction ,/O rash/B-AdverseReaction generalized/I-AdverseReaction ,/O rash/B-AdverseReaction pruritic/I-AdverseReaction ,/O rash/B-AdverseReaction erythematous/I-AdverseReaction ,/O rash/B-AdverseReaction papular/I-AdverseReaction ,/O rash/B-AdverseReaction vesicular/I-AdverseReaction ,/O rash/B-AdverseReaction macular/I-AdverseReaction ,/O and/O rash/B-AdverseReaction maculo/I-AdverseReaction -/O papular/O ./O
d/O Includes/O the/O following/O terms/O :/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction lower/I-AdverseReaction ,/O and/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ./O
e/O Includes/O the/O following/O terms/O :/O brain/B-AdverseReaction stem/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O cerebral/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O gingival/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hematuria/B-AdverseReaction ,/O vaginal/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O hemorrhage/B-AdverseReaction intracranial/I-AdverseReaction ,/O eye/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O vitreous/B-AdverseReaction hemorrhage/I-AdverseReaction ./O
f/O Includes/O the/O following/O terms/O :/O renal/B-AdverseReaction failure/I-AdverseReaction and/O renal/B-AdverseReaction failure/I-AdverseReaction acute/I-AdverseReaction ./O
Other/O clinically/O important/O adverse/O reactions/O (/O N/O 202/O )/O observed/O in/O 10/O %/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O were/O :/O Eye/O Disorders/O :/O Vision/B-AdverseReaction blurred/I-AdverseReaction ,/O transient/B-AdverseReaction blindness/I-AdverseReaction ./O
Gastrointestinal/O Disorders/O :/O Stomatitis/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ./O
General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O Asthenia/B-AdverseReaction ./O
Infections/O and/O Infestations/O :/O Cellulitis/B-AdverseReaction ,/O folliculitis/B-AdverseReaction ,/O paronychia/B-AdverseReaction ,/O rash/B-AdverseReaction pustular/I-AdverseReaction ./O
Neoplasms/O Benign/O ,/O Malignant/O ,/O and/O Unspecified/O (/O including/O cysts/O and/O polyps/O )/O :/O Skin/B-AdverseReaction papilloma/I-AdverseReaction ./O
Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Palmar/B-AdverseReaction -/I-AdverseReaction plantar/I-AdverseReaction erythrodysesthesia/O syndrome/O ,/O hyperkeratosis/B-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ./O
Vascular/O Disorders/O :/O Hypertension/B-AdverseReaction ./O
Table/O 6/O ./O
Treatment/O -/O Emergent/O Laboratory/O Abnormalities/O Occurring/O at/O 10/O %/O (/O All/O Grades/O )/O or/O 2/O %/O (/O Grades/O 3/O or/O 4/O )/O ]/O of/O Patients/O Treated/O With/O TAFINLAR/O in/O Combination/O With/O Trametinib/O in/O Trial/O 2/O Tests/O TAFINLAR/O plus/O Trametinib/O 2/O mg/O N/O 55/O TAFINLAR/O plus/O Trametinib/O 1/O mg/O N/O 54/O TAFINLAR/O N/O 53/O All/O Grades/O Grades/O 3/O and/O 4/O All/O Grades/O Grades/O 3/O and/O 4/O All/O Grades/O Grades/O 3/O and/O 4a/O Hematology/O Leukopenia/B-AdverseReaction 62/O 5/O 46/O 4/O 21/O 0/O Lymphopenia/B-AdverseReaction 55/O 22/O 59/O 19/O 40/O 6/O Neutropenia/B-AdverseReaction 55/O 13/O 37/O 2/O 9/O 2/O Anemia/B-AdverseReaction 55/O 4/O 46/O 7/O 28/O 0/O Thrombocytopenia/B-AdverseReaction 31/O 4/O 31/O 2/O 8/O 0/O Liver/O Function/O Tests/O Increased/B-AdverseReaction AST/I-AdverseReaction 60/O 5/O 54/O 0/O 15/O 0/O Increased/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction 60/O 2/O 67/O 6/O 26/O 2/O Increased/B-AdverseReaction ALT/I-AdverseReaction 42/O 4/O 35/O 4/O 11/O 0/O Hyperbilirubinemia/B-AdverseReaction 15/O 0/O 7/O 4/O 0/O 0/O Chemistry/O Hyperglycemia/B-AdverseReaction 58/O 5/O 67/O 6/O 49/O 2/O Increased/B-AdverseReaction GGT/I-AdverseReaction 56/O 11/O 54/O 17/O 38/O 2/O Hyponatremia/B-AdverseReaction 55/O 11/O 48/O 15/O 36/O 2/O Hypoalbuminemia/B-AdverseReaction 53/O 0/O 43/O 2/O 23/O 0/O Hypophosphatemia/B-AdverseReaction 47/O 5/O 41/O 11/O 40/O 0/O Hypokalemia/B-AdverseReaction 29/O 2/O 15/O 2/O 23/O 6/O Increased/B-AdverseReaction creatinine/I-AdverseReaction 24/O 5/O 20/O 2/O 9/O 0/O Hypomagnesemia/B-AdverseReaction 18/O 2/O 2/O 0/O 6/O 0/O Hyperkalemia/B-AdverseReaction 18/O 0/O 22/O 0/O 15/O 4/O Hypercalcemia/B-AdverseReaction 15/O 0/O 19/O 2/O 4/O 0/O Hypocalcemia/B-AdverseReaction 13/O 0/O 20/O 0/O 9/O 0/O a/O No/O Grade/O 4/O events/O were/O reported/O in/O patients/O receiving/O TAFINLAR/O as/O a/O single/O agent/O ./O
ALT/O Alanine/O aminotransferase/O ;/O AST/O Aspartate/O aminotransferase/O ;/O GGT/O Gamma/O glutamyltransferase/O ./O
QT/O Prolongation/O :/O In/O Trial/O 2/O ,/O QTcF/B-AdverseReaction prolongation/I-AdverseReaction to/O 500/B-Severity msec/I-Severity occurred/O in/O 4/O %/O (/O 2/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O in/O 2/O %/O (/O 1/53/O )/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
The/O QTcF/B-AdverseReaction was/I-AdverseReaction increased/I-AdverseReaction more/O than/O 60/B-Severity msec/I-Severity from/I-Severity baseline/I-Severity in/O 13/O %/O (/O 7/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O 2/O %/O (/O 1/53/O )/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O Review/O the/O Full/O Prescribing/O Information/O for/O trametinib/O prior/O to/O initiation/O of/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
The/O following/O serious/O adverse/O reactions/O of/O trametinib/O as/O a/O single/O agent/O ,/O which/O may/O occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O ,/O are/O not/O described/O in/O the/O Full/O Prescribing/O Information/O for/O TAFINLAR/O :/O Retinal/B-AdverseReaction vein/I-AdverseReaction occlusion/I-AdverseReaction Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction New/O primary/B-AdverseReaction malignancies/I-AdverseReaction ,/I-AdverseReaction cutaneous/O and/O non/O -/O cutaneous/O ,/O can/B-Factor occur/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O in/O combination/O with/O trametinib/O ./O
Monitor/O patients/O for/O new/O malignancies/O prior/O to/O initiation/O of/O therapy/O ,/O while/O on/O therapy/O ,/O and/O following/O discontinuation/O of/O TAFINLAR/O or/O the/O combination/O therapy/O ./O
(/O 5.1/O ,/O 2.3/O )/O Tumor/B-AdverseReaction Promotion/I-AdverseReaction in/I-AdverseReaction BRAF/I-AdverseReaction Wild/I-AdverseReaction -/I-AdverseReaction Type/O Melanoma/O :/O Increased/B-AdverseReaction cell/I-AdverseReaction proliferation/I-AdverseReaction can/O occur/O with/O BRAF/B-DrugClass inhibitors/I-DrugClass ./O
(/O 5.2/O )/O Hemorrhage/B-AdverseReaction :/O Major/B-Severity hemorrhagic/B-AdverseReaction events/I-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O bleeding/O ./O
(/O 5.3/O )/O Venous/B-AdverseReaction Thromboembolism/I-AdverseReaction :/O Deep/B-AdverseReaction vein/I-AdverseReaction thrombosis/I-AdverseReaction and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
(/O 5.4/O ,/O 2.3/O )/O Cardiomyopathy/B-AdverseReaction :/O Assess/O LVEF/O before/O treatment/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ,/O after/O one/O month/O of/O treatment/O ,/O then/O every/O 2/O to/O 3/O months/O thereafter/O ./O
(/O 5.5/O ,/O 2.3/O )/O Ocular/B-AdverseReaction Toxicities/I-AdverseReaction :/O Perform/O ophthalmologic/O evaluation/O for/O any/O visual/O disturbances/O ./O
(/O 5.6/O ,/O 2.3/O )/O Serious/B-Severity Febrile/B-AdverseReaction Reactions/I-AdverseReaction :/O Incidence/O and/O severity/O of/O pyrexia/B-AdverseReaction are/O increased/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
(/O 5.7/O ,/O 2.3/O )/O Serious/B-Severity Skin/B-AdverseReaction Toxicity/I-AdverseReaction :/O Monitor/O for/O skin/O toxicities/O and/O for/O secondary/O infections/O ./O
Discontinue/O for/O intolerable/O Grade/O 2/O ,/O or/O Grade/O 3/O or/O 4/O rash/O not/O improving/O within/O 3/O weeks/O despite/O interruption/O of/O TAFINLAR/O ./O
(/O 5.8/O ,/O 2.3/O )/O Hyperglycemia/B-AdverseReaction :/O Monitor/O serum/O glucose/O levels/O in/O patients/O with/O pre/O -/O existing/O diabetes/O or/O hyperglycemia/O ./O
(/O 5.9/O )/O Glucose-6-Phosphate/B-AdverseReaction Dehydrogenase/I-AdverseReaction Deficiency/I-AdverseReaction :/O Closely/O monitor/O for/O hemolytic/O anemia/O ./O
(/O 5.10/O )/O Embryofetal/B-AdverseReaction Toxicity/I-AdverseReaction :/O Can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O females/O of/O reproductive/O potential/O of/O potential/O risk/O to/O a/O fetus/O ./O
TAFINLAR/O may/O render/O hormonal/O contraceptives/O less/O effective/O and/O an/O alternative/O method/O of/O contraception/O should/O be/O used/O ./O
(/O 5.11/O ,/O 8.1/O )/O EXCERPT/O :/O 5.1/O New/O Primary/O Malignancies/O New/O primary/B-AdverseReaction malignancies/I-AdverseReaction ,/I-AdverseReaction cutaneous/O and/O non/O -/O cutaneous/O ,/O can/B-Factor occur/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O when/O used/O in/O combination/O with/O trametinib/O ./O
Cutaneous/O Malignancies/O :/O TAFINLAR/O results/O in/O an/O increased/O incidence/O of/O cutaneous/B-AdverseReaction squamous/I-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction ,/O keratoacanthoma/B-AdverseReaction ,/O and/O melanoma/B-AdverseReaction ./O
TAFINLAR/O when/O used/O in/O combination/O with/O trametinib/O results/O in/O an/O increased/O incidence/O of/O basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction ./O
In/O Trial/O 1/O ,/O cutaneous/B-AdverseReaction squamous/I-AdverseReaction cell/I-AdverseReaction carcinomas/I-AdverseReaction and/O keratoacanthomas/B-AdverseReaction (/O cuSCC/B-AdverseReaction )/O occurred/O in/O 7/O %/O (/O 14/187/O )/O of/O patients/O treated/O with/O TAFINLAR/O and/O in/O none/O of/O the/O patients/O treated/O with/O dacarbazine/O ./O
Across/O clinical/O trials/O of/O TAFINLAR/O (/O N/O 586/O )/O ,/O the/O incidence/O of/O cuSCC/B-AdverseReaction was/O 11/O %/O ./O
The/O median/O time/O to/O first/O cuSCC/B-AdverseReaction was/O 9/O weeks/O (/O range/O :/O 1/O to/O 53/O weeks/O )/O ./O
Of/O those/O patients/O who/O developed/O new/O cuSCC/B-AdverseReaction ,/O approximately/O 33/O %/O developed/O one/O or/O more/O cuSCC/B-AdverseReaction with/O continued/O administration/O of/O TAFINLAR/O ./O
The/O median/O time/O between/O diagnosis/O of/O the/O first/O cuSCC/B-AdverseReaction and/O the/O second/O cuSCC/B-AdverseReaction was/O 6/O weeks/O ./O
In/O Trial/O 1/O ,/O the/O incidence/O of/O new/O primary/B-AdverseReaction malignant/I-AdverseReaction melanomas/I-AdverseReaction was/O 2/O %/O (/O 3/187/O )/O for/O patients/O receiving/O TAFINLAR/O while/O no/O dacarbazine/O -/O treated/O patient/O was/O diagnosed/O with/O new/O primary/O malignant/O melanoma/O ./O
In/O Trial/O 2/O ,/O the/O incidence/O of/O basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction was/O increased/O in/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O :/O 9/O %/O (/O 5/55/O )/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O 2/O %/O (/O 1/53/O )/O of/O patients/O receiving/O TAFINLAR/O as/O a/O single/O agent/O ./O
The/O range/O of/O time/O to/O diagnosis/O of/O basal/B-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction was/O 28/O to/O 249/O days/O in/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O was/O 197/O days/O for/O the/O patient/O receiving/O TAFINLAR/O as/O a/O single/O agent/O ./O
Cutaneous/B-AdverseReaction squamous/I-AdverseReaction cell/I-AdverseReaction carcinoma/I-AdverseReaction (/O SCC/B-AdverseReaction )/O ,/O including/O keratoacanthoma/B-AdverseReaction ,/O occurred/O in/O 7/O %/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O 19/O %/O of/O patients/O receiving/O TAFINLAR/O as/O a/O single/O agent/O ./O
The/O range/O of/O time/O to/O diagnosis/O of/O cuSCC/B-AdverseReaction was/O 136/O to197/O days/O in/O the/O combination/O arm/O and/O was/O 9/O to/O 197/O days/O in/O the/O arm/O receiving/O TAFINLAR/O as/O a/O single/O agent/O ./O
New/O primary/B-AdverseReaction melanoma/I-AdverseReaction occurred/O in/O 2/O %/O (/O 1/53/O )/O of/O patients/O receiving/O TAFINLAR/O as/O a/O single/O agent/O and/O in/O none/O of/O the/O 55/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Perform/O dermatologic/O evaluations/O prior/O to/O initiation/O of/O TAFINLAR/O as/O a/O single/O agent/O or/O in/O combination/O with/O trametinib/O ,/O every/O 2/O months/O while/O on/O therapy/O ,/O and/O for/O up/O to/O 6/O months/O following/O discontinuation/O of/O TAFINLAR/O ./O
No/O dose/O modifications/O of/O TAFINLAR/O or/O trametinib/O are/O required/O in/O patients/O who/O develop/O new/O primary/O cutaneous/O malignancies/O ./O
Non/O -/O cutaneous/O Malignancies/O :/O Based/O on/O its/O mechanism/O of/O action/O ,/O TAFINLAR/O may/B-Factor promote/O the/O growth/O and/O development/O of/O malignancies/B-AdverseReaction with/O activation/O of/O RAS/O through/O mutation/O or/O other/O mechanisms/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
In/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O four/O cases/O of/O non/B-AdverseReaction -/I-AdverseReaction cutaneous/O malignancies/O were/O identified/O :/O KRAS/B-AdverseReaction mutation/I-AdverseReaction -/I-AdverseReaction positive/I-AdverseReaction pancreatic/O adenocarcinoma/O (/O n/O 1/O )/O ,/O recurrent/B-AdverseReaction NRAS/I-AdverseReaction mutation/I-AdverseReaction -/I-AdverseReaction positive/I-AdverseReaction colorectal/O carcinoma/O (/O n/O 1/O )/O ,/O head/B-AdverseReaction and/I-AdverseReaction neck/I-AdverseReaction carcinoma/I-AdverseReaction (/O n/O 1/O )/O ,/O and/O glioblastoma/B-AdverseReaction (/O n/O 1/O )/O ./O
Monitor/O patients/O receiving/O the/O combination/O closely/O for/O signs/O or/O symptoms/O of/O non/O -/O cutaneous/O malignancies/O ./O
Permanently/O discontinue/O TAFINLAR/O for/O RAS/O mutation/O -/O positive/O non/O -/O cutaneous/O malignancies/O ./O
If/O used/O in/O combination/O with/O trametinib/O ,/O no/O dose/O modification/O of/O trametinib/O is/O required/O for/O patients/O who/O develop/O non/O -/O cutaneous/O malignancies/O ./O
5.2/O Tumor/O Promotion/O in/O BRAF/O Wild/O -/O Type/O Melanoma/O In/O vitro/O experiments/O have/O demonstrated/O paradoxical/O activation/O of/O MAP/O -/O kinase/O signaling/O and/O increased/B-AdverseReaction cell/I-AdverseReaction proliferation/I-AdverseReaction in/O BRAF/O wild/O -/O type/O cells/O which/O are/O exposed/O to/O BRAF/B-DrugClass inhibitors/I-DrugClass ./O
Confirm/O evidence/O of/O BRAF/O V600E/O or/O V600/O K/O mutation/O status/O prior/O to/O initiation/O of/O TAFINLAR/O as/O a/O single/O agent/O or/O combination/O therapy/O [/O see/O Indications/O and/O Usage/O (/O 1/O )/O ,/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
5.3/O Hemorrhage/O Hemorrhages/B-AdverseReaction ,/O including/O major/B-Severity hemorrhages/B-AdverseReaction defined/O as/O symptomatic/B-AdverseReaction bleeding/I-AdverseReaction in/O a/O critical/O area/O or/O organ/O ,/O can/B-Factor occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O ./O
In/O Trial/O 2/O ,/O treatment/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O resulted/O in/O an/O increased/O incidence/O and/O severity/O of/O any/O hemorrhagic/B-AdverseReaction event/I-AdverseReaction :/O 16/O %/O (/O 9/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O 2/O %/O (/O 1/53/O )/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
The/O major/B-Severity hemorrhagic/B-AdverseReaction events/I-AdverseReaction of/O intracranial/O or/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction occurred/O in/O 5/O %/O (/O 3/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O none/O of/O the/O 53/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Intracranial/B-AdverseReaction hemorrhage/I-AdverseReaction was/O fatal/B-AdverseReaction in/O 4/O %/O (/O 2/55/O )/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Permanently/O discontinue/O TAFINLAR/O and/O trametinib/O for/O all/O Grade/O 4/O hemorrhagic/O events/O and/O for/O any/O Grade/O 3/O hemorrhagic/O events/O that/O do/O not/O improve/O ./O
Withhold/O TAFINLAR/O for/O Grade/O 3/O hemorrhagic/O events/O ;/O if/O improved/O resume/O at/O a/O lower/O dose/O level/O ./O
Withhold/O trametinib/O for/O up/O to/O 3/O weeks/O for/O Grade/O 3/O hemorrhagic/O events/O ;/O if/O improved/O ,/O resume/O at/O a/O lower/O dose/O level/O ./O
5.4/O Venous/O Thromboembolism/O Venous/B-AdverseReaction thromboembolism/I-AdverseReaction can/B-Factor occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O ./O
In/O Trial/O 2/O ,/O treatment/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O resulted/O in/O an/O increased/O incidence/O of/O deep/B-AdverseReaction venous/I-AdverseReaction thrombosis/I-AdverseReaction (/O DVT/B-AdverseReaction )/O and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O PE/B-AdverseReaction )/O :/O 7/O %/O (/O 4/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O none/O of/O the/O 53/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Pulmonary/B-AdverseReaction embolism/I-AdverseReaction was/O fatal/B-AdverseReaction in/O 2/O %/O (/O 1/55/O )/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Advise/O patients/O to/O immediately/O seek/O medical/O care/O if/O they/O develop/O symptoms/O of/O DVT/O or/O PE/O ,/O such/O as/O shortness/O of/O breath/O ,/O chest/O pain/O ,/O or/O arm/O or/O leg/O swelling/O ./O
Permanently/O discontinue/O TAFINLAR/O and/O trametinib/O for/O life/O -/O threatening/O PE/O ./O
Withhold/O trametinib/O and/O continue/O TAFINLAR/O at/O the/O same/O dose/O for/O uncomplicated/O DVT/O or/O PE/O ;/O if/O improved/O within/O 3/O weeks/O ,/O trametinib/O may/O be/O resumed/O at/O a/O lower/O dose/O level/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.5/O Cardiomyopathy/O Cardiomyopathy/B-AdverseReaction can/B-Factor occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O and/O with/O trametinib/O as/O a/O single/O agent/O [/O refer/O to/O Full/O Prescribing/O Information/O for/O trametinib/O ]/O ./O
In/O Trial/O 2/O ,/O cardiomyopathy/B-AdverseReaction occurred/O in/O 9/O %/O (/O 5/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O in/O none/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
The/O median/O time/O to/O onset/O of/O cardiomyopathy/B-AdverseReaction in/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O was/O 86/O days/O (/O range/O :/O 27/O to/O 253/O days/O )/O ./O
Cardiomyopathy/B-AdverseReaction was/O identified/O within/O the/O first/O month/O of/O treatment/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O in/O two/O of/O five/O patients/O ./O
Development/O of/O cardiomyopathy/B-AdverseReaction resolved/O in/O all/O five/O patients/O following/O dose/O reduction/O (/O 4/55/O )/O and/or/O dose/O interruption/O (/O 1/55/O )/O ./O
Across/O clinical/O trials/O of/O TAFINLAR/O administered/O in/O combination/O with/O trametinib/O (/O N/O 202/O )/O ,/O 8/O %/O of/O patients/O developed/O evidence/O of/O cardiomyopathy/B-AdverseReaction (/O decrease/B-AdverseReaction in/I-AdverseReaction LVEF/I-AdverseReaction below/O institutional/B-Severity lower/I-Severity limits/I-Severity of/I-Severity normal/I-Severity with/O an/O absolute/B-AdverseReaction decrease/I-AdverseReaction in/I-AdverseReaction LVEF/I-AdverseReaction 10/B-Severity %/I-Severity below/I-Severity baseline/O )/O ./O
Two/O percent/O demonstrated/O a/O decrease/B-AdverseReaction in/I-AdverseReaction LVEF/I-AdverseReaction below/O institutional/B-Severity lower/I-Severity limits/I-Severity of/I-Severity normal/I-Severity with/O an/O absolute/B-AdverseReaction decrease/I-AdverseReaction in/I-AdverseReaction LVEF/I-AdverseReaction of/O 20/B-Severity %/I-Severity below/I-Severity baseline/O ./O
Assess/O LVEF/O by/O echocardiogram/O or/O multigated/O acquisition/O (/O MUGA/O )/O scan/O before/O initiation/O of/O TAFINLAR/O in/O combination/O with/O trametinib/O ,/O one/O month/O after/O initiation/O ,/O and/O then/O at/O 2-/O to/O 3-month/O intervals/O while/O on/O treatment/O with/O the/O combination/O ./O
Withhold/O treatment/O with/O trametinib/O and/O continue/O TAFINLAR/O at/O the/O same/O dose/O if/O absolute/O LVEF/O value/O decreases/O by/O 10/O %/O from/O pretreatment/O values/O and/O is/O less/O than/O the/O lower/O limit/O of/O normal/O ./O
For/O symptomatic/O cardiomyopathy/O or/O persistent/O ,/O asymptomatic/O LV/O dysfunction/O that/O does/O not/O resolve/O within/O 4/O weeks/O ,/O permanently/O discontinue/O trametinib/O and/O withhold/O TAFINLAR/O ./O
Resume/O TAFINLAR/O at/O the/O same/O dose/O level/O upon/O recovery/O of/O cardiac/O function/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.6/O Ocular/O Toxicities/O Retinal/O Pigment/O Epithelial/O Detachment/O (/O RPED/O )/O :/O Retinal/B-AdverseReaction pigment/I-AdverseReaction epithelial/I-AdverseReaction detachments/I-AdverseReaction (/O RPED/B-AdverseReaction )/O can/B-Factor occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O and/O with/O trametinib/O as/O a/O single/O agent/O [/O refer/O to/O Full/O Prescribing/O Information/O for/O trametinib/O ]/O ./O
Retinal/B-AdverseReaction detachments/I-AdverseReaction resulting/O from/O trametinib/O are/O often/O bilateral/O and/O multifocal/O ,/O occurring/O in/O the/O macular/O region/O of/O the/O retina/O ./O
In/O Trial/O 2/O ,/O ophthalmologic/O examinations/O including/O retinal/O evaluation/O were/O performed/O pretreatment/O and/O at/O regular/O intervals/O during/O treatment/O ./O
RPED/B-AdverseReaction occurred/O in/O 2/O %/O (/O 1/55/O )/O of/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Across/O clinical/O trials/O of/O TAFINLAR/O administered/O in/O combination/O with/O trametinib/O (/O N/O 202/O )/O ,/O the/O incidence/O of/O RPED/B-AdverseReaction was/O 1/O %/O (/O 2/202/O )/O ./O
Perform/O ophthalmological/O evaluation/O at/O any/O time/O a/O patient/O reports/O visual/O disturbances/O and/O compare/O with/O baseline/O ,/O if/O available/O ./O
If/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O ,/O do/O not/O modify/O the/O dose/O of/O TAFINLAR/O ./O
Withhold/O trametinib/O if/O RPED/O is/O diagnosed/O ./O
If/O resolution/O of/O the/O RPED/O is/O documented/O on/O repeat/O ophthalmological/O evaluation/O within/O 3/O weeks/O ,/O resume/O trametinib/O at/O a/O lower/O dose/O level/O ./O
Discontinue/O trametinib/O if/O no/O improvement/O after/O 3/O weeks/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Uveitis/O and/O Iritis/O :/O Uveitis/B-AdverseReaction and/O iritis/B-AdverseReaction can/B-Factor occur/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O when/O used/O in/O combination/O with/O trametinib/O ./O
Uveitis/B-AdverseReaction (/O including/O iritis/B-AdverseReaction )/O occurred/O in/O 1/O %/O (/O 6/586/O )/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O and/O uveitis/B-AdverseReaction occurred/O in/O 1/O %/O (/O 2/202/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Symptomatic/O treatment/O employed/O in/O clinical/O trials/O included/O steroid/O and/O mydriatic/O ophthalmic/O drops/O ./O
Monitor/O patients/O for/O visual/O signs/O and/O symptoms/O of/O uveitis/O (/O e.g./O ,/O change/O in/O vision/O ,/O photophobia/O ,/O eye/O pain/O )/O ./O
If/O diagnosed/O ,/O withhold/O TAFINLAR/O for/O up/O to/O 6/O weeks/O until/O uveitis/O iritis/O resolves/O to/O Grade/O 0/O -/O 1/O ./O
If/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O ,/O do/O not/O modify/O the/O dose/O of/O trametinib/O ./O
5.7/O Serious/O Febrile/O Reactions/O Serious/B-Severity febrile/B-AdverseReaction reactions/I-AdverseReaction and/O fever/B-AdverseReaction of/O any/O severity/O complicated/O by/O hypotension/B-AdverseReaction ,/O rigors/B-AdverseReaction or/O chills/B-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O or/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O can/B-Factor occur/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O when/O used/O in/O combination/O with/O trametinib/O ./O
The/O incidence/O and/O severity/O of/O pyrexia/B-AdverseReaction are/O increased/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O compared/O with/O TAFINLAR/O as/O a/O single/O agent/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O Trial/O 1/O ,/O the/O incidence/O of/O fever/B-AdverseReaction (/O serious/B-Severity and/O non/O -/O serious/O )/O was/O 28/O %/O in/O patients/O treated/O with/O TAFINLAR/O and/O 10/O %/O in/O patients/O treated/O with/O dacarbazine/O ./O
In/O patients/O treated/O with/O TAFINLAR/O ,/O the/O median/O time/O to/O initial/O onset/O of/O fever/B-AdverseReaction (/O any/O severity/O )/O was/O 11/O days/O (/O range/O :/O 1/O to/O 202/O days/O )/O and/O the/O median/O duration/O of/O fever/B-AdverseReaction was/O 3/O days/O (/O range/O :/O 1/O to/O 129/O days/O )/O ./O
Serious/B-Severity febrile/B-AdverseReaction reactions/I-AdverseReaction and/O fever/B-AdverseReaction of/O any/O severity/O complicated/O by/O hypotension/B-AdverseReaction ,/O rigors/B-AdverseReaction or/O chills/B-AdverseReaction occurred/O in/O 3.7/O %/O (/O 7/187/O )/O of/O patients/O treated/O with/O TAFINLAR/O and/O in/O none/O of/O the/O 59/O patients/O treated/O with/O dacarbazine/O ./O
In/O Trial/O 2/O ,/O the/O incidence/O of/O fever/B-AdverseReaction (/O serious/B-Severity and/O non/O -/O serious/O )/O was/O 71/O %/O (/O 39/55/O )/O in/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O and/O 26/O %/O (/O 14/53/O )/O in/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Serious/B-Severity febrile/B-AdverseReaction reactions/I-AdverseReaction and/O fever/B-AdverseReaction of/O any/O severity/O complicated/O by/O hypotension/B-AdverseReaction ,/O rigors/B-AdverseReaction or/O chills/B-AdverseReaction occurred/O in/O 25/O %/O (/O 14/55/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O 2/O %/O (/O 1/53/O )/O of/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Fever/B-AdverseReaction was/O complicated/O with/O chills/B-AdverseReaction rigors/B-AdverseReaction in/O 51/O %/O (/O 28/55/O )/O ,/O dehydration/B-AdverseReaction in/O 9/O %/O (/O 5/55/O )/O ,/O renal/B-AdverseReaction failure/I-AdverseReaction in/O 4/O %/O (/O 2/55/O )/O ,/O and/O syncope/B-AdverseReaction in/O 4/O %/O (/O 2/55/O )/O of/O patients/O in/O Trial/O 2/O ./O
In/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ,/O the/O median/O time/O to/O initial/O onset/O of/O fever/B-AdverseReaction was/O 30/O days/O compared/O with/O 19/O days/O in/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ;/O the/O median/O duration/O of/O fever/B-AdverseReaction was/O 6/O days/O with/O the/O combination/O compared/O with/O 4/O days/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Across/O clinical/O trials/O of/O TAFINLAR/O administered/O in/O combination/O with/O trametinib/O (/O N/O 202/O )/O ,/O the/O incidence/O of/O pyrexia/B-AdverseReaction was/O 57/O %/O (/O 116/202/O )/O ./O
Withhold/O TAFINLAR/O for/O fever/O of/O 101.3oF/O or/O higher/O ./O
Withhold/O trametinib/O for/O any/O fever/O higher/O than/O 104oF./O Withhold/O TAFINLAR/O ,/O and/O trametinib/O if/O used/O in/O combination/O ,/O for/O any/O serious/O febrile/O reaction/O or/O fever/O complicated/O by/O hypotension/O ,/O rigors/O or/O chills/O ,/O dehydration/O ,/O or/O renal/O failure/O and/O evaluate/O for/O signs/O and/O symptoms/O of/O infection/O ./O
Refer/O to/O Table/O 2/O for/O recommended/O dose/O modifications/O for/O adverse/O reactions/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Prophylaxis/O with/O antipyretics/O may/O be/O required/O when/O resuming/O TAFINLAR/O or/O trametinib/O ./O
5.8/O Serious/O Skin/O Toxicity/O Serious/B-Severity skin/B-AdverseReaction toxicity/I-AdverseReaction can/B-Factor occur/O when/O TAFINLAR/O is/O used/O in/O combination/O with/O trametinib/O and/O with/O trametinib/O as/O a/O single/O agent/O [/O refer/O to/O Full/O Prescribing/O Information/O for/O trametinib/O ]/O ./O
In/O Trial/O 2/O ,/O the/O incidence/O of/O any/O skin/B-AdverseReaction toxicity/I-AdverseReaction was/O similar/O for/O patients/O receiving/O TAFINLAR/O in/O combination/O with/O trametinib/O (/O 65/O %/O [/O 36/55/O ]/O )/O compared/O with/O patients/O receiving/O TAFINLAR/O as/O a/O single/O agent/O (/O 68/O %/O [/O 36/53/O ]/O )/O ./O
The/O median/O time/O to/O onset/O of/O skin/B-AdverseReaction toxicity/I-AdverseReaction in/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O was/O 37/O days/O (/O range/O :/O 1/O to/O 225/O days/O )/O and/O median/O time/O to/O resolution/O of/O skin/B-AdverseReaction toxicity/I-AdverseReaction was/O 33/O days/O (/O range/O :/O 3/O to/O 421/O days/O )/O ./O
No/O patient/O required/O dose/O reduction/O or/O permanent/O discontinuation/O of/O TAFINLAR/O or/O trametinib/O for/O skin/O toxicity/O ./O
Across/O clinical/O trials/O of/O TAFINLAR/O in/O combination/O with/O trametinib/O (/O N/O 202/O )/O ,/O severe/B-Severity skin/B-AdverseReaction toxicity/I-AdverseReaction and/O secondary/B-AdverseReaction infections/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction skin/I-AdverseReaction requiring/O hospitalization/O occurred/O in/O 2.5/O %/O (/O 5/202/O )/O of/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Withhold/O TAFINLAR/O ,/O and/O trametinib/O if/O used/O in/O combination/O ,/O for/O intolerable/O or/O severe/O skin/O toxicity/O ./O
TAFINLAR/O and/O trametinib/O may/O be/O resumed/O at/O lower/O dose/O levels/O in/O patients/O with/O improvement/O or/O recovery/O from/O skin/O toxicity/O within/O 3/O weeks/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
5.9/O Hyperglycemia/O Hyperglycemia/B-AdverseReaction can/B-Factor occur/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O when/O used/O in/O combination/O with/O trametinib/O ./O
In/O Trial/O 1/O ,/O 5/O of/O 12/O patients/O with/O a/O history/O of/O diabetes/O required/O more/O intensive/O hypoglycemic/O therapy/O while/O taking/O TAFINLAR/O ./O
The/O incidence/O of/O Grade/B-Severity 3/I-Severity hyperglycemia/B-AdverseReaction based/O on/O laboratory/O values/O was/O 6/O %/O (/O 12/187/O )/O in/O patients/O treated/O with/O TAFINLAR/O compared/O with/O none/O of/O the/O dacarbazine/O -/O treated/O patients/O ./O
In/O Trial/O 2/O ,/O the/O incidence/O of/O Grade/B-Severity 3/I-Severity hyperglycemia/B-AdverseReaction based/O on/O laboratory/O values/O was/O 5/O %/O (/O 3/55/O )/O in/O patients/O treated/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O compared/O with/O 2/O %/O (/O 1/53/O )/O in/O patients/O treated/O with/O TAFINLAR/O as/O a/O single/O agent/O ./O
Monitor/O serum/O glucose/O levels/O as/O clinically/O appropriate/O when/O TAFINLAR/O is/O administered/O as/O a/O single/O agent/O or/O when/O used/O in/O combination/O with/O trametinib/O in/O patients/O with/O pre/O -/O existing/O diabetes/O or/O hyperglycemia/O ./O
Advise/O patients/O to/O report/O symptoms/O of/O severe/O hyperglycemia/O such/O as/O excessive/O thirst/O or/O any/O increase/O in/O the/O volume/O or/O frequency/O of/O urination/O ./O
5.10/O Glucose-6-Phosphate/O Dehydrogenase/O Deficiency/O TAFINLAR/O ,/O which/O contains/O a/O sulfonamide/O moiety/O ,/O confers/O a/O potential/O risk/B-Factor of/O hemolytic/B-AdverseReaction anemia/I-AdverseReaction in/O patients/O with/O glucose-6-phosphate/O dehydrogenase/O (/O G6PD/O )/O deficiency/O ./O
Closely/O observe/O patients/O with/O G6PD/O deficiency/O for/O signs/O of/O hemolytic/O anemia/O ./O
5.11/O Embryofetal/O Toxicity/O Based/O on/O its/O mechanism/O of/O action/O ,/O TAFINLAR/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Dabrafenib/O was/O teratogenic/B-AdverseReaction and/O embryotoxic/B-AdverseReaction in/O rats/B-Animal at/O doses/O three/O times/O greater/O than/O the/O human/O exposure/O at/O the/O recommended/O clinical/O dose/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O a/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
Advise/O female/O patients/O of/O reproductive/O potential/O to/O use/O a/O highly/O effective/O non/O -/O hormonal/O method/O of/O contraception/O since/O TAFINLAR/O can/O render/O hormonal/O contraceptives/O ineffective/O ,/O during/O treatment/O and/O for/O at/O least/O 2/O weeks/O after/O treatment/O with/O TAFINLAR/O or/O for/O 4/O months/O after/O treatment/O with/O TAFINLAR/O in/O combination/O with/O trametinib/O ./O
Advise/O patients/O to/O contact/O their/O healthcare/O provider/O if/O they/O become/O pregnant/O ,/O or/O if/O pregnancy/O is/O suspected/O ,/O while/O taking/O TAFINLAR/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O ,/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O reactions/O are/O described/O below/O or/O elsewhere/O in/O the/O prescribing/O information/O :/O Risk/B-Factor of/O Thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O Tumors/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Acute/B-AdverseReaction Pancreatitis/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hypoglycemia/B-AdverseReaction with/O Concomitant/O Use/O of/O Insulin/O Secretagogues/O or/O Insulin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Renal/B-AdverseReaction Impairment/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O EXCERPT/O :/O Adverse/O reactions/O ,/O reported/O in/O 5/O %/O of/O patients/O treated/O with/O TANZEUM/O and/O more/O frequently/O than/O in/O patients/O on/O placebo/O ,/O were/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O cough/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O and/O influenza/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GlaxoSmithKline/O at/O 1/O -/O 888/O -/O 825/O -/O 5249/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Pool/O of/O Placebo/O -/O Controlled/O Trials/O The/O data/O in/O Table/O 1/O are/O derived/O from/O 4/O placebo/O -/O controlled/O trials/O ./O
TANZEUM/O was/O used/O as/O monotherapy/O in/O 1/O trial/O and/O as/O add/O -/O on/O therapy/O in/O 3/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O data/O reflect/O exposure/O of/O 923/O patients/O to/O TANZEUM/O and/O a/O mean/O duration/O of/O exposure/O to/O TANZEUM/O of/O 93/O weeks/O ./O
The/O mean/O age/O of/O participants/O was/O 55/O years/O ,/O 1/O %/O of/O participants/O were/O 75/O years/O or/O older/O and/O 53/O %/O of/O participants/O were/O male/O ./O
The/O population/O in/O these/O studies/O was/O 48/O %/O white/O ,/O 13/O %/O African/O African/O American/O ,/O 7/O %/O Asian/O ,/O and/O 29/O %/O Hispanic/O Latino/O ./O
At/O baseline/O ,/O the/O population/O had/O type/O 2/O diabetes/O for/O an/O average/O of/O 7/O years/O and/O had/O a/O mean/O HbA1c/O of/O 8.1/O %/O ./O
At/O baseline/O ,/O 17/O %/O of/O the/O population/O in/O these/O studies/O reported/O peripheral/O neuropathy/O and/O 4/O %/O reported/O retinopathy/O ./O
Baseline/O estimated/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O eGFR/O 60/O mL/O min/1.73/O m/O 2/O )/O in/O 91/O %/O of/O the/O study/O population/O and/O moderately/O impaired/O (/O eGFR/O 30/O to/O 60/O mL/O min/1.73/O m/O 2/O )/O in/O 9/O %/O ./O
Table/O 1/O shows/O common/O adverse/O reactions/O excluding/O hypoglycemia/B-AdverseReaction associated/O with/O the/O use/O of/O TANZEUM/O in/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ./O
These/O adverse/O reactions/O were/O not/O present/O at/O baseline/O ,/O occurred/O more/O commonly/O on/O TANZEUM/O than/O on/O placebo/O ,/O and/O occurred/O in/O at/O least/O 5/O %/O of/O patients/O treated/O with/O TANZEUM/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O in/O Placebo/O -/O controlled/O Trials/O Reported/O in/O 5/O %/O of/O Patients/O Treated/O with/O TANZEUM/O a/O Adverse/O Reaction/O Placebo/O (/O N/O 468/O )/O %/O TANZEUM/O (/O N/O 923/O )/O %/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 13.0/O 14.2/O Diarrhea/B-AdverseReaction 10.5/O 13.1/O Nausea/B-AdverseReaction 9.6/O 11.1/O Injection/B-AdverseReaction site/I-AdverseReaction reactionb/I-AdverseReaction 2.1/O 10.5/O Cough/B-AdverseReaction 6.2/O 6.9/O Back/B-AdverseReaction pain/I-AdverseReaction 5.8/O 6.7/O Arthralgia/B-AdverseReaction 6.4/O 6.6/O Sinusitis/B-AdverseReaction 5.8/O 6.2/O Influenza/B-AdverseReaction 3.2/O 5.2/O a/O Adverse/O reactions/O reported/O includes/O adverse/O reactions/O occurring/O with/O the/O use/O of/O glycemic/O rescue/O medications/O which/O included/O metformin/O (/O 17/O %/O for/O placebo/O and/O 10/O %/O for/O TANZEUM/O )/O and/O insulin/O (/O 24/O %/O for/O placebo/O and/O 14/O %/O for/O TANZEUM/O )/O ./O
b/O See/O below/O for/O other/O events/O of/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction reported/O ./O
Gastrointestinal/O Adverse/O Reactions/O In/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ,/O gastrointestinal/B-AdverseReaction complaints/I-AdverseReaction occurred/O more/O frequently/O among/O patients/O receiving/O TANZEUM/O (/O 39/O %/O )/O than/O patients/O receiving/O placebo/O (/O 33/O %/O )/O ./O
In/O addition/O to/O diarrhea/B-AdverseReaction and/O nausea/B-AdverseReaction (/O see/O Table/O 1/O )/O ,/O the/O following/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction also/O occurred/O more/O frequently/O in/O patients/O receiving/O TANZEUM/O :/O vomiting/B-AdverseReaction (/O 2.6/O %/O versus/O 4.2/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction (/O 1.9/O %/O versus/O 3.5/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O and/O dyspepsia/B-AdverseReaction (/O 2.8/O %/O versus/O 3.4/O %/O for/O placebo/O versus/O TANZEUM/O )/O ./O
Constipation/B-AdverseReaction also/O contributed/O to/O the/O frequently/O reported/O reactions/O ./O
In/O the/O group/O treated/O with/O TANZEUM/O ,/O investigators/O graded/O the/O severity/O of/O GI/B-AdverseReaction reactions/I-AdverseReaction as/O "/O mild/B-Severity "/O in/O 56/O %/O of/O cases/O ,/O "/O moderate/B-Severity "/O in/O 37/O %/O of/O cases/O ,/O and/O "/O severe/B-Severity "/O in/O 7/O %/O of/O cases/O ./O
Discontinuation/O due/O to/O GI/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction occurred/O in/O 2/O %/O of/O individuals/O on/O TANZEUM/O or/O placebo/O ./O
Injection/O Site/O Reactions/O In/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ,/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction occurred/O more/O frequently/O on/O TANZEUM/O (/O 18/O %/O )/O than/O on/O placebo/O (/O 8/O %/O )/O ./O
In/O addition/O to/O the/O term/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction (/O see/O Table/O 1/O )/O ,/O the/O following/O other/O types/O of/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction also/O occurred/O more/O frequently/O on/O TANZEUM/O :/O injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction (/O 1.9/O %/O versus/O 2.1/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction (/O 0.4/O %/O versus/O 1.7/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction rash/I-AdverseReaction (/O 0/O %/O versus/O 1.4/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction hypersensitivity/I-AdverseReaction (/O 0/O %/O versus/O 0.8/O %/O for/O placebo/O versus/O TANZEUM/O )/O ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction (/O 0.6/O %/O versus/O 0.7/O %/O for/O placebo/O versus/O TANZEUM/O )/O ./O
Injection/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction also/O contributed/O to/O the/O frequently/O reported/O reactions/O ./O
The/O majority/O of/O injection/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction were/O judged/O as/O "/O mild/B-Severity "/O by/O investigators/O in/O both/O groups/O (/O 73/O %/O for/O TANZEUM/O versus/O 94/O %/O for/O placebo/O )/O ./O
More/O patients/O on/O TANZEUM/O than/O on/O placebo/O :/O discontinued/O due/O to/O an/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction (/O 2/O %/O versus/O 0.2/O %/O )/O ,/O experienced/O more/O than/O 2/O reactions/O (/O 38/O %/O versus/O 20/O %/O )/O ,/O had/O a/O reaction/O judged/O by/O investigators/O to/O be/O "/O moderate/O "/O or/O "/O severe/O "/O (/O 27/O %/O versus/O 6/O %/O )/O and/O required/O local/O or/O systemic/O treatment/O for/O the/O reactions/O (/O 36/O %/O versus/O 11/O %/O )/O ./O
Pool/O of/O Placebo-/O and/O Active/O -/O controlled/O Trials/O The/O occurrence/O of/O adverse/O reactions/O was/O also/O evaluated/O in/O a/O larger/O pool/O of/O patients/O with/O type/O 2/O diabetes/O participating/O in/O 7/O placebo-/O and/O active/O -/O controlled/O trials/O ./O
These/O trials/O evaluated/O the/O use/O of/O TANZEUM/O as/O monotherapy/O ,/O and/O as/O add/O -/O on/O therapy/O to/O oral/O antidiabetic/O agents/O ,/O and/O as/O add/O -/O on/O therapy/O to/O basal/O insulin/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
In/O this/O pool/O ,/O a/O total/O of/O 2,116/O patients/O with/O type/O 2/O diabetes/O were/O treated/O with/O TANZEUM/O for/O a/O mean/O duration/O of/O 75/O weeks/O ./O
The/O mean/O age/O of/O patients/O treated/O with/O TANZEUM/O was/O 55/O years/O ,/O 1.5/O %/O of/O the/O population/O in/O these/O studies/O was/O 75/O years/O or/O older/O and/O 51/O %/O of/O participants/O were/O male/O ./O
Forty/O -/O eight/O percent/O of/O patients/O were/O white/O ,/O 15/O %/O African/O African/O American/O ,/O 9/O %/O Asian/O ,/O and/O 26/O %/O were/O Hispanic/O Latino/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 8/O years/O and/O had/O a/O mean/O HbA1c/O of/O 8.2/O %/O ./O
At/O baseline/O ,/O 21/O %/O of/O the/O population/O reported/O peripheral/O neuropathy/O and/O 5/O %/O reported/O retinopathy/O ./O
Baseline/O estimated/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O eGFR/O 60/O mL/O min/1.73/O m/O 2/O )/O in/O 92/O %/O of/O the/O population/O and/O moderately/O impaired/O (/O eGFR/O 30/O to/O 60/O mL/O min/1.73/O m/O 2/O )/O in/O 8/O %/O of/O the/O population/O ./O
In/O the/O pool/O of/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O the/O types/O and/O frequency/O of/O common/O adverse/O reactions/O excluding/O hypoglycemia/B-AdverseReaction were/O similar/O to/O those/O listed/O in/O Table/O 1/O ./O
Other/O Adverse/O Reactions/O Hypoglycemia/O The/O proportion/O of/O patients/O experiencing/O at/O least/O one/O documented/O symptomatic/B-Severity hypoglycemic/B-AdverseReaction episode/I-AdverseReaction on/O TANZEUM/O and/O the/O proportion/O of/O patients/O experiencing/O at/O least/O one/O severe/B-Severity hypoglycemic/B-AdverseReaction episode/I-AdverseReaction on/O TANZEUM/O in/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O is/O shown/O in/O Table/O 2/O ./O
Hypoglycemia/B-AdverseReaction was/O more/O frequent/O when/O TANZEUM/O was/O added/O to/O sulfonylurea/O or/O insulin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Table/O 2/O ./O
Incidence/O (/O %/O )/O of/O Hypoglycemia/O in/O Clinical/O Trials/O of/O TANZEUM/O a/O TANZEUM/O Monotherapyb/O Placebo/O 30/O mg/O Weekly/O (/O 52/O Weeks/O )/O N/O 101/O N/O 101/O Documented/O symptomaticc/O 2/O %/O 2/O %/O Severed/O -/O -/O In/O Combination/O with/O Metformin/O Trial/O Placebo/O TANZEUM/O (/O 104/O Weeks)e/O N/O 101/O N/O 302/O Documented/O symptomatic/O 4/O %/O 3/O %/O Severe/O -/O -/O In/O Combination/O with/O Pioglitazone/O +/O /-/O Placebo/O TANZEUM/O Metformin/O (/O 52/O Weeks/O )/O N/O 151/O N/O 150/O Documented/O symptomatic/O 1/O %/O 3/O %/O Severe/O -/O 1/O %/O In/O Combination/O with/O Metformin/O and/O Placebo/O TANZEUM/O Sulfonylurea/O (/O 52/O Weeks/O )/O N/O 115/O N/O 271/O Documented/O symptomatic/O 7/O %/O 13/O %/O Severe/O -/O 0.4/O %/O In/O Combination/O with/O Insulin/O Lispro/O TANZEUM/O Insulin/O Glargine/O (/O 26/O Weeks/O )/O N/O 281/O N/O 285/O Documented/O symptomatic/O 30/O %/O 16/O %/O Severe/O 0.7/O %/O -/O In/O Combination/O with/O Insulin/O Glargine/O TANZEUM/O Metformin/O +/O /-/O Sulfonylurea/O (/O 52/O Weeks/O )/O N/O 241/O N/O 504/O Documented/O symptomatic/O 27/O %/O 17/O %/O Severe/O 0.4/O %/O 0.4/O %/O In/O Combination/O with/O OADs/O in/O Renal/O Sitagliptin/O TANZEUM/O Impairment/O (/O 26/O Weeks/O )/O N/O 246/O N/O 249/O Documented/O symptomatic/O 6/O %/O 10/O %/O Severe/O 0.8/O %/O -/O OAD/O Oral/O antidiabetic/O agents/O ./O
a/O Data/O presented/O are/O to/O the/O primary/O endpoint/O and/O include/O only/O events/O occurring/O on/O -/O therapy/O with/O randomized/O medications/O and/O excludes/O events/O occurring/O after/O use/O of/O glycemic/O rescue/O medications/O (/O i.e./O ,/O primarily/O metformin/O or/O insulin/O )/O ./O
b/O In/O this/O trial/O ,/O no/B-Negation documented/O symptomatic/B-Severity or/O severe/B-Severity hypoglycemia/B-AdverseReaction were/O reported/O for/O TANZEUM/O 50/O mg/O and/O these/O data/O are/O omitted/O from/O the/O table/O ./O
c/O Plasma/B-AdverseReaction glucose/I-AdverseReaction concentration/I-AdverseReaction 70/O mg/O dL/O and/O presence/O of/O hypoglycemic/B-AdverseReaction symptoms/I-AdverseReaction ./O
d/O Event/O requiring/O another/O person/O to/O administer/O a/O resuscitative/O action/O ./O
e/O Rate/O of/O documented/O symptomatic/B-Severity hypoglycemia/B-AdverseReaction for/O active/O controls/O 18/O %/O (/O glimepiride/O )/O and/O 2/O %/O (/O sitagliptin/O )/O ./O
Pneumonia/O In/O the/O pool/O of/O 7/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O the/O adverse/O reaction/O of/O pneumonia/B-AdverseReaction was/O reported/O more/O frequently/O in/O patients/O receiving/O TANZEUM/O (/O 1.8/O %/O )/O than/O in/O patients/O in/O the/O all/O -/O comparators/O group/O (/O 0.8/O %/O )/O ./O
More/O cases/O of/O pneumonia/B-AdverseReaction in/O the/O group/O receiving/O TANZEUM/O were/O serious/B-Severity (/O 0.4/O %/O for/O TANZEUM/O versus/O 0.1/O %/O for/O all/O comparators/O )/O ./O
Atrial/O Fibrillation/O Flutte/O r/O In/O the/O pool/O of/O 7/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O adverse/O reactions/O of/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction (/O 1.0/O %/O )/O and/O atrial/B-AdverseReaction flutter/I-AdverseReaction (/O 0.2/O %/O )/O were/O reported/O more/O frequently/O for/O TANZEUM/O than/O for/O all/O comparators/O (/O 0.5/O %/O and/O 0/O %/O ,/O respectively/O )/O ./O
In/O both/O groups/O ,/O patients/O with/O events/O were/O generally/O male/O ,/O older/O ,/O and/O had/O underlying/O renal/O impairment/O or/O cardiac/O disease/O (/O e.g./O ,/O history/O of/O arrhythmia/O ,/O palpitations/O ,/O congestive/O heart/O failure/O ,/O cardiomyopathy/O ,/O etc/O ./O
)/O ./O
Appendicitis/O In/O the/O pool/O of/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O serious/B-Severity events/O of/O appendicitis/B-AdverseReaction occurred/O in/O 0.3/O %/O of/O patients/O treated/O with/O TANZEUM/O compared/O with/O 0/O %/O among/O all/O comparators/O ./O
Immunogenicity/O In/O the/O pool/O of/O 7/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O 116/O (/O 5.5/O %/O )/O of/O 2,098/O patients/O exposed/O to/O TANZEUM/O tested/O positive/O for/O anti/O -/O albiglutide/O antibodies/O at/O any/O time/O during/O the/O trials/O ./O
None/O of/O these/O antibodies/O were/O shown/O to/O neutralize/O the/O activity/O of/O albiglutide/O in/O an/O in/O vitro/O bioassay/O ./O
Presence/O of/O antibody/O did/O not/O correlate/O with/O reduced/O efficacy/O as/O measured/O by/O HbA1c/O and/O fasting/O plasma/O glucose/O or/O specific/O adverse/O reactions/O ./O
Consistent/O with/O the/O high/O homology/O of/O albiglutide/O with/O human/O GLP-1/O ,/O the/O majority/O of/O patients/O (/O approximately/O 79/O %/O )/O with/O anti/O -/O albiglutide/O antibodies/O also/O tested/O positive/O for/O anti/O -/O GLP-1/O antibodies/O ;/O none/O were/O neutralizing/O ./O
A/O minority/O of/O patients/O (/O approximately/O 17/O %/O )/O who/O tested/O positive/O for/O anti/O -/O albiglutide/O antibodies/O also/O transiently/O tested/O positive/O for/O antibodies/O to/O human/O albumin/O ./O
The/O detection/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O the/O incidence/O of/O antibodies/O to/O albiglutide/O can/O not/O be/O directly/O compared/O with/O the/O incidence/O of/O antibodies/O of/O other/O products/O ./O
Liver/O Enzyme/O Abnormalities/O In/O the/O pool/O of/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O a/O similar/O proportion/O of/O patients/O experienced/O at/O least/O one/O event/O of/O alanine/O aminotransferase/O (/O ALT/O )/O increase/O of/O 3-fold/O or/O greater/O above/O the/O upper/O limit/O of/O normal/O (/O 0.9/O %/O and/O 0.9/O %/O for/O all/O comparators/O versus/O TANZEUM/O )/O ./O
Three/O subjects/O on/O TANZEUM/O and/O one/O subject/O in/O the/O all/O -/O comparator/O group/O experienced/O at/O least/O one/O event/O of/O ALT/B-AdverseReaction increase/I-AdverseReaction of/O 10-fold/O or/O greater/O above/O the/O upper/O limit/O of/O normal/O ./O
In/O one/O of/O the/O 3/O cases/O an/O alternate/B-Negation etiology/I-Negation was/O identified/O to/O explain/O the/O rise/B-AdverseReaction in/I-AdverseReaction liver/I-AdverseReaction enzyme/I-AdverseReaction (/O acute/O viral/O hepatitis/O )/O ./O
In/O one/O case/O ,/O insufficient/O information/O was/O obtained/O to/O establish/O or/O refute/O a/O drug/O -/O related/O causality/O ./O
In/O the/O third/O case/O ,/O elevation/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction (/O 10/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity )/O was/O accompanied/O by/O an/O increase/B-AdverseReaction in/I-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction (/O 4/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity )/O and/O occurred/O 8/O days/O after/O the/O first/O dose/O of/O TANZEUM/O ./O
The/O etiology/O of/O hepatocellular/B-AdverseReaction injury/I-AdverseReaction was/O possibly/O related/O to/O TANZEUM/O but/O direct/O attribution/O to/O TANZEUM/O was/O confounded/O by/O the/O presence/O of/O gallstone/O disease/O diagnosed/O on/O ultrasound/O 3/O weeks/O after/O the/O event/O ./O
Gamma/O Glutamyltransferase/O (/O GGT/O )/O Increase/O In/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ,/O the/O adverse/O event/O of/O increased/B-AdverseReaction GGT/I-AdverseReaction occurred/O more/O frequently/O in/O the/O group/O treated/O with/O TANZEUM/O (/O 0.9/O %/O and/O 1.5/O %/O for/O placebo/O versus/O TANZEUM/O )/O ./O
Heart/O Rate/O Increase/O In/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ,/O mean/O heart/O rate/O in/O patients/O treated/O with/O TANZEUM/O was/O higher/O by/O an/O average/O of/O 1/O to/O 2/O bpm/O compared/O with/O mean/O heart/O rate/O in/O patients/O treated/O with/O placebo/O across/O study/O visits/O ./O
The/O long/O -/O term/O clinical/O effects/O of/O the/O increase/B-AdverseReaction in/I-AdverseReaction heart/I-AdverseReaction rate/I-AdverseReaction have/O not/O been/O established/O [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O Carcinogenicity/O of/O albiglutide/O could/O not/O be/O assessed/O in/O rodents/O ,/O but/O other/O glucagon/B-DrugClass -/I-DrugClass like/I-DrugClass peptide-1/I-DrugClass (/I-DrugClass GLP-1/O )/O receptor/O agonists/O have/O caused/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rodents/B-Animal at/O clinically/O relevant/O exposures/O ./O
Human/O relevance/O of/O GLP-1/B-DrugClass receptor/I-DrugClass agonist/I-DrugClass induced/O C/B-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rodents/B-Animal has/O not/O been/O determined/O ./O
It/O is/O unknown/B-Factor whether/O TANZEUM(r/O )/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O medullary/B-AdverseReaction thyroid/I-AdverseReaction carcinoma/I-AdverseReaction (/O MTC/B-AdverseReaction )/O ,/O in/O humans/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
TANZEUM/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O or/O in/O patients/O with/O Multiple/O Endocrine/O Neoplasia/O syndrome/O type/O 2/O (/O MEN/O 2/O )/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O of/O MTC/O with/O the/O use/O of/O TANZEUM/O and/O inform/O them/O of/O the/O symptoms/O of/O thyroid/O tumors/O (/O e.g./O ,/O mass/O in/O the/O neck/O ,/O dysphagia/O ,/O dyspnea/O ,/O persistent/O hoarseness/O )/O ./O
Routine/O monitoring/O of/O serum/O calcitonin/O or/O using/O thyroid/O ultrasound/O monitoring/O is/O of/O uncertain/O value/O for/O early/O detection/O of/O MTC/O in/O patients/O treated/O with/O TANZEUM/O [/O see/O Contraindications/O (/O 4.1/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Carcinogenicity/O of/O albiglutide/O could/O not/O be/O assessed/O in/O rodents/O ,/O but/O other/O glucagon/B-DrugClass -/I-DrugClass like/I-DrugClass peptide-1/I-DrugClass (/I-DrugClass GLP-1/O )/O receptor/O agonists/O have/O caused/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rodents/B-Animal at/O clinically/O relevant/O exposures/O ./O
Human/O relevance/O of/O GLP-1/B-DrugClass receptor/I-DrugClass agonist/I-DrugClass induced/O C/B-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rodents/B-Animal has/O not/O been/O determined/O ./O
It/O is/O unknown/B-Factor whether/O TANZEUM/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O medullary/B-AdverseReaction thyroid/I-AdverseReaction carcinoma/I-AdverseReaction (/O MTC/B-AdverseReaction )/O ,/O in/O humans/O ./O
(/O 5.1/O ,/O 13.1/O )/O TANZEUM/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O or/O in/O patients/O with/O Multiple/O Endocrine/O Neoplasia/O syndrome/O type/O 2/O (/O MEN/O 2/O )/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O of/O MTC/O and/O symptoms/O of/O thyroid/O tumors/O (/O 4.1/O ,/O 5.1/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O Tumors/O :/O See/O Boxed/O Warning/O ./O
(/O 5.1/O )/O Pancreatitis/B-AdverseReaction :/O Discontinue/O promptly/O if/O suspected/O ./O
Do/O not/O restart/O if/O confirmed/O ./O
Consider/O other/O antidiabetic/O therapies/O in/O patients/O with/O a/O history/O of/O pancreatitis/O ./O
(/O 5.2/O )/O Hypoglycemia/B-AdverseReaction :/O Can/O occur/O when/O used/O in/O combination/O with/O insulin/O secretagogues/O (/O e.g./O ,/O sulfonylureas/O )/O or/O insulin/O ./O
Consider/O lowering/O sulfonylurea/O or/O insulin/O dosage/O when/O starting/O TANZEUM/O ./O
(/O 5.3/O )/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction :/O Discontinue/O TANZEUM/O if/O suspected/O ./O
Monitor/O and/O treat/O promptly/O per/O standard/O of/O care/O until/O signs/O and/O symptoms/O resolve/O ./O
(/O 5.4/O )/O Renal/B-AdverseReaction Impairment/I-AdverseReaction :/O Monitor/O renal/O function/O in/O patients/O with/O renal/O impairment/O reporting/O severe/O adverse/O gastrointestinal/O reactions/O ./O
(/O 5.5/O )/O Macrovascular/O Outcomes/O :/O There/O have/O been/O no/O clinical/O trials/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O TANZEUM/O or/O any/O other/O antidiabetic/O drug/O ./O
(/O 5.6/O )/O 5.1/O Risk/O of/O Thyroid/O C/O -/O cell/O Tumors/O Carcinogenicity/O of/O albiglutide/O could/O not/O be/O assessed/O in/O rodents/O due/O to/O the/O rapid/O development/O of/O drug/O -/O clearing/O ,/O anti/O -/O drug/O antibodies/O [/O see/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
Other/O GLP-1/B-DrugClass receptor/I-DrugClass agonists/I-DrugClass have/O caused/O dose/O -/O related/O and/O treatment/O -/O duration/O -/O dependent/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O (/O adenomas/O or/O carcinomas/O )/O in/O rodents/B-Animal ./O
Human/O relevance/O of/O GLP-1/B-DrugClass receptor/I-DrugClass agonist/I-DrugClass induced/O C/B-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rodents/B-Animal has/O not/O been/O determined/O ./O
It/O is/O unknown/B-Factor whether/O TANZEUM/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O MTC/B-AdverseReaction ,/O in/O humans/O [/O see/O Boxed/O Warning/O ,/O Contraindications/O (/O 4.1/O )/O ]/O ./O
Across/O 8/O Phase/O III/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ,/O MTC/B-AdverseReaction was/O diagnosed/O in/O 1/O patient/O receiving/O TANZEUM/O and/O 1/O patient/O receiving/O placebo/O ./O
Both/O patients/O had/O markedly/O elevated/O serum/O calcitonin/O levels/O at/O baseline/O ./O
Cases/O of/O MTC/B-AdverseReaction in/O patients/O treated/O with/O liraglutide/B-DrugClass ,/O another/O GLP-1/O receptor/O agonist/O ,/O have/O been/O reported/O in/O the/O postmarketing/O period/O ;/O the/O data/O in/O these/O reports/O are/O insufficient/O to/O establish/O or/O exclude/O a/O causal/O relationship/O between/O MTC/B-AdverseReaction and/O GLP-1/B-DrugClass receptor/I-DrugClass agonist/I-DrugClass use/O in/O humans/O ./O
TANZEUM/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O or/O in/O patients/O with/O MEN/O 2/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O for/O MTC/O with/O the/O use/O of/O TANZEUM/O and/O inform/O them/O of/O symptoms/O of/O thyroid/O tumors/O (/O e.g./O ,/O a/O mass/O in/O the/O neck/O ,/O dysphagia/O ,/O dyspnea/O ,/O or/O persistent/O hoarseness/O )/O ./O
Routine/O monitoring/O of/O serum/O calcitonin/O or/O using/O thyroid/O ultrasound/O is/O of/O uncertain/O value/O for/O early/O detection/O of/O MTC/O in/O patients/O treated/O with/O TANZEUM/O ./O
Such/O monitoring/O may/O increase/O the/O risk/O of/O unnecessary/O procedures/O ,/O due/O to/O the/O low/O specificity/O of/O serum/O calcitonin/O testing/O for/O MTC/O and/O a/O high/O background/O incidence/O of/O thyroid/O disease/O ./O
Significantly/O elevated/O serum/O calcitonin/O may/O indicate/O MTC/O and/O patients/O with/O MTC/O usually/O have/O calcitonin/O values/O 50/O ng/O L./O If/O serum/O calcitonin/O is/O measured/O and/O found/O to/O be/O elevated/O ,/O the/O patient/O should/O be/O further/O evaluated/O ./O
Patients/O with/O thyroid/O nodules/O noted/O on/O physical/O examination/O or/O neck/O imaging/O should/O also/O be/O further/O evaluated/O ./O
5.2/O Acute/O Pancreatitis/O In/O clinical/O trials/O ,/O acute/B-AdverseReaction pancreatitis/I-AdverseReaction has/O been/O reported/O in/O association/O with/O TANZEUM/O ./O
Across/O 8/O Phase/O III/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ,/O pancreatitis/B-AdverseReaction adjudicated/O as/O likely/O related/O to/O therapy/O occurred/O more/O frequently/O in/O patients/O receiving/O TANZEUM/O (/O 6/O of/O 2,365/O [/O 0.3/O %/O ]/O )/O than/O in/O patients/O receiving/O placebo/O (/O 0/O of/O 468/O [/O 0/O %/O ]/O )/O or/O active/O comparators/O (/O 2/O of/O 2,065/O [/O 0.1/O %/O ]/O )/O ./O
After/O initiation/O of/O TANZEUM/O ,/O observe/O patients/O carefully/O for/O signs/O and/O symptoms/O of/O pancreatitis/O (/O including/O persistent/O severe/O abdominal/O pain/O ,/O sometimes/O radiating/O to/O the/O back/O and/O which/O may/O or/O may/O not/O be/O accompanied/O by/O vomiting/O )/O ./O
If/O pancreatitis/O is/O suspected/O ,/O promptly/O discontinue/O TANZEUM/O ./O
If/O pancreatitis/O is/O confirmed/O ,/O TANZEUM/O should/O not/O be/O restarted/O ./O
TANZEUM/O has/O not/O been/O studied/O in/O patients/O with/O a/O history/O of/O pancreatitis/O to/O determine/O whether/O these/O patients/O are/O at/O increased/O risk/O for/O pancreatitis/O ./O
Consider/O other/O antidiabetic/O therapies/O in/O patients/O with/O a/O history/O of/O pancreatitis/O ./O
5.3/O Hypoglycemia/O with/O Concomitant/O Use/O of/O Insulin/O Secretagogues/O or/O Insulin/O The/O risk/B-Factor of/O hypoglycemia/B-AdverseReaction is/O increased/O when/O TANZEUM/O is/O used/O in/O combination/O with/O insulin/O secretagogues/O (/O e.g./O ,/O sulfonylureas/O )/O or/O insulin/O ./O
Therefore/O ,/O patients/O may/O require/O a/O lower/O dose/O of/O sulfonylurea/O or/O insulin/O to/O reduce/O the/O risk/B-Factor of/O hypoglycemia/B-AdverseReaction in/O this/O setting/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.4/O Hypersensitivity/O Reactions/O Across/O 8/O Phase/O III/O clinical/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ,/O a/O serious/B-Severity hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction with/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction occurred/O in/O a/O patient/O treated/O with/O TANZEUM/O ./O
If/O hypersensitivity/O reactions/O occur/O ,/O discontinue/O use/O of/O TANZEUM/O ;/O treat/O promptly/O per/O standard/O of/O care/O and/O monitor/O until/O signs/O and/O symptoms/O resolve/O [/O see/O Contraindications/O (/O 4.2/O )/O ]/O ./O
5.5/O Renal/O Impairment/O In/O patients/O treated/O with/O GLP-1/B-DrugClass receptor/I-DrugClass agonists/I-DrugClass ,/O there/O have/O been/O postmarketing/O reports/O of/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O worsening/B-AdverseReaction of/I-AdverseReaction chronic/I-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O which/O may/O sometimes/O require/O hemodialysis/O ./O
Some/O of/O these/O events/O were/O reported/O in/O patients/O without/O known/O underlying/O renal/O disease/O ./O
A/O majority/O of/O reported/O events/O occurred/O in/O patients/O who/O had/O experienced/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O or/O dehydration/B-AdverseReaction ./O
In/O a/O trial/O of/O TANZEUM/O in/O patients/O with/O renal/O impairment/O [/O see/O Clinical/O Studies/O (/O 14.3/O )/O ]/O ,/O the/O frequency/O of/O such/O gastrointestinal/B-AdverseReaction reactions/I-AdverseReaction increased/O as/O renal/B-AdverseReaction function/I-AdverseReaction declined/I-AdverseReaction [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
Because/O these/O reactions/O may/O worsen/O renal/O function/O ,/O use/O caution/O when/O initiating/O or/O escalating/O doses/O of/O TANZEUM/O in/O patients/O with/O renal/O impairment/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
5.6/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O trials/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O TANZEUM/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O important/O adverse/O reactions/O are/O described/O elsewhere/O in/O labeling/O :/O Anaphylaxis/B-AdverseReaction and/O Angioedema/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Lymphopenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Flushing/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O incidence/O 10/O %/O and/O 2/O %/O placebo/O )/O were/O flushing/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Biogen/O at/O 1/O -/O 800/O -/O 456/O -/O 2255/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O most/O common/O adverse/O reactions/O (/O incidence/O 10/O %/O and/O 2/O %/O more/O than/O placebo/O )/O for/O TECFIDERA/O were/O flushing/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O Trials/O In/O the/O two/O well/O -/O controlled/O studies/O demonstrating/O effectiveness/O ,/O 1529/O patients/O received/O TECFIDERA/O with/O an/O overall/O exposure/O of/O 2244/O person/O -/O years/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O adverse/O reactions/O presented/O in/O the/O table/O below/O are/O based/O on/O safety/O information/O from/O 769/O patients/O treated/O with/O TECFIDERA/O 240/O mg/O twice/O a/O day/O and/O 771/O placebo/O -/O treated/O patients/O ./O
Table/O 1/O :/O Adverse/O Reactions/O in/O Study/O 1/O and/O 2/O reported/O for/O TECFIDERA/O 240/O mg/O BID/O at/O 2/O %/O higher/O incidence/O than/O placebo/O TECFIDERA/O N=769/O %/O Placebo/O N=771/O %/O Flushing/B-AdverseReaction 40/O 6/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 18/O 10/O Diarrhea/B-AdverseReaction 14/O 11/O Nausea/B-AdverseReaction 12/O 9/O Vomiting/B-AdverseReaction 9/O 5/O Pruritus/B-AdverseReaction 8/O 4/O Rash/B-AdverseReaction 8/O 3/O Albumin/B-AdverseReaction urine/I-AdverseReaction present/I-AdverseReaction 6/O 4/O Erythema/B-AdverseReaction 5/O 1/O Dyspepsia/B-AdverseReaction 5/O 3/O Aspartate/B-AdverseReaction aminotransferase/I-AdverseReaction increased/I-AdverseReaction 4/O 2/O Lymphopenia/B-AdverseReaction 2/O 1/O Gastrointestinal/O TECFIDERA/O caused/O GI/B-AdverseReaction events/I-AdverseReaction (/O e.g./O ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O dyspepsia/B-AdverseReaction )/O ./O
The/O incidence/O of/O GI/B-AdverseReaction events/I-AdverseReaction was/O higher/O early/O in/O the/O course/O of/O treatment/O (/O primarily/O in/O month/O 1/O )/O and/O usually/O decreased/O over/O time/O in/O patients/O treated/O with/O TECFIDERA/O compared/O with/O placebo/O ./O
Four/O percent/O (/O 4/O %/O )/O of/O patients/O treated/O with/O TECFIDERA/O and/O less/O than/O 1/O %/O of/O placebo/O patients/O discontinued/O due/O to/O gastrointestinal/B-AdverseReaction events/I-AdverseReaction ./O
The/O incidence/O of/O serious/B-Severity GI/B-AdverseReaction events/I-AdverseReaction was/O 1/O %/O in/O patients/O treated/O with/O TECFIDERA/O ./O
Hepatic/O Transaminases/O An/O increased/O incidence/O of/O elevations/B-AdverseReaction of/I-AdverseReaction hepatic/I-AdverseReaction transaminases/I-AdverseReaction in/O patients/O treated/O with/O TECFIDERA/O was/O seen/O primarily/O during/O the/O first/O six/O months/O of/O treatment/O ,/O and/O most/O patients/O with/O elevations/O had/O levels/O 3/O times/O the/O upper/O limit/O of/O normal/O (/O ULN/O )/O ./O
Elevations/B-AdverseReaction of/I-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction and/O aspartate/O aminotransferase/O to/O 3/O times/O the/O ULN/O occurred/O in/O a/O small/O number/O of/O patients/O treated/O with/O both/O TECFIDERA/O and/O placebo/O and/O were/O balanced/O between/O groups/O ./O
There/O were/O no/B-Negation elevations/B-AdverseReaction in/I-AdverseReaction transaminases/I-AdverseReaction 3/B-Severity times/I-Severity the/I-Severity ULN/I-Severity with/O concomitant/O elevations/B-AdverseReaction in/I-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction 2/B-Severity times/I-Severity the/I-Severity ULN/I-Severity ./O
Discontinuations/O due/O to/O elevated/B-AdverseReaction hepatic/I-AdverseReaction transaminases/I-AdverseReaction were/O 1/O %/O and/O were/O similar/O in/O patients/O treated/O with/O TECFIDERA/O or/O placebo/O ./O
Eosinophilia/O A/O transient/B-Severity increase/B-AdverseReaction in/I-AdverseReaction mean/I-AdverseReaction eosinophil/I-AdverseReaction counts/I-AdverseReaction was/O seen/O during/O the/O first/O 2/O months/O of/O therapy/O ./O
Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O and/O Uncontrolled/O Studies/O In/O placebo/O -/O controlled/O and/O uncontrolled/O clinical/O studies/O ,/O a/O total/O of/O 2513/O patients/O have/O received/O TECFIDERA/O and/O been/O followed/O for/O periods/O up/O to/O 4/O years/O with/O an/O overall/O exposure/O of/O 4603/O person/O -/O years/O ./O
Approximately/O 1162/O patients/O have/O received/O more/O than/O 2/O years/O of/O treatment/O with/O TECFIDERA/O ./O
The/O adverse/O reaction/O profile/O of/O TECFIDERA/O in/O the/O uncontrolled/O clinical/O studies/O was/O consistent/O with/O the/O experience/O in/O the/O placebo/O -/O controlled/O clinical/O trials/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Anaphylaxis/B-AdverseReaction and/O angioedema/B-AdverseReaction :/O Discontinue/O and/O do/O not/O restart/O TECFIDERA/O if/O these/O occur/O ./O
(/O 5.1/O )/O Progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O :/O Withhold/O TECFIDERA/O at/O the/O first/O sign/O or/O symptom/O suggestive/O of/O PML/O ./O
(/O 5.2/O )/O Lymphopenia/B-AdverseReaction :/O Obtain/O a/O CBC/O including/O lymphocyte/O count/O before/O initiating/O TECFIDERA/O ,/O after/O 6/O months/O ,/O and/O every/O 6/O to/O 12/O months/O thereafter/O ./O
Consider/O interruption/O of/O TECFIDERA/O if/O lymphocyte/O counts/O 0.5/O x/O 10/O 9/O /L/O persist/O for/O more/O than/O six/O months/O ./O
(/O 5.3/O )/O 5.1/O Anaphylaxis/O and/O Angioedema/O TECFIDERA/O can/B-Factor cause/O anaphylaxis/B-AdverseReaction and/O angioedema/B-AdverseReaction after/O the/O first/O dose/O or/O at/O any/O time/O during/O treatment/O ./O
Signs/O and/O symptoms/O have/O included/O difficulty/B-AdverseReaction breathing/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O and/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction throat/I-AdverseReaction and/O tongue/O ./O
Patients/O should/O be/O instructed/O to/O discontinue/O TECFIDERA/O and/O seek/O immediate/O medical/O care/O should/O they/O experience/O signs/O and/O symptoms/O of/O anaphylaxis/O or/O angioedema/O ./O
5.2/O Progressive/O Multifocal/O Leukoencephalopathy/O A/O fatal/B-AdverseReaction case/O of/O progressive/B-AdverseReaction multifocal/I-AdverseReaction leukoencephalopathy/I-AdverseReaction (/O PML/B-AdverseReaction )/O occurred/O in/O a/O patient/O with/O MS/O who/O received/O TECFIDERA/O for/O 4/O years/O while/O enrolled/O in/O a/O clinical/O trial/O ./O
PML/O is/O an/O opportunistic/O viral/O infection/O of/O the/O brain/O caused/O by/O the/O JC/O virus/O (/O JCV/O )/O that/O typically/O only/O occurs/O in/O patients/O who/O are/O immunocompromised/O ,/O and/O that/O usually/O leads/O to/O death/O or/O severe/O disability/O ./O
During/O the/O clinical/O trial/O ,/O the/O patient/O experienced/O prolonged/B-Severity lymphopenia/B-AdverseReaction (/O lymphocyte/O counts/O predominantly/O 0.5x10/O 9/O /L/O for/O 3.5/O years/O )/O while/O taking/O TECFIDERA/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
The/O role/O of/O lymphopenia/B-AdverseReaction in/O this/O case/O is/O unknown/O ./O
The/O patient/O had/O no/O other/O identified/O systemic/O medical/O conditions/O resulting/O in/O compromised/O immune/O system/O function/O and/O had/O not/O previously/O been/O treated/O with/O natalizumab/O ,/O which/O has/O a/O known/O association/O with/O PML/O ./O
The/O patient/O was/O also/O not/O taking/O any/O immunosuppressive/O or/O immunomodulatory/O medications/O concomitantly/O ./O
At/O the/O first/O sign/O or/O symptom/O suggestive/O of/O PML/O ,/O withhold/O TECFIDERA/O and/O perform/O an/O appropriate/O diagnostic/O evaluation/O ./O
Typical/O symptoms/O associated/O with/O PML/O are/O diverse/O ,/O progress/O over/O days/O to/O weeks/O ,/O and/O include/O progressive/O weakness/O on/O one/O side/O of/O the/O body/O or/O clumsiness/O of/O limbs/O ,/O disturbance/O of/O vision/O ,/O and/O changes/O in/O thinking/O ,/O memory/O ,/O and/O orientation/O leading/O to/O confusion/O and/O personality/O changes/O ./O
5.3/O Lymphopenia/O TECFIDERA/O may/B-Factor decrease/B-AdverseReaction lymphocyte/I-AdverseReaction counts/I-AdverseReaction ./O
In/O the/O MS/O placebo/O controlled/O trials/O ,/O mean/O lymphocyte/B-AdverseReaction counts/I-AdverseReaction decreased/I-AdverseReaction by/O approximately/O 30/O %/O during/O the/O first/O year/O of/O treatment/O with/O TECFIDERA/O and/O then/O remained/O stable/O ./O
Four/O weeks/O after/O stopping/O TECFIDERA/O ,/O mean/O lymphocyte/O counts/O increased/O but/O did/O not/O return/O to/O baseline/O ./O
Six/O percent/O (/O 6/O %/O )/O of/O TECFIDERA/O patients/O and/O 1/O %/O of/O placebo/O patients/O experienced/O lymphocyte/B-AdverseReaction counts/I-AdverseReaction 0.5x10/I-AdverseReaction 9/O /L/O (/O lower/O limit/O of/O normal/O 0.91x10/O 9/O /L/O )/O ./O
The/O incidence/O of/O infections/B-AdverseReaction (/O 60/O %/O vs/O 58/O %/O )/O and/O serious/B-Severity infections/B-AdverseReaction (/O 2/O %/O vs/O 2/O %/O )/O was/O similar/O in/O patients/O treated/O with/O TECFIDERA/O or/O placebo/O ,/O respectively/O ./O
There/O was/O no/B-Negation increased/O incidence/O of/O serious/B-Severity infections/O observed/O in/O patients/O with/O lymphocyte/O counts/O 0.8x10/O 9/O /L/O or/O 0.5x10/O 9/O /L/O in/O controlled/O trials/O ,/O although/O one/O patient/O in/O an/O extension/O study/O developed/O PML/B-AdverseReaction in/O the/O setting/O of/O prolonged/B-AdverseReaction lymphopenia/I-AdverseReaction (/O lymphocyte/O counts/O predominantly/O 0.5x10/O 9/O /L/O for/O 3.5/O years/O )/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
In/O controlled/O and/O uncontrolled/O clinical/O trials/O ,/O 2/O %/O of/O patients/O experienced/O lymphocyte/B-AdverseReaction counts/I-AdverseReaction 0.5/I-AdverseReaction x/I-AdverseReaction 10/I-AdverseReaction 9/O /L/O for/O at/O least/O six/O months/O ./O
In/O these/O patients/O ,/O the/O majority/O of/O lymphocyte/O counts/O remained/O 0.5x10/O 9/O /L/O with/O continued/O therapy/O ./O
TECFIDERA/O has/O not/O been/O studied/O in/O patients/O with/O pre/O -/O existing/O low/O lymphocyte/O counts/O ./O
Before/O initiating/O treatment/O with/O TECFIDERA/O ,/O a/O CBC/O including/O lymphocyte/O count/O should/O be/O obtained/O ./O
A/O CBC/O including/O lymphocyte/O count/O should/O also/O be/O obtained/O after/O 6/O months/O of/O treatment/O ,/O every/O 6/O to/O 12/O months/O thereafter/O ,/O and/O as/O clinically/O indicated/O ./O
Consider/O interruption/O of/O TECFIDERA/O in/O patients/O with/O lymphocyte/O counts/O 0.5/O x/O 10/O 9/O /L/O persisting/O for/O more/O than/O six/O months/O ./O
Given/O the/O potential/O for/O delay/O in/O lymphocyte/O recovery/O after/O discontinuation/O of/O TECFIDERA/O ,/O consider/O following/O lymphocyte/O counts/O until/O lymphopenia/O is/O resolved/O ./O
Withholding/O treatment/O should/O be/O considered/O in/O patients/O with/O serious/O infections/O until/O the/O infection(s/O )/O is/O resolved/O ./O
Decisions/O about/O whether/O or/O not/O to/O restart/O TECFIDERA/O should/O be/O individualized/O based/O on/O clinical/O circumstances/O ./O
5.4/O Flushing/O TECFIDERA/O may/O cause/O flushing/B-AdverseReaction (/O e.g./O ,/O warmth/B-AdverseReaction ,/O redness/B-AdverseReaction ,/O itching/B-AdverseReaction ,/O and/or/O burning/B-AdverseReaction sensation/I-AdverseReaction )/O ./O
In/O clinical/O trials/O ,/O 40/O %/O of/O TECFIDERA/O treated/O patients/O experienced/O flushing/B-AdverseReaction ./O
Flushing/B-AdverseReaction symptoms/O generally/O began/O soon/O after/O initiating/O TECFIDERA/O and/O usually/O improved/O or/O resolved/O over/O time/O ./O
In/O the/O majority/O of/O patients/O who/O experienced/O flushing/B-AdverseReaction ,/O it/O was/O mild/B-Severity or/O moderate/B-Severity in/O severity/O ./O
Three/O percent/O (/O 3/O %/O )/O of/O patients/O discontinued/O TECFIDERA/O for/O flushing/B-AdverseReaction and/O 1/O %/O had/O serious/B-Severity flushing/B-AdverseReaction symptoms/O that/O were/O not/B-Severity life/I-Severity -/O threatening/O but/O led/O to/O hospitalization/O ./O
Administration/O of/O TECFIDERA/O with/O food/O may/O reduce/O the/O incidence/O of/O flushing/B-AdverseReaction ./O
Alternatively/O ,/O administration/O of/O non/O -/O enteric/O coated/O aspirin/O (/O up/O to/O a/O dose/O of/O 325/O mg/O )/O 30/O minutes/O prior/O to/O TECFIDERA/O dosing/O may/O reduce/O the/O incidence/O or/O severity/O of/O flushing/B-AdverseReaction [/O see/O Dosing/O and/O Administration/O (/O 2.1/O )/O and/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
6/O ./O
ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O are/O described/O in/O greater/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -Associated/I-AdverseReaction diarrhea/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Direct/B-AdverseReaction Coombs/I-AdverseReaction '/I-AdverseReaction Test/I-AdverseReaction Seroconversion/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O occurring/O in/O 2/O %/O of/O patients/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Forest/O Laboratories/O ,/O LLC/O ,/O at/O 1/O -/O 800/O -/O 678/O -/O 1605/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O compared/O directly/O to/O rates/O from/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O rates/O observed/O in/O practice/O ./O
Teflaro/O was/O evaluated/O in/O four/O controlled/O comparative/O Phase/O 3/O clinical/O trials/O (/O two/O in/O ABSSSI/O and/O two/O in/O CABP/O )/O which/O included/O 1300/O adult/O patients/O treated/O with/O Teflaro/O (/O 600/O mg/O administered/O by/O IV/O over/O 1/O hour/O every/O 12h/O )/O and/O 1297/O patients/O treated/O with/O comparator/O (/O vancomycin/O plus/O aztreonam/O or/O ceftriaxone/O )/O for/O a/O treatment/O period/O up/O to/O 21/O days/O ./O
The/O median/O age/O of/O patients/O treated/O with/O Teflaro/O was/O 54/O years/O ,/O ranging/O between/O 18/O and/O 99/O years/O old/O ./O
Patients/O treated/O with/O Teflaro/O were/O predominantly/O male/O (/O 63/O %/O )/O and/O Caucasian/O (/O 82/O %/O )/O ./O
Serious/O Adverse/O Reactions/O and/O Adverse/O Reactions/O Leading/O to/O Discontinuation/O In/O the/O four/O pooled/O Phase/O 3/O clinical/O trials/O ,/O serious/O adverse/O reactions/O (/O SARs/O )/O occurred/O in/O 98/1300/O (/O 7.5/O %/O )/O of/O patients/O receiving/O Teflaro/O and/O 100/1297/O (/O 7.7/O %/O )/O of/O patients/O receiving/O comparator/O drugs/O ./O
Treatment/O discontinuation/O due/O to/O adverse/O reactions/O occurred/O in/O 35/1300/O (/O 2.7/O %/O )/O of/O patients/O receiving/O Teflaro/O and/O 48/1297/O (/O 3.7/O %/O )/O of/O patients/O receiving/O comparator/O drugs/O with/O the/O most/O common/O adverse/O reactions/O leading/O to/O discontinuation/O being/O hypersensitivity/B-AdverseReaction for/O both/O treatment/O groups/O at/O a/O rate/O of/O 0.3/O %/O in/O the/O Teflaro/O group/O and/O 0.5/O %/O in/O comparator/O group/O ./O
Most/O Common/O Adverse/O Reactions/O No/O adverse/O reactions/O occurred/O in/O greater/O than/O 5/O %/O of/O patients/O receiving/O Teflaro/O ./O
The/O most/O common/O adverse/O reactions/O occurring/O in/O 2/O %/O of/O patients/O receiving/O Teflaro/O in/O the/O pooled/O phase/O 3/O clinical/O trials/O were/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
Table/O 4/O lists/O adverse/O reactions/O occurring/O in/O 2/O %/O of/O patients/O receiving/O Teflaro/O in/O the/O pooled/O Phase/O 3/O clinical/O trials/O ./O
Table/O 4/O :/O Adverse/O Reactions/O Occurring/O in/O 2/O %/O of/O Patients/O Receiving/O Teflaro/O in/O the/O Pooled/O Phase/O 3/O Clinical/O Trials/O a/O Comparators/O included/O vancomycin/O 1/O gram/O IV/O every/O 12h/O plus/O aztreonam/O 1/O gram/O IV/O every/O 12h/O in/O the/O Phase/O 3/O ABSSSI/O trials/O ,/O and/O ceftriaxone/O 1/O gram/O IV/O every/O 24h/O in/O the/O Phase/O 3/O CABP/O trials/O ./O
Adverse/O Reactions/O Pooled/O Phase/O 3/O Clinical/O Trials/O (/O four/O trials/O ,/O two/O in/O ABSSSI/O and/O two/O in/O CABP/O )/O Teflaro/O (/O N=1300/O )/O Pooled/O Comparators/O a/O (/O N=1297/O )/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 5/O %/O 3/O %/O Nausea/B-AdverseReaction 4/O %/O 4/O %/O Constipation/B-AdverseReaction 2/O %/O 2/O %/O Vomiting/B-AdverseReaction 2/O %/O 2/O %/O Laboratory/O Investigations/O Increased/B-AdverseReaction transaminases/I-AdverseReaction 2/O %/O 3/O %/O Metabolism/O and/O Nutrition/O disorders/O Hypokalemia/B-AdverseReaction 2/O %/O 3/O %/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Rash/B-AdverseReaction 3/O %/O 2/O %/O Vascular/O Disorders/O Phlebitis/B-AdverseReaction 2/O %/O 1/O %/O Other/O Adverse/O Reactions/O Observed/O During/O Clinical/O Trials/O of/O Teflaro/O Following/O is/O a/O list/O of/O additional/O adverse/O reactions/O reported/O by/O the/O 1740/O patients/O who/O received/O Teflaro/O in/O any/O clinical/O trial/O with/O incidences/O less/O than/O 2/O %/O ./O
Blood/O and/O lymphatic/O system/O disorders/O -/O Anemia/B-AdverseReaction ,/O Eosinophilia/B-AdverseReaction ,/O Neutropenia/B-AdverseReaction ,/O Thrombocytopenia/B-AdverseReaction Cardiac/O disorders/O -/O Bradycardia/B-AdverseReaction ,/O Palpitations/B-AdverseReaction Gastrointestinal/O disorders/O -/O Abdominal/B-AdverseReaction pain/I-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O -/O Pyrexia/B-AdverseReaction Hepatobiliary/O disorders/O -/O Hepatitis/B-AdverseReaction Immune/O system/O disorders/O -/O Hypersensitivity/B-AdverseReaction ,/O Anaphylaxis/B-AdverseReaction Infections/O and/O infestations/O -/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction colitis/O Metabolism/O and/O nutrition/O disorders/O -/O Hyperglycemia/B-AdverseReaction ,/O Hyperkalemia/B-AdverseReaction Nervous/O system/O disorders/O -/O Dizziness/B-AdverseReaction ,/O Convulsion/B-AdverseReaction Renal/O and/O urinary/O disorders/O -/O Renal/B-AdverseReaction failure/I-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O -/O Urticaria/B-AdverseReaction 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reaction/O has/O been/O identified/O during/O postapproval/O use/O of/O Teflaro/O ./O
Because/O this/O adverse/O reaction/O was/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O possible/O to/O estimate/O its/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Blood/O and/O lymphatic/O system/O disorders/O :/O Agranulocytosis/B-AdverseReaction ./O
5/O ./O
WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Serious/B-Severity hypersensitivity/O (/O anaphylactic/O )/O reactions/O have/O been/O reported/O with/O beta/O -/O lactam/O antibacterial/O drugs/O ,/O including/O Teflaro/O ./O
If/O a/O hypersensitivity/O reaction/O occurs/O ,/O discontinue/O Teflaro/O ./O
(/O 5.1/O )/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/I-AdverseReaction (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O with/O nearly/O all/O systemic/O antibacterial/O agents/O ,/O including/O Teflaro/O ./O
Evaluate/O if/O diarrhea/O occurs/O ./O
(/O 5.2/O )/O Direct/B-AdverseReaction Coombs/I-AdverseReaction '/I-AdverseReaction test/I-AdverseReaction seroconversion/O has/O been/O reported/O with/O Teflaro/O ./O
If/O anemia/O develops/O during/O or/O after/O therapy/O ,/O a/O diagnostic/O workup/O for/O drug/O -/O induced/O hemolytic/O anemia/O should/O be/O performed/O and/O consideration/O given/O to/O discontinuation/O of/O Teflaro/O ./O
(/O 5.3/O )/O 5.1/O Hypersensitivity/O Reactions/O Serious/B-Severity and/O occasionally/O fatal/B-AdverseReaction hypersensitivity/O (/O anaphylactic/O )/O reactions/O and/O serious/B-Severity skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O in/O patients/O receiving/O beta/B-DrugClass -/I-DrugClass lactam/I-DrugClass antibacterial/O drugs/O ./O
Before/O therapy/O with/O Teflaro/O is/O instituted/O ,/O careful/O inquiry/O about/O previous/O hypersensitivity/O reactions/O to/O other/O cephalosporins/O ,/O penicillins/O ,/O or/O carbapenems/O should/O be/O made/O ./O
Maintain/O clinical/O supervision/O if/O this/O product/O is/O to/O be/O given/O to/O a/O penicillin-/O or/O other/O beta/O -/O lactam/O -/O allergic/O patient/O ,/O because/O cross/O sensitivity/O among/O beta/O -/O lactam/O antibacterial/O agents/O has/O been/O clearly/O established/O ./O
If/O an/O allergic/O reaction/O to/O Teflaro/O occurs/O ,/O discontinue/O Teflaro/O and/O institute/O appropriate/O treatment/O and/O supportive/O measures/O ./O
5.2/O Clostridium/O difficile/O -/O Associated/O Diarrhea/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/O (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O for/O nearly/O all/O systemic/O antibacterial/O agents/O ,/O including/O Teflaro/O ,/O and/O may/O range/O in/O severity/O from/O mild/B-Severity diarrhea/B-AdverseReaction to/O fatal/B-AdverseReaction colitis/B-AdverseReaction ./O
Treatment/O with/O antibacterial/O agents/O alters/O the/O normal/O flora/O of/O the/O colon/O and/O may/O permit/O overgrowth/O of/O C./O difficile/O ./O
C./O difficile/O produces/O toxins/O A/O and/O B/O which/O contribute/O to/O the/O development/O of/O CDAD/O ./O
Hypertoxin/O -/O producing/O strains/O of/O C./O difficile/O cause/O increased/O morbidity/O and/O mortality/O ,/O as/O these/O infections/O can/O be/O refractory/O to/O antimicrobial/O therapy/O and/O may/O require/O colectomy/O ./O
CDAD/O must/O be/O considered/O in/O all/O patients/O who/O present/O with/O diarrhea/O following/O antibiotic/O use/O ./O
Careful/O medical/O history/O is/O necessary/O because/O CDAD/O has/O been/O reported/O to/O occur/O more/O than/O 2/O months/O after/O the/O administration/O of/O antibacterial/O agents/O ./O
If/O CDAD/O is/O suspected/O or/O confirmed/O ,/O antibacterials/O not/O directed/O against/O C./O difficile/O should/O be/O discontinued/O ,/O if/O possible/O ./O
Appropriate/O fluid/O and/O electrolyte/O management/O ,/O protein/O supplementation/O ,/O antibiotic/O treatment/O of/O C./O difficile/O ,/O and/O surgical/O evaluation/O should/O be/O instituted/O as/O clinically/O indicated/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.3/O Direct/O Coombs/O '/O Test/O Seroconversion/O Seroconversion/B-AdverseReaction from/I-AdverseReaction a/I-AdverseReaction negative/I-AdverseReaction to/I-AdverseReaction a/I-AdverseReaction positive/I-AdverseReaction direct/I-AdverseReaction Coombs/I-AdverseReaction '/I-AdverseReaction test/I-AdverseReaction result/O occurred/O in/O 120/1114/O (/O 10.8/O %/O )/O of/O patients/O receiving/O Teflaro/O and/O 49/1116/O (/O 4.4/O %/O )/O of/O patients/O receiving/O comparator/O drugs/O in/O the/O four/O pooled/O Phase/O 3/O trials/O ./O
In/O the/O pooled/O Phase/O 3/O CABP/O trials/O ,/O 51/520/O (/O 9.8/O %/O )/O of/O Teflaro/O -/O treated/O patients/O compared/O to/O 24/534/O (/O 4.5/O %/O )/O of/O ceftriaxone/O -/O treated/O patients/O seroconverted/B-AdverseReaction from/I-AdverseReaction a/I-AdverseReaction negative/I-AdverseReaction to/I-AdverseReaction a/I-AdverseReaction positive/I-AdverseReaction direct/I-AdverseReaction Coombs/I-AdverseReaction '/I-AdverseReaction test/I-AdverseReaction result/O ./O
No/B-Negation adverse/O reactions/O representing/O hemolytic/B-AdverseReaction anemia/I-AdverseReaction were/O reported/O in/O any/O treatment/O group/O ./O
If/O anemia/O develops/O during/O or/O after/O treatment/O with/O Teflaro/O ,/O drug/O -/O induced/O hemolytic/O anemia/O should/O be/O considered/O ./O
Diagnostic/O studies/O including/O a/O direct/O Coombs/O '/O test/O ,/O should/O be/O performed/O ./O
If/O drug/O -/O induced/O hemolytic/O anemia/O is/O suspected/O ,/O discontinuation/O of/O Teflaro/O should/O be/O considered/O and/O supportive/O care/O should/O be/O administered/O to/O the/O patient/O (/O i.e./O transfusion/O )/O if/O clinically/O indicated/O ./O
5.4/O Development/O of/O Drug/O -/O Resistant/O Bacteria/O Prescribing/O Teflaro/O in/O the/O absence/O of/O a/O proven/O or/O strongly/O suspected/O bacterial/O infection/O is/O unlikely/O to/O provide/O benefit/O to/O the/O patient/O and/O increases/O the/O risk/O of/O the/O development/O of/O drug/O -/O resistant/O bacteria/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O drug/O reactions/O (/O adverse/O events/O assessed/O as/O causally/O related/O by/O the/O investigator/O or/O ADRs/O )/O are/O discussed/O in/O other/O sections/O of/O the/O labeling/O :/O Hypersensitivity/B-AdverseReaction reactions/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Effects/O on/O serum/O liver/O biochemistries/O in/O patients/O with/O hepatitis/O B/O or/O C/O co/O -/O infection/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Fat/B-AdverseReaction Redistribution/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Immune/B-AdverseReaction Reconstitution/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O with/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O of/O moderate/B-Severity to/O severe/B-Severity intensity/O and/O incidence/O at/O least/O 2/O %/O (/O in/O those/O receiving/O TIVICAY/O in/O any/O one/O adult/O trial/O )/O are/O insomnia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O ViiV/O Healthcare/O at/O 1/O -/O 877/O -/O 844/O -/O 8872/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trials/O Experience/O in/O Adult/O Subjects/O Treatment/O -/O emergent/O Adverse/O Drug/O Reactions/O (/O ADRs/O )/O Treatment/O -/O naive/O Subjects/O :/O The/O safety/O assessment/O of/O TIVICAY/O in/O HIV-1-infected/O treatment/O -/O naive/O subjects/O is/O based/O on/O the/O analyses/O of/O 96-week/O data/O from/O 2/O international/O ,/O multicenter/O ,/O double/O -/O blind/O trials/O ,/O SPRING-2/O (/O ING113086/O )/O and/O SINGLE/O (/O ING114467/O )/O and/O 48-week/O data/O from/O the/O international/O ,/O multicenter/O ,/O open/O -/O label/O FLAMINGO/O (/O ING114915/O )/O trial/O ./O
In/O SPRING-2/O ,/O 822/O subjects/O were/O randomized/O and/O received/O at/O least/O 1/O dose/O of/O either/O TIVICAY/O 50/O mg/O once/O daily/O or/O raltegravir/O 400/O mg/O twice/O daily/O ,/O both/O in/O combination/O with/O fixed/O -/O dose/O dual/O nucleoside/O reverse/O transcriptase/O inhibitor/O (/O NRTI/O )/O treatment/O (/O either/O abacavir/O sulfate/O and/O lamivudine/O [/O EPZICOM/O (/O r/O )/O ]/O or/O emtricitabine/O tenofovir/O [/O TRUVADA/O (/O r/O )/O ]/O )/O ./O
There/O were/O 808/O subjects/O included/O in/O the/O efficacy/O and/O safety/O analyses/O ./O
Through/O 96/O weeks/O ,/O the/O rate/O of/O adverse/O events/O leading/O to/O discontinuation/O was/O 2/O %/O in/O both/O treatment/O arms/O ./O
In/O SINGLE/O ,/O 833/O subjects/O were/O randomized/O and/O received/O at/O least/O 1/O dose/O of/O either/O TIVICAY/O 50/O mg/O with/O fixed/O -/O dose/O abacavir/O sulfate/O and/O lamivudine/O (/O EPZICOM/O )/O once/O daily/O or/O fixed/O -/O dose/O efavirenz/O emtricitabine/O tenofovir/O (/O ATRIPLA/O (/O r/O )/O )/O once/O daily/O ./O
Through/O 96/O weeks/O ,/O the/O rates/O of/O adverse/O events/O leading/O to/O discontinuation/O were/O 3/O %/O in/O subjects/O receiving/O TIVICAY/O 50/O mg/O once/O daily/O +/O EPZICOM/O and/O 12/O %/O in/O subjects/O receiving/O ATRIPLA/O once/O daily/O ./O
Treatment/O -/O emergent/O ADRs/O of/O moderate/O to/O severe/O intensity/O observed/O in/O at/O least/O 2/O %/O of/O subjects/O in/O either/O treatment/O arm/O in/O SPRING-2/O and/O SINGLE/O trials/O are/O provided/O in/O Table/O 2/O ./O
Side/O -/O by/O -/O side/O tabulation/O is/O to/O simplify/O presentation/O ;/O direct/O comparisons/O across/O trials/O should/O not/O be/O made/O due/O to/O differing/O trial/O designs/O ./O
Table/O 2/O ./O
Treatment/O -/O emergent/O Adverse/O Drug/O Reactions/O of/O at/O Least/O Moderate/O Intensity/O (/O Grades/O 2/O to/O 4/O )/O and/O at/O Least/O 2/O %/O Frequency/O in/O Treatment/O -/O naive/O Subjects/O in/O SPRING-2/O and/O SINGLE/O Trials/O (/O Week/O 96/O Analysis/O )/O System/O Organ/O Class//O Preferred/O Term/O SPRING-2/O SINGLE/O TIVICAY/O 50/O mg/O Once/O Daily/O +/O 2/O NRTIs/O (/O n/O 403/O )/O Raltegravir/O 400/O mg/O Twice/O Daily/O +/O 2/O NRTIs(n/O 405/O )/O TIVICAY/O 50/O mg/O +/O EPZICOM/O Once/O Daily(n/O 414/O )/O ATRIPLA/O Once/O Daily(n/O 419/O )/O Psychiatric/O Insomnia/B-AdverseReaction 1/O %/O 1/O %/O 3/O %/O 2/O %/O Depression/B-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 2/O %/O Abnormal/B-AdverseReaction dreams/I-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 2/O %/O Nervous/O System/O Dizziness/B-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 5/O %/O Headache/B-AdverseReaction 1/O %/O 1/O %/O 2/O %/O 2/O %/O Gastrointestinal/O Nausea/B-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 3/O %/O Diarrhea/B-AdverseReaction 1/O %/O 1/O %/O 1/O %/O 2/O %/O Skin/O and/O Subcutaneous/O Tissue/O Rasha/B-AdverseReaction 0/O 1/O %/O 1/O %/O 6/O %/O General/O Disorders/O Fatigue/B-AdverseReaction 1/O %/O 1/O %/O 2/O %/O 2/O %/O Ear/O and/O Labyrinth/O Vertigo/B-AdverseReaction 0/O 1/O %/O 0/O 2/O %/O a/O Includes/O pooled/O terms/O :/O rash/B-AdverseReaction ,/O rash/B-AdverseReaction generalized/I-AdverseReaction ,/O rash/B-AdverseReaction macular/I-AdverseReaction ,/O rash/B-AdverseReaction maculo/I-AdverseReaction -/O papular/O ,/O rash/B-AdverseReaction pruritic/I-AdverseReaction ,/O and/O drug/B-AdverseReaction eruption/I-AdverseReaction ./O
In/O addition/O ,/O Grade/B-Severity 1/I-Severity insomnia/B-AdverseReaction was/O reported/O by/O 1/O %/O and/O less/O than/O 1/O %/O of/O subjects/O receiving/O TIVICAY/O and/O raltegravir/O ,/O respectively/O ,/O in/O SPRING-2/O ;/O whereas/O in/O SINGLE/O the/O rates/O were/O 7/O %/O and/O 4/O %/O for/O TIVICAY/O and/O ATRIPLA/O ,/O respectively/O ./O
These/O events/O were/O not/O treatment/O limiting/O ./O
In/O a/O multicenter/O ,/O open/O -/O label/O trial/O (/O FLAMINGO/O )/O ,/O 243/O subjects/O received/O TIVICAY/O 50/O mg/O once/O daily/O versus/O 242/O subjects/O who/O received/O darunavir/O 800/O mg/O ritonavir/O 100/O mg/O once/O daily/O ,/O both/O in/O combination/O with/O investigator/O -/O selected/O NRTI/O background/O regimen/O (/O either/O EPZICOM/O or/O TRUVADA/O )/O ./O
There/O were/O 484/O subjects/O included/O in/O the/O efficacy/O and/O safety/O analyses/O ./O
Through/O 48/O weeks/O ,/O the/O rates/O of/O adverse/O events/O leading/O to/O discontinuation/O were/O 2/O %/O in/O subjects/O receiving/O TIVICAY/O and/O 4/O %/O in/O subjects/O receiving/O darunavir/O ritonavir/O ./O
The/O ADRs/O observed/O in/O FLAMINGO/O were/O generally/O consistent/O with/O those/O seen/O in/O SPRING-2/O and/O SINGLE/O ./O
Treatment/O -/O experienced/O ,/O Integrase/O Strand/O Transfer/O Inhibitor/O -/O naive/O Subjects/O :/O In/O an/O international/O ,/O multicenter/O ,/O double/O -/O blind/O trial/O (/O ING111762/O ,/O SAILING/O )/O ,/O 719/O HIV-1-infected/O ,/O antiretroviral/O treatment/O -/O experienced/O adults/O were/O randomized/O and/O received/O either/O TIVICAY/O 50/O mg/O once/O daily/O or/O raltegravir/O 400/O mg/O twice/O daily/O with/O investigator/O -/O selected/O background/O regimen/O consisting/O of/O up/O to/O 2/O agents/O ,/O including/O at/O least/O one/O fully/O active/O agent/O ./O
At/O 48/O weeks/O ,/O the/O rates/O of/O adverse/O events/O leading/O to/O discontinuation/O were/O 3/O %/O in/O subjects/O receiving/O TIVICAY/O 50/O mg/O once/O daily/O +/O background/O regimen/O and/O 4/O %/O in/O subjects/O receiving/O raltegravir/O 400/O mg/O twice/O daily/O +/O background/O regimen/O ./O
The/O only/O treatment/O -/O emergent/O ADR/O of/O moderate/B-Severity to/O severe/B-Severity intensity/O with/O at/O least/O 2/O %/O frequency/O in/O either/O treatment/O group/O was/O diarrhea/B-AdverseReaction ,/O 2/O %/O (/O 6/O of/O 354/O )/O in/O subjects/O receiving/O TIVICAY/O 50/O mg/O once/O daily/O +/O background/O regimen/O and/O 1/O %/O (/O 5/O of/O 361/O )/O in/O subjects/O receiving/O raltegravir/O 400/O mg/O twice/O daily/O +/O background/O regimen/O ./O
Treatment/O -/O experienced/O ,/O Integrase/O Strand/O Transfer/O Inhibitor/O -/O experienced/O Subjects/O :/O In/O a/O multicenter/O ,/O open/O -/O label/O ,/O single/O -/O arm/O trial/O (/O ING112574/O ,/O VIKING-3/O )/O ,/O 183/O HIV-1-infected/O ,/O antiretroviral/O treatment/O -/O experienced/O adults/O with/O virological/O failure/O and/O current/O or/O historical/O evidence/O of/O raltegravir/O and/or/O elvitegravir/O resistance/O received/O TIVICAY/O 50/O mg/O twice/O daily/O with/O the/O current/O failing/O background/O regimen/O for/O 7/O days/O and/O with/O optimized/O background/O therapy/O from/O Day/O 8/O ./O
The/O rate/O of/O adverse/O events/O leading/O to/O discontinuation/O was/O 4/O %/O of/O subjects/O at/O Week/O 48/O ./O
Treatment/O -/O emergent/O ADRs/O in/O VIKING-3/O were/O generally/O similar/O compared/O with/O observations/O with/O the/O 50-mg/O once/O -/O daily/O dose/O in/O adult/O Phase/O 3/O trials/O ./O
Less/O Common/O Adverse/O Reactions/O Observed/O in/O Treatment/O -/O naive/O and/O Treatment/O -/O experienced/O Trials/O The/O following/O ADRs/O occurred/O in/O less/O than/O 2/O %/O of/O treatment/O -/O naive/O or/O treatment/O -/O experienced/O subjects/O receiving/O TIVICAY/O in/O a/O combination/O regimen/O in/O any/O one/O trial/O ./O
These/O events/O have/O been/O included/O because/O of/O their/O seriousness/O and/O assessment/O of/O potential/O causal/O relationship/O ./O
Gastrointestinal/O Disorders/O :/O Abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction ,/O vomiting/B-AdverseReaction ./O
Hepatobiliary/O Disorders/O :/O Hepatitis/B-AdverseReaction ./O
Musculoskeletal/O Disorders/O :/O Myositis/B-AdverseReaction ./O
Psychiatric/O Disorders/O :/O Suicidal/B-AdverseReaction ideation/I-AdverseReaction ,/O attempt/O ,/O behavior/O ,/O or/O completion/O ./O
These/O events/O were/O observed/O primarily/O in/O subjects/O with/O a/O pre/O -/O existing/O history/O of/O depression/O or/O other/O psychiatric/O illness/O ./O
Renal/O and/O Urinary/O Disorders/O :/O Renal/B-AdverseReaction impairment/I-AdverseReaction ./O
Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Pruritus/B-AdverseReaction ./O
Laboratory/O Abnormalities/O Treatment/O -/O naive/O Subjects/O :/O Selected/O laboratory/O abnormalities/O (/O Grades/O 2/O to/O 4/O )/O with/O a/O worsening/O grade/O from/O baseline/O and/O representing/O the/O worst/O -/O grade/O toxicity/O in/O at/O least/O 2/O %/O of/O subjects/O are/O presented/O in/O Table/O 3/O ./O
The/O mean/O change/O from/O baseline/O observed/O for/O selected/O lipid/O values/O is/O presented/O in/O Table/O 4/O ./O
Side/O -/O by/O -/O side/O tabulation/O is/O to/O simplify/O presentation/O ;/O direct/O comparisons/O across/O trials/O should/O not/O be/O made/O due/O to/O differing/O trial/O designs/O ./O
Table/O 3/O ./O
Selected/O Laboratory/O Abnormalities/O (/O Grades/O 2/O to/O 4/O )/O in/O Treatment/O -/O naive/O Subjects/O in/O SPRING-2/O and/O SINGLE/O Trials/O (/O Week/O 96/O Analysis/O )/O Laboratory/O Parameter/O Preferred/O Term/O SPRING-2/O SINGLE/O TIVICAY/O 50/O mg/O Once/O Daily/O +/O 2/O NRTIs/O (/O n/O 403/O )/O Raltegravir/O 400/O mg/O Twice/O Daily/O +/O 2/O NRTIs/O (/O n/O 405/O )/O TIVICAY/O 50/O mg/O +/O EPZICOM/O Once/O Daily/O (/O n/O 414/O )/O ATRIPLA/O Once/O Daily/O (/O n/O 419/O )/O ALT/O 4/O %/O 4/O %/O 2/O %/O 5/O %/O 2/O %/O 2/O %/O 1/O %/O 1/O %/O AST/O 5/O %/O 3/O %/O 3/O %/O 3/O %/O 3/O %/O 2/O %/O 1/O %/O 3/O %/O 3/O %/O 2/O %/O 1/O %/O 0/O 1/O %/O 1/O %/O 1/O %/O 0/O Creatine/O kinase/O 2/O %/O 5/O %/O 4/O %/O 1/O %/O 7/O %/O 4/O %/O 5/O %/O 7/O %/O Hyperglycemia/B-AdverseReaction 6/O %/O 6/O %/O 7/O %/O 5/O %/O 1/O %/O 2/O %/O 2/O %/O 1/O %/O Lipase/O 7/O %/O 7/O %/O 9/O %/O 9/O %/O 2/O %/O 5/O %/O 4/O %/O 3/O %/O Total/O neutrophils/O 4/O %/O 3/O %/O 3/O %/O 5/O %/O 2/O %/O 2/O %/O 2/O %/O 3/O %/O ULN/O Upper/O limit/O of/O normal/O ./O
Table/O 4/O ./O
Mean/O Change/O from/O Baseline/O in/O Fasted/O Lipid/O Values/O in/O Treatment/O -/O naive/O Subjects/O in/O SPRING-2/O and/O SINGLE/O Trials/O (/O Week/O 96/O Analysisa/O )/O Laboratory/O Parameter/O Preferred/O Term/O SPRING-2/O SINGLE/O TIVICAY/O 50/O mg/O Once/O Daily/O +/O 2/O NRTIs/O (/O n/O 403/O )/O Raltegravir/O 400/O mg/O Twice/O Daily/O +/O 2/O NRTIs/O (/O n/O 405/O )/O TIVICAY/O 50/O mg/O +/O EPZICOM/O Once/O Daily/O (/O n/O 414/O )/O ATRIPLA/O Once/O Daily/O (/O n/O 419/O )/O Cholesterol/O (/O mg/O dL/O )/O 8.1/O 10.1/O 23.2/O 28.0/O HDL/O cholesterol/O (/O mg/O dL/O )/O 2.0/O 2.3/O 5.2/O 7.4/O LDL/O cholesterol/O (/O mg/O dL/O )/O 5.1/O 6.1/O 14.5/O 18.0/O Triglycerides/O (/O mg/O dL/O )/O 6.7/O 6.6/O 17.2/O 17.4/O a/O Subjects/O on/O lipid/O -/O lowering/O agents/O at/O baseline/O were/O excluded/O from/O these/O analyses/O (/O 19/O subjects/O in/O each/O arm/O in/O SPRING-2/O ,/O and/O in/O SINGLE/O :/O TIVICAY/O n/O 30/O and/O ATRIPLA/O n/O 27/O )/O ./O
Seventy/O -/O seven/O subjects/O initiated/O a/O lipid/O -/O lowering/O agent/O post/O -/O baseline/O ;/O their/O last/O fasted/O on/O -/O treatment/O values/O (/O prior/O to/O starting/O the/O agent/O )/O were/O used/O regardless/O if/O they/O discontinued/O the/O agent/O (/O SPRING-2/O :/O TIVICAY/O n/O 9/O ,/O raltegravir/O n/O 13/O ;/O SINGLE/O :/O TIVICAY/O n/O 25/O and/O ATRIPLA/O :/O n/O 30/O )/O ./O
Laboratory/O abnormalities/O observed/O in/O the/O FLAMINGO/O trial/O were/O generally/O consistent/O with/O observations/O in/O SPRING-2/O and/O SINGLE/O ./O
Treatment/O -/O experienced/O ,/O Integrase/O Strand/O Transfer/O Inhibitor/O -/O naive/O Subjects/O :/O Laboratory/O abnormalities/O observed/O in/O SAILING/O were/O generally/O similar/O compared/O with/O observations/O seen/O in/O the/O treatment/O -/O naive/O (/O SPRING-2/O and/O SINGLE/O )/O trials/O ./O
Treatment/O -/O experienced/O ,/O Integrase/O Strand/O Transfer/O Inhibitor/O -/O experienced/O Subjects/O :/O The/O most/O common/O treatment/O -/O emergent/O laboratory/O abnormalities/O (/O greater/O than/O 5/O %/O for/O Grades/O 2/O to/O 4/O combined/O )/O observed/O in/O VIKING-3/O at/O Week/O 48/O were/O elevated/B-AdverseReaction ALT/I-AdverseReaction (/O 9/O %/O )/O ,/O AST/O (/O 8/O %/O )/O ,/O cholesterol/O (/O 10/O %/O )/O ,/O creatine/O kinase/O (/O 6/O %/O )/O ,/O hyperglycemia/B-AdverseReaction (/O 14/O %/O )/O ,/O and/O lipase/O (/O 10/O %/O )/O ./O
Two/O percent/O (/O 4/O of/O 183/O )/O of/O subjects/O had/O a/O Grade/O 3/O to/O 4/O treatment/O -/O emergent/O hematology/O laboratory/O abnormality/O ,/O with/O neutropenia/B-AdverseReaction (/O 2/O %/O [/O 3/O of/O 183/O ]/O )/O being/O the/O most/O frequently/O reported/O ./O
Hepatitis/O B/O and/or/O Hepatitis/O C/O Virus/O Co/O -/O infection/O :/O In/O Phase/O 3/O trials/O ,/O subjects/O with/O hepatitis/O B/O and/or/O C/O virus/O co/O -/O infection/O were/O permitted/O to/O enroll/O provided/O that/O baseline/O liver/O chemistry/O tests/O did/O not/O exceed/O 5/O times/O the/O upper/O limit/O of/O normal/O ./O
Overall/O ,/O the/O safety/O profile/O in/O subjects/O with/O hepatitis/O B/O and/or/O C/O virus/O co/O -/O infection/O was/O similar/O to/O that/O observed/O in/O subjects/O without/O hepatitis/O B/O or/O C/O co/O -/O infection/O ,/O although/O the/O rates/O of/O AST/O and/O ALT/B-AdverseReaction abnormalities/I-AdverseReaction were/O higher/O in/O the/O subgroup/O with/O hepatitis/O B/O and/or/O C/O virus/O co/O -/O infection/O for/O all/O treatment/O groups/O ./O
Grades/B-Severity 2/I-Severity to/I-Severity 4/I-Severity ALT/B-AdverseReaction abnormalities/I-AdverseReaction in/O hepatitis/O B/O and/or/O C/O co/O -/O infected/O compared/O with/O HIV/O mono/O -/O infected/O subjects/O receiving/O TIVICAY/O were/O observed/O in/O 18/O %/O vs./O 3/O %/O with/O the/O 50-mg/O once/O -/O daily/O dose/O and/O 13/O %/O vs./O 8/O %/O with/O the/O 50-mg/O twice/O -/O daily/O dose/O ./O
Liver/B-AdverseReaction chemistry/I-AdverseReaction elevations/I-AdverseReaction consistent/O with/O immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction were/O observed/O in/O some/O subjects/O with/O hepatitis/O B/O and/or/O C/O at/O the/O start/O of/O therapy/O with/O TIVICAY/O ,/O particularly/O in/O the/O setting/O where/O anti/O -/O hepatitis/O therapy/O was/O withdrawn/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Changes/O in/O Serum/O Creatinine/O Dolutegravir/O has/O been/O shown/O to/O increase/B-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction due/O to/O inhibition/O of/O tubular/O secretion/O of/O creatinine/O without/O affecting/O renal/O glomerular/O function/O [/O see/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
Increases/B-AdverseReaction in/I-AdverseReaction serum/I-AdverseReaction creatinine/I-AdverseReaction occurred/O within/O the/O first/O 4/O weeks/O of/O treatment/O and/O remained/O stable/O through/O 48/O to/O 96/O weeks/O ./O
In/O treatment/O -/O naive/O subjects/O ,/O a/O mean/O change/O from/O baseline/O of/O 0.15/O mg/O per/O dL/O (/O range/O :/O -0.32/O mg/O per/O dL/O to/O 0.65/O mg/O per/O dL/O )/O was/O observed/O after/O 96/O weeks/O of/O treatment/O ./O
Creatinine/B-AdverseReaction increases/I-AdverseReaction were/O comparable/O by/O background/O NRTIs/O and/O were/O similar/O in/O treatment/O -/O experienced/O subjects/O ./O
6.2/O Clinical/O Trials/O Experience/O in/O Pediatric/O Subjects/O IMPAACT/O P1093/O is/O an/O ongoing/O multicenter/O ,/O open/O -/O label/O ,/O non/O -/O comparative/O trial/O of/O approximately/O 160/O HIV-1-infected/O pediatric/O subjects/O aged/O 6/O weeks/O to/O less/O than/O 18/O years/O ,/O of/O which/O 23/O treatment/O -/O experienced/O ,/O INSTI/O -/O naive/O subjects/O aged/O 12/O to/O less/O than/O 18/O years/O were/O enrolled/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ,/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
The/O adverse/O reaction/O profile/O was/O similar/O to/O that/O for/O adults/O ./O
Grade/B-Severity 2/I-Severity ADRs/O reported/O in/O at/O least/O 1/O subject/O were/O rash/B-AdverseReaction (/O n/O 1/O )/O ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction (/O n/O 1/O )/O ,/O and/O diarrhea/B-AdverseReaction (/O n/O 1/O )/O ./O
No/O Grade/O 3/O or/O 4/O ADRs/O were/O reported/O ./O
The/O Grade/B-Severity 3/I-Severity laboratory/O abnormalities/O were/O elevated/B-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction and/O lipase/O reported/O in/O 1/O subject/O each/O ./O
No/O Grade/O 4/O laboratory/O abnormalities/O were/O reported/O ./O
The/O changes/O in/O mean/O serum/O creatinine/O were/O similar/O to/O those/O observed/O in/O adults/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction characterized/O by/O rash/B-AdverseReaction ,/O constitutional/O findings/O ,/O and/O sometimes/O organ/B-AdverseReaction dysfunction/I-AdverseReaction ,/O including/O liver/B-AdverseReaction injury/I-AdverseReaction ,/O have/O been/O reported/O ./O
Discontinue/O TIVICAY/O and/O other/O suspect/O agents/O immediately/O if/O signs/O or/O symptoms/O of/O hypersensitivity/O reactions/O develop/O ,/O as/O a/O delay/O in/O stopping/O treatment/O may/O result/O in/O a/O life/O -/O threatening/O reaction/O ./O
(/O 5.1/O )/O Patients/O with/O underlying/O hepatitis/O B/O or/O C/O may/O be/O at/O increased/O risk/B-Factor for/O worsening/O or/O development/O of/O transaminase/B-AdverseReaction elevations/I-AdverseReaction with/O use/O of/O TIVICAY/O ./O
Appropriate/O laboratory/O testing/O prior/O to/O initiating/O therapy/O and/O monitoring/O for/O hepatotoxicity/O during/O therapy/O with/O TIVICAY/O is/O recommended/O in/O patients/O with/O underlying/O hepatic/O disease/O such/O as/O hepatitis/O B/O or/O C./O (/O 5.2/O )/O Redistribution/O accumulation/B-AdverseReaction of/I-AdverseReaction body/I-AdverseReaction fat/I-AdverseReaction and/O immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction have/O been/O reported/O in/O patients/O treated/O with/O combination/B-DrugClass antiretroviral/I-DrugClass therapy/I-DrugClass ./O
(/O 5.3/O ,/O 5.4/O )/O 5.1/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/O have/O been/O reported/O and/O were/O characterized/O by/O rash/B-AdverseReaction ,/O constitutional/O findings/O ,/O and/O sometimes/O organ/B-AdverseReaction dysfunction/I-AdverseReaction ,/O including/O liver/B-AdverseReaction injury/I-AdverseReaction ./O
The/O events/O were/O reported/O in/O less/O than/O 1/O %/O of/O subjects/O receiving/O TIVICAY/O in/O Phase/O 3/O clinical/O trials/O ./O
Discontinue/O TIVICAY/O and/O other/O suspect/O agents/O immediately/O if/O signs/O or/O symptoms/O of/O hypersensitivity/O reactions/O develop/O (/O including/O ,/O but/O not/O limited/O to/O ,/O severe/O rash/O or/O rash/O accompanied/O by/O fever/O ,/O general/O malaise/O ,/O fatigue/O ,/O muscle/O or/O joint/O aches/O ,/O blisters/O or/O peeling/O of/O the/O skin/O ,/O oral/O blisters/O or/O lesions/O ,/O conjunctivitis/O ,/O facial/O edema/O ,/O hepatitis/O ,/O eosinophilia/O ,/O angioedema/O ,/O difficulty/O breathing/O )/O ./O
Clinical/O status/O ,/O including/O liver/O aminotransferases/O ,/O should/O be/O monitored/O and/O appropriate/O therapy/O initiated/O ./O
Delay/O in/O stopping/O treatment/O with/O TIVICAY/O or/O other/O suspect/O agents/O after/O the/O onset/O of/O hypersensitivity/O may/O result/O in/O a/O life/O -/O threatening/O reaction/O ./O
TIVICAY/O is/O contraindicated/O in/O patients/O who/O have/O experienced/O a/O previous/O hypersensitivity/O reaction/O to/O dolutegravir/O ./O
5.2/O Effects/O on/O Serum/O Liver/O Biochemistries/O in/O Patients/O with/O Hepatitis/O B/O or/O C/O Co/O -/O infection/O Patients/O with/O underlying/O hepatitis/O B/O or/O C/O may/O be/O at/O increased/O risk/B-Factor for/O worsening/O or/O development/O of/O transaminase/B-AdverseReaction elevations/I-AdverseReaction with/O use/O of/O TIVICAY/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O some/O cases/O the/O elevations/B-AdverseReaction in/I-AdverseReaction transaminases/I-AdverseReaction were/O consistent/O with/O immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction or/O hepatitis/B-AdverseReaction B/I-AdverseReaction reactivation/I-AdverseReaction particularly/O in/O the/O setting/O where/O anti/O -/O hepatitis/O therapy/O was/O withdrawn/O ./O
Appropriate/O laboratory/O testing/O prior/O to/O initiating/O therapy/O and/O monitoring/O for/O hepatotoxicity/O during/O therapy/O with/O TIVICAY/O are/O recommended/O in/O patients/O with/O underlying/O hepatic/O disease/O such/O as/O hepatitis/O B/O or/O C./O 5.3/O Fat/O Redistribution/O Redistribution/O accumulation/B-AdverseReaction of/I-AdverseReaction body/I-AdverseReaction fat/I-AdverseReaction ,/O including/O central/B-AdverseReaction obesity/I-AdverseReaction ,/O dorsocervical/B-AdverseReaction fat/I-AdverseReaction enlargement/I-AdverseReaction (/O buffalo/B-AdverseReaction hump/I-AdverseReaction )/O ,/O peripheral/O wasting/O ,/O facial/B-AdverseReaction wasting/I-AdverseReaction ,/O breast/B-AdverseReaction enlargement/I-AdverseReaction ,/O and/O "/O cushingoid/B-AdverseReaction appearance/I-AdverseReaction "/O have/O been/O observed/O in/O patients/O receiving/O antiretroviral/B-DrugClass therapy/I-DrugClass ./O
The/O mechanism/O and/O long/O -/O term/O consequences/O of/O these/O events/O are/O currently/O unknown/O ./O
A/O causal/O relationship/O has/O not/O been/O established/O ./O
5.4/O Immune/O Reconstitution/O Syndrome/O Immune/B-AdverseReaction reconstitution/I-AdverseReaction syndrome/I-AdverseReaction has/O been/O reported/O in/O patients/O treated/O with/O combination/O antiretroviral/O therapy/O ,/O including/O TIVICAY/O ./O
During/O the/O initial/O phase/O of/O combination/O antiretroviral/O treatment/O ,/O patients/O whose/O immune/O systems/O respond/O may/B-Factor develop/O an/O inflammatory/B-AdverseReaction response/I-AdverseReaction to/O indolent/O or/O residual/B-AdverseReaction opportunistic/I-AdverseReaction infections/I-AdverseReaction (/O such/O as/O Mycobacterium/B-AdverseReaction avium/I-AdverseReaction infection/O ,/O cytomegalovirus/B-AdverseReaction ,/O Pneumocystis/B-AdverseReaction jirovecii/I-AdverseReaction pneumonia/O [/O PCP/B-AdverseReaction ]/O ,/O or/O tuberculosis/B-AdverseReaction )/O ,/O which/O may/O necessitate/O further/O evaluation/O and/O treatment/O ./O
Autoimmune/B-AdverseReaction disorders/I-AdverseReaction (/O such/O as/O Graves/B-AdverseReaction '/I-AdverseReaction disease/O ,/O polymyositis/B-AdverseReaction ,/O and/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O )/O have/O also/O been/O reported/O to/O occur/O in/O the/O setting/O of/O immune/O reconstitution/O ;/O however/O ,/O the/O time/O to/O onset/O is/O more/O variable/O and/O can/O occur/O many/O months/O after/O initiation/O of/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O The/O most/O frequently/O reported/O adverse/O events/O (/O 4/O %/O )/O for/O Toviaz/O were/O :/O dry/B-AdverseReaction mouth/I-AdverseReaction (/O placebo/O ,/O 7/O %/O ;/O Toviaz/O 4/O mg/O ,/O 19/O %/O ;/O Toviaz/O 8/O mg/O ,/O 35/O %/O )/O and/O constipation/B-AdverseReaction (/O placebo/O ,/O 2/O %/O ;/O Toviaz/O 4/O mg/O ,/O 4/O %/O ;/O Toviaz/O 8/O mg/O ,/O 6/O %/O )/O ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pfizer/O Inc/O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O The/O safety/O of/O Toviaz/O was/O evaluated/O in/O Phase/O 2/O and/O 3/O controlled/O trials/O in/O a/O total/O of/O 2859/O patients/O with/O overactive/O bladder/O ,/O of/O which/O 2288/O were/O treated/O with/O fesoterodine/O ./O
Of/O this/O total/O ,/O 782/O received/O Toviaz/O 4/O mg/O day/O ,/O and/O 785/O received/O Toviaz/O 8/O mg/O day/O in/O Phase/O 2/O or/O 3/O studies/O with/O treatment/O periods/O of/O 8/O or/O 12/O weeks/O ./O
Approximately/O 80/O %/O of/O these/O patients/O had/O 10/O weeks/O exposure/O to/O Toviaz/O in/O these/O trials/O ./O
A/O total/O of/O 1964/O patients/O participated/O in/O two/O 12-week/O ,/O Phase/O 3/O efficacy/O and/O safety/O studies/O and/O subsequent/O open/O -/O label/O extension/O studies/O ./O
In/O these/O two/O studies/O combined/O ,/O 554/O patients/O received/O Toviaz/O 4/O mg/O day/O and/O 566/O patients/O received/O Toviaz/O 8/O mg/O day/O ./O
In/O Phase/O 2/O and/O 3/O placebo/O -/O controlled/O trials/O combined/O ,/O the/O incidences/O of/O serious/O adverse/O events/O in/O patients/O receiving/O placebo/O ,/O Toviaz/O 4/O mg/O ,/O and/O Toviaz/O 8/O mg/O were/O 1.9/O %/O ,/O 3.5/O %/O ,/O and/O 2.9/O %/O ,/O respectively/O ./O
All/O serious/O adverse/O events/O were/O judged/O to/O be/O not/O related/O or/O unlikely/O to/O be/O related/O to/O study/O medication/O by/O the/O investigator/O ,/O except/O for/O four/O patients/O receiving/O Toviaz/O who/O reported/O one/O serious/O adverse/O event/O each/O :/O angina/B-AdverseReaction ,/O chest/B-AdverseReaction pain/I-AdverseReaction ,/O gastroenteritis/B-AdverseReaction ,/O and/O QT/B-AdverseReaction prolongation/I-AdverseReaction on/O ECG/O ./O
The/O most/O commonly/O reported/O adverse/O event/O in/O patients/O treated/O with/O Toviaz/O was/O dry/B-AdverseReaction mouth/I-AdverseReaction ./O
The/O incidence/O of/O dry/B-AdverseReaction mouth/I-AdverseReaction was/O higher/O in/O those/O taking/O 8/O mg/O day/O (/O 35/O %/O )/O and/O in/O those/O taking/O 4/O mg/O day/O (/O 19/O %/O )/O ,/O as/O compared/O to/O placebo/O (/O 7/O %/O )/O ./O
Dry/B-AdverseReaction mouth/I-AdverseReaction led/O to/O discontinuation/O in/O 0.4/O %/O ,/O 0.4/O %/O ,/O and/O 0.8/O %/O of/O patients/O receiving/O placebo/O ,/O Toviaz/O 4/O mg/O ,/O and/O Toviaz/O 8/O mg/O ,/O respectively/O ./O
For/O those/O patients/O who/O reported/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O most/O had/O their/O first/O occurrence/O of/O the/O event/O within/O the/O first/O month/O of/O treatment/O ./O
The/O second/O most/O commonly/O reported/O adverse/O event/O was/O constipation/B-AdverseReaction ./O
The/O incidence/O of/O constipation/B-AdverseReaction was/O 2/O %/O in/O those/O taking/O placebo/O ,/O 4/O %/O in/O those/O taking/O 4/O mg/O day/O ,/O and/O 6/O %/O in/O those/O taking/O 8/O mg/O day/O ./O
Table/O 1/O lists/O adverse/O events/O ,/O regardless/O of/O causality/O ,/O that/O were/O reported/O in/O the/O combined/O Phase/O 3/O ,/O randomized/O ,/O placebo/O -/O controlled/O trials/O at/O an/O incidence/O greater/O than/O placebo/O and/O in/O 1/O %/O or/O more/O of/O patients/O treated/O with/O Toviaz/O 4/O or/O 8/O mg/O once/O daily/O for/O up/O to/O 12/O weeks/O ./O
Table/O 1/O :/O Adverse/O events/O with/O an/O incidence/O exceeding/O the/O placebo/O rate/O and/O reported/O by/O 1/O %/O of/O patients/O from/O double/O -/O blind/O ,/O placebo/O -/O controlled/O Phase/O 3/O trials/O of/O 12/O weeks/O treatment/O duration/O System/O organ/O class/O Preferred/O term/O Placebo/O N=554/O %/O Toviaz/O 4/O mg/O day/O N=554/O %/O Toviaz/O 8/O mg/O day/O N=566/O %/O ALT/O alanine/O aminotransferase/O ;/O GGT/O gamma/O glutamyltransferase/O Gastrointestinal/O disorders/O Dry/B-AdverseReaction mouth/I-AdverseReaction 7.0/O 18.8/O 34.6/O Constipation/B-AdverseReaction 2.0/O 4.2/O 6.0/O Dyspepsia/B-AdverseReaction 0.5/O 1.6/O 2.3/O Nausea/B-AdverseReaction 1.3/O 0.7/O 1.9/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction 0.5/O 1.1/O 0.5/O Infections/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 3.1/O 3.2/O 4.2/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 2.2/O 2.5/O 1.8/O Eye/O disorders/O Dry/B-AdverseReaction eyes/I-AdverseReaction 0/O 1.4/O 3.7/O Renal/O and/O urinary/O disorders/O Dysuria/B-AdverseReaction 0.7/O 1.3/O 1.6/O Urinary/B-AdverseReaction retention/I-AdverseReaction 0.2/O 1.1/O 1.4/O Respiratory/O disorders/O Cough/B-AdverseReaction 0.5/O 1.6/O 0.9/O Dry/B-AdverseReaction throat/I-AdverseReaction 0.4/O 0.9/O 2.3/O General/O disorders/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 0.7/O 0.7/O 1.2/O Musculoskeletal/O disorders/O Back/B-AdverseReaction pain/I-AdverseReaction 0.4/O 2.0/O 0.9/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 0.5/O 1.3/O 0.4/O Investigations/O ALT/B-AdverseReaction increased/I-AdverseReaction 0.9/O 0.5/O 1.2/O GGT/B-AdverseReaction increased/I-AdverseReaction 0.4/O 0.4/O 1.2/O Skin/O disorders/O Rash/B-AdverseReaction 0.5/O 0.7/O 1.1/O Patients/O also/O received/O Toviaz/O for/O up/O to/O three/O years/O in/O open/O -/O label/O extension/O phases/O of/O one/O Phase/O 2/O and/O two/O Phase/O 3/O controlled/O trials/O ./O
In/O all/O open/O -/O label/O trials/O combined/O ,/O 857/O ,/O 701/O ,/O 529/O ,/O and/O 105/O patients/O received/O Toviaz/O for/O at/O least/O 6/O months/O ,/O 1/O year/O ,/O 2/O years/O ,/O and/O 3/O years/O ,/O respectively/O ./O
The/O adverse/O events/O observed/O during/O long/O -/O term/O ,/O open/O -/O label/O studies/O were/O similar/O to/O those/O observed/O in/O the/O 12-week/O ,/O placebo/O -/O controlled/O studies/O ,/O and/O included/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O dry/B-AdverseReaction eyes/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O and/O abdominal/B-AdverseReaction pain/I-AdverseReaction ./O
Similar/O to/O the/O controlled/O studies/O ,/O most/O adverse/O events/O of/O dry/B-AdverseReaction mouth/I-AdverseReaction and/O constipation/B-AdverseReaction were/O mild/B-Severity to/I-Severity moderate/B-Severity in/O intensity/O ./O
Serious/O adverse/O events/O ,/O judged/O to/O be/O at/O least/O possibly/O related/O to/O study/O medication/O by/O the/O investigator/O and/O reported/O more/O than/O once/O during/O the/O open/O -/O label/O treatment/O period/O of/O up/O to/O 3/O years/O ,/O included/O urinary/B-AdverseReaction retention/I-AdverseReaction (/O 3/O cases/O )/O ,/O diverticulitis/B-AdverseReaction (/O 3/O cases/O )/O ,/O constipation/B-AdverseReaction (/O 2/O cases/O )/O ,/O irritable/B-AdverseReaction bowel/I-AdverseReaction syndrome/I-AdverseReaction (/O 2/O cases/O )/O ,/O and/O electrocardiogram/O QT/B-AdverseReaction corrected/I-AdverseReaction interval/I-AdverseReaction prolongation/I-AdverseReaction (/O 2/O cases/O )/O ./O
6.2/O Post/O -/O marketing/O Experience/O The/O following/O events/O have/O been/O reported/O in/O association/O with/O fesoterodine/O use/O in/O worldwide/O post/O -/O marketing/O experience/O :/O Eye/O disorders/O :/O Blurred/B-AdverseReaction vision/I-AdverseReaction ;/O Cardiac/O disorders/O :/O Palpitations/B-AdverseReaction ;/O General/O disorders/O and/O administrative/O site/O conditions/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O angioedema/B-AdverseReaction with/O airway/B-AdverseReaction obstruction/I-AdverseReaction ,/O face/B-AdverseReaction edema/I-AdverseReaction ;/O Central/O nervous/O system/O disorders/O :/O Dizziness/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O somnolence/B-AdverseReaction ;/O Skin/O and/O subcutaneous/O tissue/O disorders/O :/O Urticaria/B-AdverseReaction ,/O pruritus/B-AdverseReaction Because/O these/O spontaneously/O reported/O events/O are/O from/O the/O worldwide/O post/O -/O marketing/O experience/O ,/O the/O frequency/O of/O events/O and/O the/O role/O of/O fesoterodine/O in/O their/O causation/O can/O not/O be/O reliably/O determined/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Angioedema/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction face/I-AdverseReaction ,/O lips/O ,/O tongue/O ,/O and/or/O larynx/O has/O been/O reported/O with/O fesoterodine/O ./O
(/O 5.1/O )/O ./O
Toviaz/O should/O be/O administered/O with/O caution/O to/O patients/O with/O clinically/O significant/O bladder/O outlet/O obstruction/O because/O of/O the/O risk/O of/O urinary/O retention/O ./O
(/O 5.2/O )/O Toviaz/O ,/O like/O other/O antimuscarinic/O drugs/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O decreased/O gastrointestinal/O motility/O ,/O such/O as/O those/O with/O severe/O constipation/O ./O
(/O 5.3/O )/O Toviaz/O should/O be/O used/O with/O caution/O in/O patients/O being/O treated/O for/O narrow/O -/O angle/O glaucoma/O ,/O and/O only/O where/O the/O potential/O benefits/O outweigh/O the/O risks/O (/O 5.4/O )/O Central/B-AdverseReaction Nervous/I-AdverseReaction System/I-AdverseReaction Effects/I-AdverseReaction :/O Somnolence/B-AdverseReaction has/O been/O reported/O with/O Toviaz/O ./O
Advise/O patients/O not/O to/O drive/O or/O operate/O heavy/O machinery/O until/O they/O know/O how/O Toviaz/O affects/O them/O (/O 5.5/O )/O Toviaz/O should/O be/O used/O with/O caution/O in/O patients/O with/O myasthenia/O gravis/O ,/O a/O disease/O characterized/O by/O decreased/O cholinergic/O activity/O at/O the/O neuromuscular/O junction/O ./O
(/O 5.9/O )/O 5.1/O Angioedema/O Angioedema/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction face/I-AdverseReaction ,/O lips/O ,/O tongue/O ,/O and/or/O larynx/O has/O been/O reported/O with/O fesoterodine/O ./O
In/O some/O cases/O angioedema/O occurred/O after/O the/O first/O dose/O ./O
Angioedema/B-AdverseReaction associated/O with/O upper/B-AdverseReaction airway/I-AdverseReaction swelling/I-AdverseReaction may/B-Factor be/O life/B-Severity -/O threatening/O ./O
If/O involvement/O of/O the/O tongue/O ,/O hypopharynx/O ,/O or/O larynx/O occurs/O ,/O fesoterodine/O should/O be/O promptly/O discontinued/O and/O appropriate/O therapy/O and/or/O measures/O to/O ensure/O a/O patent/O airway/O should/O be/O promptly/O provided/O ./O
5.2/O Bladder/O Outlet/O Obstruction/O Toviaz/O should/O be/O administered/O with/O caution/O to/O patients/O with/O clinically/O significant/O bladder/O outlet/O obstruction/O because/O of/O the/O risk/O of/O urinary/O retention/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.3/O Decreased/O Gastrointestinal/O Motility/O Toviaz/O ,/O like/O other/O antimuscarinic/O drugs/O ,/O should/O be/O used/O with/O caution/O in/O patients/O with/O decreased/O gastrointestinal/O motility/O ,/O such/O as/O those/O with/O severe/O constipation/O ./O
5.4/O Controlled/O Narrow/O -/O Angle/O Glaucoma/O Toviaz/O should/O be/O used/O with/O caution/O in/O patients/O being/O treated/O for/O narrow/O -/O angle/O glaucoma/O ,/O and/O only/O where/O the/O potential/O benefits/O outweigh/O the/O risks/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.5/O Central/O Nervous/O System/O Effects/O Toviaz/O is/O associated/O with/O anticholinergic/O central/O nervous/O sytem/O (/O CNS/O )/O effects/O [/O see/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
A/O variety/O of/O CNS/B-AdverseReaction anticholinergic/I-AdverseReaction effects/I-AdverseReaction have/O been/O reported/O ,/O including/O headache/B-AdverseReaction ,/O dizziness/B-AdverseReaction ,/O and/O somnolence/B-AdverseReaction ./O
Patients/O should/O be/O monitored/O for/O signs/O of/O anticholinergic/O CNS/O effects/O ,/O particularly/O after/O beginning/O treatment/O or/O increasing/O the/O dose/O ./O
Advise/O patients/O not/O to/O drive/O or/O operate/O heavy/O machinery/O until/O they/O know/O how/O Toviaz/O affects/O them/O ./O
If/O a/O patient/O experiences/O anticholinergic/O CNS/O effects/O ,/O dose/O reduction/O or/O drug/O discontinuation/O should/O be/O considered/O ./O
5.6/O Hepatic/O Impairment/O Toviaz/O has/O not/O been/O studied/O in/O patients/O with/O severe/O hepatic/O impairment/O and/O therefore/O is/O not/O recommended/O for/O use/O in/O this/O patient/O population/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O and/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.7/O Renal/O Impairment/O Doses/O of/O Toviaz/O greater/O than/O 4/O mg/O are/O not/O recommended/O in/O patients/O with/O severe/O renal/O impairment/O [/O see/O Use/O In/O Specific/O Populations/O (/O 8.6/O )/O and/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.8/O Concomitant/O Administration/O with/O CYP3A4/O Inhibitors/O Doses/O of/O Toviaz/O greater/O than/O 4/O mg/O are/O not/O recommended/O in/O patients/O taking/O a/O potent/O CYP3A4/O inhibitor/O (/O e.g./O ,/O ketoconazole/O ,/O itraconazole/O ,/O clarithromycin/O )/O ./O
No/O dosing/O adjustments/O are/O recommended/O in/O the/O presence/O of/O moderate/O CYP3A4/O inhibitors/O (/O e.g./O ,/O erythromycin/O ,/O fluconazole/O ,/O diltiazem/O ,/O verapamil/O and/O grapefruit/O juice/O )/O ./O
While/O the/O effect/O of/O weak/O CYP3A4/O inhibitors/O (/O e.g./O cimetidine/O )/O was/O not/O examined/O by/O clinical/O study/O ,/O some/O pharmacokinetic/O interaction/O is/O expected/O ,/O albeit/O less/O than/O that/O observed/O with/O moderate/O CYP3A4/O inhibitors/O [/O see/O Drug/O Interactions/O (/O 7.2/O )/O and/O Dosage/O and/O Administration/O (/O 2/O )/O ]/O ./O
5.9/O Myasthenia/O Gravis/O Toviaz/O should/O be/O used/O with/O caution/O in/O patients/O with/O myasthenia/O gravis/O ,/O a/O disease/O characterized/O by/O decreased/O cholinergic/O activity/O at/O the/O neuromuscular/O junction/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O have/O been/O associated/O with/O TREANDA/O in/O clinical/O trials/O and/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O label/O ./O
Myelosuppression/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Infections/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Anaphylaxis/B-AdverseReaction and/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Skin/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Other/O Malignancies/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Extravasation/B-AdverseReaction injury/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O Most/O common/O non/O -/O hematologic/O adverse/O reactions/O for/O CLL/O (/O frequency/O 15/O %/O )/O are/O pyrexia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction ./O
(/O 6.1/O )/O Most/O common/O non/O -/O hematologic/O adverse/O reactions/O for/O NHL/O (/O frequency/O 15/O %/O )/O are/O nausea/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O anorexia/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O weight/B-AdverseReaction decreased/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O stomatitis/B-AdverseReaction ./O
(/O 6.1/O )/O Most/O common/O hematologic/B-AdverseReaction abnormalities/I-AdverseReaction for/O both/O indications/O (/O frequency/O 15/O %/O )/O are/O lymphopenia/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O leukopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ,/O and/O neutropenia/B-AdverseReaction ./O
(/O 6.1/O )/O EXCERPT/O :/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Teva/O Pharmaceuticals/O at/O 1/O -/O 800/O -/O 896/O -/O 5855/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Chronic/O Lymphocytic/O Leukemia/O The/O data/O described/O below/O reflect/O exposure/O to/O TREANDA/O in/O 153/O patients/O with/O CLL/O studied/O in/O an/O active/O -/O controlled/O ,/O randomized/O trial/O ./O
The/O population/O was/O 45/O -/O 77/O years/O of/O age/O ,/O 63/O %/O male/O ,/O 100/O %/O white/O ,/O and/O were/O treatment/O naive/O ./O
All/O patients/O started/O the/O study/O at/O a/O dose/O of/O 100/O mg/O m/O 2/O intravenously/O over/O 30/O minutes/O on/O Days/O 1/O and/O 2/O every/O 28/O days/O ./O
Adverse/O reactions/O were/O reported/O according/O to/O NCI/O CTC/O v.2.0/O ./O
Non/O -/O hematologic/O adverse/O reactions/O (/O any/O grade/O )/O in/O the/O TREANDA/O group/O that/O occurred/O with/O a/O frequency/O greater/O than/O 15/O %/O were/O pyrexia/B-AdverseReaction (/O 24/O %/O )/O ,/O nausea/B-AdverseReaction (/O 20/O %/O )/O ,/O and/O vomiting/B-AdverseReaction (/O 16/O %/O )/O ./O
Other/O adverse/O reactions/O seen/O frequently/O in/O one/O or/O more/O studies/O included/O asthenia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O malaise/B-AdverseReaction ,/O and/O weakness/B-AdverseReaction ;/O dry/B-AdverseReaction mouth/I-AdverseReaction ;/O somnolence/B-AdverseReaction ;/O cough/B-AdverseReaction ;/O constipation/B-AdverseReaction ;/O headache/B-AdverseReaction ;/O mucosal/B-AdverseReaction inflammation/I-AdverseReaction and/O stomatitis/B-AdverseReaction ./O
Worsening/B-AdverseReaction hypertension/I-AdverseReaction was/O reported/O in/O 4/O patients/O treated/O with/O TREANDA/O in/O the/O CLL/O trial/O and/O in/O none/O treated/O with/O chlorambucil/O ./O
Three/O of/O these/O 4/O adverse/O reactions/O were/O described/O as/O a/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction and/O were/O managed/O with/O oral/O medications/O and/O resolved/O ./O
The/O most/O frequent/O adverse/O reactions/O leading/O to/O study/O withdrawal/O for/O patients/O receiving/O TREANDA/O were/O hypersensitivity/B-AdverseReaction (/O 2/O %/O )/O and/O pyrexia/B-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 1/O contains/O the/O treatment/O emergent/O adverse/O reactions/O ,/O regardless/O of/O attribution/O ,/O that/O were/O reported/O in/O 5/O %/O of/O patients/O in/O either/O treatment/O group/O in/O the/O randomized/O CLL/O clinical/O study/O ./O
Table/O 1/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O Occurring/O in/O Randomized/O CLL/O Clinical/O Study/O in/O at/O Least/O 5/O %/O of/O Patients/O Number/O (/O %/O )/O of/O patients/O TREANDA(N=153/O )/O Chlorambucil(N=143/O )/O System/O organ/O class/O Preferred/O term/O All/O Grades/O Grade/O 3/4/O All/O Grades/O Grade/O 3/4/O Total/O number/O of/O patients/O with/O at/O least/O 1/O adverse/O reaction/O 121/O (/O 79/O )/O 52/O (/O 34/O )/O 96/O (/O 67/O )/O 25/O (/O 17/O )/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 31/O (/O 20/O )/O 1/O (/O 1/O )/O 21/O (/O 15/O )/O 1/O (/O 1/O )/O Vomiting/B-AdverseReaction 24/O (/O 16/O )/O 1/O (/O 1/O )/O 9/O (/O 6/O )/O 0/O Diarrhea/B-AdverseReaction 14/O (/O 9/O )/O 2/O (/O 1/O )/O 5/O (/O 3/O )/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Pyrexia/B-AdverseReaction 36/O (/O 24/O )/O 6/O (/O 4/O )/O 8/O (/O 6/O )/O 2/O (/O 1/O )/O Fatigue/B-AdverseReaction 14/O (/O 9/O )/O 2/O (/O 1/O )/O 8/O (/O 6/O )/O 0/O Asthenia/B-AdverseReaction 13/O (/O 8)/O 0/O 6/O (/O 4/O )/O 0/O Chills/B-AdverseReaction 9/O (/O 6/O )/O 0/O 1/O (/O 1/O )/O 0/O Immune/O system/O disorders/O Hypersensitivity/B-AdverseReaction 7/O (/O 5/O )/O 2/O (/O 1/O )/O 3/O (/O 2/O )/O 0/O Infections/O and/O infestations/O Nasopharyngitis/B-AdverseReaction 10/O (/O 7/O )/O 0/O 12/O (/O 8)/O 0/O Infection/B-AdverseReaction 9/O (/O 6/O )/O 3/O (/O 2/O )/O 1/O (/O 1/O )/O 1/O (/O 1/O )/O Herpes/B-AdverseReaction simplex/I-AdverseReaction 5/O (/O 3/O )/O 0/O 7/O (/O 5/O )/O 0/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 11/O (/O 7/O )/O 0/O 5/O (/O 3/O )/O 0/O Metabolism/O and/O nutrition/O disorders/O Hyperuricemia/B-AdverseReaction 11/O (/O 7/O )/O 3/O (/O 2/O )/O 2/O (/O 1/O )/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 6/O (/O 4/O )/O 1/O (/O 1/O )/O 7/O (/O 5/O )/O 1/O (/O 1/O )/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 12/O (/O 8)/O 4/O (/O 3/O )/O 7/O (/O 5/O )/O 3/O (/O 2/O )/O Pruritus/B-AdverseReaction 8/O (/O 5/O )/O 0/O 2/O (/O 1/O )/O 0/O The/O Grade/O 3/O and/O 4/O hematology/O laboratory/O test/O values/O by/O treatment/O group/O in/O the/O randomized/O CLL/O clinical/O study/O are/O described/O in/O Table/O 2/O ./O
These/O findings/O confirm/O the/O myelosuppressive/B-AdverseReaction effects/I-AdverseReaction seen/O in/O patients/O treated/O with/O TREANDA/O ./O
Red/O blood/O cell/O transfusions/O were/O administered/O to/O 20/O %/O of/O patients/O receiving/O TREANDA/O compared/O with/O 6/O %/O of/O patients/O receiving/O chlorambucil/O ./O
Table/O 2/O :/O Incidence/O of/O Hematology/O Laboratory/O Abnormalities/O in/O Patients/O Who/O Received/O TREANDA/O or/O Chlorambucil/O in/O the/O Randomized/O CLL/O Clinical/O Study/O TREANDA/O N=150/O ChlorambucilN=141/O Laboratory/O Abnormality/O All/O Gradesn/O (/O %/O )/O Grade/O 3/4n/O (/O %/O )/O All/O Gradesn/O (/O %/O )/O Grade/O 3/4n/O (/O %/O )/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 134/O (/O 89/O )/O 20/O (/O 13/O )/O 115/O (/O 82/O )/O 12/O (/O 9/O )/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 116/O (/O 77/O )/O 16/O (/O 11/O )/O 110/O (/O 78/O )/O 14/O (/O 10/O )/O Leukocytes/B-AdverseReaction Decreased/I-AdverseReaction 92/O (/O 61/O )/O 42/O (/O 28/O )/O 26/O (/O 18/O )/O 4/O (/O 3/O )/O Lymphocytes/B-AdverseReaction Decreased/I-AdverseReaction 102/O (/O 68/O )/O 70/O (/O 47/O )/O 27/O (/O 19/O )/O 6/O (/O 4/O )/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 113/O (/O 75/O )/O 65/O (/O 43/O )/O 86/O (/O 61/O )/O 30/O (/O 21/O )/O In/O the/O CLL/O trial/O ,/O 34/O %/O of/O patients/O had/O bilirubin/B-AdverseReaction elevations/I-AdverseReaction ,/O some/O without/B-Negation associated/O significant/B-Severity elevations/B-AdverseReaction in/I-AdverseReaction AST/I-AdverseReaction and/O ALT/O ./O
Grade/B-Severity 3/I-Severity or/O 4/O increased/B-AdverseReaction bilirubin/I-AdverseReaction occurred/O in/O 3/O %/O of/O patients/O ./O
Increases/B-AdverseReaction in/I-AdverseReaction AST/I-AdverseReaction and/O ALT/O of/O Grade/B-Severity 3/I-Severity or/O 4/O were/O limited/O to/O 1/O %/O and/O 3/O %/O of/O patients/O ,/O respectively/O ./O
Patients/O treated/O with/O TREANDA/O may/B-Factor also/O have/O changes/O in/O their/O creatinine/O levels/O ./O
If/O abnormalities/O are/O detected/O ,/O monitoring/O of/O these/O parameters/O should/O be/O continued/O to/O ensure/O that/O further/O deterioration/O does/O not/O occur/O ./O
Non/O -/O Hodgkin/O Lymphoma/O The/O data/O described/O below/O reflect/O exposure/O to/O TREANDA/O in/O 176/O patients/O with/O indolent/O B/O -/O cell/O NHL/O treated/O in/O two/O single/O -/O arm/O studies/O ./O
The/O population/O was/O 31/O -/O 84/O years/O of/O age/O ,/O 60/O %/O male/O ,/O and/O 40/O %/O female/O ./O
The/O race/O distribution/O was/O 89/O %/O White/O ,/O 7/O %/O Black/O ,/O 3/O %/O Hispanic/O ,/O 1/O %/O other/O ,/O and/O 1/O %/O Asian/O ./O
These/O patients/O received/O TREANDA/O at/O a/O dose/O of/O 120/O mg/O m/O 2/O intravenously/O on/O Days/O 1/O and/O 2/O for/O up/O to/O eight/O 21-day/O cycles/O ./O
The/O adverse/O reactions/O occurring/O in/O at/O least/O 5/O %/O of/O the/O NHL/O patients/O ,/O regardless/O of/O severity/O ,/O are/O shown/O in/O Table/O 3/O ./O
The/O most/O common/O non/O -/O hematologic/O adverse/O reactions/O (/O 30/O %/O )/O were/O nausea/B-AdverseReaction (/O 75/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 57/O %/O )/O ,/O vomiting/B-AdverseReaction (/O 40/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 37/O %/O )/O and/O pyrexia/B-AdverseReaction (/O 34/O %/O )/O ./O
The/O most/O common/O non/O -/O hematologic/O Grade/O 3/O or/O 4/O adverse/O reactions/O (/O 5/O %/O )/O were/O fatigue/B-AdverseReaction (/O 11/O %/O )/O ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction (/O 6/O %/O )/O ,/O and/O pneumonia/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction and/O dehydration/B-AdverseReaction ,/O each/O reported/O in/O 5/O %/O of/O patients/O ./O
Table/O 3/O :/O Non/O -/O Hematologic/O Adverse/O Reactions/O Occurring/O in/O at/O Least/O 5/O %/O of/O NHL/O Patients/O Treated/O with/O TREANDA/O by/O System/O Organ/O Class/O and/O Preferred/O Term/O (/O N=176/O )/O System/O organ/O class/O Number/O (/O %/O )/O of/O patients/O Preferred/O term/O All/O Grades/O Grade/O 3/4/O Total/O number/O of/O patients/O with/O at/O least/O 1/O adverse/O reaction/O 176/O (/O 100/O )/O 94/O (/O 53/O )/O Cardiac/O disorders/O Tachycardia/B-AdverseReaction 13/O (/O 7/O )/O 0/O Gastrointestinal/O disorders/O Nausea/B-AdverseReaction 132/O (/O 75/O )/O 7/O (/O 4/O )/O Vomiting/B-AdverseReaction 71/O (/O 40/O )/O 5/O (/O 3/O )/O Diarrhea/B-AdverseReaction 65/O (/O 37/O )/O 6/O (/O 3/O )/O Constipation/B-AdverseReaction 51/O (/O 29/O )/O 1/O (/O 1/O )/O Stomatitis/B-AdverseReaction 27/O (/O 15/O )/O 1/O (/O 1/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 22/O (/O 13/O )/O 2/O (/O 1/O )/O Dyspepsia/B-AdverseReaction 20/O (/O 11/O )/O 0/O Gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction 18/O (/O 10/O )/O 0/O Dry/B-AdverseReaction mouth/I-AdverseReaction 15/O (/O 9/O )/O 1/O (/O 1/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction 8/O (/O 5/O )/O 0/O Abdominal/B-AdverseReaction distension/I-AdverseReaction 8/O (/O 5/O )/O 0/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction 101/O (/O 57/O )/O 19/O (/O 11/O )/O Pyrexia/B-AdverseReaction 59/O (/O 34/O )/O 3/O (/O 2/O )/O Chills/B-AdverseReaction 24/O (/O 14/O )/O 0/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 23/O (/O 13/O )/O 1/O (/O 1/O )/O Asthenia/B-AdverseReaction 19/O (/O 11/O )/O 4/O (/O 2/O )/O Chest/B-AdverseReaction pain/I-AdverseReaction 11/O (/O 6/O )/O 1/O (/O 1/O )/O Infusion/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 11/O (/O 6/O )/O 0/O Pain/B-AdverseReaction 10/O (/O 6/O )/O 0/O Catheter/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 8/O (/O 5/O )/O 0/O Infections/O and/O infestations/O Herpes/B-AdverseReaction zoster/I-AdverseReaction 18/O (/O 10/O )/O 5/O (/O 3/O )/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 18/O (/O 10/O )/O 0/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 17/O (/O 10/O )/O 4/O (/O 2/O )/O Sinusitis/B-AdverseReaction 15/O (/O 9/O )/O 0/O Pneumonia/B-AdverseReaction 14/O (/O 8)/O 9/O (/O 5/O )/O Febrile/B-AdverseReaction neutropenia/I-AdverseReaction 11/O (/O 6/O )/O 11/O (/O 6/O )/O Oral/B-AdverseReaction candidiasis/I-AdverseReaction 11/O (/O 6/O )/O 2/O (/O 1/O )/O Nasopharyngitis/B-AdverseReaction 11/O (/O 6/O )/O 0/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 31/O (/O 18/O )/O 3/O (/O 2/O )/O Metabolism/O and/O nutrition/O disorders/O Anorexia/B-AdverseReaction 40/O (/O 23/O )/O 3/O (/O 2/O )/O Dehydration/B-AdverseReaction 24/O (/O 14/O )/O 8/O (/O 5/O )/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 22/O (/O 13/O )/O 1/O (/O 1/O )/O Hypokalemia/B-AdverseReaction 15/O (/O 9/O )/O 9/O (/O 5/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Back/B-AdverseReaction pain/I-AdverseReaction 25/O (/O 14/O )/O 5/O (/O 3/O )/O Arthralgia/B-AdverseReaction 11/O (/O 6/O )/O 0/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 8/O (/O 5/O )/O 2/O (/O 1/O )/O Bone/B-AdverseReaction pain/I-AdverseReaction 8/O (/O 5/O )/O 0/O Nervous/O system/O disorders/O Headache/B-AdverseReaction 36/O (/O 21/O )/O 0/O Dizziness/B-AdverseReaction 25/O (/O 14/O )/O 0/O Dysgeusia/B-AdverseReaction 13/O (/O 7/O )/O 0/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 23/O (/O 13/O )/O 0/O Anxiety/B-AdverseReaction 14/O (/O 8)/O 1/O (/O 1/O )/O Depression/B-AdverseReaction 10/O (/O 6/O )/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 38/O (/O 22/O )/O 1/O (/O 1/O )/O Dyspnea/B-AdverseReaction 28/O (/O 16/O )/O 3/O (/O 2/O )/O Pharyngolaryngeal/B-AdverseReaction pain/I-AdverseReaction 14/O (/O 8)/O 1/O (/O 1/O )/O Wheezing/B-AdverseReaction 8/O (/O 5/O )/O 0/O Nasal/B-AdverseReaction congestion/I-AdverseReaction 8/O (/O 5/O )/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 28/O (/O 16/O )/O 1/O (/O 1/O )/O Pruritus/B-AdverseReaction 11/O (/O 6/O )/O 0/O Dry/B-AdverseReaction skin/I-AdverseReaction 9/O (/O 5/O )/O 0/O Night/B-AdverseReaction sweats/I-AdverseReaction 9/O (/O 5/O )/O 0/O Hyperhidrosis/B-AdverseReaction 8/O (/O 5/O )/O 0/O Vascular/O disorders/O Hypotension/B-AdverseReaction 10/O (/O 6/O )/O 2/O (/O 1/O )/O Patients/O may/O have/O reported/O more/O than/O 1/O adverse/O reaction/O ./O
NOTE/O :/O Patients/O counted/O only/O once/O in/O each/O preferred/O term/O category/O and/O once/O in/O each/O system/O organ/O class/O category/O ./O
Hematologic/B-AdverseReaction toxicities/I-AdverseReaction ,/O based/O on/O laboratory/O values/O and/O CTC/O grade/O ,/O in/O NHL/O patients/O treated/O in/O both/O single/O arm/O studies/O combined/O are/O described/O in/O Table/O 4/O ./O
Clinically/O important/O chemistry/O laboratory/O values/O that/O were/O new/O or/O worsened/O from/O baseline/O and/O occurred/O in/O 1/O %/O of/O patients/O at/O Grade/O 3/O or/O 4/O ,/O in/O NHL/O patients/O treated/O in/O both/O single/O arm/O studies/O combined/O were/O hyperglycemia/B-AdverseReaction (/O 3/O %/O )/O ,/O elevated/B-AdverseReaction creatinine/I-AdverseReaction (/O 2/O %/O )/O ,/O hyponatremia/B-AdverseReaction (/O 2/O %/O )/O ,/O and/O hypocalcemia/B-AdverseReaction (/O 2/O %/O )/O ./O
Table/O 4/O :/O Incidence/O of/O Hematology/O Laboratory/O Abnormalities/O in/O Patients/O Who/O Received/O TREANDA/O in/O the/O NHL/O Studies/O Percent/O of/O patients/O Hematology/O variable/O All/O Grades/O Grades/O 3/4/O Lymphocytes/B-AdverseReaction Decreased/I-AdverseReaction 99/O 94/O Leukocytes/B-AdverseReaction Decreased/I-AdverseReaction 94/O 56/O Hemoglobin/B-AdverseReaction Decreased/I-AdverseReaction 88/O 11/O Neutrophils/B-AdverseReaction Decreased/I-AdverseReaction 86/O 60/O Platelets/B-AdverseReaction Decreased/I-AdverseReaction 86/O 25/O In/O both/O studies/O ,/O serious/O adverse/O reactions/O ,/O regardless/O of/O causality/O ,/O were/O reported/O in/O 37/O %/O of/O patients/O receiving/O TREANDA/O ./O
The/O most/O common/O serious/O adverse/O reactions/O occurring/O in/O 5/O %/O of/O patients/O were/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction and/O pneumonia/B-AdverseReaction ./O
Other/O important/O serious/O adverse/O reactions/O reported/O in/O clinical/O trials/O and/or/O postmarketing/O experience/O were/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ,/O hypersensitivity/B-AdverseReaction ,/O skin/B-AdverseReaction reactions/I-AdverseReaction ,/O pulmonary/B-AdverseReaction fibrosis/I-AdverseReaction ,/O and/O myelodysplastic/B-AdverseReaction syndrome/I-AdverseReaction ./O
Serious/O drug/O -/O related/O adverse/O reactions/O reported/O in/O clinical/O trials/O included/O myelosuppression/B-AdverseReaction ,/O infection/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction and/O infusion/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5/O )/O ]/O ./O
Adverse/O reactions/O occurring/O less/O frequently/O but/O possibly/B-Factor related/O to/O TREANDA/O treatment/O were/O hemolysis/B-AdverseReaction ,/O dysgeusia/B-AdverseReaction taste/B-AdverseReaction disorder/I-AdverseReaction ,/O atypical/B-AdverseReaction pneumonia/I-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction ,/O erythema/B-AdverseReaction ,/O dermatitis/B-AdverseReaction ,/O and/O skin/B-AdverseReaction necrosis/I-AdverseReaction ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O TREANDA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O :/O anaphylaxis/B-AdverseReaction ;/O and/O injection/O or/O infusion/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction including/O phlebitis/O ,/O pruritus/O ,/O irritation/O ,/O pain/O ,/O and/O swelling/O ;/O pneumocystis/B-AdverseReaction jiroveci/I-AdverseReaction pneumonia/I-AdverseReaction and/O pneumonitis/B-AdverseReaction ./O
Skin/B-AdverseReaction reactions/I-AdverseReaction including/O SJS/B-AdverseReaction and/O TEN/B-AdverseReaction have/O occurred/O when/O TREANDA/O was/O administered/O concomitantly/O with/O allopurinol/O and/O other/O medications/O known/O to/O cause/O these/O syndromes/O ./O
[/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Myelosuppression/B-AdverseReaction :/O Delay/O or/O reduce/O dose/O ./O
Restart/O treatment/O based/O on/O ANC/O and/O platelet/O count/O recovery/O ./O
(/O 2.2/O )/O Complications/O of/O myelosuppression/B-AdverseReaction may/B-Factor lead/O to/O death/B-AdverseReaction ./O
(/O 5.1/O )/O Infections/B-AdverseReaction :/O Monitor/O for/O fever/O and/O other/O signs/O of/O infection/O and/O treat/O promptly/O ./O
(/O 5.2/O )/O Anaphylaxis/B-AdverseReaction and/O Infusion/B-AdverseReaction Reactions/I-AdverseReaction :/O Severe/O and/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O ;/O monitor/O clinically/O and/O discontinue/O TREANDA/O ./O
Pre/O -/O medicate/O in/O subsequent/O cycles/O for/O milder/O reactions/O ./O
(/O 5.3/O )/O Tumor/B-AdverseReaction Lysis/I-AdverseReaction Syndrome/I-AdverseReaction :/O Acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O death/B-AdverseReaction ;/O anticipate/O and/O use/O supportive/O measures/O ./O
(/O 5.4/O )/O Skin/B-AdverseReaction Reactions/I-AdverseReaction :/O Discontinue/O for/O severe/O skin/O reactions/O ./O
Cases/O of/O SJS/B-AdverseReaction and/O TEN/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O when/O TREANDA/O was/O administered/O concomitantly/O with/O allopurinol/O and/O other/O medications/O known/O to/O cause/O these/O syndromes/O ./O
(/O 5.5/O )/O Other/O Malignancies/B-AdverseReaction :/O Pre/O -/O malignant/O and/O malignant/B-AdverseReaction diseases/I-AdverseReaction have/O been/O reported/O ./O
(/O 5.6/O )/O Extravasation/B-AdverseReaction :/O Assure/O good/O venous/O access/O and/O monitor/O infusion/O site/O during/O and/O after/O administration/O ./O
(/O 5.7/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O :/O Fetal/B-AdverseReaction harm/I-AdverseReaction can/B-Factor occur/O when/O administered/O to/O a/O pregnant/O woman/O ./O
Women/O should/O be/O advised/O to/O avoid/O becoming/O pregnant/O when/O receiving/O TREANDA/O ./O
(/O 5.8/O ,/O 8.1/O )/O 5.1/O Myelosuppression/O TREANDA/O caused/O severe/B-Severity myelosuppression/B-AdverseReaction (/O Grade/B-Severity 3/I-Severity -/O 4/O )/O in/O 98/O %/O of/O patients/O in/O the/O two/O NHL/O studies/O (/O see/O Table/O 4/O )/O ./O
Three/O patients/O (/O 2/O %/O )/O died/B-AdverseReaction from/O myelosuppression/B-AdverseReaction -/I-AdverseReaction related/I-AdverseReaction adverse/O reactions/O ;/O one/O each/O from/O neutropenic/B-AdverseReaction sepsis/I-AdverseReaction ,/O diffuse/B-AdverseReaction alveolar/I-AdverseReaction hemorrhage/I-AdverseReaction with/O Grade/B-Severity 3/O thrombocytopenia/B-AdverseReaction ,/O and/O pneumonia/B-AdverseReaction from/O an/O opportunistic/B-AdverseReaction infection/I-AdverseReaction (/O CMV/O )/O ./O
In/O the/O event/O of/O treatment/O -/O related/O myelosuppression/O ,/O monitor/O leukocytes/O ,/O platelets/O ,/O hemoglobin/O (/O Hgb/O )/O ,/O and/O neutrophils/O frequently/O ./O
In/O the/O clinical/O trials/O ,/O blood/O counts/O were/O monitored/O every/O week/O initially/O ./O
Hematologic/O nadirs/O were/O observed/O predominantly/O in/O the/O third/O week/O of/O therapy/O ./O
Myelosuppression/O may/O require/O dose/O delays/O and/or/O subsequent/O dose/O reductions/O if/O recovery/O to/O the/O recommended/O values/O has/O not/O occurred/O by/O the/O first/O day/O of/O the/O next/O scheduled/O cycle/O ./O
Prior/O to/O the/O initiation/O of/O the/O next/O cycle/O of/O therapy/O ,/O the/O ANC/O should/O be/O 1/O x/O 10/O 9/O /L/O and/O the/O platelet/O count/O should/O be/O 75/O x/O 10/O 9/O /L./O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O (/O 2.3/O )/O ]/O 5.2/O Infections/O Infection/B-AdverseReaction ,/O including/O pneumonia/B-AdverseReaction ,/O sepsis/B-AdverseReaction ,/O septic/B-AdverseReaction shock/I-AdverseReaction ,/O and/O death/B-AdverseReaction have/O occurred/O in/O adult/O and/O pediatric/O patients/O in/O clinical/O trials/O and/O in/O postmarketing/O reports/O ./O
Patients/O with/O myelosuppression/B-AdverseReaction following/O treatment/O with/O TREANDA/O are/O more/O susceptible/B-Factor to/O infections/B-AdverseReaction ./O
Advise/O patients/O with/O myelosuppression/O following/O TREANDA/O treatment/O to/O contact/O a/O physician/O if/O they/O have/O symptoms/O or/O signs/O of/O infection/O ./O
5.3/O Anaphylaxis/O and/O Infusion/O Reactions/O Infusion/B-AdverseReaction reactions/I-AdverseReaction to/O TREANDA/O have/O occurred/O commonly/O in/O clinical/O trials/O ./O
Symptoms/O include/O fever/B-AdverseReaction ,/O chills/B-AdverseReaction ,/O pruritus/B-AdverseReaction and/O rash/B-AdverseReaction ./O
In/O rare/O instances/O severe/B-Severity anaphylactic/O and/O anaphylactoid/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O ,/O particularly/O in/O the/O second/O and/O subsequent/O cycles/O of/O therapy/O ./O
Monitor/O clinically/O and/O discontinue/O drug/O for/O severe/O reactions/O ./O
Ask/O patients/O about/O symptoms/O suggestive/O of/O infusion/O reactions/O after/O their/O first/O cycle/O of/O therapy/O ./O
Patients/O who/O experience/O Grade/O 3/O or/O worse/O allergic/O -/O type/O reactions/O should/O not/O be/O rechallenged/O ./O
Consider/O measures/O to/O prevent/O severe/O reactions/O ,/O including/O antihistamines/O ,/O antipyretics/O and/O corticosteroids/O in/O subsequent/O cycles/O in/O patients/O who/O have/O experienced/O Grade/O 1/O or/O 2/O infusion/O reactions/O ./O
Discontinue/O TREANDA/O for/O patients/O with/O Grade/O 4/O infusion/O reactions/O ./O
Consider/O discontinuation/O for/O Grade/O 3/O infusions/O reactions/O as/O clinically/O appropriate/O considering/O individual/O benefits/O ,/O risks/O ,/O and/O supportive/O care/O ./O
5.4/O Tumor/O Lysis/O Syndrome/O Tumor/B-AdverseReaction lysis/I-AdverseReaction syndrome/I-AdverseReaction associated/O with/O TREANDA/O treatment/O has/O occurred/O in/O patients/O in/O clinical/O trials/O and/O in/O postmarketing/O reports/O ./O
The/O onset/O tends/O to/O be/O within/O the/O first/O treatment/O cycle/O of/O TREANDA/O and/O ,/O without/O intervention/O ,/O may/B-Factor lead/O to/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O death/B-AdverseReaction ./O
Preventive/O measures/O include/O vigorous/O hydration/O and/O close/O monitoring/O of/O blood/O chemistry/O ,/O particularly/O potassium/O and/O uric/O acid/O levels/O ./O
Allopurinol/O has/O also/O been/O used/O during/O the/O beginning/O of/O TREANDA/O therapy/O ./O
However/O ,/O there/O may/O be/O an/O increased/O risk/B-Factor of/O severe/B-Severity skin/B-AdverseReaction toxicity/I-AdverseReaction when/O TREANDA/O and/O allopurinol/O are/O administered/O concomitantly/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
5.5/O Skin/O Reactions/O Skin/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O with/O TREANDA/O treatment/O in/O clinical/O trials/O and/O postmarketing/O safety/O reports/O ,/O including/O rash/B-AdverseReaction ,/O toxic/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction and/O bullous/B-AdverseReaction exanthema/I-AdverseReaction ./O
Some/O events/O occurred/O when/O TREANDA/O was/O given/O in/O combination/O with/O other/O anticancer/O agents/O ./O
In/O a/O study/O of/O TREANDA/O (/O 90/O mg/O m/O 2/O )/O in/O combination/O with/O rituximab/O ,/O one/O case/O of/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction (/O TEN/B-AdverseReaction )/O occurred/O ./O
TEN/O has/O been/O reported/O for/O rituximab/O (/O see/O rituximab/O package/O insert/O )/O ./O
Cases/O of/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O (/O SJS/B-AdverseReaction )/O and/O TEN/B-AdverseReaction ,/O some/O fatal/B-AdverseReaction ,/O have/O been/O reported/O when/O TREANDA/O was/O administered/O concomitantly/O with/O allopurinol/O and/O other/O medications/O known/O to/O cause/O these/O syndromes/O ./O
The/O relationship/O to/O TREANDA/O can/O not/O be/O determined/O ./O
Where/O skin/B-AdverseReaction reactions/I-AdverseReaction occur/O ,/O they/O may/O be/O progressive/O and/O increase/O in/O severity/O with/O further/O treatment/O ./O
Monitor/O patients/O with/O skin/O reactions/O closely/O ./O
If/O skin/O reactions/O are/O severe/O or/O progressive/O ,/O withhold/O or/O discontinue/O TREANDA/O ./O
5.6/O Other/O Malignancies/O There/O are/O reports/O of/O pre/O -/O malignant/O and/O malignant/B-AdverseReaction diseases/I-AdverseReaction that/O have/O developed/O in/O patients/O who/O have/O been/O treated/O with/O TREANDA/O ,/O including/O myelodysplastic/B-AdverseReaction syndrome/I-AdverseReaction ,/O myeloproliferative/B-AdverseReaction disorders/I-AdverseReaction ,/O acute/B-AdverseReaction myeloid/I-AdverseReaction leukemia/I-AdverseReaction and/O bronchial/B-AdverseReaction carcinoma/I-AdverseReaction ./O
The/O association/O with/O TREANDA/O therapy/O has/O not/O been/O determined/O ./O
5.7/O Extravasation/O Injury/O TREANDA/O extravasations/B-AdverseReaction have/O been/O reported/O in/O post/O marketing/O resulting/O in/O hospitalizations/O from/O erythema/B-AdverseReaction ,/O marked/B-Severity swelling/B-AdverseReaction ,/O and/O pain/B-AdverseReaction ./O
Assure/O good/O venous/O access/O prior/O to/O starting/O TREANDA/O infusion/O and/O monitor/O the/O intravenous/O infusion/O site/O for/O redness/O ,/O swelling/O ,/O pain/O ,/O infection/O ,/O and/O necrosis/O during/O and/O after/O administration/O of/O TREANDA/O ./O
5.8/O Embryo/O -/O fetal/O Toxicity/O TREANDA/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Single/O intraperitoneal/O doses/O of/O bendamustine/O in/O mice/B-Animal and/O rats/B-Animal administered/O during/O organogenesis/O caused/O an/O increase/B-AdverseReaction in/I-AdverseReaction resorptions/I-AdverseReaction ,/O skeletal/O and/O visceral/B-AdverseReaction malformations/I-AdverseReaction ,/O and/O decreased/B-AdverseReaction fetal/I-AdverseReaction body/I-AdverseReaction weights/I-AdverseReaction ./O
[/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O 6/O ADVERSE/O REACTIONS/O The/O following/O serious/O reactions/O are/O described/O below/O or/O elsewhere/O in/O the/O prescribing/O information/O :/O Risk/B-Factor of/O Thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O Tumors/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Pancreatitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Hypoglycemia/B-AdverseReaction with/O Concomitant/O Use/O of/O Insulin/O Secretagogues/O or/O Insulin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Hypersensitivity/B-AdverseReaction reactions/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Renal/B-AdverseReaction impairment/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Severe/B-Severity Gastrointestinal/B-AdverseReaction Disease/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O ,/O reported/O in/O 5/O %/O of/O patients/O treated/O with/O TRULICITY/O are/O :/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O and/O decreased/B-AdverseReaction appetite/I-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Eli/O Lilly/O and/O Company/O at/O 1/O -/O 800-LillyRx/O (/O 1/O -/O 800/O -/O 545/O -/O 5979/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Pool/O of/O Placebo/O -/O controlled/O Trials/O The/O data/O in/O Table/O 1/O are/O derived/O from/O the/O placebo/O -/O controlled/O trials/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O data/O reflect/O exposure/O of/O 1670/O patients/O to/O TRULICITY/O and/O a/O mean/O duration/O of/O exposure/O to/O TRULICITY/O of/O 23.8/O weeks/O ./O
Across/O the/O treatment/O arms/O ,/O the/O mean/O age/O of/O patients/O was/O 56/O years/O ,/O 1/O %/O were/O 75/O years/O or/O older/O and/O 53/O %/O were/O male/O ./O
The/O population/O in/O these/O studies/O was/O 69/O %/O White/O ,/O 7/O %/O Black/O or/O African/O American/O ,/O 13/O %/O Asian/O ;/O 30/O %/O were/O of/O Hispanic/O or/O Latino/O ethnicity/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 8.0/O years/O and/O had/O a/O mean/O HbA1c/O of/O 8.0/O %/O ./O
At/O baseline/O ,/O 2.5/O %/O of/O the/O population/O reported/O retinopathy/O ./O
Baseline/O estimated/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O eGFR/O 60mL/O min/1.73/O m/O 2/O )/O in/O 96.0/O %/O of/O the/O pooled/O study/O populations/O ./O
Table/O 1/O shows/O common/O adverse/O reactions/O ,/O excluding/O hypoglycemia/B-AdverseReaction ,/O associated/O with/O the/O use/O of/O TRULICITY/O in/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ./O
These/O adverse/O reactions/O were/O not/O present/O at/O baseline/O ,/O occurred/O more/O commonly/O on/O TRULICITY/O than/O on/O placebo/O ,/O and/O occurred/O in/O at/O least/O 5/O %/O of/O patients/O treated/O with/O TRULICITY/O ./O
Table/O 1/O :/O Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O Trials/O Reported/O in/O 5/O %/O of/O TRULICITY/O -/O Treated/O Patients/O a/O Includes/O diarrhea/B-AdverseReaction ,/O fecal/B-AdverseReaction volume/I-AdverseReaction increased/I-AdverseReaction ,/O frequent/B-AdverseReaction bowel/I-AdverseReaction movements/I-AdverseReaction ./O
b/O Includes/O retching/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O vomiting/B-AdverseReaction projectile/I-AdverseReaction ./O
c/O Includes/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction lower/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction upper/I-AdverseReaction ,/O abdominal/B-AdverseReaction tenderness/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction pain/I-AdverseReaction ./O
d/O Includes/O fatigue/B-AdverseReaction ,/O asthenia/B-AdverseReaction ,/O malaise/B-AdverseReaction ./O
Note/O :/O Percentages/O reflect/O the/O number/O of/O patients/O that/O reported/O at/O least/O 1/O treatment-/O emergent/O occurrence/O of/O the/O adverse/O reaction/O ./O
Adverse/O Reaction/O Placebo/O (/O N=568/O )/O %/O Trulicity/O 0.75/O mg/O (/O N=836/O )/O %/O Trulicity/O 1.5/O mg/O (/O N=834/O )/O %/O Nausea/B-AdverseReaction 5.3/O 12.4/O 21.1/O Diarrhea/B-AdverseReaction a/O 6.7/O 8.9/O 12.6/O Vomiting/B-AdverseReaction b/O 2.3/O 6.0/O 12.7/O Abdominal/B-AdverseReaction Pain/I-AdverseReaction c/O 4.9/O 6.5/O 9.4/O Decreased/B-AdverseReaction Appetite/I-AdverseReaction 1.6/O 4.9/O 8.6/O Dyspepsia/B-AdverseReaction 2.3/O 4.1/O 5.8/O Fatigue/B-AdverseReaction d/O 2.6/O 4.2/O 5.6/O Gastrointestinal/O Adverse/O Reactions/O In/O the/O pool/O of/O placebo/O -/O controlled/O trials/O ,/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction occurred/O more/O frequently/O among/O patients/O receiving/O TRULICITY/O than/O placebo/O (/O placebo/O 21.3/O %/O ,/O 0.75/O mg/O 31.6/O %/O ,/O 1.5/O mg/O 41.0/O %/O )/O ./O
More/O patients/O receiving/O TRULICITY/O 0.75/O mg/O (/O 1.3/O %/O )/O and/O TRULICITY/O 1.5/O mg/O (/O 3.5/O %/O )/O discontinued/O treatment/O due/O to/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction than/O patients/O receiving/O placebo/O (/O 0.2/O %/O )/O ./O
Investigators/O graded/O the/O severity/O of/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction occurring/O on/O 0.75/O mg/O and/O 1.5/O mg/O of/O TRULICITY/O as/O "/O mild/B-Severity "/O in/O 58/O %/O and/O 48/O %/O of/O cases/O ,/O respectively/O ,/O "/O moderate/B-Severity "/O in/O 35/O %/O and/O 42/O %/O of/O cases/O ,/O respectively/O ,/O or/O "/O severe/B-Severity "/O in/O 7/O %/O and/O 11/O %/O of/O cases/O ,/O respectively/O ./O
In/O addition/O to/O the/O reactions/O in/O Table/O 1/O ,/O the/O following/O adverse/O reactions/O were/O reported/O more/O frequently/O in/O TRULICITY/O -/O treated/O patients/O than/O placebo/O (/O frequencies/O listed/O ,/O respectively/O ,/O as/O :/O placebo/O ;/O 0.75/O mg/O ;/O 1.5/O mg/O )/O :/O constipation/B-AdverseReaction (/O 0.7/O %/O ,/O 3.9/O %/O ,/O 3.7/O %/O )/O ,/O flatulence/B-AdverseReaction (/O 1.4/O %/O ,/O 1.4/O %/O ,/O 3.4/O %/O )/O ,/O abdominal/B-AdverseReaction distension/I-AdverseReaction (/O 0.7/O %/O ,/O 2.9/O %/O ,/O 2.3/O %/O )/O ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction (/O 0.5/O %/O ,/O 1.7/O %/O ,/O 2.0/O %/O )/O ,/O and/O eructation/B-AdverseReaction (/O 0.2/O %/O ,/O 0.6/O %/O ,/O 1.6/O %/O )/O ./O
Pool/O of/O Placebo-/O and/O Active/O -/O Controlled/O Trials/O The/O occurrence/O of/O adverse/O reactions/O was/O also/O evaluated/O in/O a/O larger/O pool/O of/O patients/O with/O type/O 2/O diabetes/O participating/O in/O 6/O placebo-/O and/O active/O -/O controlled/O trials/O evaluating/O the/O use/O of/O TRULICITY/O as/O monotherapy/O and/O add/O -/O on/O therapy/O to/O oral/O medications/O or/O insulin/O ./O
[/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
In/O this/O pool/O ,/O a/O total/O of/O 3342/O patients/O with/O type/O 2/O diabetes/O were/O treated/O with/O TRULICITY/O for/O a/O mean/O duration/O of/O 52/O weeks/O ./O
The/O mean/O age/O of/O patients/O was/O 56/O years/O ,/O 2/O %/O were/O 75/O years/O or/O older/O and/O 51/O %/O were/O male/O ./O
The/O population/O in/O these/O studies/O was/O 71/O %/O White/O ,/O 7/O %/O Black/O or/O African/O American/O ,/O 11/O %/O Asian/O ;/O 32/O %/O were/O of/O Hispanic/O or/O Latino/O ethnicity/O ./O
At/O baseline/O ,/O the/O population/O had/O diabetes/O for/O an/O average/O of/O 8.2/O years/O and/O had/O a/O mean/O HbA1c/O of/O 7.6/O -/O 8.5/O %/O ./O
At/O baseline/O ,/O 5.2/O %/O of/O the/O population/O reported/O retinopathy/O ./O
Baseline/O estimated/O renal/O function/O was/O normal/O or/O mildly/O impaired/O (/O eGFR/O 60/O ml/O min/1.73/O m2/O )/O in/O 95.7/O %/O of/O the/O TRULICITY/O population/O ./O
In/O the/O pool/O of/O placebo-/O and/O active/O -/O controlled/O trials/O ,/O the/O types/O and/O frequency/O of/O common/O adverse/O reactions/O ,/O excluding/O hypoglycemia/B-AdverseReaction ,/O were/O similar/O to/O those/O listed/O in/O Table/O 1/O ./O
Other/O Adverse/O Reactions/O Hypoglycemia/O Table/O 2/O summarizes/O the/O incidence/O of/O documented/O symptomatic/O (/O 70/O mg/O dL/O glucose/O threshold/O )/O and/O severe/B-Severity hypoglycemia/B-AdverseReaction in/O the/O placebo/O -/O controlled/O clinical/O studies/O ./O
Table/O 2/O :/O Incidence/O (/O %/O )/O of/O Documented/O Symptomatic/O and/O Severe/B-Severity Hypoglycemia/B-AdverseReaction Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O Trials/O Placebo/O TRULICITY/O 0.75/O mg/O TRULICITY/O 1.5/O mg/O Add/O -/O on/O to/O Metformin/O (/O 26/O weeks/O )/O N=177/O N=302/O N=304/O Documented/O symptomatic/O 1.1/O %/O 2.6/O %/O 5.6/O %/O Severe/O 0/O 0/O 0/O Add/O -/O on/O to/O Metformin/O +/O Pioglitazone/O (/O 26/O weeks/O )/O N=141/O N=280/O N=279/O Documented/O symptomatic/O 1.4/O %/O 4.6/O %/O 5.0/O %/O Severe/O 0/O 0/O 0/O Hypoglycemia/B-AdverseReaction was/O more/O frequent/O when/O TRULICITY/O was/O used/O in/O combination/O with/O a/O sulfonylurea/O or/O insulin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Documented/O symptomatic/B-AdverseReaction hypoglycemia/I-AdverseReaction occurred/O in/O 39/O %/O and/O 40/O %/O of/O patients/O when/O TRULICITY/O 0.75/O mg/O and/O 1.5/O mg/O ,/O respectively/O ,/O was/O co/O -/O administered/O with/O a/O sulfonylurea/O ./O
Severe/B-Severity hypoglycemia/B-AdverseReaction occurred/O in/O 0/O %/O and/O 0.7/O %/O of/O patients/O when/O TRULICITY/O 0.75/O mg/O and/O 1.5/O mg/O ,/O respectively/O ,/O was/O co/O -/O administered/O with/O a/O sulfonylurea/O ./O
Documented/O symptomatic/B-AdverseReaction hypoglycemia/I-AdverseReaction occurred/O in/O 85/O %/O and/O 80/O %/O of/O patients/O when/O TRULICITY/O 0.75/O mg/O and/O 1.5/O mg/O ,/O respectively/O ,/O was/O co/O -/O administered/O with/O prandial/O insulin/O ./O
Severe/B-Severity hypoglycemia/B-AdverseReaction occurred/O in/O 2.4/O %/O and/O 3.4/O %/O of/O patients/O when/O TRULICITY/O 0.75/O mg/O and/O 1.5/O mg/O ,/O respectively/O ,/O was/O co/O -/O administered/O with/O prandial/O insulin/O ./O
Heart/O Rate/O Increase/O and/O Tachycardia/O Related/O Adverse/O Reactions/O ./O
TRULICITY/O 0.75/O mg/O and/O 1.5/O mg/O resulted/O in/O a/O mean/O increase/B-AdverseReaction in/I-AdverseReaction heart/I-AdverseReaction rate/I-AdverseReaction (/O HR/O )/O of/O 2/O -/O 4/O beats/O per/O minute/O (/O bpm/O )/O ./O
The/O long/O -/O term/O clinical/O effects/O of/O the/O increase/B-AdverseReaction in/I-AdverseReaction HR/I-AdverseReaction have/O not/O been/O established/O [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O ./O
Adverse/O reactions/O of/O sinus/B-AdverseReaction tachycardia/I-AdverseReaction were/O reported/O more/O frequently/O in/O patients/O exposed/O to/O TRULICITY/O ./O
Sinus/B-AdverseReaction tachycardia/I-AdverseReaction was/O reported/O in/O 3.0/O %/O ,/O 2.8/O %/O ,/O and/O 5.6/O %/O of/O patient/O treated/O with/O placebo/O ,/O TRULICITY/O 0.75/O mg/O and/O TRULICITY/O 1.5/O mg/O ,/O respectively/O ./O
Persistence/B-AdverseReaction of/I-AdverseReaction sinus/I-AdverseReaction tachycardia/I-AdverseReaction (/O reported/O at/O more/O than/O 2/O visits/O )/O was/O reported/O in/O 0.2/O %/O ,/O 0.4/O %/O and/O 1.6/O %/O of/O patients/O treated/O with/O placebo/O ,/O TRULICITY/O 0.75/O mg/O and/O TRULICITY/O 1.5/O mg/O ,/O respectively/O ./O
Episodes/O of/O sinus/B-AdverseReaction tachycardia/I-AdverseReaction ,/O associated/O with/O a/O concomitant/O increase/O from/O baseline/O in/O heart/O rate/O of/O 15/O beats/O per/O minute/O ,/O were/O reported/O in/O 0.7/O %/O ,/O 1.3/O %/O and/O 2.2/O %/O of/O patient/O treated/O with/O placebo/O ,/O TRULICITY/O 0.75/O mg/O and/O TRULICITY/O 1.5/O mg/O ,/O respectively/O ./O
Immunogenicity/O Across/O four/O Phase/O 2/O and/O five/O Phase/O 3/O clinical/O studies/O ,/O 64/O (/O 1.6/O %/O )/O TRULICITY/O treated/O patients/O developed/O anti/O -/O drug/O antibodies/O (/O ADAs/O )/O to/O the/O active/O ingredient/O in/O TRULICITY/O (/O i.e./O ,/O dulaglutide/O )/O ./O
Of/O the/O 64/O dulaglutide/O -/O treated/O patients/O that/O developed/O dulaglutide/O ADAs/O ,/O 34/O patients/O (/O 0.9/O %/O of/O the/O overall/O population/O )/O had/O dulaglutide/O -/O neutralizing/O antibodies/O ,/O and/O 36/O patients/O (/O 0.9/O %/O of/O the/O overall/O population/O )/O developed/O antibodies/O against/O native/O GLP-1/O ./O
The/O detection/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O the/O incidence/O of/O antibodies/O to/O dulaglutide/O can/O not/O be/O directly/O compared/O with/O the/O incidence/O of/O antibodies/O of/O other/O products/O ./O
Hypersensitivity/O Systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction adverse/O reactions/O sometimes/O severe/B-Severity (/O e.g./O ,/O severe/B-Severity urticaria/B-AdverseReaction ,/O systemic/B-AdverseReaction rash/I-AdverseReaction ,/O facial/B-AdverseReaction edema/I-AdverseReaction ,/O lip/B-AdverseReaction swelling/I-AdverseReaction )/O occurred/O in/O 0.5/O %/O of/O patients/O on/O TRULICITY/O in/O the/O four/O Phase/O 2/O and/O five/O Phase/O 3/O studies/O ./O
Injection/O -/O site/O Reactions/O In/O the/O placebo/O -/O controlled/O studies/O ,/O injection/B-AdverseReaction -/I-AdverseReaction site/O reactions/O (/O e.g./O ,/O injection/B-AdverseReaction -/I-AdverseReaction site/O rash/O ,/O erythema/O )/O were/O reported/O in/O 0.5/O %/O of/O TRULICITY/O -/O treated/O patients/O and/O in/O 0.0/O %/O of/O placebo/O -/O treated/O patients/O ./O
PR/O Interval/O Prolongation/O and/O Adverse/O Reactions/O of/O First/O Degree/O Atrioventricular/O (/O AV/O )/O Block/O A/O mean/O increase/O from/O baseline/O in/O PR/O interval/O of/O 2/O -/O 3/O milliseconds/O was/O observed/O in/O TRULICITY/O -/O treated/O patients/O in/O contrast/O to/O a/O mean/O decrease/O of/O 0.9/O millisecond/O in/O placebo/O -/O treated/O patients/O ./O
The/O adverse/O reaction/O of/O first/B-AdverseReaction degree/I-AdverseReaction AV/I-AdverseReaction block/I-AdverseReaction occurred/O more/O frequently/O in/O patients/O treated/O with/O TRULICITY/O than/O placebo/O (/O 0.9/O %/O ,/O 1.7/O %/O and/O 2.3/O %/O for/O placebo/O ,/O TRULICITY/O 0.75/O mg/O and/O TRULICITY/O 1.5/O mg/O ,/O respectively/O )/O ./O
On/O electrocardiograms/O ,/O a/O PR/B-AdverseReaction interval/I-AdverseReaction increase/I-AdverseReaction to/O at/O least/O 220/O milliseconds/O was/O observed/O in/O 0.7/O %/O ,/O 2.5/O %/O and/O 3.2/O %/O of/O patients/O treated/O with/O placebo/O ,/O TRULICITY/O 0.75/O mg/O and/O TRULICITY/O 1.5/O mg/O ,/O respectively/O ./O
Amylase/O and/O Lipase/O Increase/O Patients/O exposed/O to/O TRULICITY/O had/O mean/O increases/O from/O baseline/O in/O lipase/O and/or/O pancreatic/O amylase/O of/O 14/O %/O to/O 20/O %/O ,/O while/O placebo/O -/O treated/O patients/O had/O mean/O increases/O of/O up/O to/O 3/O %/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O In/O male/O and/O female/O rats/B-Animal ,/O dulaglutide/O causes/O a/O dose/O -/O related/O and/O treatment/O -/O duration/O -/O dependent/O increase/O in/O the/O incidence/O of/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O (/O adenomas/O and/O carcinomas/O )/O after/O lifetime/O exposure/O ./O
It/O is/O unknown/B-Factor whether/O TRULICITY/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O medullary/B-AdverseReaction thyroid/I-AdverseReaction carcinoma/I-AdverseReaction (/O MTC/B-AdverseReaction )/O ,/O in/O humans/O as/O human/O relevance/O of/O dulaglutide/O -/O induced/O rodent/B-Animal thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O has/O not/O been/O determined/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ,/O and/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
TRULICITY/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O and/O in/O patients/O with/O Multiple/O Endocrine/O Neoplasia/O syndrome/O type/O 2/O (/O MEN/O 2/O )/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O of/O MTC/O with/O use/O of/O TRULICITY/O and/O inform/O them/O of/O symptoms/O of/O thyroid/O tumors/O (/O e.g./O ,/O mass/O in/O the/O neck/O ,/O dysphagia/O ,/O dyspnea/O ,/O persistent/O hoarseness/O )/O ./O
Routine/O monitoring/O of/O serum/O calcitonin/O or/O using/O thyroid/O ultrasound/O is/O of/O uncertain/O value/O for/O early/O detection/O of/O MTC/O in/O patients/O treated/O with/O TRULICITY/O [/O see/O Contraindications/O (/O 4.1/O )/O and/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O RISK/B-Factor OF/O THYROID/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction CELL/O TUMORS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Dulaglutide/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O in/O rats/B-Animal ./O
It/O is/O unknown/B-Factor whether/O TRULICITY/O causes/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O medullary/B-AdverseReaction thyroid/I-AdverseReaction carcinoma/I-AdverseReaction (/O MTC/B-AdverseReaction )/O ,/O in/O humans/O as/O the/O human/O relevance/O of/O dulaglutide/O -/O induced/O rodent/B-Animal thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O has/O not/O been/O determined/O (/O 5.1/O ,/O 13.1/O )/O ./O
TRULICITY/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O and/O in/O patients/O with/O Multiple/O Endocrine/O Neoplasia/O syndrome/O type/O 2/O (/O MEN/O 2/O )/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O of/O MTC/O and/O symptoms/O of/O thyroid/O tumors/O (/O 4.1/O ,/O 5.1/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O Tumors/O :/O See/O Boxed/O Warning/O (/O 5.1/O )/O ./O
Pancreatitis/B-AdverseReaction :/O Has/O been/O reported/O in/O clinical/O trials/O ./O
Discontinue/O promptly/O if/O pancreatitis/O is/O suspected/O ./O
Do/O not/O restart/O if/O pancreatitis/O is/O confirmed/O ./O
Consider/O other/O antidiabetic/O therapies/O in/O patients/O with/O history/O of/O pancreatitis/O (/O 5.2/O )/O ./O
Hypoglycemia/B-AdverseReaction :/O When/O TRULICITY/O is/O used/O with/O an/O insulin/O secretagogue/O (/O e.g./O ,/O a/O sulfonylurea/O )/O or/O insulin/O ,/O consider/O lowering/O the/O dose/O of/O the/O sulfonylurea/O or/O insulin/O to/O reduce/O the/O risk/O of/O hypoglycemia/O (/O 5.3/O )/O ./O
Hypersensitivity/B-AdverseReaction Reactions/O :/O Discontinue/O TRULICITY/O if/O suspected/O ./O
Monitor/O and/O treat/O promptly/O per/O standard/O of/O care/O until/O signs/O and/O symptoms/O resolve/O (/O 5.4/O )/O ./O
Renal/B-AdverseReaction Impairment/I-AdverseReaction :/O Monitor/O renal/O function/O in/O patients/O with/O renal/O impairment/O reporting/O severe/O adverse/O gastrointestinal/O reactions/O (/O 5.5/O )/O ./O
Macrovascular/O outcomes/O :/O There/O have/O been/O no/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O TRULICITY/O or/O any/O other/O antidiabetic/O drug/O (/O 5.7/O )/O ./O
5.1/O Risk/O of/O Thyroid/O C/O -/O cell/O Tumors/O In/O male/O and/O female/O rats/B-Animal ,/O dulaglutide/O causes/O a/O dose/O -/O related/O and/O treatment/O -/O duration/O -/O dependent/O increase/O in/O the/O incidence/O of/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O (/O adenomas/O and/O carcinomas/O )/O after/O lifetime/O exposure/O [/O see/O Nonclinical/O Toxicology/O (/O 13.1/O )/O ]/O ./O
Glucagon/O -/O like/O peptide/O (/O GLP-1/O )/O receptor/O agonists/O have/O induced/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O adenomas/O and/O carcinomas/O in/O mice/B-Animal and/O rats/B-Animal at/O clinically/O relevant/O exposures/O ./O
It/O is/O unknown/B-Factor whether/O TRULICITY/O will/O cause/O thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O ,/O including/O medullary/B-AdverseReaction thyroid/I-AdverseReaction carcinoma/I-AdverseReaction (/O MTC/B-AdverseReaction )/O ,/O in/O humans/O ,/O as/O the/O human/O relevance/O of/O dulaglutide/O -/O induced/O rodent/B-Animal thyroid/B-AdverseReaction C/I-AdverseReaction -/I-AdverseReaction cell/O tumors/O has/O not/O been/O determined/O ./O
One/O case/O of/O MTC/B-AdverseReaction was/O reported/O in/O a/O patient/O treated/O with/O TRULICITY/O ./O
This/O patient/O had/O pretreatment/O calcitonin/O levels/O approximately/O 8/O times/O the/O upper/O limit/O of/O normal/O (/O ULN/O )/O ./O
Cases/O of/O MTC/B-AdverseReaction in/O patients/O treated/O with/O liraglutide/O ,/O another/O GLP-1/B-DrugClass receptor/I-DrugClass agonist/I-DrugClass ,/O have/O been/O reported/O in/O the/O postmarketing/O period/O ;/O the/O data/O in/O these/O reports/O are/O insufficient/O to/O establish/O or/O exclude/O a/O causal/O relationship/O between/O MTC/B-AdverseReaction and/O GLP-1/O receptor/O agonist/O use/O in/O humans/O ./O
TRULICITY/O is/O contraindicated/O in/O patients/O with/O a/O personal/O or/O family/O history/O of/O MTC/O or/O in/O patients/O with/O MEN/O 2/O ./O
Counsel/O patients/O regarding/O the/O potential/O risk/O for/O MTC/O with/O the/O use/O of/O TRULICITY/O and/O inform/O them/O of/O symptoms/O of/O thyroid/O tumors/O (/O e.g./O a/O mass/O in/O the/O neck/O ,/O dysphagia/O ,/O dyspnea/O ,/O persistent/O hoarseness/O )/O ./O
Routine/O monitoring/O of/O serum/O calcitonin/O or/O using/O thyroid/O ultrasound/O is/O of/O uncertain/O value/O for/O early/O detection/O of/O MTC/O in/O patients/O treated/O with/O TRULICITY/O ./O
Such/O monitoring/O may/O increase/O the/O risk/O of/O unnecessary/O procedures/O ,/O due/O to/O the/O low/O test/O specificity/O for/O serum/O calcitonin/O and/O a/O high/O background/O incidence/O of/O thyroid/O disease/O ./O
Significantly/O elevated/O serum/O calcitonin/O value/O may/O indicate/O MTC/O and/O patients/O with/O MTC/O usually/O have/O calcitonin/O values/O 50/O ng/O L./O If/O serum/O calcitonin/O is/O measured/O and/O found/O to/O be/O elevated/O ,/O the/O patient/O should/O be/O further/O evaluated/O ./O
Patients/O with/O thyroid/O nodules/O noted/O on/O physical/O examination/O or/O neck/O imaging/O should/O also/O be/O further/O evaluated/O ./O
5.2/O Pancreatitis/O In/O Phase/O 2/O and/O Phase/O 3/O clinical/O studies/O ,/O 12/O (/O 3.4/O cases/O per/O 1000/O patient/O years/O )/O pancreatitis/B-AdverseReaction related/O adverse/O reactions/O were/O reported/O in/O patients/O exposed/O to/O TRULICITY/O versus/O 3/O in/O non/O -/O incretin/O comparators/O (/O 2.7/O cases/O per/O 1000/O patient/O years/O )/O ./O
An/O analyses/O of/O adjudicated/O events/O revealed/O 5/O cases/O of/O confirmed/O pancreatitis/B-AdverseReaction in/O patients/O exposed/O to/O TRULICITY/O (/O 1.4/O cases/O per/O 1000/O patient/O years/O )/O versus/O 1/O case/O in/O non/O -/O incretin/O comparators/O (/O 0.88/O cases/O per/O 1000/O patient/O years/O )/O ./O
After/O initiation/O of/O TRULICITY/O ,/O observe/O patients/O carefully/O for/O signs/O and/O symptoms/O of/O pancreatitis/O ,/O including/O persistent/O severe/O abdominal/O pain/O ./O
If/O pancreatitis/O is/O suspected/O ,/O promptly/O discontinue/O TRULICITY/O ./O
If/O pancreatitis/O is/O confirmed/O ,/O TRULICITY/O should/O not/O be/O restarted/O ./O
TRULICITY/O has/O not/O been/O evaluated/O in/O patients/O with/O a/O prior/O history/O of/O pancreatitis/O ./O
Consider/O other/O antidiabetic/O therapies/O in/O patients/O with/O a/O history/O of/O pancreatitis/O ./O
5.3/O Hypoglycemia/O with/O Concomitant/O Use/O of/O Insulin/O Secretagogues/O or/O Insulin/O The/O risk/B-Factor of/O hypoglycemia/B-AdverseReaction is/O increased/O when/O TRULICITY/O is/O used/O in/O combination/O with/O insulin/O secretagogues/O (/O e.g./O ,/O sulfonylureas/O )/O or/O insulin/O ./O
Patients/O may/O require/O a/O lower/O dose/O of/O sulfonylurea/O or/O insulin/O to/O reduce/O the/O risk/O of/O hypoglycemia/O in/O this/O setting/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.4/O Hypersensitivity/O Reactions/O Systemic/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/O were/O observed/O in/O patients/O receiving/O TRULICITY/O in/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
If/O a/O hypersensitivity/O reaction/O occurs/O ,/O the/O patient/O should/O discontinue/O TRULICITY/O and/O promptly/O seek/O medical/O advice/O ./O
5.5/O Renal/O Impairment/O In/O patients/O treated/O with/O GLP-1/B-DrugClass receptor/I-DrugClass agonists/I-DrugClass ,/O there/O have/O been/O postmarketing/O reports/O of/O acute/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction and/O worsening/O of/O chronic/B-AdverseReaction renal/I-AdverseReaction failure/I-AdverseReaction ,/O which/O may/O sometimes/O require/O hemodialysis/O ./O
Some/O of/O these/O events/O were/O reported/O in/O patients/O without/O known/O underlying/O renal/O disease/O ./O
A/O majority/O of/O reported/O events/O occurred/O in/O patients/O who/O had/O experienced/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O or/O dehydration/B-AdverseReaction ./O
Because/O these/O reactions/O may/O worsen/O renal/O function/O ,/O use/O caution/O when/O initiating/O or/O escalating/O doses/O of/O TRULICITY/O in/O patients/O with/O renal/O impairment/O ./O
Monitor/O renal/O function/O in/O patients/O with/O renal/O impairment/O reporting/O severe/O adverse/O gastrointestinal/O reactions/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ,/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O ]/O ./O
5.6/O Severe/O Gastrointestinal/O Disease/O Use/O of/O TRULICITY/O may/O be/O associated/O with/O gastrointestinal/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ,/O sometimes/O severe/B-Severity [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
TRULICITY/O has/O not/O been/O studied/O in/O patients/O with/O severe/O gastrointestinal/O disease/O ,/O including/O severe/O gastroparesis/O ,/O and/O is/O therefore/O not/O recommended/O in/O these/O patients/O ./O
5.7/O Macrovascular/O Outcomes/O There/O have/O been/O no/O clinical/O studies/O establishing/O conclusive/O evidence/O of/O macrovascular/O risk/O reduction/O with/O TRULICITY/O or/O any/O other/O antidiabetic/O drug/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O described/O in/O greater/O detail/O in/O other/O sections/O :/O Paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Worsening/B-AdverseReaction of/I-AdverseReaction narrow/I-AdverseReaction -/I-AdverseReaction angle/O glaucoma/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Worsening/B-AdverseReaction of/I-AdverseReaction urinary/I-AdverseReaction retention/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Immediate/B-AdverseReaction Hypersensitivity/I-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O =3/O %/O incidence/O and/O greater/O than/O placebo/O )/O are/O headache/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction and/O cough/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O Contact/O AstraZeneca/O at/O 1/O -/O 800/O -/O 236/O -/O 9933/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
3-Month/O and/O 6-Month/O Trials/O TUDORZA/O PRESSAIR/O was/O studied/O in/O two/O 3-month/O (/O Trials/O B/O and/O C/O )/O and/O one/O 6-month/O (/O Trial/O D/O )/O placebo/O -/O controlled/O trials/O in/O patients/O with/O COPD/O ./O
In/O these/O trials/O ,/O 636/O patients/O were/O treated/O with/O TUDORZA/O PRESSAIR/O at/O the/O recommended/O dose/O of/O 400/O mcg/O twice/O daily/O ./O
The/O population/O had/O a/O mean/O age/O of/O 64/O years/O (/O ranging/O from/O 40/O to/O 89/O years/O )/O ,/O with/O 58/O %/O males/O ,/O 94/O %/O Caucasian/O ,/O and/O had/O COPD/O with/O a/O mean/O pre/O -/O bronchodilator/O forced/O expiratory/O volume/O in/O one/O second/O (/O FEV1/O )/O percent/O predicted/O of/O 48/O %/O ./O
Patients/O with/O unstable/O cardiac/O disease/O ,/O narrow/O -/O angle/O glaucoma/O ,/O or/O symptomatic/O prostatic/O hypertrophy/O or/O bladder/O outlet/O obstruction/O were/O excluded/O from/O these/O trials/O ./O
Table/O 1shows/O all/O adverse/O reactions/O that/O occurred/O with/O a/O frequency/O of/O greater/O than/O or/O equal/O to/O 1/O %/O in/O the/O TUDORZA/O PRESSAIR/O group/O in/O the/O two/O 3-month/O and/O one/O 6-month/O placebo/O -/O controlled/O trials/O where/O the/O rates/O in/O the/O TUDORZA/O PRESSAIR/O group/O exceeded/O placebo/O ./O
Table/O 1/O :/O Adverse/O Reactions/O (/O %/O Patients/O )/O in/O Placebo/O -/O Controlled/O Clinical/O Trials/O Treatment/O Adverse/O Reactions/O TUDORZA/O PRESSAIR/O Placebo/O Preferred/O Term/O (/O N=636/O )/O (/O N=640/O )/O n/O (/O %/O )/O n/O (/O %/O )/O Headache/B-AdverseReaction 42/O (/O 6.6/O )/O 32/O (/O 5.0/O )/O Nasopharyngitis/B-AdverseReaction 35/O (/O 5.5/O )/O 25/O (/O 3.9/O )/O Cough/B-AdverseReaction 19/O (/O 3.0/O )/O 14/O (/O 2.2/O )/O Diarrhea/B-AdverseReaction 17/O (/O 2.7/O )/O 9/O (/O 1.4/O )/O Sinusitis/B-AdverseReaction 11/O (/O 1.7/O )/O 5/O (/O 0.8/O )/O Rhinitis/B-AdverseReaction 10/O (/O 1.6/O )/O 8/O (/O 1.2/O )/O Toothache/B-AdverseReaction 7/O (/O 1.1/O )/O 5/O (/O 0.8/O )/O Fall/B-AdverseReaction 7/O (/O 1.1/O )/O 3/O (/O 0.5/O )/O Vomiting/B-AdverseReaction 7/O (/O 1.1/O )/O 3/O (/O 0.5/O )/O In/O addition/O ,/O among/O the/O adverse/O reactions/O observed/O in/O the/O clinical/O trials/O with/O an/O incidence/O of/O less/O than/O 1/O %/O were/O diabetes/B-AdverseReaction mellitus/I-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O 1st/B-Severity degree/I-Severity AV/B-AdverseReaction block/I-AdverseReaction ,/O osteoarthritis/B-AdverseReaction ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction ,/O and/O cardio/B-AdverseReaction -/I-AdverseReaction respiratory/O arrest/O ./O
Long/O -/O term/O Safety/O Trials/O TUDORZA/O PRESSAIR/O was/O studied/O in/O three/O long/O term/O safety/O trials/O ,/O two/O double/O blind/O and/O one/O open/O label/O ,/O ranging/O from/O 40/O to/O 52/O weeks/O in/O patients/O with/O moderate/O to/O severe/O COPD/O ./O
Two/O of/O these/O trials/O were/O extensions/O of/O the/O 3-month/O trials/O ,/O and/O one/O was/O a/O dedicated/O long/O term/O safety/O trial/O ./O
In/O these/O trials/O ,/O 891/O patients/O were/O treated/O with/O TUDORZA/O PRESSAIR/O at/O the/O recommended/O dose/O of/O 400/O mcg/O twice/O daily/O ./O
The/O demographic/O and/O baseline/O characteristics/O of/O the/O long/O term/O safety/O trials/O were/O similar/O to/O those/O of/O the/O placebo/O -/O controlled/O trials/O ./O
The/O adverse/O events/O reported/O in/O the/O long/O term/O safety/O trials/O were/O similar/O to/O those/O occurring/O in/O the/O placebo/O -/O controlled/O trials/O of/O 3/O to/O 6/O months/O ./O
No/O new/O safety/O findings/O were/O reported/O compared/O to/O the/O placebo/O controlled/O trials/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O postapproval/O use/O of/O drug/O TUDORZA/O PRESSAIR/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
In/O postmarketing/O experience/O with/O TUDORZA/O PRESSAIR/O ,/O immediate/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction (/O including/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction lips/I-AdverseReaction ,/O tongue/O ,/O or/O throat/O )/O ,/O urticaria/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O or/O itching/B-AdverseReaction have/O been/O reported/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Not/O for/O acute/O use/O :/O Not/O for/O use/O as/O a/O rescue/O medication/O ./O
(/O 5.1/O )/O Paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction :/O Discontinue/O TUDORZA/O PRESSAIR/O and/O consider/O other/O treatments/O if/O paradoxical/O bronchospasm/O occurs/O ./O
(/O 5.2/O )/O Worsening/B-AdverseReaction of/I-AdverseReaction narrow/I-AdverseReaction -/I-AdverseReaction angle/O glaucoma/O may/B-Factor occur/O ./O
Use/O with/O caution/O in/O patients/O with/O narrow/O -/O angle/O glaucoma/O and/O instruct/O patients/O to/O consult/O a/O physician/O immediately/O if/O this/O occurs/O ./O
(/O 5.3/O )/O Worsening/B-AdverseReaction of/I-AdverseReaction urinary/I-AdverseReaction retention/I-AdverseReaction may/B-Factor occur/O ./O
Use/O with/O caution/O in/O patients/O with/O prostatic/O hyperplasia/O or/O bladder/O -/O neck/O obstruction/O and/O instruct/O patients/O to/O consult/O a/O physician/O immediately/O if/O this/O occurs/O ./O
(/O 5.4/O )/O Immediate/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction :/O Discontinue/O TUDORZA/O PRESSAIR/O at/O once/O and/O consider/O alternatives/O if/O immediate/O hypersensitivity/O reactions/O ,/O including/O angioedema/O ,/O bronchospasm/O ,/O or/O anaphylaxis/O ,/O occur/O ./O
Use/O with/O caution/O in/O patients/O with/O severe/O hypersensitivity/O to/O milk/O proteins/O ./O
(/O 5.5/O )/O 5.1/O Not/O for/O Acute/O Use/O TUDORZA/O PRESSAIR/O is/O intended/O as/O a/O twice/O -/O daily/O maintenance/O treatment/O for/O COPD/O and/O is/O not/O indicated/O for/O the/O initial/O treatment/O of/O acute/O episodes/O of/O bronchospasm/O (/O i.e./O ,/O rescue/O therapy/O )/O ./O
5.2/O Paradoxical/O Bronchospasm/O Inhaled/O medicines/O ,/O including/O TUDORZA/O PRESSAIR/O ,/O may/B-Factor cause/O paradoxical/B-AdverseReaction bronchospasm/I-AdverseReaction ./O
If/O this/O occurs/O ,/O treatment/O with/O TUDORZA/O PRESSAIR/O should/O be/O stopped/O and/O other/O treatments/O considered/O ./O
5.3/O Worsening/O of/O Narrow/O -/O Angle/O Glaucoma/O TUDORZA/O PRESSAIR/O should/O be/O used/O with/O caution/O in/O patients/O with/O narrow/O -/O angle/O glaucoma/O ./O
Prescribers/O and/O patients/O should/O be/O alert/O for/O signs/O and/O symptoms/O of/O acute/O narrow/O -/O angle/O glaucoma/O (/O e.g./O ,/O eye/O pain/O or/O discomfort/O ,/O blurred/O vision/O ,/O visual/O halos/O or/O colored/O images/O in/O association/O with/O red/O eyes/O from/O conjunctival/O congestion/O and/O corneal/O edema/O )/O ./O
Instruct/O patients/O to/O consult/O a/O physician/O immediately/O should/O any/O of/O these/O signs/O or/O symptoms/O develop/O ./O
5.4/O Worsening/O of/O Urinary/O Retention/O TUDORZA/O PRESSAIR/O should/O be/O used/O with/O caution/O in/O patients/O with/O urinary/O retention/O ./O
Prescribers/O and/O patients/O should/O be/O alert/O for/O signs/O and/O symptoms/O of/O prostatic/O hyperplasia/O or/O bladder/O -/O neck/O obstruction/O (/O e.g./O ,/O difficulty/O passing/O urine/O ,/O painful/O urination/O )/O ./O
Instruct/O patients/O to/O consult/O a/O physician/O immediately/O should/O any/O of/O these/O signs/O or/O symptoms/O develop/O ./O
5.5/O Immediate/O Hypersensitivity/O Reactions/O Immediate/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction ,/O angioedema/B-AdverseReaction (/O including/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction lips/I-AdverseReaction ,/O tongue/O ,/O or/O throat/O )/O ,/O urticaria/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O bronchospasm/B-AdverseReaction ,/O or/O itching/B-AdverseReaction ,/O have/O occurred/O after/O administration/O of/O TUDORZA/O PRESSAIR/O ./O
If/O such/O a/O reaction/O occurs/O ,/O therapy/O with/O TUDORZA/O PRESSAIR/O should/O be/O stopped/O at/O once/O and/O alternative/O treatments/O should/O be/O considered/O ./O
Given/O the/O similar/O structural/O formula/O of/O atropine/O to/O aclidinium/O ,/O patients/O with/O a/O history/O of/O hypersensitivity/O reactions/O to/O atropine/O should/O be/O closely/O monitored/O for/O similar/O hypersensitivity/O reactions/O to/O TUDORZA/O PRESSAIR/O ./O
In/O addition/O ,/O TUDORZA/O PRESSAIR/O should/O be/O used/O with/O caution/O in/O patients/O with/O severe/O hypersensitivity/O to/O milk/O proteins/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 1/O %/O and/O more/O common/O than/O with/O placebo/O )/O :/O ocular/B-AdverseReaction irritation/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction irritation/I-AdverseReaction ,/O and/O application/B-AdverseReaction site/I-AdverseReaction anesthesia/I-AdverseReaction and/O hypoesthesia/O ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Zylera/O Pharmaceuticals/O ,/O LLC/O ./O
at/O 1/O -/O 866/O -/O 416/O -/O 9637/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O rates/O of/O adverse/O reactions/O below/O were/O derived/O from/O two/O randomized/O ,/O multi/O -/O center/O ,/O vehicle/O -/O controlled/O clinical/O trials/O and/O one/O open/O -/O label/O study/O in/O subjects/O with/O head/O lice/O infestation/O ./O
Skin/O ,/O scalp/O ,/O and/O ocular/O irritation/O were/O monitored/O in/O the/O clinical/O trials/O ./O
All/O subjects/O were/O queried/O about/O the/O presence/O of/O skin/O and/O scalp/O symptoms/O ;/O the/O results/O are/O presented/O in/O Table/O 2/O ./O
Table/O 2/O :/O Monitored/O Adverse/O Reactions/O -/O Application/O Site/O Symptoms/O Event/O ULESFIA/O (/O r/O )/O Lotion/O Vehicle/O Application/B-AdverseReaction site/I-AdverseReaction Irritation/I-AdverseReaction 2/O %/O (/O 11/478/O )/O 1/O %/O (/O 2/336/O )/O Application/B-AdverseReaction site/I-AdverseReaction anesthesia/I-AdverseReaction &/O hypoesthesia/O 2/O %/O (/O 10/478/O )/O 0/O %/O (/O 0/336/O )/O Pain/B-AdverseReaction 1/O %/O (/O 5/478/O )/O 0/O %/O (/O 1/336/O )/O The/O subset/O of/O subjects/O who/O did/O not/O have/O pruritus/O ,/O erythema/O ,/O edema/O or/O pyoderma/O of/O skin/O and/O scalp/O ,/O or/O ocular/O irritation/O prior/O to/O treatment/O were/O assessed/O for/O these/O signs/O and/O symptoms/O after/O treatment/O ;/O the/O results/O are/O presented/O in/O Table/O 3/O ./O
Table/O 3/O :/O Monitored/O Adverse/O Reactions/O -/O Pruritus/B-AdverseReaction ,/O Erythema/B-AdverseReaction ,/O Pyoderma/B-AdverseReaction and/O Ocular/B-AdverseReaction Irritation/I-AdverseReaction with/O Onset/O After/O Treatment/O Signs/O Symptoms/O ULESFIA/O (/O r/O )/O Lotion/O Vehicle/O Pruritus/B-AdverseReaction 12/O %/O (/O 14/116/O )/O 4/O %/O (/O 3/67/O )/O Erythema/B-AdverseReaction 10/O %/O (/O 32/309/O )/O 9/O %/O (/O 19/217/O )/O Pyoderma/B-AdverseReaction 7/O %/O (/O 22/308/O )/O 4/O %/O (/O 10/230/O )/O Ocular/B-AdverseReaction irritation/I-AdverseReaction 6/O %/O (/O 26/428/O )/O 1/O %/O (/O 3/313/O )/O Other/O less/O common/O reactions/O (/O less/O than/O 1/O %/O but/O more/O than/O 0.1/O %/O )/O were/O ,/O in/O decreasing/O order/O of/O incidence/O :/O application/B-AdverseReaction site/I-AdverseReaction dryness/I-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction excoriation/I-AdverseReaction ,/O paraesthesia/B-AdverseReaction ,/O application/B-AdverseReaction site/I-AdverseReaction dermatitis/I-AdverseReaction ,/O excoriation/B-AdverseReaction ,/O thermal/B-AdverseReaction burn/I-AdverseReaction ,/O dandruff/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O skin/B-AdverseReaction exfoliation/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Neonatal/B-AdverseReaction toxicity/I-AdverseReaction :/O Risk/B-Factor of/O gasping/B-AdverseReaction syndrome/I-AdverseReaction if/O benzyl/O alcohol/O is/O used/O in/O neonates/O ./O
(/O 5.1/O )/O Eye/B-AdverseReaction irritation/I-AdverseReaction :/O Avoid/O eye/O exposure/O ./O
Flush/O immediately/O with/O water/O if/O ULESFIA/O (/O r/O )/O Lotion/O comes/O into/O contact/O with/O eyes/O ./O
(/O 5.2/O )/O Contact/B-AdverseReaction dermatitis/I-AdverseReaction :/O May/B-Factor occur/O with/O ULESFIA/O (/O r/O )/O Lotion/O ./O
(/O 5.3/O )/O Use/O in/O children/O :/O ULESFIA/O (/O r/O )/O Lotion/O should/O only/O be/O used/O on/O children/O under/O the/O direct/O supervision/O of/O an/O adult/O ./O
Keep/O out/O of/O reach/O of/O children/O ./O
(/O 5.4/O )/O 5/O ./O
1/O Neonatal/O Toxicity/O Intravenous/O administration/O of/O products/O containing/O benzyl/O alcohol/O has/O been/O associated/O with/O neonatal/B-AdverseReaction gasping/I-AdverseReaction syndrome/I-AdverseReaction consisting/O of/O severe/B-Severity metabolic/B-AdverseReaction acidosis/I-AdverseReaction ,/O gasping/B-AdverseReaction respirations/I-AdverseReaction ,/O progressive/B-AdverseReaction hypotension/I-AdverseReaction ,/O seizures/B-AdverseReaction ,/O central/B-AdverseReaction nervous/I-AdverseReaction system/I-AdverseReaction depression/I-AdverseReaction ,/O intraventricular/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O death/B-AdverseReaction in/O preterm/O ,/O low/O birth/O weight/O infants/O ./O
Neonates/O (/O i.e./O patients/O less/O than/O 1/O month/O of/O age/O or/O preterm/O infants/O with/O a/O corrected/O age/O of/O less/O than/O 44/O weeks/O )/O could/O be/O at/O risk/B-Factor for/O gasping/B-AdverseReaction syndrome/I-AdverseReaction if/O treated/O with/O ULESFIA/O (/O r/O )/O Lotion/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.4/O )/O ]/O ./O
5.2/O Eye/O Irritation/O Avoid/O eye/O exposure/O ./O
ULESFIA/O (/O r/O )/O Lotion/O may/B-Factor cause/O eye/B-AdverseReaction irritation/I-AdverseReaction ./O
If/O ULESFIA/O (/O r/O )/O Lotion/O comes/O in/O contact/O with/O the/O eyes/O ,/O flush/O them/O immediately/O with/O water/O ./O
If/O irritation/O persists/O ,/O consult/O a/O physician/O ./O
5/O ./O
3/O Contact/O Dermatitis/O ULESFIA/O (/O r/O )/O Lotion/O may/B-Factor cause/O allergic/O or/O irritant/B-AdverseReaction dermatitis/I-AdverseReaction ./O
5.4/O Use/O in/O Children/O ULESFIA/O (/O r/O )/O Lotion/O should/O only/O be/O used/O on/O children/O (/O 6/O months/O of/O age/O and/O older/O )/O under/O the/O direct/O supervision/O of/O an/O adult/O ./O
Keep/O out/O of/O reach/O of/O children/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Adverse/O reactions/O occurring/O in/O at/O least/O 1/O %/O of/O ULORIC/O -/O treated/O patients/O ,/O and/O at/O least/O 0.5/O %/O greater/O than/O placebo/O ,/O are/O liver/B-AdverseReaction function/I-AdverseReaction abnormalities/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Takeda/O Pharmaceuticals/O at/O 1/O -/O 877-TAKEDA-7/O (/O 1/O -/O 877/O -/O 825/O -/O 3327/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
A/O total/O of/O 2757/O subjects/O with/O hyperuricemia/O and/O gout/O were/O treated/O with/O ULORIC/O 40/O mg/O or/O 80/O mg/O daily/O in/O clinical/O studies/O ./O
For/O ULORIC/O 40/O mg/O ,/O 559/O patients/O were/O treated/O for/O 6/O months/O ./O
For/O ULORIC/O 80/O mg/O ,/O 1377/O subjects/O were/O treated/O for/O 6/O months/O ,/O 674/O patients/O were/O treated/O for/O 1/O year/O and/O 515/O patients/O were/O treated/O for/O 2/O years/O ./O
Most/O Common/O Adverse/O Reactions/O In/O three/O randomized/O ,/O controlled/O clinical/O studies/O (/O Studies/O 1/O ,/O 2/O and/O 3/O )/O ,/O which/O were/O six/O to/O 12/O months/O in/O duration/O ,/O the/O following/O adverse/O reactions/O were/O reported/O by/O the/O treating/O physician/O as/O related/O to/O study/O drug/O ./O
Table/O 1/O summarizes/O adverse/O reactions/O reported/O at/O a/O rate/O of/O at/O least/O 1/O %/O in/O ULORIC/O treatment/O groups/O and/O at/O least/O 0.5/O %/O greater/O than/O placebo/O ./O
Table/O 1/O :/O Adverse/O Reactions/O Occurring/O in/O 1/O %/O of/O ULORIC/O -/O Treated/O Patients/O and/O at/O Least/O 0.5%Greater/O than/O Seen/O in/O Patients/O Receiving/O Placebo/O in/O Controlled/O Studies/O Adverse/O Reactions/O Placebo/O ULORIC/O allopurinolOf/O the/O subjects/O who/O received/O allopurinol/O ,/O 10/O received/O 100/O mg/O ,/O 145/O received/O 200/O mg/O ,/O and/O 1122/O received/O 300/O mg/O ,/O based/O on/O level/O of/O renal/O impairment/O ./O
(/O N=134/O )/O 40/O mg/O daily(N=757/O )/O 80/O mg/O daily(N=1279/O )/O (/O N=1277/O )/O Liver/B-AdverseReaction Function/I-AdverseReaction Abnormalities/I-AdverseReaction 0.7/O %/O 6.6/O %/O 4.6/O %/O 4.2/O %/O Nausea/B-AdverseReaction 0.7/O %/O 1.1/O %/O 1.3/O %/O 0.8/O %/O Arthralgia/B-AdverseReaction 0/O %/O 1.1/O %/O 0.7/O %/O 0.7/O %/O Rash/B-AdverseReaction 0.7/O %/O 0.5/O %/O 1.6/O %/O 1.6/O %/O The/O most/O common/O adverse/O reaction/O leading/O to/O discontinuation/O from/O therapy/O was/O liver/B-AdverseReaction function/I-AdverseReaction abnormalities/I-AdverseReaction in/O 1.8/O %/O of/O ULORIC/O 40/O mg/O ,/O 1.2/O %/O of/O ULORIC/O 80/O mg/O ,/O and/O in/O 0.9/O %/O of/O allopurinol/O -/O treated/O subjects/O ./O
In/O addition/O to/O the/O adverse/O reactions/O presented/O in/O Table/O 1/O ,/O dizziness/B-AdverseReaction was/O reported/O in/O more/O than/O 1/O %/O of/O ULORIC/O -/O treated/O subjects/O although/O not/O at/O a/O rate/O more/O than/O 0.5/O %/O greater/O than/O placebo/O ./O
Less/O Common/O Adverse/O Reactions/O In/O Phase/O 2/O and/O 3/O clinical/O studies/O the/O following/O adverse/O reactions/O occurred/O in/O less/O than/O 1/O %/O of/O subjects/O and/O in/O more/O than/O one/O subject/O treated/O with/O doses/O ranging/O from/O 40/O mg/O to/O 240/O mg/O of/O ULORIC/O ./O
This/O list/O also/O includes/O adverse/O reactions/O (/O less/O than/O 1/O %/O of/O subjects/O )/O associated/O with/O organ/O systems/O from/O Warnings/O and/O Precautions/O ./O
Blood/O and/O Lymphatic/O System/O Disorders/O :/O anemia/B-AdverseReaction ,/O idiopathic/B-AdverseReaction thrombocytopenic/I-AdverseReaction purpura/I-AdverseReaction ,/O leukocytosis/B-AdverseReaction leukopenia/B-AdverseReaction ,/O neutropenia/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction ,/O splenomegaly/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction ./O
Cardiac/O Disorders/O :/O angina/B-AdverseReaction pectoris/I-AdverseReaction ,/O atrial/B-AdverseReaction fibrillation/I-AdverseReaction flutter/O ,/O cardiac/B-AdverseReaction murmur/I-AdverseReaction ,/O ECG/B-AdverseReaction abnormal/I-AdverseReaction ,/O palpitations/B-AdverseReaction ,/O sinus/B-AdverseReaction bradycardia/I-AdverseReaction ,/O tachycardia/B-AdverseReaction ./O
Ear/O and/O Labyrinth/O Disorders/O :/O deafness/B-AdverseReaction ,/O tinnitus/B-AdverseReaction ,/O vertigo/B-AdverseReaction ./O
Eye/O Disorders/O :/O vision/B-AdverseReaction blurred/I-AdverseReaction ./O
Gastrointestinal/O Disorders/O :/O abdominal/B-AdverseReaction distention/I-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O frequent/B-AdverseReaction stools/I-AdverseReaction ,/O gastritis/B-AdverseReaction ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction ,/O gastrointestinal/B-AdverseReaction discomfort/I-AdverseReaction ,/O gingival/B-AdverseReaction pain/I-AdverseReaction ,/O haematemesis/B-AdverseReaction ,/O hyperchlorhydria/B-AdverseReaction ,/O hematochezia/B-AdverseReaction ,/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O peptic/B-AdverseReaction ulcer/I-AdverseReaction ,/O vomiting/B-AdverseReaction ./O
General/O Disorders/O and/O Administration/O Site/O Conditions/O :/O asthenia/B-AdverseReaction ,/O chest/B-AdverseReaction pain/I-AdverseReaction discomfort/O ,/O edema/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O feeling/B-AdverseReaction abnormal/I-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O influenza/B-AdverseReaction -/I-AdverseReaction like/O symptoms/O ,/O mass/B-AdverseReaction ,/O pain/B-AdverseReaction ,/O thirst/B-AdverseReaction ./O
Hepatobiliary/O Disorders/O :/O cholelithiasis/B-AdverseReaction cholecystitis/B-AdverseReaction ,/O hepatic/B-AdverseReaction steatosis/I-AdverseReaction ,/O hepatitis/B-AdverseReaction ,/O hepatomegaly/B-AdverseReaction ./O
Immune/O System/O Disorder/O :/O hypersensitivity/B-AdverseReaction ./O
Infections/O and/O Infestations/O :/O herpes/B-AdverseReaction zoster/I-AdverseReaction ./O
Procedural/O Complications/O :/O contusion/B-AdverseReaction ./O
Metabolism/O and/O Nutrition/O Disorders/O :/O anorexia/B-AdverseReaction ,/O appetite/B-AdverseReaction decreased/I-AdverseReaction increased/O ,/O dehydration/B-AdverseReaction ,/O diabetes/B-AdverseReaction mellitus/I-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O hyperlipidemia/B-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O weight/B-AdverseReaction decreased/I-AdverseReaction increased/O ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O arthritis/B-AdverseReaction ,/O joint/B-AdverseReaction stiffness/I-AdverseReaction ,/O joint/B-AdverseReaction swelling/I-AdverseReaction ,/O muscle/B-AdverseReaction spasms/I-AdverseReaction twitching/O tightness/O weakness/O ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction stiffness/O ,/O myalgia/B-AdverseReaction ./O
Nervous/O System/O Disorders/O :/O altered/B-AdverseReaction taste/I-AdverseReaction ,/O balance/B-AdverseReaction disorder/I-AdverseReaction ,/O cerebrovascular/B-AdverseReaction accident/I-AdverseReaction ,/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O ,/O headache/B-AdverseReaction ,/O hemiparesis/B-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O hyposmia/B-AdverseReaction ,/O lacunar/B-AdverseReaction infarction/I-AdverseReaction ,/O lethargy/B-AdverseReaction ,/O mental/B-AdverseReaction impairment/I-AdverseReaction ,/O migraine/B-AdverseReaction ,/O paresthesia/B-AdverseReaction ,/O somnolence/B-AdverseReaction ,/O transient/B-AdverseReaction ischemic/I-AdverseReaction attack/I-AdverseReaction ,/O tremor/B-AdverseReaction ./O
Psychiatric/O Disorders/O :/O agitation/B-AdverseReaction ,/O anxiety/B-AdverseReaction ,/O depression/B-AdverseReaction ,/O insomnia/B-AdverseReaction ,/O irritability/B-AdverseReaction ,/O libido/B-AdverseReaction decreased/I-AdverseReaction ,/O nervousness/B-AdverseReaction ,/O panic/B-AdverseReaction attack/I-AdverseReaction ,/O personality/B-AdverseReaction change/I-AdverseReaction ./O
Renal/O and/O Urinary/O Disorders/O :/O hematuria/B-AdverseReaction ,/O nephrolithiasis/B-AdverseReaction ,/O pollakiuria/B-AdverseReaction ,/O proteinuria/B-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O renal/B-AdverseReaction insufficiency/I-AdverseReaction ,/O urgency/O ,/O incontinence/O ./O
Reproductive/O System/O and/O Breast/O Changes/O :/O breast/B-AdverseReaction pain/I-AdverseReaction ,/O erectile/B-AdverseReaction dysfunction/I-AdverseReaction ,/O gynecomastia/B-AdverseReaction ./O
Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O bronchitis/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O epistaxis/B-AdverseReaction ,/O nasal/B-AdverseReaction dryness/I-AdverseReaction ,/O paranasal/B-AdverseReaction sinus/I-AdverseReaction hypersecretion/I-AdverseReaction ,/O pharyngeal/B-AdverseReaction edema/I-AdverseReaction ,/O respiratory/B-AdverseReaction tract/I-AdverseReaction congestion/I-AdverseReaction ,/O sneezing/B-AdverseReaction ,/O throat/B-AdverseReaction irritation/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O alopecia/B-AdverseReaction ,/O angio/B-AdverseReaction -/O edema/O ,/O dermatitis/B-AdverseReaction ,/O dermographism/B-AdverseReaction ,/O ecchymosis/B-AdverseReaction ,/O eczema/B-AdverseReaction ,/O hair/B-AdverseReaction color/I-AdverseReaction changes/I-AdverseReaction ,/O hair/B-AdverseReaction growth/I-AdverseReaction abnormal/I-AdverseReaction ,/O hyperhidrosis/B-AdverseReaction ,/O peeling/B-AdverseReaction skin/I-AdverseReaction ,/O petechiae/B-AdverseReaction ,/O photosensitivity/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O purpura/B-AdverseReaction ,/O skin/B-AdverseReaction discoloration/I-AdverseReaction altered/O pigmentation/O ,/O skin/B-AdverseReaction lesion/I-AdverseReaction ,/O skin/B-AdverseReaction odor/I-AdverseReaction abnormal/I-AdverseReaction ,/O urticaria/B-AdverseReaction ./O
Vascular/O Disorders/O :/O flushing/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O hypotension/B-AdverseReaction ./O
Laboratory/O Parameters/O :/O activated/B-AdverseReaction partial/I-AdverseReaction thromboplastin/I-AdverseReaction time/I-AdverseReaction prolonged/I-AdverseReaction ,/O creatine/B-AdverseReaction increased/I-AdverseReaction ,/O bicarbonate/B-AdverseReaction decreased/I-AdverseReaction ,/O sodium/B-AdverseReaction increased/I-AdverseReaction ,/O EEG/B-AdverseReaction abnormal/I-AdverseReaction ,/O glucose/B-AdverseReaction increased/I-AdverseReaction ,/O cholesterol/B-AdverseReaction increased/I-AdverseReaction ,/O triglycerides/B-AdverseReaction increased/I-AdverseReaction ,/O amylase/B-AdverseReaction increased/I-AdverseReaction ,/O potassium/B-AdverseReaction increased/I-AdverseReaction ,/O TSH/B-AdverseReaction increased/I-AdverseReaction ,/O platelet/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction ,/O hematocrit/B-AdverseReaction decreased/I-AdverseReaction ,/O hemoglobin/B-AdverseReaction decreased/I-AdverseReaction ,/O MCV/B-AdverseReaction increased/I-AdverseReaction ,/O RBC/B-AdverseReaction decreased/I-AdverseReaction ,/O creatinine/B-AdverseReaction increased/I-AdverseReaction ,/O blood/B-AdverseReaction urea/I-AdverseReaction increased/I-AdverseReaction ,/O BUN/B-AdverseReaction creatinine/I-AdverseReaction ratio/O increased/O ,/O creatine/O phosphokinase/O (/O CPK/O )/O increased/O ,/O alkaline/B-AdverseReaction phosphatase/I-AdverseReaction increased/I-AdverseReaction ,/O LDH/B-AdverseReaction increased/I-AdverseReaction ,/O PSA/B-AdverseReaction increased/I-AdverseReaction ,/O urine/B-AdverseReaction output/I-AdverseReaction increased/I-AdverseReaction decreased/O ,/O lymphocyte/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction ,/O neutrophil/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction ,/O WBC/B-AdverseReaction increased/I-AdverseReaction decreased/O ,/O coagulation/B-AdverseReaction test/I-AdverseReaction abnormal/I-AdverseReaction ,/O low/O density/O lipoprotein/O (/O LDL/O )/O increased/O ,/O prothrombin/B-AdverseReaction time/I-AdverseReaction prolonged/I-AdverseReaction ,/O urinary/B-AdverseReaction casts/I-AdverseReaction ,/O urine/B-AdverseReaction positive/I-AdverseReaction for/I-AdverseReaction white/I-AdverseReaction blood/I-AdverseReaction cells/I-AdverseReaction and/O protein/O ./O
Cardiovascular/O Safety/O Cardiovascular/B-AdverseReaction events/I-AdverseReaction and/O deaths/B-AdverseReaction were/O adjudicated/O to/O one/O of/O the/O pre/O -/O defined/O endpoints/O from/O the/O Anti/O -/O Platelet/O Trialists/O '/O Collaborations/O (/O APTC/O )/O (/O cardiovascular/B-AdverseReaction death/I-AdverseReaction ,/O non/B-Severity -/O fatal/O myocardial/B-AdverseReaction infarction/I-AdverseReaction ,/O and/O non/B-Severity -/O fatal/O stroke/B-AdverseReaction )/O in/O the/O randomized/O controlled/O and/O long/O -/O term/O extension/O studies/O ./O
In/O the/O Phase/O 3/O randomized/O controlled/O studies/O ,/O the/O incidences/O of/O adjudicated/O APTC/O events/O per/O 100/O patient/O -/O years/O of/O exposure/O were/O :/O Placebo/O 0/O (/O 95/O %/O CI/O 0.00/O -/O 6.16/O )/O ,/O ULORIC/O 40/O mg/O 0/O (/O 95/O %/O CI/O 0.00/O -/O 1.08/O )/O ,/O ULORIC/O 80/O mg/O 1.09/O (/O 95/O %/O CI/O 0.44/O -/O 2.24/O )/O ,/O and/O allopurinol/O 0.60/O (/O 95/O %/O CI/O 0.16/O -/O 1.53/O )/O ./O
In/O the/O long/O -/O term/O extension/O studies/O ,/O the/O incidences/O of/O adjudicated/O APTC/O events/O were/O :/O ULORIC/O 80/O mg/O 0.97/O (/O 95/O %/O CI/O 0.57/O -/O 1.56/O )/O ,/O and/O allopurinol/O 0.58/O (/O 95/O %/O CI/O 0.02/O -/O 3.24/O )/O ./O
Overall/O ,/O a/O higher/O rate/O of/O APTC/O events/O was/O observed/O in/O ULORIC/O than/O in/O allopurinol/O -/O treated/O patients/O ./O
A/O causal/O relationship/O with/O ULORIC/O has/O not/O been/O established/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O MI/O and/O stroke/O ./O
6.2/O Postmarketing/O Experience/O Adverse/O reactions/O have/O been/O identified/O during/O postapproval/O use/O of/O ULORIC/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O ./O
Hepatobiliary/O Disorders/O :/O hepatic/B-AdverseReaction failure/I-AdverseReaction (/O some/O fatal/B-AdverseReaction )/O ,/O jaundice/B-AdverseReaction ,/O serious/B-Severity cases/O of/O abnormal/B-AdverseReaction liver/I-AdverseReaction function/I-AdverseReaction test/O results/O ,/O liver/B-AdverseReaction disorder/I-AdverseReaction ./O
Immune/O System/O Disorders/O :/O anaphylaxis/B-AdverseReaction ,/O anaphylactic/B-AdverseReaction reaction/I-AdverseReaction ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O rhabdomyolysis/B-AdverseReaction ./O
Psychiatric/O Disorders/O :/O psychotic/B-AdverseReaction behavior/I-AdverseReaction including/O aggressive/B-AdverseReaction thoughts/I-AdverseReaction ./O
Renal/O and/O Urinary/O Disorders/O :/O tubulointerstitial/B-AdverseReaction nephritis/I-AdverseReaction ./O
Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O generalized/B-AdverseReaction rash/I-AdverseReaction ,/O Stevens/B-AdverseReaction Johnson/I-AdverseReaction Syndrome/I-AdverseReaction ,/O hypersensitivity/B-AdverseReaction skin/I-AdverseReaction reactions/I-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Gout/B-AdverseReaction Flare/I-AdverseReaction :/O An/O increase/O in/O gout/B-AdverseReaction flares/I-AdverseReaction is/O frequently/O observed/O during/O initiation/O of/O anti/O -/O hyperuricemic/O agents/O ,/O including/O ULORIC/O ./O
If/O a/O gout/O flare/O occurs/O during/O treatment/O ,/O ULORIC/O need/O not/O be/O discontinued/O ./O
Prophylactic/O therapy/O (/O i.e./O ,/O non/O -/O steroidal/O anti/O -/O inflammatory/O drug/O [/O NSAID/O ]/O or/O colchicine/O upon/O initiation/O of/O treatment/O )/O may/O be/O beneficial/O for/O up/O to/O six/O months/O ./O
(/O 2.4/O ,/O 5.1/O )/O Cardiovascular/B-AdverseReaction Events/I-AdverseReaction :/O A/O higher/O rate/O of/O cardiovascular/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction was/O observed/O in/O patients/O treated/O with/O ULORIC/O than/O allopurinol/O in/O clinical/O trials/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O MI/O and/O stroke/O ./O
(/O 5.2/O )/O Hepatic/B-AdverseReaction Effects/I-AdverseReaction :/O Postmarketing/O reports/O of/O hepatic/B-AdverseReaction failure/I-AdverseReaction ,/O sometimes/O fatal/B-AdverseReaction ./O
Causality/O can/O not/O be/O excluded/O ./O
If/O liver/O injury/O is/O detected/O ,/O promptly/O interrupt/O ULORIC/O and/O assess/O patient/O for/O probable/O cause/O ,/O then/O treat/O cause/O if/O possible/O ,/O to/O resolution/O or/O stabilization/O ./O
Do/O not/O restart/O ULORIC/O if/O liver/O injury/O is/O confirmed/O and/O no/O alternate/O etiology/O can/O be/O found/O ./O
(/O 5.3/O )/O 5.1/O Gout/O Flare/O After/O initiation/O of/O ULORIC/O ,/O an/O increase/O in/O gout/B-AdverseReaction flares/I-AdverseReaction is/O frequently/O observed/O ./O
This/O increase/O is/O due/O to/O reduction/O in/O serum/O uric/O acid/O levels/O ,/O resulting/O in/O mobilization/O of/O urate/O from/O tissue/O deposits/O ./O
In/O order/O to/O prevent/O gout/O flares/O when/O ULORIC/O is/O initiated/O ,/O concurrent/O prophylactic/O treatment/O with/O an/O NSAID/O or/O colchicine/O is/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.4/O )/O ]/O ./O
5.2/O Cardiovascular/O Events/O In/O the/O randomized/O controlled/O studies/O ,/O there/O was/O a/O higher/O rate/O of/O cardiovascular/B-AdverseReaction thromboembolic/I-AdverseReaction events/I-AdverseReaction (/O cardiovascular/B-AdverseReaction deaths/I-AdverseReaction ,/O non/B-Severity -/O fatal/O myocardial/B-AdverseReaction infarctions/I-AdverseReaction ,/O and/O non/B-Severity -/O fatal/O strokes/B-AdverseReaction )/O in/O patients/O treated/O with/O ULORIC/O (/O 0.74/O per/O 100/O P/O -/O Y/O [/O 95/O %/O Confidence/O Interval/O (/O CI/O )/O 0.36/O -/O 1.37/O ]/O )/O than/O allopurinol/O (/O 0.60/O per/O 100/O P/O -/O Y/O [/O 95/O %/O CI/O 0.16/O -/O 1.53/O ]/O )/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
A/O causal/O relationship/O with/O ULORIC/O has/O not/O been/O established/O ./O
Monitor/O for/O signs/O and/O symptoms/O of/O myocardial/O infarction/O (/O MI/O )/O and/O stroke/O ./O
5.3/O Hepatic/O Effects/O There/O have/O been/O postmarketing/O reports/O of/O fatal/B-AdverseReaction and/O non/O -/O fatal/O hepatic/B-AdverseReaction failure/I-AdverseReaction in/O patients/O taking/O ULORIC/O ,/O although/O the/O reports/O contain/O insufficient/O information/O necessary/O to/O establish/O the/O probable/O cause/O ./O
During/O randomized/O controlled/O studies/O ,/O transaminase/B-AdverseReaction elevations/I-AdverseReaction greater/O than/O three/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O ULN/O )/O were/O observed/O (/O AST/O :/O 2/O %/O ,/O 2/O %/O ,/O and/O ALT/O :/O 3/O %/O ,/O 2/O %/O in/O ULORIC/O and/O allopurinol/O -/O treated/O patients/O ,/O respectively/O )/O ./O
No/O dose/O -/O effect/O relationship/O for/O these/O transaminase/O elevations/O was/O noted/O [/O see/O Clinical/O Pharmacology/O (/O 12.3/O )/O ]/O ./O
Obtain/O a/O liver/O test/O panel/O (/O serum/O alanine/O aminotransferase/O [/O ALT/O ]/O ,/O aspartate/O aminotransferase/O [/O AST/O ]/O ,/O alkaline/O phosphatase/O ,/O and/O total/O bilirubin/O )/O as/O a/O baseline/O before/O initiating/O ULORIC/O ./O
Measure/O liver/O tests/O promptly/O in/O patients/O who/O report/O symptoms/O that/O may/O indicate/O liver/O injury/O ,/O including/O fatigue/O ,/O anorexia/O ,/O right/O upper/O abdominal/O discomfort/O ,/O dark/O urine/O or/O jaundice/O ./O
In/O this/O clinical/O context/O ,/O if/O the/O patient/O is/O found/O to/O have/O abnormal/O liver/O tests/O (/O ALT/O greater/O than/O three/O times/O the/O upper/O limit/O of/O the/O reference/O range/O )/O ,/O ULORIC/O treatment/O should/O be/O interrupted/O and/O investigation/O done/O to/O establish/O the/O probable/O cause/O ./O
ULORIC/O should/O not/O be/O restarted/O in/O these/O patients/O without/O another/O explanation/O for/O the/O liver/O test/O abnormalities/O ./O
Patients/O who/O have/O serum/O ALT/O greater/O than/O three/O times/O the/O reference/O range/O with/O serum/O total/O bilirubin/O greater/O than/O two/O times/O the/O reference/O range/O without/O alternative/O etiologies/O are/O at/O risk/O for/O severe/O drug/O -/O induced/O liver/O injury/O and/O should/O not/O be/O restarted/O on/O ULORIC/O ./O
For/O patients/O with/O lesser/O elevations/O of/O serum/O ALT/O or/O bilirubin/O and/O with/O an/O alternate/O probable/O cause/O ,/O treatment/O with/O ULORIC/O can/O be/O used/O with/O caution/O ./O
6/O ADVERSE/O REACTIONS/O See/O the/O peginterferon/O alfa/O and/O ribavirin/O prescribing/O information/O for/O description/O of/O adverse/O reactions/O associated/O with/O their/O use/O ./O
EXCERPT/O :/O The/O most/O commonly/O reported/O adverse/O reactions/O (/O greater/O than/O 35/O %/O of/O subjects/O )/O in/O clinical/O trials/O in/O adult/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O and/O REBETOL/O were/O fatigue/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction and/O dysgeusia/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Merck/O Sharp/O &/O Dohme/O Corp./O ,/O a/O subsidiary/O of/O Merck/O &/O Co./O ,/O Inc./O ,/O at/O 1/O -/O 877/O -/O 888/O -/O 4231/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O VICTRELIS/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O following/O serious/O and/O otherwise/O important/O adverse/O drug/O reactions/O (/O ADRs/O )/O are/O discussed/O in/O detail/O in/O another/O section/O of/O the/O labeling/O :/O Anemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Neutropenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Pancytopenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Hypersensitivity/B-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O The/O most/O commonly/O reported/O adverse/O reactions/O (/O more/O than/O 35/O %/O of/O subjects/O regardless/O of/O investigator/O 's/O causality/O assessment/O )/O in/O adult/O subjects/O were/O fatigue/B-AdverseReaction ,/O anemia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O dysgeusia/B-AdverseReaction when/O VICTRELIS/O was/O used/O in/O combination/O with/O PegIntron/O and/O REBETOL/O ./O
The/O safety/O of/O the/O combination/O of/O VICTRELIS/O 800/O mg/O three/O times/O daily/O with/O PegIntron/O REBETOL/O was/O assessed/O in/O 2095/O subjects/O with/O chronic/O hepatitis/O C/O in/O one/O Phase/O 2/O ,/O open/O -/O label/O trial/O and/O two/O Phase/O 3/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O clinical/O trials/O ./O
SPRINT-1/O (/O subjects/O who/O were/O previously/O untreated/O )/O evaluated/O the/O use/O of/O VICTRELIS/O in/O combination/O with/O PegIntron/O REBETOL/O with/O or/O without/O a/O four/O -/O week/O lead/O -/O in/O period/O with/O PegIntron/O REBETOL/O compared/O to/O PegIntron/O REBETOL/O alone/O ./O
SPRINT-2/O (/O subjects/O who/O were/O previously/O untreated/O )/O and/O RESPOND-2/O (/O subjects/O who/O had/O failed/O previous/O therapy/O )/O evaluated/O the/O use/O of/O VICTRELIS/O 800/O mg/O three/O times/O daily/O in/O combination/O with/O PegIntron/O REBETOL/O with/O a/O four/O -/O week/O lead/O -/O in/O period/O with/O PegIntron/O REBETOL/O compared/O to/O PegIntron/O REBETOL/O alone/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
The/O population/O studied/O had/O a/O mean/O age/O of/O 49/O years/O (/O 3/O %/O of/O subjects/O were/O older/O than/O 65/O years/O of/O age/O )/O ,/O 39/O %/O were/O female/O ,/O 82/O %/O were/O white/O and/O 15/O %/O were/O black/O ./O
During/O the/O four/O week/O lead/O -/O in/O period/O with/O PegIntron/O REBETOL/O in/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O ,/O 28/1263/O (/O 2/O %/O )/O subjects/O experienced/O adverse/O reactions/O leading/O to/O discontinuation/O of/O treatment/O ./O
During/O the/O entire/O course/O of/O treatment/O ,/O the/O proportion/O of/O subjects/O who/O discontinued/O treatment/O due/O to/O adverse/O reactions/O was/O 13/O %/O for/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O and/O 12/O %/O for/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O ./O
Events/O resulting/O in/O discontinuation/O were/O similar/O to/O those/O seen/O in/O previous/O studies/O with/O PegIntron/O REBETOL/O ./O
Only/O anemia/B-AdverseReaction and/O fatigue/B-AdverseReaction were/O reported/O as/O events/O that/O led/O to/O discontinuation/O in/O more/O than/O 1/O %/O of/O subjects/O in/O any/O arm/O ./O
Adverse/O reactions/O that/O led/O to/O dose/O modifications/O of/O any/O drug/O (/O primarily/O PegIntron/O and/O REBETOL/O )/O occurred/O in/O 39/O %/O of/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O compared/O to/O 24/O %/O of/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O ./O
The/O most/O common/O reason/O for/O dose/O reduction/O was/O anemia/B-AdverseReaction ,/O which/O occurred/O more/O frequently/O in/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O than/O in/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O ./O
Serious/O adverse/O events/O were/O reported/O in/O 11/O %/O of/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O and/O in/O 8/O %/O of/O subjects/O receiving/O PegIntron/O REBETOL/O ./O
Adverse/O events/O (/O regardless/O of/O investigator/O 's/O causality/O assessment/O )/O reported/O in/O greater/O than/O or/O equal/O to/O 10/O %/O of/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O and/O reported/O at/O a/O rate/O of/O greater/O than/O or/O equal/O to/O 5/O %/O than/O PegIntron/O REBETOL/O alone/O in/O SPRINT-1/O ,/O SPRINT-2/O ,/O and/O RESPOND-2/O are/O presented/O in/O Table/O 3/O ./O
Table/O 3/O Adverse/O Events/O Reported/O in/O 10/O %/O of/O Subjects/O Receiving/O the/O Combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O and/O Reported/O at/O a/O Rate/O of/O 5/O %/O than/O PegIntron/O REBETOL/O alone/O Adverse/O Events/O Previously/O Untreated(SPRINT-1/O and/O SPRINT-2/O )/O Previous/O Treatment/O Failures(RESPOND-2/O )/O Percentage/O of/O Subjects/O Reporting/O Adverse/O Events/O Percentage/O of/O Subjects/O Reporting/O Adverse/O Events/O Body/O System/O Organ/O Class/O VICTRELIS/O +/O PegIntron/O +/O REBETOL(n=1225/O )/O PegIntron/O +/O REBETOL(n=467/O )/O VICTRELIS/O +/O PegIntron/O +/O REBETOL(n=323/O )/O PegIntron/O +/O REBETOL(n=80/O )/O Median/O Exposure/O (/O days/O )/O 197/O 216/O 253/O 104/O Blood/O and/O Lymphatic/O System/O Disorders/O Anemia/B-AdverseReaction 50/O 30/O 45/O 20/O Neutropenia/B-AdverseReaction 25/O 19/O 14/O 10/O Gastrointestinal/O Disorders/O Nausea/B-AdverseReaction 46/O 42/O 43/O 38/O Dysgeusia/B-AdverseReaction 35/O 16/O 44/O 11/O Diarrhea/B-AdverseReaction 25/O 22/O 24/O 16/O Vomiting/B-AdverseReaction 20/O 13/O 15/O 8/O Dry/B-AdverseReaction Mouth/I-AdverseReaction 11/O 10/O 15/O 9/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Fatigue/B-AdverseReaction 58/O 59/O 55/O 50/O Chills/B-AdverseReaction 34/O 29/O 33/O 30/O Asthenia/B-AdverseReaction 15/O 18/O 21/O 16/O Metabolism/O and/O Nutrition/O Disorders/O Decreased/B-AdverseReaction Appetite/I-AdverseReaction 25/O 24/O 26/O 16/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Arthralgia/B-AdverseReaction 19/O 19/O 23/O 16/O Nervous/O System/O Disorders/O Dizziness/B-AdverseReaction 19/O 16/O 16/O 10/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 34/O 34/O 30/O 24/O Irritability/B-AdverseReaction 22/O 23/O 21/O 13/O Respiratory/O ,/O Thoracic/O ,/O and/O Mediastinal/O Disorders/O Dyspnea/B-AdverseReaction Exertional/I-AdverseReaction 8/O 8/O 11/O 5/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Alopecia/B-AdverseReaction 27/O 27/O 22/O 16/O Dry/B-AdverseReaction Skin/I-AdverseReaction 18/O 18/O 22/O 9/O Rash/B-AdverseReaction 17/O 19/O 16/O 6/O Other/O Important/O Adverse/O Reactions/O Reported/O in/O Clinical/O Trials/O Among/O subjects/O (/O previously/O untreated/O subjects/O or/O those/O who/O failed/O previous/O therapy/O )/O who/O received/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O ,/O the/O following/O adverse/O drug/O reactions/O were/O reported/O ./O
These/O events/O are/O notable/O because/O of/O their/O seriousness/O ,/O severity/O ,/O or/O increased/O frequency/O in/O subjects/O who/O received/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O compared/O with/O subjects/O who/O received/O only/O peginterferon/O alfa/O and/O ribavirin/O ./O
Gastrointestinal/O Disorders/O Dysgeusia/B-AdverseReaction (/O alteration/B-AdverseReaction of/I-AdverseReaction taste/I-AdverseReaction )/O was/O an/O adverse/O event/O reported/O at/O an/O increased/O frequency/O in/O subjects/O receiving/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O compared/O with/O subjects/O receiving/O peginterferon/O alfa/O and/O ribavirin/O alone/O (/O Table/O 3/O )/O ./O
Adverse/O events/O such/O as/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction and/O diarrhea/B-AdverseReaction were/O also/O reported/O at/O an/O increased/O frequency/O in/O subjects/O receiving/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O ./O
Laboratory/O Values/O Changes/O in/O selected/O hematological/O parameters/O during/O treatment/O of/O adult/O subjects/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O and/O REBETOL/O are/O described/O in/O Table/O 4/O ./O
Hemoglobin/O Decreases/O in/O hemoglobin/O may/O require/O a/O decrease/O in/O dosage/O or/O discontinuation/O of/O ribavirin/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O and/O Clinical/O Studies/O (/O 14/O )/O ]/O [/O see/O prescribing/O information/O for/O ribavirin/O ]/O ./O
If/O ribavirin/O is/O permanently/O discontinued/O ,/O then/O peginterferon/O alfa/O and/O VICTRELIS/O must/O also/O be/O discontinued/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Neutrophils/O and/O Platelets/O The/O proportion/O of/O subjects/O with/O decreased/O neutrophil/O and/O platelet/O counts/O was/O higher/O in/O subjects/O treated/O with/O VICTRELIS/O in/O combination/O with/O PegIntron/O REBETOL/O compared/O to/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O ./O
Three/O percent/O of/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O had/O platelet/B-AdverseReaction counts/I-AdverseReaction of/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 50/I-AdverseReaction 10/I-AdverseReaction 9/I-AdverseReaction per/O L/O compared/O to/O 1/O %/O of/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O ./O
Decreases/O in/O neutrophils/O or/O platelets/O may/O require/O a/O decrease/O in/O dosage/O or/O interruption/O of/O peginterferon/O alfa/O ,/O or/O discontinuation/O of/O therapy/O [/O see/O prescribing/O information/O for/O peginterferon/O alfa/O and/O ribavirin/O ]/O ./O
If/O peginterferon/O alfa/O is/O permanently/O discontinued/O ,/O then/O ribavirin/O and/O VICTRELIS/O must/O also/O be/O discontinued/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Table/O 4/O Selected/O Hematological/O Parameters/O Previously/O Untreated(SPRINT-1/O and/O SPRINT-2/O )/O Previous/O Treatment/O Failures(RESPOND-2/O )/O Percentage/O of/O Subjects/O Reporting/O Selected/O Hematological/O Parameters/O Percentage/O of/O Subjects/O Reporting/O Selected/O Hematological/O Parameters/O Hematological/O Parameters/O VICTRELIS/O +/O PegIntron/O +/O REBETOL(n=1225/O )/O PegIntron/O +/O REBETOL(n=467/O )/O VICTRELIS/O +/O PegIntron/O +/O REBETOL(n=323/O )/O PegIntron/O +/O REBETOL(n=80/O )/O Hemoglobin/B-AdverseReaction (/I-AdverseReaction g/I-AdverseReaction dL/O )/O 10/O 49/O 29/O 49/O 25/O 8.5/O 6/O 3/O 10/O 1/O Neutrophils/B-AdverseReaction (/I-AdverseReaction 10/I-AdverseReaction 9/I-AdverseReaction /L/O )/O 0.75/O 31/O 18/O 26/O 13/O 0.5/O 8/O 4/O 7/O 4/O Platelets/B-AdverseReaction (/I-AdverseReaction 10/I-AdverseReaction 9/I-AdverseReaction /L/O )/O 50/O 3/O 1/O 4/O 0/O 25/O 1/O 0/O 0/O 0/O 6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O post/O -/O approval/O use/O of/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Blood/O and/O Lymphatic/O System/O Disorders/O :/O agranulocytosis/B-AdverseReaction ,/O pancytopenia/B-AdverseReaction ,/O thrombocytopenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Gastrointestinal/O Disorders/O :/O mouth/B-AdverseReaction ulceration/I-AdverseReaction ,/O stomatitis/B-AdverseReaction Infections/O and/O Infestations/O :/O pneumonia/B-AdverseReaction ,/O sepsis/B-AdverseReaction Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O angioedema/B-AdverseReaction ,/O urticaria/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ;/O drug/O rash/O with/O eosinophilia/O and/O systemic/O symptoms/O (/O DRESS/O )/O syndrome/O ,/O exfoliative/B-AdverseReaction rash/I-AdverseReaction ,/O exfoliative/B-AdverseReaction dermatitis/I-AdverseReaction ,/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O toxic/B-AdverseReaction skin/I-AdverseReaction eruption/I-AdverseReaction ,/O toxicoderma/B-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Use/O of/O VICTRELIS/O with/O Ribavirin/O and/O Peginterferon/O alfa/O :/O Embryofetal/B-AdverseReaction Toxicity/I-AdverseReaction (/O Use/O with/O Ribavirin/O and/O Peginterferon/O Alfa/O )/O :/O Ribavirin/O may/B-Factor cause/O birth/B-AdverseReaction defects/I-AdverseReaction and/O fetal/B-AdverseReaction death/I-AdverseReaction ;/O avoid/O pregnancy/O in/O female/O patients/O and/O female/O partners/O of/O male/O patients/O ./O
Patients/O must/O have/O a/O negative/O pregnancy/O test/O prior/O to/O therapy/O ;/O use/O two/O or/O more/O forms/O of/O contraception/O ,/O and/O have/O monthly/O pregnancy/O tests/O ./O
(/O 5.1/O )/O Anemia/B-AdverseReaction -/O The/O addition/O of/O VICTRELIS/O to/O peginterferon/O alfa/O and/O ribavirin/O is/O associated/O with/O an/O additional/O decrease/B-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction concentrations/I-AdverseReaction compared/O with/O peginterferon/O alfa/O and/O ribavirin/O alone/O ./O
(/O 5.2/O )/O Neutropenia/B-AdverseReaction -/O The/O addition/O of/O VICTRELIS/O to/O peginterferon/O alfa/O and/O ribavirin/O may/B-Factor result/O in/O worsening/B-AdverseReaction of/I-AdverseReaction neutropenia/I-AdverseReaction associated/O with/O peginterferon/O alfa/O and/O ribavirin/O therapy/O alone/O ./O
(/O 5.3/O )/O Hypersensitivity/B-AdverseReaction -/O Serious/B-Severity acute/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction (/O e.g./O ,/O urticaria/B-AdverseReaction ,/O angioedema/B-AdverseReaction )/O have/O been/O observed/O during/O combination/O therapy/O with/O VICTRELIS/O ,/O peginterferon/O alfa/O and/O ribavirin/O ./O
(/O 5.5/O )/O 5.1/O Embryofetal/O Toxicity/O (/O Use/O with/O Ribavirin/O and/O Peginterferon/O Alfa/O )/O Ribavirin/O may/B-Factor cause/O birth/B-AdverseReaction defects/I-AdverseReaction and/or/O death/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction exposed/I-AdverseReaction fetus/I-AdverseReaction ./O
Extreme/O care/O must/O be/O taken/O to/O avoid/O pregnancy/O in/O female/O patients/O and/O in/O female/O partners/O of/O male/O patients/O ./O
Ribavirin/O therapy/O should/O not/O be/O started/O unless/O a/O report/O of/O a/O negative/O pregnancy/O test/O has/O been/O obtained/O immediately/O prior/O to/O initiation/O of/O therapy/O ./O
Refer/O to/O the/O prescribing/O information/O for/O ribavirin/O for/O additional/O information/O ./O
Women/O of/O childbearing/O potential/O and/O men/O must/O use/O at/O least/O two/O forms/O of/O effective/O contraception/O during/O treatment/O and/O for/O at/O least/O 6/O months/O after/O treatment/O has/O concluded/O ./O
One/O of/O these/O forms/O of/O contraception/O can/O be/O a/O combined/O oral/O contraceptive/O product/O containing/O at/O least/O 1/O mg/O of/O norethindrone/O ./O
Oral/O contraceptives/O containing/O lower/O doses/O of/O norethindrone/O and/O other/O forms/O of/O hormonal/O contraception/O have/O not/O been/O studied/O or/O are/O contraindicated/O ./O
Routine/O monthly/O pregnancy/O tests/O must/O be/O performed/O during/O this/O time/O [/O see/O Contraindications/O (/O 4/O )/O and/O Drug/O Interactions/O (/O 7/O )/O ]/O ./O
5.2/O Anemia/O (/O Use/O with/O Ribavirin/O and/O Peginterferon/O Alfa/O )/O Anemia/B-AdverseReaction has/O been/O reported/O with/O peginterferon/O alfa/O and/O ribavirin/O therapy/O ./O
The/O addition/O of/O VICTRELIS/O to/O peginterferon/O alfa/O and/O ribavirin/O is/O associated/O with/O an/O additional/B-AdverseReaction decrease/I-AdverseReaction in/I-AdverseReaction hemoglobin/I-AdverseReaction concentrations/I-AdverseReaction ./O
Complete/O blood/O counts/O (/O with/O white/O blood/O cell/O differential/O counts/O )/O should/O be/O obtained/O pretreatment/O ,/O and/O at/O Treatment/O Weeks/O 2/O ,/O 4/O ,/O 8/O ,/O and/O 12/O ,/O and/O should/O be/O monitored/O closely/O at/O other/O time/O points/O ,/O as/O clinically/O appropriate/O ./O
If/O hemoglobin/O is/O less/O than/O 10/O g/O per/O dL/O ,/O a/O decrease/O in/O dosage/O of/O ribavirin/O is/O recommended/O ;/O and/O if/O hemoglobin/O is/O less/O than/O 8.5/O g/O per/O dL/O ,/O discontinuation/O of/O ribavirin/O is/O recommended/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O and/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
If/O ribavirin/O is/O permanently/O discontinued/O for/O management/O of/O anemia/O ,/O then/O peginterferon/O alfa/O and/O VICTRELIS/O must/O also/O be/O discontinued/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Refer/O to/O the/O prescribing/O information/O for/O ribavirin/O for/O additional/O information/O regarding/O dose/O reduction/O and/or/O discontinuation/O ./O
In/O clinical/O trials/O with/O VICTRELIS/O ,/O the/O proportion/O of/O subjects/O who/O experienced/O hemoglobin/B-AdverseReaction values/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 10/I-AdverseReaction g/I-AdverseReaction per/I-AdverseReaction dL/I-AdverseReaction and/O less/O than/O 8.5/O g/O per/O dL/O was/O higher/O in/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O (/O r/O )/O /REBETOL/O (/O r/O )/O than/O in/O those/O treated/O with/O PegIntron/O REBETOL/O alone/O (/O see/O Table/O 4/O )/O ./O
With/O the/O interventions/O used/O for/O anemia/O management/O in/O the/O clinical/O trials/O ,/O the/O average/O additional/O decrease/O of/O hemoglobin/O was/O approximately/O 1/O g/O per/O dL./O In/O clinical/O trials/O ,/O the/O median/O time/O to/O onset/O of/O hemoglobin/B-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 10/I-AdverseReaction g/I-AdverseReaction per/I-AdverseReaction dL/I-AdverseReaction from/O the/O initiation/O of/O therapy/O was/O similar/O among/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O and/O PegIntron/O REBETOL/O (/O 71/O days/O with/O a/O range/O of/O 15/O -/O 337/O days/O )/O ,/O compared/O to/O those/O who/O received/O PegIntron/O REBETOL/O (/O 71/O days/O with/O a/O range/O of/O 8/O -/O 337/O days/O )/O ./O
Certain/O adverse/O reactions/O consistent/O with/O symptoms/O of/O anemia/B-AdverseReaction ,/O such/O as/O dyspnea/B-AdverseReaction ,/O exertional/B-AdverseReaction dyspnea/I-AdverseReaction ,/O dizziness/B-AdverseReaction and/O syncope/B-AdverseReaction were/O reported/O more/O frequently/O in/O subjects/O who/O received/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O than/O in/O those/O treated/O with/O PegIntron/O REBETOL/O alone/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
In/O clinical/O trials/O with/O VICTRELIS/O ,/O dose/O modifications/O (/O generally/O of/O PegIntron/O REBETOL/O )/O due/O to/O anemia/B-AdverseReaction occurred/O twice/O as/O often/O in/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O (/O 26/O %/O )/O compared/O to/O PegIntron/O REBETOL/O (/O 13/O %/O )/O ./O
The/O proportion/O of/O subjects/O who/O discontinued/O study/O drug/O due/O to/O anemia/B-AdverseReaction was/O 1/O %/O in/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O and/O 1/O %/O in/O subjects/O who/O received/O PegIntron/O REBETOL/O ./O
The/O use/O of/O erythropoiesis/O stimulating/O agents/O (/O ESAs/O )/O was/O permitted/O for/O management/O of/O anemia/O ,/O at/O the/O investigator/O 's/O discretion/O ,/O with/O or/O without/O ribavirin/O dose/O reduction/O in/O the/O Phase/O 2/O and/O 3/O clinical/O trials/O ./O
The/O proportion/O of/O subjects/O who/O received/O an/O ESA/O was/O 43/O %/O in/O those/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O compared/O to/O 24/O %/O in/O those/O treated/O with/O PegIntron/O REBETOL/O alone/O ./O
The/O proportion/O of/O subjects/O who/O received/O a/O transfusion/O for/O the/O management/O of/O anemia/O was/O 3/O %/O of/O subjects/O treated/O with/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O compared/O to/O less/O than/O 1/O %/O in/O subjects/O who/O received/O PegIntron/O REBETOL/O alone/O ./O
Thromboembolic/O events/O have/O been/O associated/O with/O ESA/O use/O in/O other/O disease/O states/O ;/O and/O have/O also/O been/O reported/O with/O peginterferon/O alfa/O use/O in/O hepatitis/O C/O patients/O ./O
Thromboembolic/B-AdverseReaction events/I-AdverseReaction were/O reported/O in/O clinical/O trials/O with/O VICTRELIS/O among/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O ,/O and/O among/O those/O receiving/O PegIntron/O REBETOL/O alone/O ,/O regardless/O of/O ESA/O use/O ./O
No/O definite/O causality/O assessment/O or/O benefit/O risk/O assessment/O could/O be/O made/O for/O these/O events/O due/O to/O the/O presence/O of/O confounding/O factors/O and/O lack/O of/O randomization/O of/O ESA/O use/O ./O
A/O randomized/O ,/O parallel/O -/O arm/O ,/O open/O -/O label/O clinical/O trial/O was/O conducted/O in/O previously/O untreated/O CHC/O subjects/O with/O genotype/O 1/O infection/O to/O compare/O use/O of/O an/O ESA/O versus/O ribavirin/O dose/O reduction/O for/O initial/O management/O of/O anemia/O during/O therapy/O with/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa-2b/O and/O ribavirin/O ./O
Similar/O SVR/O rates/O were/O reported/O in/O subjects/O who/O were/O randomized/O to/O receive/O ribavirin/O dose/O reduction/O compared/O to/O subjects/O who/O were/O randomized/O to/O receive/O an/O ESA/O ./O
In/O this/O trial/O ,/O use/O of/O ESAs/O was/O associated/O with/O an/O increased/O risk/O of/O thromboembolic/O events/O including/O pulmonary/O embolism/O ,/O acute/O myocardial/O infarction/O ,/O cerebrovascular/O accident/O ,/O and/O deep/O vein/O thrombosis/O compared/O to/O ribavirin/O dose/O reduction/O alone/O ./O
The/O treatment/O discontinuation/O rate/O due/O to/O anemia/B-AdverseReaction was/O similar/O in/O subjects/O randomized/O to/O receive/O ribavirin/O dose/O reduction/O compared/O to/O subjects/O randomized/O to/O receive/O ESA/O (/O 2/O %/O in/O each/O group/O )/O ./O
The/O transfusion/O rate/O was/O 4/O %/O in/O subjects/O randomized/O to/O receive/O ribavirin/O dose/O reduction/O and/O 2/O %/O in/O subjects/O randomized/O to/O receive/O ESA/O ./O
Ribavirin/O dose/O reduction/O is/O recommended/O for/O the/O initial/O management/O of/O anemia/O ./O
5.3/O Neutropenia/O (/O Use/O with/O Ribavirin/O and/O Peginterferon/O Alfa/O )/O In/O Phase/O 2/O and/O 3/O clinical/O trials/O ,/O seven/O percent/O of/O subjects/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O had/O neutrophil/B-AdverseReaction counts/I-AdverseReaction of/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 0.5/I-AdverseReaction 10/I-AdverseReaction 9/I-AdverseReaction per/O L/O compared/O to/O 4/O %/O of/O subjects/O receiving/O PegIntron/O REBETOL/O alone/O (/O see/O Table/O 4/O )/O ./O
Three/O subjects/O experienced/O severe/B-Severity or/O life/B-Severity -/O threatening/O infections/B-AdverseReaction associated/O with/O neutropenia/B-AdverseReaction ,/O and/O two/O subjects/O experienced/O life/B-Severity -/O threatening/O neutropenia/B-AdverseReaction while/O receiving/O the/O combination/O of/O VICTRELIS/O with/O PegIntron/O REBETOL/O ./O
Complete/O blood/O counts/O (/O with/O white/O blood/O cell/O differential/O counts/O )/O should/O be/O obtained/O at/O pretreatment/O ,/O and/O at/O Treatment/O Weeks/O 2/O ,/O 4/O ,/O 8/O ,/O and/O 12/O ,/O and/O should/O be/O monitored/O closely/O at/O other/O time/O points/O ,/O as/O clinically/O appropriate/O ./O
Decreases/O in/O neutrophil/O counts/O may/O require/O dose/O reduction/O or/O discontinuation/O of/O peginterferon/O alfa/O and/O ribavirin/O ./O
If/O peginterferon/O alfa/O and/O ribavirin/O are/O permanently/O discontinued/O ,/O then/O VICTRELIS/O must/O also/O be/O discontinued/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Refer/O to/O the/O prescribing/O information/O for/O peginterferon/O alfa/O and/O ribavirin/O for/O additional/O information/O regarding/O dose/O reduction/O or/O discontinuation/O ./O
5.4/O Pancytopenia/O (/O Use/O with/O Ribavirin/O and/O Peginterferon/O Alfa/O )/O Serious/B-Severity cases/O of/O pancytopenia/B-AdverseReaction have/O been/O reported/O postmarketing/O in/O patients/O receiving/O VICTRELIS/O in/O combination/O with/O peginterferon/O alfa/O and/O ribavirin/O ./O
Complete/O blood/O counts/O (/O with/O white/O blood/O cell/O differential/O counts/O )/O should/O be/O obtained/O at/O pretreatment/O ,/O and/O at/O Treatment/O Weeks/O 2/O ,/O 4/O ,/O 8/O ,/O and/O 12/O ,/O and/O should/O be/O monitored/O closely/O at/O other/O time/O points/O ,/O as/O clinically/O appropriate/O ./O
Refer/O to/O the/O prescribing/O information/O for/O ribavirin/O and/O peginterferon/O alfa/O for/O guidelines/O for/O discontinuation/O of/O therapy/O based/O on/O laboratory/O parameters/O ./O
5.5/O Hypersensitivity/O Serious/B-Severity acute/B-AdverseReaction hypersensitivity/I-AdverseReaction reactions/I-AdverseReaction (/O e.g./O ,/O urticaria/B-AdverseReaction ,/O angioedema/B-AdverseReaction )/O have/O been/O observed/O during/O combination/O therapy/O with/O VICTRELIS/O ,/O peginterferon/O alfa/O and/O ribavirin/O ./O
If/O such/O an/O acute/O reaction/O occurs/O ,/O combination/O therapy/O should/O be/O discontinued/O and/O appropriate/O medical/O therapy/O immediately/O instituted/O [/O see/O Contraindications/O (/O 4/O )/O and/O Adverse/O Reactions/O (/O 6.2/O )/O ]/O ./O
5.6/O Drug/O Interactions/O See/O Table/O 2/O for/O a/O listing/O of/O drugs/O that/O are/O contraindicated/O for/O use/O with/O VICTRELIS/O due/O to/O potentially/O life/O -/O threatening/O adverse/O events/O ,/O significant/O drug/O interactions/O or/O loss/O of/O virologic/O activity/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
Please/O refer/O to/O Table/O 5/O for/O established/O and/O other/O potentially/O significant/O drug/O interactions/O [/O see/O Drug/O Interactions/O (/O 7.3/O )/O ]/O ./O
5.7/O Laboratory/O Tests/O HCV/O -/O RNA/O levels/O should/O be/O monitored/O at/O Treatment/O Weeks/O 4/O ,/O 8/O ,/O 12/O ,/O and/O 24/O ,/O at/O the/O end/O of/O treatment/O ,/O during/O treatment/O follow/O -/O up/O ,/O and/O for/O other/O time/O points/O as/O clinically/O indicated/O ./O
Use/O of/O a/O sensitive/O real/O -/O time/O reverse/O -/O transcription/O polymerase/O chain/O reaction/O (/O RT/O -/O PCR/O )/O assay/O for/O monitoring/O HCV/O -/O RNA/O levels/O during/O treatment/O is/O recommended/O ./O
The/O assay/O should/O have/O a/O lower/O limit/O of/O HCV/O -/O RNA/O quantification/O of/O equal/O to/O or/O less/O than/O 25/O IU/O per/O mL/O ,/O and/O a/O limit/O of/O HCV/O -/O RNA/O detection/O of/O approximately/O 10/O to/O 15/O IU/O per/O mL./O For/O the/O purposes/O of/O assessing/O Response/O -/O Guided/O Therapy/O milestones/O ,/O a/O confirmed/O "/O detectable/O but/O below/O limit/O of/O quantification/O "/O HCV/O -/O RNA/O result/O should/O not/O be/O considered/O equivalent/O to/O an/O "/O undetectable/O "/O HCV/O -/O RNA/O result/O (/O reported/O as/O "/O Target/O Not/O Detected/O "/O or/O "/O HCV/O -/O RNA/O Not/O Detected/O "/O )/O ./O
Complete/O blood/O count/O (/O with/O white/O blood/O cell/O differential/O counts/O )/O should/O be/O obtained/O at/O pretreatment/O ,/O and/O at/O Treatment/O Weeks/O 2/O ,/O 4/O ,/O 8/O ,/O and/O 12/O ,/O and/O should/O be/O monitored/O closely/O at/O other/O time/O points/O ,/O as/O clinically/O appropriate/O ./O
Refer/O to/O the/O prescribing/O information/O for/O peginterferon/O alfa/O and/O ribavirin/O for/O pre/O -/O treatment/O ,/O on/O -/O treatment/O and/O post/O -/O treatment/O laboratory/O testing/O recommendations/O including/O hematology/O ,/O biochemistry/O (/O including/O hepatic/O function/O tests/O )/O ,/O and/O pregnancy/O testing/O requirements/O ./O
6/O ADVERSE/O REACTIONS/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O following/O serious/O adverse/O reactions/O are/O described/O below/O and/O elsewhere/O in/O the/O labeling/O :/O ./O
Anaphylaxis/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O observed/O across/O pre/O -/O marketing/O clinical/O trials/O were/O similar/O in/O type/O and/O frequency/O as/O those/O observed/O in/O the/O placebo/O -/O controlled/O trial/O (/O see/O Table1/O )/O ./O
The/O acute/O reactions/O requiring/O intervention/O were/O managed/O by/O either/O temporarily/O interrupting/O or/O discontinuing/O infusion/O ,/O and/O administering/O additional/O antihistamine/O ,/O antipyretics/O ,/O or/O corticosteroids/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 10/O %/O in/O Vimizim/O patients/O and/O occurring/O at/O a/O higher/O incidence/O than/O placebo/O -/O treated/O patients/O )/O were/O pyrexia/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O chills/B-AdverseReaction ,/O and/O fatigue/B-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O BioMarin/O at/O 1/O -/O 866/O -/O 906/O -/O 6100/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O A/O 24-week/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O clinical/O trial/O of/O Vimizim/O was/O conducted/O in/O 176/O patients/O with/O MPS/O IVA/O ,/O ages/O 5/O to/O 57/O years/O old/O ./O
Approximately/O half/O of/O the/O patients/O (/O 49/O %/O )/O were/O male/O ./O
Of/O the/O 176/O patients/O ,/O 65/O %/O were/O White/O ,/O 23/O %/O Asian/O ,/O 3/O %/O Black/O ,/O and/O 10/O %/O Other/O race/O ./O
The/O majority/O of/O patients/O (/O 78/O %/O )/O were/O non/O -/O Hispanic/O ./O
Patients/O were/O randomized/O to/O three/O treatment/O groups/O :/O Vimizim/O 2/O mg/O kg/O once/O per/O week/O (/O n=58/O )/O ,/O Vimizim/O 2/O mg/O kg/O once/O every/O other/O week/O (/O n=59/O )/O ,/O or/O placebo/O (/O n=59/O )/O ./O
All/O patients/O were/O treated/O with/O antihistamines/O prior/O to/O each/O infusion/O ./O
Table/O 1/O summarizes/O the/O most/O common/O adverse/O reactions/O that/O occurred/O in/O the/O placebo/O -/O controlled/O trial/O with/O an/O incidence/O of/O 10/O %/O in/O patients/O treated/O with/O Vimizim/O 2/O mg/O kg/O once/O per/O week/O and/O with/O a/O higher/O incidence/O than/O in/O the/O placebo/O -/O treated/O patients/O ./O
Table/O 1/O :/O Adverse/O Reactions/O That/O Occurred/O in/O the/O Placebo/O -/O Controlled/O Trial/O in/O At/O Least/O 10/O %/O of/O Patients/O in/O the/O Vimizim/O 2/O mg/O kg/O Once/O Per/O Week/O Group/O and/O with/O a/O Higher/O Incidence/O than/O in/O the/O Placebo/O Group/O Adverse/O Reaction/O Vimizim/O 2/O mg/O kg/O once/O per/O week/O Placebo/O N=/O 58n/O (/O %/O )/O N=/O 59/O n/O (/O %/O )/O Pyrexia/B-AdverseReaction 19/O (/O 33/O %/O )/O 8/O (/O 14/O %/O )/O Vomiting/B-AdverseReaction 18/O (/O 31/O %/O )/O 4/O (/O 7/O %/O )/O Headache/B-AdverseReaction 15/O (/O 26/O %/O )/O 9/O (/O 15/O %/O )/O Nausea/B-AdverseReaction 14/O (/O 24/O %/O )/O 4/O (/O 7/O %/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 12/O (/O 21/O %/O )/O 1/O (/O 1.7/O %/O )/O Chills/B-AdverseReaction 6/O (/O 10.3/O %/O )/O 1/O (/O 1.7/O %/O )/O Fatigue/B-AdverseReaction 6/O (/O 10.3/O %/O )/O 2/O (/O 3.4/O %/O )/O Extension/O Trial/O An/O open/O -/O label/O extension/O trial/O was/O conducted/O in/O 173/O patients/O who/O completed/O the/O placebo/O -/O controlled/O trial/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
No/O new/O adverse/O reactions/O were/O reported/O ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
All/O patients/O treated/O with/O Vimizim/O 2/O mg/O kg/O once/O per/O week/O in/O the/O placebo/O -/O controlled/O trial/O developed/O anti/O -/O drug/O antibodies/O by/O Week/O 4/O ./O
Anti/O -/O drug/O antibody/O titers/O were/O sustained/O or/O increased/O for/O the/O duration/O of/O Vimizim/O treatment/O ./O
Because/O all/O patients/O developed/O anti/O -/O drug/O antibodies/O ,/O associations/O between/O antibody/O titers/O and/O reductions/O in/O treatment/O effect/O or/O the/O occurrence/O of/O anaphylaxis/O or/O other/O hypersensitivity/O reactions/O could/O not/O be/O determined/O ./O
All/O patients/O treated/O with/O Vimizim/O 2/O mg/O kg/O once/O per/O week/O tested/O positive/O for/O neutralizing/O antibodies/O capable/O of/O inhibiting/O the/O drug/O from/O binding/O to/O the/O mannose-6-phosphate/O receptor/O at/O least/O once/O during/O the/O trial/O ./O
Binding/O to/O this/O receptor/O is/O required/O for/O Vimizim/O to/O be/O taken/O into/O cells/O where/O it/O is/O active/O ./O
Neutralizing/O antibody/O titers/O were/O not/O determined/O in/O the/O patients/O ./O
Therefore/O ,/O the/O possibility/O of/O an/O association/O between/O neutralizing/O antibody/O titer/O and/O treatment/O effect/O can/O not/O be/O assessed/O ./O
Assessment/O of/O the/O incidence/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O to/O Vimizim/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction Life/B-Severity -/O threatening/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O in/O some/O patients/O during/O Vimizim/O infusions/O ./O
Anaphylaxis/B-AdverseReaction ,/O presenting/O as/O cough/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O and/O gastrointestinal/B-AdverseReaction symptoms/I-AdverseReaction (/O e.g./O ,/O nausea/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O retching/B-AdverseReaction ,/O and/O vomiting/B-AdverseReaction )/O in/O conjunction/O with/O urticaria/B-AdverseReaction ,/O have/O been/O reported/O to/O occur/O during/O Vimizim/O infusions/O ,/O regardless/O of/O duration/O of/O the/O course/O of/O treatment/O ./O
Closely/O observe/O patients/O during/O and/O after/O Vimizim/O administration/O and/O be/O prepared/O to/O manage/O anaphylaxis/O ./O
Inform/O patients/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O and/O have/O them/O seek/O immediate/O medical/O care/O should/O symptoms/O occur/O ./O
Patients/O with/O acute/O respiratory/O illness/O may/O be/O at/O risk/O of/O serious/O acute/O exacerbation/O of/O their/O respiratory/O compromise/O due/O to/O hypersensitivity/O reactions/O ,/O and/O require/O additional/O monitoring/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O RISK/B-Factor OF/O ANAPHYLAXIS/B-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Life/B-Severity -/O threatening/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction have/O occurred/O in/O some/O patients/O during/O Vimizim/O infusions/O ./O
Anaphylaxis/B-AdverseReaction ,/O presenting/O as/O cough/B-AdverseReaction ,/O erythema/B-AdverseReaction ,/O throat/B-AdverseReaction tightness/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O cyanosis/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O chest/B-AdverseReaction discomfort/I-AdverseReaction ,/O and/O gastrointestinal/B-AdverseReaction symptoms/I-AdverseReaction in/O conjunction/O with/O urticaria/B-AdverseReaction ,/O have/O been/O reported/O to/O occur/O during/O infusions/O ,/O regardless/O of/O duration/O of/O the/O course/O of/O treatment/O ./O
Closely/O observe/O patients/O during/O and/O after/O Vimizim/O administration/O and/O be/O prepared/O to/O manage/O anaphylaxis/O ./O
Inform/O patients/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O and/O have/O them/O seek/O immediate/O medical/O care/O should/O symptoms/O occur/O ./O
Patients/O with/O acute/O respiratory/O illness/O may/O be/O at/O risk/O of/O serious/O acute/O exacerbation/O of/O their/O respiratory/O compromise/O due/O to/O hypersensitivity/O reactions/O ,/O and/O require/O additional/O monitoring/O (/O 5.1/O ,/O 5.2/O ,/O 6/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O ./O
Anaphylaxis/B-AdverseReaction and/O Hypersensitivity/B-AdverseReaction Reactions/I-AdverseReaction :/O Life/B-Severity -/O threatening/O anaphylaxis/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction reactions/O have/O been/O observed/O in/O some/O patients/O during/O treatment/O with/O Vimizim/O ./O
If/O anaphylaxis/O or/O severe/O hypersensitivity/O reactions/O occur/O ,/O immediately/O stop/O the/O infusion/O and/O initiate/O appropriate/O medical/O treatment/O ./O
Pre/O -/O treatment/O with/O antihistamines/O with/O or/O without/O antipyretics/O is/O recommended/O prior/O to/O the/O start/O of/O infusion/O (/O 5.1/O )/O ./O
Risk/O of/O Acute/O Respiratory/O Complications/O :/O Patients/O with/O acute/O febrile/O or/O respiratory/O illness/O may/O be/O at/O higher/O risk/O of/O life/O -/O threatening/O complications/O from/O hypersensitivity/O reactions/O ./O
Careful/O consideration/O should/O be/O given/O to/O the/O patient/O 's/O clinical/O status/O prior/O to/O administration/O of/O Vimizim/O and/O consider/O delaying/O the/O Vimizim/O infusion/O (/O 5.2/O )/O ./O
5.1/O Anaphylaxis/O and/O Hypersensitivity/O Reactions/O Anaphylaxis/O and/O hypersensitivity/O reactions/O have/O been/O reported/O in/O patients/O treated/O with/O Vimizim/O ./O
In/O premarketing/O clinical/O trials/O ,/O 18/O of/O 235/O (/O 7.7/O %/O )/O patients/O treated/O with/O Vimizim/O experienced/O signs/O and/O symptoms/O consistent/O with/O anaphylaxis/O ./O
These/O 18/O patients/O experienced/O 26/O anaphylactic/O reactions/O during/O infusion/O with/O signs/O and/O symptoms/O including/O cough/O ,/O erythema/O ,/O throat/O tightness/O ,/O urticaria/O ,/O flushing/O ,/O cyanosis/O ,/O hypotension/O ,/O rash/O ,/O dyspnea/O ,/O chest/O discomfort/O ,/O and/O gastrointestinal/O symptoms/O (/O e.g./O ,/O nausea/O ,/O abdominal/O pain/O ,/O retching/O ,/O and/O vomiting/O )/O in/O conjunction/O with/O urticaria/O ./O
These/O cases/O of/O anaphylaxis/O occurred/O as/O early/O as/O 30/O minutes/O from/O the/O start/O of/O infusion/O and/O up/O to/O three/O hours/O after/O infusion/O ./O
Anaphylaxis/O occurred/O as/O late/O into/O treatment/O as/O the/O 47/O th/O infusion/O ./O
In/O clinical/O trials/O with/O Vimizim/O ,/O 44/O of/O 235/O (/O 18.7/O %/O )/O patients/O experienced/O hypersensitivity/O reactions/O ,/O including/O anaphylaxis/O ./O
Hypersensitivity/O reactions/O have/O occurred/O as/O early/O as/O 30/O minutes/O from/O the/O start/O of/O infusion/O but/O as/O late/O as/O six/O days/O after/O infusion/O ./O
Frequent/O symptoms/O of/O hypersensitivity/O reactions/O (/O occurring/O in/O more/O than/O 2/O patients/O )/O included/O anaphylactic/O reactions/O ,/O urticaria/O ,/O peripheral/O edema/O ,/O cough/O ,/O dyspnea/O ,/O and/O flushing/O ./O
Due/O to/O the/O potential/O for/O anaphylaxis/O ,/O appropriate/O medical/O support/O should/O be/O readily/O available/O when/O Vimizim/O is/O administered/O ./O
Observe/O patients/O closely/O for/O an/O appropriate/O period/O of/O time/O after/O administration/O of/O Vimizim/O ,/O taking/O into/O account/O the/O time/O to/O onset/O of/O anaphylaxis/O seen/O in/O premarketing/O clinical/O trials/O ./O
Inform/O patients/O of/O the/O signs/O and/O symptoms/O of/O anaphylaxis/O ,/O and/O instruct/O them/O to/O seek/O immediate/O medical/O care/O should/O signs/O and/O symptoms/O occur/O ./O
Because/O of/O the/O potential/O for/O hypersensitivity/O reactions/O ,/O administer/O antihistamines/O with/O or/O without/O antipyretics/O prior/O to/O infusion/O ./O
Management/O of/O hypersensitivity/O reactions/O should/O be/O based/O on/O the/O severity/O of/O the/O reaction/O and/O include/O slowing/O or/O temporary/O interruption/O of/O the/O infusion/O and/or/O administration/O of/O additional/O antihistamines/O ,/O antipyretics/O ,/O and/or/O corticosteroids/O for/O mild/O reactions/O ./O
However/O ,/O if/O severe/O hypersensitivity/O reactions/O occur/O ,/O immediately/O stop/O the/O infusion/O of/O Vimizim/O and/O initiate/O appropriate/O treatment/O ./O
Consider/O the/O risks/O and/O benefits/O of/O re/O -/O administering/O Vimizim/O following/O a/O severe/O reaction/O ./O
5.2/O Risk/O of/O Acute/O Respiratory/O Complications/O Patients/O with/O acute/O febrile/O or/O respiratory/O illness/O at/O the/O time/O of/O Vimizim/O infusion/O may/O be/O at/O higher/O risk/O of/O life/O -/O threatening/O complications/O from/O hypersensitivity/O reactions/O ./O
Careful/O consideration/O should/O be/O given/O to/O the/O patient/O 's/O clinical/O status/O prior/O to/O administration/O of/O Vimizim/O and/O consider/O delaying/O the/O Vimizim/O infusion/O ./O
Sleep/O apnea/O is/O common/O in/O MPS/O IVA/O patients/O ./O
Evaluation/O of/O airway/O patency/O should/O be/O considered/O prior/O to/O initiation/O of/O treatment/O with/O Vimizim/O ./O
Patients/O using/O supplemental/O oxygen/O or/O continuous/O positive/O airway/O pressure/O (/O CPAP/O )/O during/O sleep/O should/O have/O these/O treatments/O readily/O available/O during/O infusion/O in/O the/O event/O of/O an/O acute/O reaction/O ,/O or/O extreme/O drowsiness/O sleep/O induced/O by/O antihistamine/O use/O ./O
5.3/O Spinal/O or/O Cervical/O Cord/O Compression/O Spinal/O or/O cervical/O cord/O compression/O (/O SCC/O )/O is/O a/O known/O and/O serious/O complication/O of/O MPS/O IVA/O and/O may/O occur/O as/O part/O of/O the/O natural/O history/O of/O the/O disease/O ./O
In/O clinical/O trials/O ,/O SCC/O was/O observed/O both/O in/O patients/O receiving/O Vimizim/O and/O patients/O receiving/O placebo/O ./O
Patients/O with/O MPS/O IVA/O should/O be/O monitored/O for/O signs/O and/O symptoms/O of/O SCC/O (/O including/O back/O pain/O ,/O paralysis/O of/O limbs/O below/O the/O level/O of/O compression/O ,/O urinary/O and/O fecal/O incontinence/O )/O and/O given/O appropriate/O clinical/O care/O ./O
6/O ADVERSE/O REACTIONS/O EXCERPT/O :/O Most/O commonly/O reported/O adverse/O reactions/O were/O flushing/B-AdverseReaction (/O 2/O %/O )/O ,/O headache/B-AdverseReaction (/O 1/O %/O )/O ,/O increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction (/O 2/O %/O )/O ,/O nausea/B-AdverseReaction (/O 1/O %/O )/O ,/O and/O dizziness/B-AdverseReaction (/O 1/O %/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O GE/O Healthcare/O at/O 1/O -/O 800/O -/O 654/O -/O 0118/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
(/O 6/O )/O 6.1/O Clinical/O Trials/O Experience/O Clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O and/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O Vizamyl/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
In/O clinical/O trials/O ,/O 761/O adults/O (/O 367/O men/O and/O 394/O women/O ,/O 91/O %/O Caucasian/O )/O with/O a/O mean/O age/O of/O 62/O years/O (/O range/O 18/O -/O 93/O years/O )/O received/O Vizamyl/O ./O
Most/O subjects/O (/O 530/O ,/O 70/O %/O )/O received/O a/O dose/O of/O 185/O MBq/O (/O 5/O mCi/O )/O ./O
One/O subject/O out/O of/O 761/O administered/O Vizamyl/O experienced/O a/O serious/B-Severity hypersensitivity/B-AdverseReaction reaction/I-AdverseReaction with/O flushing/B-AdverseReaction ,/O dyspnea/B-AdverseReaction and/O chest/B-AdverseReaction pressure/I-AdverseReaction within/O minutes/O following/O Vizamyl/O administration/O and/O recovered/O with/O treatment/O ./O
Most/O adverse/O reactions/O were/O mild/O to/O moderate/O in/O intensity/O and/O resolved/O spontaneously/O ./O
The/O most/O commonly/O reported/O adverse/O reactions/O (/O occurring/O in/O at/O least/O 1/O %/O of/O subjects/O )/O in/O Vizamyl/O -/O treated/O subjects/O are/O shown/O in/O Table/O 2/O ./O
Table/O 2/O :/O Adverse/O Reactions/O Reported/O in/O Clinical/O Trials/O of/O Vizamyl/O (/O N/O 761/O subjects/O )/O Adverse/O Reaction/O N/O (/O percent/O of/O patients/O )/O Flushing/B-AdverseReaction 16/O (/O 2/O %/O )/O Increased/B-AdverseReaction blood/I-AdverseReaction pressure/I-AdverseReaction 13/O (/O 2/O %/O )/O Headache/B-AdverseReaction 10/O (/O 1/O %/O )/O Nausea/B-AdverseReaction 8/O (/O 1/O %/O )/O Dizziness/B-AdverseReaction 8/O (/O 1/O %/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction :/O Ask/O patients/O about/O prior/O reactions/O to/O Vizamyl/O ./O
Observe/O for/O hypersensitivity/O signs/O and/O symptoms/O following/O Vizamyl/O administration/O ./O
Have/O resuscitation/O equipment/O and/O trained/O personnel/O available/O at/O time/O of/O Vizamyl/O administration/O (/O 5.1/O )/O Image/O interpretation/O errors/O (/O especially/O false/O positives/O )/O have/O been/O observed/O (/O 5.2/O )/O Radiation/B-AdverseReaction risk/I-AdverseReaction :/O Vizamyl/O ,/O similar/O to/O all/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O (/O 2.1/O ,/O 5.3/O )/O 5.1/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction such/O as/O flushing/B-AdverseReaction and/O dyspnea/B-AdverseReaction have/O been/O observed/O within/O minutes/O following/O Vizamyl/O administration/O ./O
These/O reactions/O may/O occur/O in/O patients/O with/O no/O history/O of/O prior/O exposure/O to/O Vizamyl/O ./O
Before/O administering/O Vizamyl/O ,/O ask/O patients/O about/O prior/O reactions/O to/O drugs/O ,/O especially/O those/O containing/O polysorbate/O 80/O ./O
Have/O resuscitation/O equipment/O and/O trained/O personnel/O immediately/O available/O at/O the/O time/O of/O Vizamyl/O administration/O [/O see/O Contraindications/O (/O 4/O )/O ]/O ./O
5.2/O Risk/O for/O Image/O Misinterpretation/O and/O Other/O Errors/O Errors/O may/O occur/O while/O using/O Vizamyl/O PET/O images/O to/O estimate/O brain/O neuritic/O plaque/O density/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
Image/O interpretation/O is/O performed/O independently/O of/O the/O patient/O 's/O clinical/O information/O ./O
The/O use/O of/O clinical/O information/O in/O the/O interpretation/O of/O Vizamyl/O images/O has/O not/O been/O evaluated/O and/O may/O lead/O to/O errors/O ./O
Extensive/O brain/O atrophy/O may/O limit/O the/O ability/O to/O distinguish/O grey/O and/O white/O matter/O on/O a/O Vizamyl/O scan/O [/O see/O Dosage/O and/O Administration/O (/O 2.5/O )/O ]/O ./O
Motion/O artifacts/O may/O distort/O the/O image/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O ]/O ./O
Vizamyl/O scan/O results/O are/O indicative/O of/O the/O brain/O neuritic/O amyloid/O plaque/O content/O only/O at/O the/O time/O of/O image/O acquisition/O and/O a/O negative/O scan/O result/O does/O not/O preclude/O the/O development/O of/O brain/O amyloid/O in/O the/O future/O ./O
5.3/O Radiation/O Risk/O Vizamyl/O ,/O similar/O to/O other/O radiopharmaceuticals/O ,/O contributes/O to/O a/O patient/O 's/O overall/O long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O ./O
Long/B-AdverseReaction -/I-AdverseReaction term/I-AdverseReaction cumulative/I-AdverseReaction radiation/O exposure/O is/O associated/O with/O an/O increased/O risk/B-Factor of/O cancer/B-AdverseReaction ./O
Ensure/O safe/O handling/O to/O protect/O patients/O and/O health/O care/O workers/O from/O unintentional/O radiation/O exposure/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O Serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction ,/O may/B-Factor occur/O ./O
The/O most/O common/O adverse/O reactions/O (/O incidence/O 1/O %/O )/O with/O VORAXAZE/O are/O paraesthesias/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O nausea/B-AdverseReaction and/or/O vomiting/B-AdverseReaction ,/O hypotension/B-AdverseReaction ,/O and/O headache/B-AdverseReaction ./O
EXCERPT/O :/O In/O clinical/O trials/O ,/O the/O most/O common/O related/O adverse/O events/O (/O occurring/O in/O 1/O %/O of/O patients/O )/O were/O paraesthesia/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O nausea/B-AdverseReaction and/or/O vomiting/B-AdverseReaction ,/O hypotension/B-AdverseReaction and/O headache/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O call/O 877/O -/O 377/O -/O 3784/O or/O contact/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O controlled/O but/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O clinical/O trials/O of/O VORAXAZE/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O other/O drugs/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O evaluation/O of/O adverse/O reactions/O in/O patients/O treated/O with/O VORAXAZE/O is/O confounded/O by/O the/O population/O in/O which/O it/O was/O studied/O ,/O patients/O with/O toxic/O plasma/O methotrexate/O levels/O due/O to/O impaired/O renal/O function/O ./O
Adverse/O reactions/O related/O to/O toxic/O methotrexate/O levels/O due/O to/O prolonged/O methotrexate/O clearance/O include/O myelosuppression/O ,/O mucositis/O ,/O acute/O hepatitis/O ,/O and/O renal/O dysfunction/O and/O failure/O ./O
The/O safety/O of/O VORAXAZE/O is/O based/O on/O data/O from/O 290/O patients/O who/O were/O treated/O in/O 2/O single/O -/O arm/O ,/O open/O -/O label/O ,/O multicenter/O trials/O enrolling/O patients/O who/O had/O markedly/O delayed/O methotrexate/O clearance/O secondary/O to/O renal/O dysfunction/O ./O
Patients/O with/O osteosarcoma/O were/O eligible/O for/O these/O studies/O if/O the/O plasma/O methotrexate/O concentration/O was/O greater/O than/O 50/O mumol/O L/O at/O 24/O hours/O ,/O greater/O that/O 5/O mumol/O L/O at/O 48/O hours/O ,/O or/O greater/O than/O 2/O standard/O deviations/O above/O the/O mean/O methotrexate/O elimination/O curve/O at/O least/O 12/O hours/O after/O methotrexate/O administration/O and/O there/O was/O a/O 2-fold/O or/O greater/O increase/O in/O serum/O creatinine/O above/O baseline/O ./O
All/O other/O patients/O were/O eligible/O for/O these/O studies/O if/O the/O plasma/O methotrexate/O level/O was/O greater/O than/O 10/O mumol/O L/O more/O than/O 42/O hours/O after/O the/O start/O of/O the/O methotrexate/O or/O the/O plasma/O level/O was/O greater/O than/O 2/O standard/O deviations/O above/O the/O mean/O methotrexate/O excretion/O curve/O at/O least/O 12/O hours/O following/O methotrexate/O and/O the/O serum/O creatinine/O was/O greater/O than/O 1.5/O times/O the/O upper/O limit/O of/O normal/O or/O the/O creatinine/O clearance/O was/O less/O than/O 60/O mL/O min/O at/O least/O 12/O hours/O following/O methotrexate/O administration/O ./O
Study/O 1/O ,/O conducted/O by/O the/O National/O Cancer/O Institute/O (/O NCI/O )/O ,/O enrolled/O 184/O patients/O ;/O safety/O information/O is/O available/O for/O 149/O patients/O ./O
VORAXAZE/O was/O given/O at/O a/O dose/O of/O 50/O Units/O kg/O as/O an/O intravenous/O injection/O over/O 5/O minutes/O ./O
Patients/O with/O pre/O -/O VORAXAZE/O methotrexate/O concentrations/O 100/O mumol/O L/O were/O to/O receive/O a/O second/O dose/O of/O VORAXAZE/O 48/O hours/O after/O the/O first/O dose/O ./O
The/O protocol/O specified/O that/O patients/O continue/O receiving/O intravenous/O hydration/O ,/O urinary/O alkalinization/O and/O leucovorin/O ,/O and/O that/O leucovorin/O administration/O be/O adjusted/O to/O ensure/O that/O it/O was/O not/O administered/O within/O two/O hours/O before/O or/O after/O VORAXAZE/O ./O
In/O Study/O 1/O ,/O VORAXAZE/O -/O related/O adverse/O reactions/O were/O collected/O on/O a/O flow/O sheet/O with/O a/O daily/O log/O of/O adverse/O reactions/O characterized/O as/O "/O glucarpidase/O toxicity/O ./O
"/O Additional/O safety/O information/O was/O collected/O from/O clinical/O records/O submitted/O by/O treating/O physicians/O ./O
This/O information/O was/O abstracted/O and/O categorized/O using/O the/O National/O Cancer/O Institute/O (/O NCI/O )/O "/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O "/O (/O CTCAE/O )/O version/O 3/O scale/O ./O
The/O Study/O 1/O population/O enrolled/O patients/O with/O a/O median/O age/O of/O 18/O years/O (/O 1/O month/O to/O 85/O years/O )/O ;/O 63/O %/O were/O male/O ,/O and/O the/O underlying/O malignancies/O were/O osteosarcoma/O sarcomas/O in/O 32/O %/O ,/O and/O leukemia/O or/O lymphoma/O in/O 63/O %/O of/O patients/O ./O
One/O (/O n=106/O )/O or/O 2/O (/O n=/O 30/O )/O doses/O of/O VORAXAZE/O were/O administered/O intravenously/O ;/O the/O number/O of/O doses/O was/O not/O specified/O in/O 13/O patients/O ./O
Doses/O ranged/O from/O 18/O to/O 98/O Units/O kg/O ,/O with/O a/O median/O dose/O of/O 49/O Units/O kg/O ./O
Study/O 2/O is/O an/O ongoing/O expanded/O access/O program/O ./O
At/O the/O time/O of/O data/O cut/O -/O off/O ,/O 243/O patients/O were/O enrolled/O and/O safety/O data/O was/O available/O for/O 141/O patients/O ./O
VORAXAZE/O was/O given/O at/O a/O dose/O of/O 50/O Units/O kg/O as/O an/O intravenous/O injection/O over/O 5/O minutes/O ./O
The/O criterion/O for/O allowing/O patients/O to/O receive/O a/O second/O glucarpidase/O dose/O was/O not/O specified/O in/O the/O protocol/O ./O
The/O protocol/O specified/O that/O patients/O continue/O receiving/O intravenous/O hydration/O ,/O urinary/O alkalinization/O and/O leucovorin/O ,/O and/O that/O leucovorin/O administration/O be/O adjusted/O to/O ensure/O that/O it/O was/O not/O administered/O within/O two/O hours/O before/O or/O after/O VORAXAZE/O ./O
Study/O 2/O enrolled/O patients/O with/O a/O median/O age/O of/O 17/O years/O (/O 6/O months/O to/O 85/O years/O )/O ;/O 64/O %/O were/O male/O ,/O and/O the/O underlying/O malignancies/O were/O osteogenic/O sarcoma/O in/O 32/O %/O ,/O and/O leukemia/O or/O lymphoma/O in/O 62/O %/O of/O patients/O ./O
One/O (/O n=122/O )/O or/O 2/O (/O n=/O 18/O )/O doses/O of/O VORAXAZE/O were/O administered/O intravenously/O ;/O the/O number/O of/O doses/O was/O not/O specified/O for/O 1/O patient/O ./O
Doses/O ranged/O from/O 6/O to/O 189/O Units/O kg/O ,/O with/O a/O median/O dose/O of/O 50/O Units/O kg/O ./O
In/O Study/O 2/O only/O VORAXAZE/O -/O related/O adverse/O reactions/O were/O collected/O and/O severity/O was/O graded/O according/O to/O NCI/O CTCAE/O version/O 3/O ./O
Among/O the/O 290/O patients/O included/O in/O the/O safety/O evaluation/O of/O VORAXAZE/O ,/O there/O were/O 8/O deaths/B-AdverseReaction within/O 30/O days/O of/O VORAXAZE/O exposure/O that/O were/O not/O related/O to/O progressive/O disease/O ./O
Twenty/O -/O one/O of/O 290/O patients/O (/O 7/O %/O )/O experienced/O adverse/O reactions/O that/O were/O assessed/O as/O related/O to/O VORAXAZE/O ./O
Most/O were/O Grade/O 1/O or/O 2/O events/O ./O
One/O patient/O experienced/O related/O Grade/B-Severity 3/I-Severity flushing/B-AdverseReaction ./O
The/O most/O common/O related/O adverse/O reactions/O that/O were/O not/O hematologic/O ,/O hepatic/O or/O renal/O events/O were/O paresthesia/B-AdverseReaction ,/O flushing/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction and/or/O vomiting/B-AdverseReaction ,/O which/O each/O occurred/O in/O 2/O %/O of/O patients/O (/O Table/O 1/O )/O ./O
Table/O 1/O :/O Per/O Patient/O Incidence/O of/O Grade/O 1/O and/O 2/O Adverse/O Reactions/O Assessed/O as/O Possibly/O ,/O Probably/O ,/O or/O Definitely/O Related/O to/O VORAXAZE/O Excluding/O Hematologic/O ,/O Hepatic/O ,/O or/O Renal/O Adverse/O Reactions/O 1/O This/O incidence/O includes/O the/O following/O terms/O :/O flushing/B-AdverseReaction ,/O feeling/B-AdverseReaction hot/I-AdverseReaction ,/O burning/B-AdverseReaction sensation/I-AdverseReaction ./O
2/O One/O of/O these/O reactions/O was/O classified/O as/O Grade/O 3/O in/O severity/O ./O
Adverse/O Reaction/O N=/O 290n/O (/O %/O )/O Paresthesias/B-AdverseReaction 7/O (/O 2/O %/O )/O Flushing/B-AdverseReaction 1,2/O 5/O (/O 2/O %/O )/O Nausea/B-AdverseReaction Vomiting/B-AdverseReaction 5/O (/O 2/O %/O )/O Headache/B-AdverseReaction 2/O (/O 1/O %/O )/O Hypotension/B-AdverseReaction 2/O (/O 1/O %/O )/O Blurred/B-AdverseReaction Vision/I-AdverseReaction 1/O (/O 1/O %/O )/O Diarrhea/B-AdverseReaction 1/O (/O 1/O %/O )/O Hypersensitivity/B-AdverseReaction 1/O (/O 1/O %/O )/O Hypertension/B-AdverseReaction 1/O (/O 1/O %/O )/O Rash/B-AdverseReaction 1/O (/O 1/O %/O )/O Throat/B-AdverseReaction irritation/I-AdverseReaction Throat/B-AdverseReaction tightness/I-AdverseReaction 1/O (/O 1/O %/O )/O Tremor/B-AdverseReaction 1/O (/O 1/O %/O )/O 6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O potential/O for/O immunogenicity/O ./O
In/O clinical/O trials/O ,/O 121/O patients/O who/O received/O one/O (/O n=99/O )/O ,/O two/O (/O n=21/O )/O ,/O or/O three/O (/O n=1/O )/O doses/O of/O VORAXAZE/O were/O evaluated/O for/O anti/O -/O glucarpidase/O antibodies/O ./O
Twenty/O -/O five/O of/O these/O 121/O patients/O (/O 21/O %/O )/O had/O detectable/O anti/O -/O glucarpidase/O antibodies/O following/O VORAXAZE/O administration/O ,/O of/O which/O 19/O received/O a/O single/O dose/O of/O VORAXAZE/O and/O 6/O received/O two/O doses/O of/O VORAXAZE/O ./O
Antibody/O titers/O were/O determined/O using/O a/O bridging/O enzyme/O -/O linked/O immunosorbent/O assay/O (/O ELISA/O )/O for/O anti/O -/O glucarpidase/O antibodies/O ./O
Neutralizing/O antibodies/O were/O detected/O in/O 11/O of/O the/O 25/O patients/O who/O tested/O positive/O for/O anti/O -/O glucarpidase/O binding/O antibodies/O ./O
Eight/O of/O these/O 11/O patients/O had/O received/O a/O single/O dose/O of/O VORAXAZE/O ./O
However/O ,/O the/O development/O of/O neutralizing/O antibodies/O may/O be/O underreported/O due/O to/O lack/O of/O assay/O sensitivity/O ./O
The/O detection/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
Additionally/O ,/O the/O observed/O incidence/O of/O antibody/O (/O including/O neutralizing/O antibody/O )/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O ,/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O incidence/O of/O antibodies/O to/O VORAXAZE/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylactic/B-AdverseReaction reactions/I-AdverseReaction ,/O may/B-Factor occur/O ./O
(/O 5.1/O )/O Measurement/O of/O methotrexate/O using/O immunoassays/O is/O unreliable/O for/O samples/O collected/O within/O 48/O hours/O following/O VORAXAZE/O administration/O ./O
(/O 5.2/O )/O Continue/O therapy/O with/O leucovorin/O until/O the/O methotrexate/O concentration/O has/O been/O maintained/O below/O the/O leucovorin/O treatment/O threshold/O for/O a/O minimum/O of/O 3/O days/O ./O
(/O 5.3/O )/O Do/O not/O administer/O leucovorin/O within/O 2/O hours/O before/O or/O after/O a/O dose/O of/O VORAXAZE/O ./O
(/O 5.3/O )/O For/O 48/O hours/O after/O VORAXAZE/O administration/O ,/O determine/O the/O leucovorin/O dose/O based/O on/O the/O patient/O 's/O pre/O -/O VORAXAZE/O methotrexate/O concentration/O ./O
(/O 5.3/O )/O Continue/O hydration/O and/O alkalinization/O of/O the/O urine/O as/O indicated/O ./O
(/O 5.3/O )/O 5.1/O Serious/O Allergic/O Reactions/O Serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction occurred/O in/O less/O than/O 1/O %/O of/O patients/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.2/O Monitoring/O Methotrexate/O Concentration/O Interference/O with/O Assay/O Methotrexate/O concentrations/O within/O 48/O hours/O following/O administration/O of/O VORAXAZE/O can/O only/O be/O reliably/O measured/O by/O a/O chromatographic/O method/O ./O
DAMPA/O (/O 4-deoxy-4-amino/O -/O N/O 10/O -methylpteroic/O acid/O )/O is/O an/O inactive/O metabolite/O of/O methotrexate/O resulting/O from/O treatment/O with/O VORAXAZE/O ./O
DAMPA/O interferes/O with/O the/O measurement/O of/O methotrexate/O concentration/O using/O immunoassays/O resulting/O in/O an/O erroneous/O measurement/O which/O overestimates/O the/O methotrexate/O concentration/O ./O
Due/O to/O the/O long/O half/O -/O life/O of/O DAMPA/O (/O t1/2of/O approximately/O 9/O hours/O )/O ,/O measurement/O of/O methotrexate/O using/O immunoassays/O is/O unreliable/O for/O samples/O collected/O within/O 48/O hours/O following/O VORAXAZE/O administration/O [/O see/O Clinical/O Pharmacology/O (/O 12.1/O )/O ]/O ./O
5.3/O Continuation/O and/O Timing/O of/O Leucovorin/O Rescue/O Continue/O to/O administer/O leucovorin/O after/O VORAXAZE/O ./O
Do/O not/O administer/O leucovorin/O within/O 2/O hours/O before/O or/O after/O a/O dose/O of/O VORAXAZE/O because/O leucovorin/O is/O a/O substrate/O for/O VORAXAZE/O [/O see/O Drug/O Interactions/O (/O 7.1/O )/O ]/O ./O
For/O the/O first/O 48/O hours/O after/O VORAXAZE/O ,/O administer/O the/O same/O leucovorin/O dose/O as/O given/O prior/O to/O VORAXAZE/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Beyond/O 48/O hours/O after/O VORAXAZE/O ,/O administer/O leucovorin/O based/O on/O the/O measured/O methotrexate/O concentration/O ./O
Do/O not/O discontinue/O therapy/O with/O leucovorin/O based/O on/O the/O determination/O of/O a/O single/O methotrexate/O concentration/O below/O the/O leucovorin/O treatment/O threshold/O ./O
Therapy/O with/O leucovorin/O should/O be/O continued/O until/O the/O methotrexate/O concentration/O has/O been/O maintained/O below/O the/O leucovorin/O treatment/O threshold/O for/O a/O minimum/O of/O 3/O days/O ./O
Continue/O hydration/O and/O alkalinization/O of/O the/O urine/O as/O indicated/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction Pneumonitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O QT/B-AdverseReaction Interval/I-AdverseReaction Prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Bradycardia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Severe/B-Severity Visual/B-AdverseReaction Loss/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 25/O %/O )/O are/O vision/B-AdverseReaction disorders/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O edema/B-AdverseReaction ,/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O and/O dysgeusia/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Pfizer/O Inc./O at/O 1/O -/O 800/O -/O 438/O -/O 1985/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O safety/O of/O XALKORI/O is/O based/O primarily/O on/O 343/O patients/O with/O ALK/O -/O positive/O metastatic/O NSCLC/O who/O received/O XALKORI/O 250/O mg/O twice/O daily/O in/O two/O open/O -/O label/O ,/O randomized/O ,/O active/O -/O controlled/O trials/O (/O Studies/O 1/O and/O 2/O )/O ./O
This/O is/O supplemented/O with/O information/O on/O adverse/O drug/O reactions/O in/O 1326/O patients/O with/O ALK/O -/O positive/O metastatic/O NSCLC/O who/O received/O XALKORI/O 250/O mg/O twice/O daily/O across/O clinical/O trials/O ,/O for/O a/O total/O of/O 1669/O patients/O across/O all/O clinical/O studies/O ./O
The/O most/O common/O adverse/O reactions/O (/O 25/O %/O )/O of/O XALKORI/O in/O Studies/O 1/O and/O 2/O are/O vision/B-AdverseReaction disorders/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O constipation/B-AdverseReaction ,/O edema/B-AdverseReaction ,/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O and/O dysgeusia/B-AdverseReaction ./O
Previously/O Untreated/O ALK/O -/O Positive/O Metastatic/O NSCLC/O -/O Study/O 1/O The/O data/O in/O Table/O 3/O are/O derived/O from/O 340/O patients/O with/O ALK/O -/O positive/O metastatic/O NSCLC/O who/O had/O not/O received/O previous/O systemic/O treatment/O for/O advanced/O disease/O who/O received/O treatment/O in/O a/O randomized/O ,/O multicenter/O ,/O open/O -/O label/O ,/O active/O -/O controlled/O trial/O (/O Study/O 1/O )/O ./O
Patients/O in/O the/O XALKORI/O arm/O (/O n=171/O )/O received/O XALKORI/O 250/O mg/O orally/O twice/O daily/O until/O documented/O disease/O progression/O ,/O intolerance/O to/O therapy/O ,/O or/O the/O investigator/O determined/O that/O the/O patient/O was/O no/O longer/O experiencing/O clinical/O benefit/O ./O
A/O total/O of/O 169/O patients/O in/O the/O chemotherapy/O arm/O received/O pemetrexed/O 500/O mg/O m/O 2/O in/O combination/O with/O cisplatin/O 75/O mg/O m/O 2/O (/O n=91/O )/O or/O carboplatin/O at/O a/O dose/O calculated/O to/O produce/O an/O area/O under/O the/O concentration/O -/O time/O curve/O (/O AUC/O )/O of/O 5/O or/O 6/O mg?min/O mL/O (/O n=78/O )/O ./O
Chemotherapy/O was/O given/O by/O intravenous/O infusion/O every/O 3/O weeks/O for/O up/O to/O 6/O cycles/O ,/O in/O the/O absence/O of/O dose/O -/O limiting/O chemotherapy/O -/O related/O toxicities/O ./O
After/O 6/O cycles/O ,/O patients/O remained/O on/O study/O with/O no/O additional/O anticancer/O treatment/O ,/O and/O tumor/O assessments/O continued/O until/O documented/O disease/O progression/O ./O
The/O median/O duration/O of/O study/O treatment/O was/O 10.9/O months/O for/O patients/O in/O the/O XALKORI/O arm/O and/O 4.1/O months/O for/O patients/O in/O the/O chemotherapy/O arm/O ./O
Median/O duration/O of/O treatment/O was/O 5.2/O months/O for/O patients/O who/O received/O XALKORI/O after/O cross/O over/O from/O chemotherapy/O ./O
Across/O the/O 340/O patients/O who/O were/O treated/O in/O Study/O 1/O ,/O the/O median/O age/O was/O 53/O years/O ;/O 16/O %/O of/O patients/O were/O older/O than/O 65/O years/O ./O
A/O total/O of/O 62/O %/O of/O patients/O were/O female/O and/O 46/O %/O were/O Asian/O ./O
Serious/O adverse/O events/O were/O reported/O in/O 58/O patients/O (/O 34/O %/O )/O treated/O with/O XALKORI/O ./O
The/O most/O frequent/O serious/O adverse/O events/O reported/O in/O patients/O treated/O with/O XALKORI/O were/O dyspnea/B-AdverseReaction (/O 4.1/O %/O )/O and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 2.9/O %/O )/O ./O
Fatal/B-AdverseReaction adverse/O events/O in/O XALKORI/O -/O treated/O patients/O occurred/O in/O 2.3/O %/O patients/O ,/O consisting/O of/O septic/B-AdverseReaction shock/I-AdverseReaction ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction failure/I-AdverseReaction ,/O and/O diabetic/B-AdverseReaction ketoacidosis/I-AdverseReaction ./O
Dose/O reductions/O due/O to/O adverse/O reactions/O were/O required/O in/O 6.4/O %/O of/O XALKORI/O -/O treated/O patients/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O dose/O reduction/O in/O these/O patients/O were/O nausea/B-AdverseReaction (/O 1.8/O %/O )/O and/O elevated/B-AdverseReaction transaminases/I-AdverseReaction (/O 1.8/O %/O )/O ./O
Permanent/O discontinuation/O of/O XALKORI/O treatment/O for/O adverse/O reactions/O was/O 8.2/O %/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O permanent/O discontinuation/O in/O XALKORI/O -/O treated/O patients/O were/O elevated/B-AdverseReaction transaminases/I-AdverseReaction (/O 1.2/O %/O )/O ,/O hepatotoxicity/B-AdverseReaction (/O 1.2/O %/O )/O ,/O and/O ILD/B-AdverseReaction (/O 1.2/O %/O )/O ./O
Tables/O 3/O and/O 4/O summarize/O common/O adverse/O reactions/O and/O laboratory/O abnormalities/O in/O XALKORI/O -/O treated/O patients/O ./O
Table/O 3/O ./O
Adverse/O Reactions/O Reported/O at/O a/O Higher/O Incidence/O (/O 5/O %/O Higher/O for/O All/O Grades/O or/O 2/O %/O Higher/O for/O Grades/O 3/4/O )/O with/O XALKORI/O than/O Chemotherapy/O in/O Study/O 1/O Adverse/O Reaction/O XALKORI(N=171/O )/O Chemotherapy/O (/O Pemetrexed/O Cisplatin/O or/O Pemetrexed/O Carboplatin)(N=169/O )/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O Includes/O cases/O reported/O within/O the/O clustered/O terms/O :/O Cardiac/O Disorders/O Electrocardiogram/B-AdverseReaction QT/I-AdverseReaction prolonged/I-AdverseReaction 6/O 2/O 2/O 0/O Bradycardia/B-AdverseReaction 14/O 1/O 1/O 0/O Eye/O Disorders/O Vision/B-AdverseReaction disorder/I-AdverseReaction 71/O 1/O 10/O 0/O Gastrointestinal/O Disorders/O Vomiting/B-AdverseReaction 46/O 2/O 36/O 3/O Diarrhea/B-AdverseReaction 61/O 2/O 13/O 1/O Constipation/B-AdverseReaction 43/O 2/O 30/O 0/O Dyspepsia/B-AdverseReaction 14/O 0/O 2/O 0/O Dysphagia/B-AdverseReaction 10/O 1/O 2/O 1/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 26/O 0/O 12/O 0/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Edema/B-AdverseReaction 49/O 1/O 12/O 1/O Pyrexia/B-AdverseReaction 19/O 0/O 11/O 1/O Infections/O and/O Infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction 32/O 0/O 12/O 1/O Investigations/O Weight/B-AdverseReaction increased/I-AdverseReaction 8/O 1/O 2/O 0/O Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 16/O 0/O 7/O 0/O Muscle/B-AdverseReaction spasm/I-AdverseReaction 8/O 0/O 2/O 1/O Nervous/O System/O Disorder/O Dizziness/B-AdverseReaction 18/O 0/O 10/O 1/O Dysgeusia/B-AdverseReaction 26/O 0/O 5/O 0/O Headache/B-AdverseReaction 22/O 1/O 15/O 0/O Additional/O adverse/O reactions/O occurring/O at/O an/O overall/O incidence/O between/O 1/O %/O and/O 60/O %/O in/O patients/O treated/O with/O XALKORI/O included/O nausea/B-AdverseReaction (/O 56/O %/O )/O ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction (/O 30/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 29/O %/O )/O ,/O neuropathy/B-AdverseReaction (/O 21/O %/O ;/O which/O included/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O hypoaesthesia/B-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O neuralgia/B-AdverseReaction ,/O neuropathy/B-AdverseReaction peripheral/I-AdverseReaction ,/O paraesthesia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O polyneuropathy/B-AdverseReaction ,/O sensory/B-AdverseReaction disturbance/I-AdverseReaction )/O ,/O rash/B-AdverseReaction (/O 11/O %/O )/O ,/O renal/B-AdverseReaction cyst/I-AdverseReaction (/O 5/O %/O )/O ,/O ILD/B-AdverseReaction (/O 1/O %/O ;/O ILD/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction )/O ,/O and/O syncope/B-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 4/O ./O
Summary/O of/O Treatment/O -/O Emergent/O Laboratory/O Abnormalities/O with/O Grade/O 3/O or/O 4/O Incidence/O of/O 4/O %/O in/O XALKORI/O -/O Treated/O Patients/O in/O Study/O 1/O Laboratory/O Abnormality/O XALKORI/O Chemotherapy/O Any/O Grade(%/O )/O Grade/O 3/4(%/O )/O Any/O Grade(%/O )/O Grade/O 3/4(%/O )/O Hematology/O Neutropenia/B-AdverseReaction 52/O 11/O 59/O 16/O Lymphopenia/B-AdverseReaction 48/O 7/O 53/O 13/O Chemistry/O ALT/B-AdverseReaction elevation/I-AdverseReaction 79/O 15/O 33/O 2/O AST/B-AdverseReaction elevation/I-AdverseReaction 66/O 8/O 28/O 1/O Hypophosphatemia/B-AdverseReaction 32/O 10/O 21/O 6/O Previously/O Treated/O ALK/O -/O Positive/O Metastatic/O NSCLC/O -/O Study/O 2/O The/O data/O in/O Table/O 5/O are/O derived/O from/O 343/O patients/O with/O ALK/O -/O positive/O metastatic/O NSCLC/O enrolled/O in/O a/O randomized/O ,/O multicenter/O ,/O active/O -/O controlled/O ,/O open/O -/O label/O trial/O (/O Study/O 2/O )/O ./O
Patients/O in/O the/O XALKORI/O arm/O (/O n=172/O )/O received/O XALKORI/O 250/O mg/O orally/O twice/O daily/O until/O documented/O disease/O progression/O ,/O intolerance/O to/O therapy/O ,/O or/O the/O investigator/O determined/O that/O the/O patient/O was/O no/O longer/O experiencing/O clinical/O benefit/O ./O
A/O total/O of/O 171/O patients/O in/O the/O chemotherapy/O arm/O received/O pemetrexed/O 500/O mg/O m/O 2/O (/O n=99/O )/O or/O docetaxel/O 75/O mg/O m/O 2/O (/O n=72/O )/O by/O intravenous/O infusion/O every/O three/O weeks/O until/O documented/O disease/O progression/O ,/O intolerance/O to/O therapy/O ,/O or/O the/O investigator/O determined/O that/O the/O patient/O was/O no/O longer/O experiencing/O clinical/O benefit/O ./O
Patients/O in/O the/O chemotherapy/O arm/O received/O pemetrexed/O unless/O they/O had/O received/O pemetrexed/O as/O part/O of/O first/O -/O line/O or/O maintenance/O treatment/O ./O
The/O median/O duration/O of/O study/O treatment/O was/O 7.1/O months/O for/O patients/O who/O received/O XALKORI/O and/O 2.8/O months/O for/O patients/O who/O received/O chemotherapy/O ./O
Across/O the/O 347/O patients/O who/O were/O randomized/O to/O study/O treatment/O (/O 343/O received/O at/O least/O one/O dose/O of/O study/O treatment/O )/O ,/O the/O median/O age/O was/O 50/O years/O ;/O 14/O %/O of/O patients/O were/O older/O than/O 65/O years/O ./O
A/O total/O of/O 56/O %/O of/O patients/O were/O female/O and/O 45/O %/O of/O patients/O were/O Asian/O ./O
Serious/O adverse/O reactions/O were/O reported/O in/O 64/O patients/O (/O 37.2/O %/O )/O treated/O with/O XALKORI/O and/O 40/O patients/O (/O 23.4/O %/O )/O in/O the/O chemotherapy/O arm/O ./O
The/O most/O frequent/O serious/O adverse/O reactions/O reported/O in/O patients/O treated/O with/O XALKORI/O were/O pneumonia/B-AdverseReaction (/O 4.1/O %/O )/O ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 3.5/O %/O )/O ,/O dyspnea/B-AdverseReaction (/O 2.3/O %/O )/O ,/O and/O ILD/B-AdverseReaction (/O 2.9/O %/O )/O ./O
Fatal/B-AdverseReaction adverse/O reactions/O in/O XALKORI/O -/O treated/O patients/O in/O Study/O 2/O occurred/O in/O 9/O (/O 5/O %/O )/O patients/O ,/O consisting/O of/O :/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction ,/O arrhythmia/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction ,/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction ,/O ILD/B-AdverseReaction ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction and/O sepsis/B-AdverseReaction ./O
Dose/O reductions/O due/O to/O adverse/O reactions/O were/O required/O in/O 16/O %/O of/O XALKORI/O -/O treated/O patients/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O dose/O reduction/O in/O the/O patients/O treated/O with/O XALKORI/O were/O alanine/O aminotransferase/O (/O ALT/O )/O elevation/O (/O 7.6/O %/O )/O including/O some/O patients/O with/O concurrent/O aspartate/O aminotransferase/O (/O AST/O )/O elevation/O ,/O QTc/B-AdverseReaction prolongation/I-AdverseReaction (/O 2.9/O %/O )/O ,/O and/O neutropenia/B-AdverseReaction (/O 2.3/O %/O )/O ./O
XALKORI/O was/O discontinued/O for/O adverse/O reactions/O in/O 15/O %/O of/O patients/O ./O
The/O most/O frequent/O adverse/O reactions/O that/O led/O to/O discontinuation/O of/O XALKORI/O were/O ILD/B-AdverseReaction (/O 1.7/O %/O )/O ,/O ALT/O and/O AST/B-AdverseReaction elevation/I-AdverseReaction (/O 1.2/O %/O )/O ,/O dyspnea/B-AdverseReaction (/O 1.2/O %/O )/O ,/O and/O pulmonary/B-AdverseReaction embolism/I-AdverseReaction (/O 1.2/O %/O )/O ./O
Tables/O 5/O and/O 6/O summarize/O common/O adverse/O reactions/O and/O laboratory/O abnormalities/O in/O XALKORI/O -/O treated/O patients/O ./O
Table/O 5/O ./O
Adverse/O Reactions/O Reported/O at/O a/O Higher/O Incidence/O (/O 5/O %/O Higher/O for/O All/O Grades/O or/O 2/O %/O Higher/O for/O Grades/O 3/4/O )/O with/O XALKORI/O than/O Chemotherapy/O in/O Study/O 2/O Adverse/O Reaction/O XALKORI(N=172/O )/O Chemotherapy/O (/O Pemetrexed/O or/O Docetaxel)(N=171/O )/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O All/O Grades(%/O )/O Grade/O 3/4(%/O )/O Includes/O cases/O reported/O within/O the/O clustered/O terms/O :/O Nervous/O System/O Disorder/O Dizziness/B-AdverseReaction 22/O 1/O 8/O 0/O Dysgeusia/B-AdverseReaction 26/O 0/O 9/O 0/O Syncope/B-AdverseReaction 3/O 3/O 0/O 0/O Eye/O Disorders/O Vision/B-AdverseReaction disorder/I-AdverseReaction 60/O 0/O 9/O 0/O Cardiac/O Disorders/O Electrocardiogram/B-AdverseReaction QT/I-AdverseReaction prolonged/I-AdverseReaction 5/O 3/O 0/O 0/O Bradycardia/B-AdverseReaction 5/O 0/O 0/O 0/O Investigations/O Weight/B-AdverseReaction decreased/I-AdverseReaction 10/O 1/O 4/O 0/O Gastrointestinal/O Disorders/O Vomiting/B-AdverseReaction 47/O 1/O 18/O 0/O Nausea/B-AdverseReaction 55/O 1/O 37/O 1/O Diarrhea/B-AdverseReaction 60/O 0/O 19/O 1/O Constipation/B-AdverseReaction 42/O 2/O 23/O 0/O Dyspepsia/B-AdverseReaction 8/O 0/O 3/O 0/O Infections/O and/O Infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction infection/I-AdverseReaction 26/O 0/O 13/O 1/O Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O Pulmonary/B-AdverseReaction embolism/I-AdverseReaction 6/O 5/O 2/O 2/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Edema/B-AdverseReaction 31/O 0/O 16/O 0/O Additional/O adverse/O reactions/O occurring/O at/O an/O overall/O incidence/O between/O 1/O %/O and/O 30/O %/O in/O patients/O treated/O with/O XALKORI/O included/O (/O %/O )/O ,/O fatigue/B-AdverseReaction (/O 27/O %/O )/O ,/O neuropathy/B-AdverseReaction (/O 19/O %/O ;/O dysesthesia/B-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O neuralgia/B-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O parasthesia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O polyneuropathy/B-AdverseReaction ,/O burning/B-AdverseReaction sensation/I-AdverseReaction in/I-AdverseReaction skin/I-AdverseReaction )/O ,/O rash/B-AdverseReaction (/O 9/O %/O )/O ,/O ILD/B-AdverseReaction (/O 4/O %/O ;/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction ,/O ILD/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction )/O ,/O renal/B-AdverseReaction cyst/I-AdverseReaction (/O 4/O %/O )/O ,/O and/O hepatic/B-AdverseReaction failure/I-AdverseReaction (/O 1/O %/O )/O ./O
Table/O 6/O ./O
Summary/O of/O Treatment/O -/O Emergent/O Laboratory/O Abnormalities/O with/O Grade/O 3/O or/O 4/O Incidence/O of/O 4/O %/O in/O XALKORI/O -/O Treated/O Patients/O in/O Study/O 2/O Laboratory/O Abnormality/O XALKORI/O Chemotherapy/O Any/O Grade(%/O )/O Grade/O 3/4(%/O )/O Any/O Grade(%/O )/O Grade/O 3/4(%/O )/O Hematology/O Neutropenia/B-AdverseReaction 49/O 12/O 28/O 12/O Lymphopenia/B-AdverseReaction 51/O 9/O 60/O 25/O Chemistry/O ALT/B-AdverseReaction elevation/I-AdverseReaction 76/O 17/O 38/O 4/O AST/B-AdverseReaction elevation/I-AdverseReaction 61/O 9/O 33/O 0/O Hypokalemia/B-AdverseReaction 18/O 4/O 10/O 1/O Hypophosphatemia/B-AdverseReaction 28/O 5/O 25/O 6/O Description/O of/O Selected/O Adverse/O Drug/O Reactions/O Vision/O disorders/O Vision/B-AdverseReaction disorders/I-AdverseReaction ,/O most/O commonly/O visual/B-AdverseReaction impairment/I-AdverseReaction ,/O photopsia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O or/O vitreous/B-AdverseReaction floaters/I-AdverseReaction ,/O occurred/O in/O 1038/O (/O 62/O %/O )/O of/O 1669/O patients/O ./O
The/O majority/O (/O 95/O %/O )/O of/O these/O patients/O had/O Grade/B-Severity 1/I-Severity visual/B-AdverseReaction adverse/I-AdverseReaction reactions/I-AdverseReaction ./O
There/O were/O 13/O (/O 0.8/O %/O )/O patients/O with/O Grade/B-Severity 3/I-Severity and/O 4/O (/O 0.2/O %/O )/O patients/O with/O Grade/B-Severity 4/I-Severity visual/B-AdverseReaction impairment/I-AdverseReaction ./O
Based/O on/O the/O Visual/O Symptom/O Assessment/O Questionnaire/O (/O VSAQ/O -/O ALK/O )/O ,/O patients/O treated/O with/O XALKORI/O in/O Studies/O 1/O and/O 2/O reported/O a/O higher/O incidence/O of/O visual/B-AdverseReaction disturbances/I-AdverseReaction compared/O to/O patients/O treated/O with/O chemotherapy/O ./O
The/O onset/O of/O vision/B-AdverseReaction disorder/I-AdverseReaction generally/O was/O within/O the/O first/O week/O of/O drug/O administration/O ./O
The/O majority/O of/O patients/O on/O the/O XALKORI/O arms/O in/O Studies/O 1/O and/O 2/O (/O 50/O %/O )/O reported/O visual/B-AdverseReaction disturbances/I-AdverseReaction which/O occurred/O at/O a/O frequency/O of/O 4/O -/O 7/O days/O each/O week/O ,/O lasted/O up/O to/O 1/O minute/O ,/O and/O had/O mild/O or/O no/O impact/O (/O scores/O 0/O to/O 3/O out/O of/O a/O maximum/O score/O of/O 10/O )/O on/O daily/O activities/O as/O captured/O in/O the/O VSAQ/O -/O ALK/O questionnaire/O ./O
Neuropathy/O Neuropathy/B-AdverseReaction ,/O most/O commonly/O sensory/O in/O nature/O ,/O occurred/O in/O 419/O (/O 25/O %/O )/O of/O 1669/O patients/O ./O
Most/O events/O (/O 95/O %/O )/O were/O Grade/O 1/O or/O Grade/O 2/O in/O severity/O ./O
Renal/O Cysts/O Renal/B-AdverseReaction cysts/I-AdverseReaction were/O experienced/O by/O 50/O (/O 3/O %/O )/O of/O 1669/O patients/O ./O
Renal/B-AdverseReaction cysts/I-AdverseReaction occurred/O in/O 8/O (/O 5/O %/O )/O patients/O treated/O with/O XALKORI/O and/O 1/O (/O 1/O %/O )/O patient/O treated/O with/O chemotherapy/O in/O Study/O 1/O ./O
Renal/B-AdverseReaction cysts/I-AdverseReaction occurred/O in/O 8/O (/O 5/O %/O )/O patients/O treated/O with/O XALKORI/O and/O 1/O (/O 1/O %/O )/O patient/O treated/O with/O chemotherapy/O in/O Study/O 2/O ./O
The/O majority/O of/O renal/B-AdverseReaction cysts/I-AdverseReaction in/O XALKORI/O -/O treated/O patients/O were/O complex/O ./O
Local/B-AdverseReaction cystic/I-AdverseReaction invasion/I-AdverseReaction beyond/I-AdverseReaction the/I-AdverseReaction kidney/I-AdverseReaction occurred/O ,/O in/O some/O cases/O with/O imaging/O characteristics/O suggestive/B-Factor of/O abscess/B-AdverseReaction formation/O ./O
However/O ,/O across/O clinical/O trials/O no/B-Negation renal/B-AdverseReaction abscesses/I-AdverseReaction were/O confirmed/O by/O microbiology/O tests/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Hepatotoxicity/B-AdverseReaction :/O Fatal/B-AdverseReaction hepatotoxicity/B-AdverseReaction occurred/O in/O 0.1/O %/O of/O patients/O ./O
Monitor/O with/O periodic/O liver/O testing/O ./O
Temporarily/O suspend/O ,/O dose/O reduce/O ,/O or/O permanently/O discontinue/O XALKORI/O ./O
(/O 5.1/O )/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction (/O ILD)/Pneumonitis/B-AdverseReaction :/O Occurred/O in/O 2.9/O %/O of/O patients/O ./O
Permanently/O discontinue/O in/O patients/O with/O ILD/O pneumonitis/O ./O
(/O 5.2/O )/O QT/B-AdverseReaction Interval/I-AdverseReaction Prolongation/I-AdverseReaction :/O Occurred/O in/O 2.1/O %/O of/O patients/O ./O
Monitor/O with/O electrocardiograms/O and/O electrolytes/O in/O patients/O who/O have/O a/O history/O of/O or/O predisposition/O for/O QTc/O prolongation/O ,/O or/O who/O are/O taking/O medications/O that/O prolong/O QT/O ./O
Temporarily/O suspend/O ,/O dose/O reduce/O ,/O or/O permanently/O discontinue/O XALKORI/O ./O
(/O 5.3/O )/O Bradycardia/B-AdverseReaction :/O XALKORI/O can/B-Factor cause/O bradycardia/B-AdverseReaction ./O
Monitor/O heart/O rate/O and/O blood/O pressure/O regularly/O ./O
Temporarily/O suspend/O ,/O dose/O reduce/O ,/O or/O permanently/O discontinue/O XALKORI/O ./O
(/O 5.4/O )/O Severe/B-Severity Visual/B-AdverseReaction Loss/I-AdverseReaction :/O Reported/O in/O 0.2/O %/O of/O patients/O ./O
Discontinue/O XALKORI/O in/O patients/O with/O severe/O visual/O loss/O ./O
Perform/O an/O ophthalmological/O evaluation/O ./O
(/O 5.5/O )/O Embryofetal/B-AdverseReaction Toxicity/I-AdverseReaction :/O Can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O females/O of/O reproductive/O potential/O of/O the/O potential/O risk/O to/O a/O fetus/O and/O use/O of/O effective/O contraception/O ./O
(/O 5.6/O ,/O 8.1/O ,/O 8.3/O )/O 5.1/O Hepatotoxicity/O Drug/O -/O induced/O hepatotoxicity/B-AdverseReaction with/O fatal/B-AdverseReaction outcome/O occurred/O in/O 2/O (/O 0.1/O %/O )/O of/O the/O 1669/O patients/O treated/O with/O XALKORI/O across/O clinical/O trials/O in/O patients/O with/O NSCLC/O ./O
Concurrent/O elevations/B-AdverseReaction in/I-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction (/O ALT/O )/O or/O aspartate/O aminotransferase/O (/O AST/O )/O greater/O than/O or/O equal/O to/O three/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/I-Severity ULN/O )/O and/O total/O bilirubin/O greater/O than/O or/O equal/O to/O two/O times/O the/O ULN/O ,/O with/O normal/O alkaline/O phosphatase/O ,/O occurred/O in/O 10/O patients/O (/O 0.6/O %/O )/O treated/O with/O XALKORI/O ./O
Additionally/O ,/O elevations/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction or/O AST/O greater/O than/O five/B-Severity times/I-Severity the/I-Severity ULN/I-Severity occurred/O in/O 184/O (/O 11/O %/O )/O and/O 93/O (/O 5.7/O %/O )/O patients/O ,/O respectively/O ./O
Seventeen/O patients/O (/O 1.0/O %/O )/O required/O permanent/O discontinuation/O due/O to/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ./O
Transaminase/B-AdverseReaction elevations/I-AdverseReaction generally/O occurred/O within/O the/O first/O 2/O months/O of/O treatment/O ./O
Monitor/O with/O liver/O function/O tests/O including/O ALT/O and/O total/O bilirubin/O every/O 2/O weeks/O during/O the/O first/O 2/O months/O of/O treatment/O ,/O then/O once/O a/O month/O and/O as/O clinically/O indicated/O ,/O with/O more/O frequent/O repeat/O testing/O for/O increased/O liver/O transaminases/O ,/O alkaline/O phosphatase/O ,/O or/O total/O bilirubin/O in/O patients/O who/O develop/O transaminase/O elevations/O ./O
Temporarily/O suspend/O ,/O dose/O reduce/O ,/O or/O permanently/O discontinue/O XALKORI/O as/O described/O in/O Table/O 2/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.2/O Interstitial/O Lung/O Disease/O (/O Pneumonitis/O )/O Severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction (/O ILD)/pneumonitis/B-AdverseReaction can/B-Factor occur/O in/O patients/O treated/O with/O XALKORI/O ./O
Across/O clinical/O trials/O (/O n=1669/O )/O ,/O 49/O XALKORI/O -/O treated/O patients/O (/O 2.9/O %/O )/O had/O ILD/B-AdverseReaction of/O any/O grade/O ,/O 18/O patients/O (/O 1.1/O %/O )/O had/O Grade/B-Severity 3/I-Severity or/O 4/O ILD/B-AdverseReaction ,/O and/O 8/O patients/O (/O 0.5/O %/O )/O had/O fatal/B-AdverseReaction ILD/B-AdverseReaction ./O
These/O cases/O generally/O occurred/O within/O 3/O months/O after/O the/O initiation/O of/O XALKORI/O ./O
Monitor/O patients/O for/O pulmonary/O symptoms/O indicative/O of/O ILD/O pneumonitis/O ./O
Exclude/O other/O potential/O causes/O of/O ILD/O pneumonitis/O ,/O and/O permanently/O discontinue/O XALKORI/O in/O patients/O diagnosed/O with/O drug/O -/O related/O ILD/O pneumonitis/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.3/O QT/O Interval/O Prolongation/O QTc/B-AdverseReaction prolongation/I-AdverseReaction can/B-Factor occur/O in/O patients/O treated/O with/O XALKORI/O ./O
Across/O clinical/O trials/O ,/O 32/O of/O 1560/O patients/O (/O 2.1/O %/O )/O had/O QTcF/O (/O corrected/O QT/O by/O the/O Fridericia/O method/O )/O greater/O than/O or/O equal/O to/O 500/O ms/O and/O 76/O of/O 1520/O patients/O (/O 5.0/O %/O )/O had/O an/O increase/O from/O baseline/O QTcF/O greater/O than/O or/O equal/O to/O 60/B-Severity ms/I-Severity by/O automated/O machine/O -/O read/O evaluation/O of/O ECG/O ./O
Avoid/O use/O of/O XALKORI/O in/O patients/O with/O congenital/O long/O QT/O syndrome/O ./O
Consider/O periodic/O monitoring/O with/O electrocardiograms/O (/O ECGs/O )/O and/O electrolytes/O in/O patients/O with/O congestive/O heart/O failure/O ,/O bradyarrhythmias/O ,/O electrolyte/O abnormalities/O ,/O or/O who/O are/O taking/O medications/O that/O are/O known/O to/O prolong/O the/O QT/O interval/O ./O
Permanently/O discontinue/O XALKORI/O in/O patients/O who/O develop/O QTc/O greater/O than/O 500/O ms/O or/O greater/O than/O or/O equal/O to/O 60/O ms/O change/O from/O baseline/O with/O Torsade/O de/O pointes/O or/O polymorphic/O ventricular/O tachycardia/O or/O signs/O symptoms/O of/O serious/O arrhythmia/O ./O
Withhold/O XALKORI/O in/O patients/O who/O develop/O QTc/O greater/O than/O 500/O ms/O on/O at/O least/O 2/O separate/O ECGs/O until/O recovery/O to/O a/O QTc/O less/O than/O or/O equal/O to/O 480/O ms/O ,/O then/O resume/O XALKORI/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 2/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.4/O Bradycardia/O Symptomatic/B-AdverseReaction bradycardia/I-AdverseReaction can/O occur/O in/O patients/O receiving/O XALKORI/O ./O
Across/O clinical/O trials/O ,/O bradycardia/B-AdverseReaction occurred/O in/O 205/O (/O 12.3/O %/O )/O of/O 1669/O patients/O treated/O with/O XALKORI/O ./O
A/O total/O of/O 242/O (/O 14.9/O %/O )/O patients/O had/O a/O heart/B-AdverseReaction rate/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 50/I-AdverseReaction beats/I-AdverseReaction per/I-AdverseReaction minute/I-AdverseReaction ./O
In/O Studies/O 1/O and/O 2/O ,/O Grade/B-Severity 3/I-Severity syncope/B-AdverseReaction occurred/O in/O 2.0/O %/O of/O XALKORI/O -/O treated/O patients/O and/O in/O 0.6/O %/O of/O the/O chemotherapy/O -/O treated/O patients/O ./O
Avoid/O using/O XALKORI/O in/O combination/O with/O other/O agents/O known/O to/O cause/O bradycardia/O (/O e.g./O ,/O beta/O -/O blockers/O ,/O non/O -/O dihydropyridine/O calcium/O channel/O blockers/O ,/O clonidine/O and/O digoxin/O )/O to/O the/O extent/O possible/O ./O
Monitor/O heart/O rate/O and/O blood/O pressure/O regularly/O ./O
In/O cases/O of/O symptomatic/O bradycardia/O that/O is/O not/O life/O -/O threatening/O ,/O hold/O XALKORI/O until/O recovery/O to/O asymptomatic/O bradycardia/O or/O to/O a/O heart/O rate/O of/O 60/O bpm/O or/O above/O ,/O re/O -/O evaluate/O the/O use/O of/O concomitant/O medications/O ,/O and/O adjust/O the/O dose/O of/O XALKORI/O ./O
Permanently/O discontinue/O for/O life/O -/O threatening/O bradycardia/O due/O to/O XALKORI/O ;/O however/O ,/O if/O associated/O with/O concomitant/O medications/O known/O to/O cause/O bradycardia/O or/O hypotension/O ,/O hold/O XALKORI/O until/O recovery/O to/O asymptomatic/O bradycardia/O or/O to/O a/O heart/O rate/O of/O 60/O bpm/O or/O above/O ,/O and/O if/O concomitant/O medications/O can/O be/O adjusted/O or/O discontinued/O ,/O restart/O XALKORI/O at/O 250/O mg/O once/O daily/O with/O frequent/O monitoring/O [/O see/O Dosage/O and/O Administration/O (/O 2.3/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.5/O Severe/O Visual/O Loss/O Across/O all/O clinical/O trials/O ,/O the/O incidence/O of/O Grade/B-Severity 4/I-Severity visual/B-AdverseReaction field/I-AdverseReaction defect/I-AdverseReaction with/O vision/B-AdverseReaction loss/I-AdverseReaction was/O 0.2/O %/O (/O 4/1669/O )/O ./O
Optic/B-AdverseReaction atrophy/I-AdverseReaction and/O optic/B-AdverseReaction nerve/I-AdverseReaction disorder/I-AdverseReaction have/O been/O reported/O as/O potential/B-Factor causes/O of/O vision/B-AdverseReaction loss/I-AdverseReaction ./O
Discontinue/O XALKORI/O in/O patients/O with/O new/O onset/O of/O severe/O visual/O loss/O (/O best/O corrected/O vision/O less/O than/O 20/200/O in/O one/O or/O both/O eyes/O )/O ./O
Perform/O an/O ophthalmological/O evaluation/O consisting/O of/O best/O corrected/O visual/O acuity/O ,/O retinal/O photographs/O ,/O visual/O fields/O ,/O optical/O coherence/O tomography/O (/O OCT/O )/O and/O other/O evaluations/O as/O appropriate/O for/O new/O onset/O of/O severe/O visual/O loss/O ./O
There/O is/O insufficient/O information/O to/O characterize/O the/O risks/O of/O resumption/O of/O XALKORI/O in/O patients/O with/O a/O severe/O visual/O loss/O ;/O a/O decision/O to/O resume/O XALKORI/O should/O consider/O the/O potential/O benefits/O to/O the/O patient/O ./O
5.6/O Embryofetal/O Toxicity/O Based/O on/O its/O mechanism/O of/O action/O ,/O XALKORI/O can/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
In/O animal/O reproduction/O studies/O ,/O oral/O administration/O of/O crizotinib/O in/O pregnant/O rats/B-Animal during/O organogenesis/O at/O exposures/O similar/O to/O those/O observed/O with/O the/O maximum/O recommended/O human/O dose/O resulted/O in/O embryotoxicity/B-AdverseReaction and/O fetotoxicity/B-AdverseReaction ./O
Advise/O pregnant/O women/O of/O the/O potential/O risk/O to/O a/O fetus/O ./O
Advise/O females/O of/O reproductive/O potential/O to/O use/O effective/O contraception/O during/O treatment/O with/O XALKORI/O and/O for/O at/O least/O 45/O days/O following/O the/O final/O dose/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O ,/O 8.3/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O to/O XEOMIN/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Hypersensitivity/B-AdverseReaction [/O see/O Contraindications/O (/O 4/O )/O and/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Dysphagia/B-AdverseReaction and/O Breathing/B-AdverseReaction Difficulties/I-AdverseReaction in/O Treatment/O of/O cervical/O dystonia/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Spread/B-AdverseReaction of/I-AdverseReaction Effects/I-AdverseReaction from/I-AdverseReaction Toxin/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O EXCERPT/O :/O Cervical/O Dystonia/O :/O The/O most/O commonly/O observed/O adverse/O reactions/O (/O 5/O %/O of/O patients/O and/O placebo/O )/O are/O dysphagia/B-AdverseReaction ,/O neck/B-AdverseReaction pain/I-AdverseReaction ,/O muscle/B-AdverseReaction weakness/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction (/O 6.1/O )/O ./O
Blepharospasm/O :/O The/O most/O commonly/O observed/O adverse/O reactions/O (/O 5/O %/O of/O patients/O and/O placebo/O )/O are/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O dry/B-AdverseReaction eye/I-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O visual/B-AdverseReaction impairment/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction (/O 6.1/O )/O ./O
Glabellar/O Lines/O :/O The/O most/O commonly/O observed/O adverse/O reaction/O (/O 1/O %/O of/O patients/O and/O placebo/O )/O is/O headache/B-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Merz/O Pharmaceuticals/O ,/O LLC/O at/O 888/O -/O 493/O -/O 6646/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O ,/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Cervical/O Dystonia/O The/O data/O described/O below/O reflect/O exposure/O to/O a/O single/O intramuscular/O dose/O of/O XEOMIN/O in/O a/O placebo/O -/O controlled/O ,/O Phase/O 3/O trial/O in/O patients/O with/O cervical/O dystonia/O [/O see/O Clinical/O Studies/O (/O 14.1/O )/O ]/O ./O
In/O this/O study/O ,/O 159/O patients/O received/O XEOMIN/O (/O 78/O were/O randomized/O to/O receive/O a/O total/O dose/O of/O 120/O Units/O ,/O and/O 81/O were/O randomized/O to/O receive/O a/O total/O dose/O of/O 240/O Units/O )/O ./O
XEOMIN/O -/O treated/O patients/O were/O 18/O to/O 79/O years/O old/O (/O mean/O 53/O years/O )/O ,/O and/O were/O predominantly/O female/O (/O 66/O %/O )/O and/O Caucasian/O (/O 91/O %/O )/O ./O
At/O study/O baseline/O ,/O approximately/O 25/O %/O had/O mild/O ,/O 50/O %/O had/O moderate/O ,/O and/O 25/O %/O had/O severe/O cervical/O dystonia/O ./O
Approximately/O 61/O %/O of/O XEOMIN/O -/O treated/O patients/O had/O previously/O received/O another/O botulinum/O toxin/O type/O A/O product/O ./O
Common/O adverse/O events/O (/O 5/O %/O in/O any/O XEOMIN/O treatment/O group/O )/O observed/O in/O patients/O who/O received/O XEOMIN/O (/O 120/O Units/O or/O 240/O Units/O )/O included/O dysphagia/B-AdverseReaction ,/O neck/B-AdverseReaction pain/I-AdverseReaction ,/O muscle/B-AdverseReaction weakness/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ./O
Table/O 2/O :/O Most/O Common/O TEAEs/O (/O 5/O %/O )/O and/O Greater/O than/O Placebo/O :/O Double/O -/O Blind/O Phase/O of/O Clinical/O Trial/O Double/O -/O Blind/O Phase/O System/O Organ/O ClassPreferred/O Term/O XEOMIN/O 120/O Units(N=77/O )/O XEOMIN/O 240/O Units(N=82/O )/O Placebo(N=74/O )/O Any/O TEAEs/O 57/O %/O 55/O %/O 42/O %/O Musculoskeletal/O and/O connective/O tissue/O disorders/O 23/O %/O 32/O %/O 11/O %/O Neck/B-AdverseReaction pain/I-AdverseReaction 7/O %/O 15/O %/O 4/O %/O Muscular/B-AdverseReaction weakness/I-AdverseReaction 7/O %/O 11/O %/O 1/O %/O Musculoskeletal/B-AdverseReaction pain/I-AdverseReaction 7/O %/O 4/O %/O 1/O %/O Gastrointestinal/O disorders/O 18/O %/O 24/O %/O 4/O %/O Dysphagia/B-AdverseReaction 13/O %/O 18/O %/O 3/O %/O Nervous/O system/O disorders/O 16/O %/O 17/O %/O 7/O %/O General/O disorders/O and/O administration/O site/O conditions/O 16/O %/O 11/O %/O 11/O %/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 9/O %/O 4/O %/O 7/O %/O Infections/O and/O infestations/O 14/O %/O 13/O %/O 11/O %/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O 13/O %/O 10/O %/O 3/O %/O Blepharospasm/O In/O the/O placebo/O -/O controlled/O Phase/O 3/O trial/O in/O patients/O with/O blepharospasm/B-AdverseReaction previously/O treated/O with/O onabotulinumtoxinA/O (/O Botox/O )/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ,/O 74/O patients/O received/O XEOMIN/O at/O a/O mean/O dose/O of/O approximately/O 33/O Units/O per/O eye/O (/O minimum/O 10/O Units/O ,/O maximum/O 50/O Units/O )/O ./O
XEOMIN/O -/O treated/O patients/O were/O 22/O to/O 79/O years/O of/O age/O (/O mean/O 62/O years/O )/O ,/O predominantly/O female/O (/O 65/O %/O )/O ,/O Caucasian/O (/O 79/O %/O )/O ,/O and/O had/O a/O mean/O time/O since/O diagnosis/O of/O approximately/O 5/O years/O ./O
The/O adverse/O events/O occurring/O in/O 5/O %/O of/O XEOMIN/O -/O treated/O patients/O and/O greater/O than/O placebo/O in/O the/O Phase/O 3/O study/O were/O eyelid/B-AdverseReaction ptosis/I-AdverseReaction ,/O dry/B-AdverseReaction eye/I-AdverseReaction ,/O dry/B-AdverseReaction mouth/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O visual/B-AdverseReaction impairment/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O nasopharyngitis/B-AdverseReaction ,/O and/O respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ./O
No/O serious/O adverse/O events/O occurred/O in/O patients/O who/O received/O XEOMIN/O ;/O one/O placebo/B-Factor -/O treated/O patient/O experienced/O a/O serious/B-Severity adverse/O event/O (/O dyspnea/B-AdverseReaction )/O ./O
Table/O 3/O :/O Most/O Common/O TEAEs/O (/O 5/O %/O )/O and/O Greater/O than/O Placebo/O :/O Double/O -/O Blind/O Phase/O of/O Clinical/O Trial/O Double/O -/O Blind/O Phase/O System/O Organ/O Class/O Preferred/O Term/O XEOMIN(N=74/O )/O Placebo(N=34/O )/O Subjects/O with/O TEAEs/O 70/O %/O 62/O %/O Eye/O disorders/O 38/O %/O 21/O %/O Eyelid/B-AdverseReaction ptosis/I-AdverseReaction 19/O %/O 9/O %/O Dry/B-AdverseReaction eye/I-AdverseReaction 16/O %/O 12/O %/O Visual/B-AdverseReaction impairment/I-AdverseReaction 12/O %/O 6/O %/O Gastrointestinal/O disorders/O 30/O %/O 15/O %/O Dry/B-AdverseReaction mouth/I-AdverseReaction 16/O %/O 3/O %/O Diarrhoea/B-AdverseReaction 8/O %/O -/O Infections/O and/O infestations/O 20/O %/O 15/O %/O Nasopharyngitis/B-AdverseReaction 5/O %/O 3/O %/O Respiratory/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 5/O %/O 3/O %/O Nervous/O system/O disorders/O 14/O %/O 9/O %/O Headache/B-AdverseReaction 7/O %/O 3/O %/O General/O disorders/O and/O administration/O site/O conditions/O 11/O %/O 9/O %/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O 11/O %/O 3/O %/O Dyspnoea/B-AdverseReaction 5/O %/O 3/O %/O Glabellar/O Lines/O In/O three/O placebo/O -/O controlled/O trials/O in/O 803/O subjects/O with/O glabellar/O lines/O ,/O 535/O subjects/O received/O a/O single/O dose/O of/O 20/O Units/O XEOMIN/O and/O 268/O subjects/O received/O placebo/O ./O
XEOMIN/O treated/O subjects/O were/O 24/O to/O 74/O years/O old/O ,/O and/O were/O predominantly/O female/O (/O 88/O %/O )/O ./O
The/O most/O frequent/O adverse/O reactions/O in/O XEOMIN/O treated/O subjects/O were/O :/O headache/B-AdverseReaction 29/O (/O 5.4/O %/O )/O ,/O facial/B-AdverseReaction paresis/I-AdverseReaction 4/O (/O 0.7/O %/O )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction 3/O (/O 0.6/O %/O )/O and/O eyelid/B-AdverseReaction edema/I-AdverseReaction 2/O (/O 0.4/O %/O )/O ./O
Four/O serious/O adverse/O events/O occurred/O in/O two/O placebo/O -/O treated/O subjects/O ./O
Six/O XEOMIN/O treated/O subjects/O experienced/O six/O serious/O adverse/O events/O ./O
All/O serious/O adverse/O events/O were/O assessed/O as/O unrelated/O to/O study/O drug/O ./O
The/O adverse/O reactions/O below/O reflect/O exposure/O to/O XEOMIN/O with/O glabellar/O lines/O in/O placebo/O -/O controlled/O studies/O ./O
Adverse/O reactions/O are/O adverse/O events/O in/O which/O there/O is/O some/O basis/O to/O believe/O there/O is/O a/O causal/O relationship/O between/O the/O drug/O and/O the/O occurrence/O of/O the/O adverse/O event/O ./O
Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Table/O 4/O :/O Adverse/O Reactions/O in/O Placebo/O -/O Controlled/O Trials/O Adverse/O reactions/O XEOMIN(N=535/O )/O (/O %/O )/O Placebo(N=268/O )/O (/O %/O )/O Nervous/O system/O disorders/O 33/O (/O 6.1/O )/O 6/O (/O 2.2/O )/O Headache/B-AdverseReaction 1/O 29/O (/O 5.4/O )/O 6/O (/O 2.2/O )/O Facial/B-AdverseReaction paresis/I-AdverseReaction (/O brow/B-AdverseReaction ptosis/I-AdverseReaction )/O 4/O (/O 0.7/O )/O 0/O General/O disorders/O and/O administration/O site/O conditions/O 5/O (/O 0.9/O )/O 2/O (/O 0.7/O )/O Injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction 3/O (/O 0.6/O )/O 0/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 1/O (/O 0.2/O )/O 0/O Facial/B-AdverseReaction pain/I-AdverseReaction 1/O (/O 0.2/O )/O 0/O Injection/B-AdverseReaction site/I-AdverseReaction swelling/I-AdverseReaction 0/O 1/O (/O 0.4/O )/O Sensation/B-AdverseReaction of/I-AdverseReaction pressure/I-AdverseReaction 0/O 1/O (/O 0.4/O )/O Eye/O disorders/O 5/O (/O 0.9/O )/O 0/O Eyelid/B-AdverseReaction edema/I-AdverseReaction 2/O (/O 0.4/O )/O 0/O Blepharospasm/B-AdverseReaction 1/O (/O 0.2/O )/O 0/O Eye/B-AdverseReaction disorder/I-AdverseReaction 1(0.2/O )/O 0/O Eyelid/B-AdverseReaction ptosis/I-AdverseReaction 1(0.2/O )/O 0/O In/O open/O label/O ,/O multiple/O dose/O trials/O ,/O adverse/O reactions/O were/O reported/O for/O 105/O of/O the/O 800/O subjects/O (/O 13.1/O %/O )/O ./O
Headache/B-AdverseReaction was/O the/O most/O common/O adverse/O reaction/O ,/O reported/O for/O 57/O subjects/O (/O 7.1/O %/O )/O ,/O followed/O by/O injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction in/O 8/O subjects/O (/O 1.0/O %/O )/O ./O
Adverse/O reactions/O reported/O in/O less/O than/O 1/O %/O of/O subjects/O were/O :/O facial/B-AdverseReaction paresis/I-AdverseReaction (/O brow/B-AdverseReaction ptosis/I-AdverseReaction )/O ,/O muscle/B-AdverseReaction disorder/I-AdverseReaction (/O elevation/B-AdverseReaction of/I-AdverseReaction eyebrow/I-AdverseReaction )/O ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O eyelid/B-AdverseReaction edema/I-AdverseReaction ./O
6.2/O Immunogenicity/O As/O with/O all/O therapeutic/O proteins/O ,/O there/O is/O a/O potential/O for/O immunogenicity/O ./O
The/O incidence/O of/O antibody/O formation/O is/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O ./O
In/O addition/O ,/O the/O observed/O incidence/O of/O antibody/O positivity/O in/O an/O assay/O may/O be/O influenced/O by/O several/O factors/O including/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O the/O incidence/O of/O antibodies/O across/O products/O in/O this/O class/O may/O be/O misleading/O ./O
6.3/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O reported/O during/O post/O -/O approval/O use/O with/O XEOMIN/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O :/O eye/B-AdverseReaction swelling/I-AdverseReaction ,/O eyelid/B-AdverseReaction edema/I-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O flu/B-AdverseReaction -/I-AdverseReaction like/O symptoms/O ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O allergic/B-AdverseReaction dermatitis/I-AdverseReaction ,/O localized/B-AdverseReaction allergic/I-AdverseReaction reactions/I-AdverseReaction like/O swelling/O ,/O edema/O ,/O erythema/O ,/O pruritus/O or/O rash/O ,/O herpes/B-AdverseReaction zoster/I-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O muscle/B-AdverseReaction spasm/I-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O myalgia/B-AdverseReaction and/O hypersensitivity/B-AdverseReaction ./O
BOXED/O WARNING/O :/O WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction Postmarketing/O reports/O indicate/O that/O the/O effects/O of/O XEOMIN/O and/O all/O botulinum/O toxin/O products/O may/B-Factor spread/B-AdverseReaction from/I-AdverseReaction the/I-AdverseReaction area/I-AdverseReaction of/I-AdverseReaction injection/I-AdverseReaction to/O produce/O symptoms/O consistent/O with/O botulinum/O toxin/B-AdverseReaction effects/I-AdverseReaction ./O
These/O may/B-Factor include/O asthenia/B-AdverseReaction ,/O generalized/B-AdverseReaction muscle/I-AdverseReaction weakness/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O ptosis/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O urinary/B-AdverseReaction incontinence/I-AdverseReaction and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/O be/O life/B-Severity threatening/I-Severity and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction ./O
The/O risk/O of/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O also/O occur/O in/O adults/O treated/O for/O spasticity/O and/O other/O conditions/O ,/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
In/O unapproved/O uses/O ,/O including/O spasticity/O in/O children/O and/O adults/O ,/O and/O in/O approved/O indications/O ,/O cases/O of/O spread/B-AdverseReaction of/I-AdverseReaction effect/I-AdverseReaction have/O been/O reported/O at/O doses/O comparable/O to/O those/O used/O to/O treat/O cervical/O dystonia/O and/O at/O lower/O doses/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O DISTANT/B-AdverseReaction SPREAD/I-AdverseReaction OF/I-AdverseReaction TOXIN/I-AdverseReaction EFFECT/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
The/O effects/O of/O XEOMIN/O and/O all/O botulinum/O toxin/O products/O may/B-Factor spread/B-AdverseReaction from/I-AdverseReaction the/I-AdverseReaction area/I-AdverseReaction of/I-AdverseReaction injection/I-AdverseReaction to/O produce/O symptoms/O consistent/O with/O botulinum/O toxin/B-AdverseReaction effects/I-AdverseReaction ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/B-Factor be/O life/B-Severity threatening/I-Severity and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction ./O
The/O risk/O of/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O also/O occur/O in/O adults/O ,/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
(/O 5.1/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O For/O All/O Indications/O :/O The/O potency/O Units/O of/O XEOMIN/O are/O not/O interchangeable/O with/O other/O preparations/O of/O botulinum/O toxin/O products/O ./O
Therefore/O ,/O Units/O of/O biological/O activity/O of/O XEOMIN/O can/O not/O be/O compared/O to/O or/O converted/O into/O Units/O of/O any/O other/O botulinum/O toxin/O products/O (/O 5.2/O )/O ./O
Immediate/O medical/O attention/O may/O be/O required/O in/O cases/O of/O respiratory/O ,/O speech/O or/O swallowing/O difficulties/O (/O 5.1/O ,/O 5.4/O )/O ./O
Use/O with/O caution/O in/O patients/O with/O compromised/O respiratory/O function/O or/O dysphagia/O (/O 5.4/O )/O ./O
Concomitant/O neuromuscular/O disorders/O may/O exacerbate/O clinical/O effects/O of/O treatment/O (/O 5.5/O )/O ./O
Cervical/O Dystonia/O (/O 5.4/O ):/O Patients/O with/O smaller/O neck/O muscle/O mass/O and/O patients/O who/O require/O bilateral/O injections/O into/O the/O sternocleidomastoid/O muscles/O are/O at/O greater/O risk/B-Factor of/O dysphagia/B-AdverseReaction ./O
Limiting/O the/O dose/O injected/O into/O the/O sternocleidomastoid/O muscle/O may/O decrease/O the/O occurrence/O of/O dysphagia/O ./O
Blepharospasm/O (/O 5.6/O ):/O Corneal/B-AdverseReaction exposure/I-AdverseReaction and/O ulceration/O Injection/O of/O XEOMIN/O into/O the/O orbicularis/O oculi/O muscle/O may/B-Factor lead/O to/O reduced/B-AdverseReaction blinking/I-AdverseReaction and/O corneal/B-AdverseReaction exposure/I-AdverseReaction with/O possible/B-Factor ulceration/O or/O perforation/O ./O
Lower/O lid/O injections/O should/O not/O be/O repeated/O if/O diplopia/O occurred/O with/O previous/O botulinum/O toxin/O injections/O ./O
Glabellar/O Lines/O (/O 5.7/O ):/O Risk/B-Factor of/O ptosis/B-AdverseReaction (/O 5.7/O )/O ./O
5.1/O Spread/O of/O Toxin/O Effect/O Postmarketing/O safety/O data/O from/O XEOMIN/O and/O other/O approved/O botulinum/O toxins/O suggest/O that/O botulinum/O toxin/O effects/O may/B-Factor ,/O in/O some/O cases/O ,/O be/O observed/O beyond/O the/O site/O of/O local/O injection/O ./O
The/O symptoms/O are/O consistent/O with/O the/O mechanism/O of/O action/O of/O botulinum/O toxin/O and/O may/O include/O asthenia/B-AdverseReaction ,/O generalized/B-AdverseReaction muscle/I-AdverseReaction weakness/I-AdverseReaction ,/O diplopia/B-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O ptosis/B-AdverseReaction ,/O dysphagia/B-AdverseReaction ,/O dysphonia/B-AdverseReaction ,/O dysarthria/B-AdverseReaction ,/O urinary/B-AdverseReaction incontinence/I-AdverseReaction ,/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
These/O symptoms/O have/O been/O reported/O hours/O to/O weeks/O after/O injection/O ./O
Swallowing/O and/O breathing/B-AdverseReaction difficulties/I-AdverseReaction can/B-Factor be/O life/B-Severity threatening/I-Severity and/O there/O have/O been/O reports/O of/O death/B-AdverseReaction related/O to/O the/O spread/B-AdverseReaction of/I-AdverseReaction toxin/I-AdverseReaction effects/I-AdverseReaction ./O
The/O risk/O of/O symptoms/O is/O probably/O greatest/O in/O children/O treated/O for/O spasticity/O but/O symptoms/O can/O occur/O in/O adults/O treated/O for/O spasticity/O and/O other/O conditions/O ,/O and/O particularly/O in/O those/O patients/O who/O have/O underlying/O conditions/O that/O would/O predispose/O them/O to/O these/O symptoms/O ./O
In/O unapproved/O uses/O ,/O including/O spasticity/O in/O children/O and/O adults/O ,/O and/O in/O approved/O indications/O ,/O symptoms/O consistent/O with/O spread/B-AdverseReaction of/I-AdverseReaction toxin/I-AdverseReaction effect/I-AdverseReaction have/O been/O reported/O at/O doses/O comparable/O to/O or/O lower/O than/O doses/O used/O to/O treat/O cervical/O dystonia/O ./O
Patients/O or/O caregivers/O should/O be/O advised/O to/O seek/O immediate/O medical/O care/O if/O swallowing/O ,/O speech/O ,/O or/O respiratory/O disorders/O occur/O ./O
5.2/O Lack/O of/O Interchangeability/O between/O Botulinum/O Toxin/O Products/O The/O potency/O Units/O of/O XEOMIN/O are/O specific/O to/O the/O preparation/O and/O assay/O method/O utilized/O ./O
They/O are/O not/O interchangeable/O with/O the/O other/O preparations/O of/O botulinum/O toxin/O products/O and/O ,/O therefore/O ,/O Units/O of/O biological/O activity/O of/O XEOMIN/O can/O not/O be/O compared/O to/O or/O converted/O into/O Units/O of/O any/O other/O botulinum/O toxin/O products/O assessed/O with/O any/O other/O specific/O assay/O method/O [/O see/O Description/O (/O 11/O )/O ]/O ./O
5.3/O Hypersensitivity/O Reactions/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction have/O been/O reported/O with/O botulinum/B-DrugClass toxin/I-DrugClass products/I-DrugClass (/O anaphylaxis/B-AdverseReaction ,/O serum/B-AdverseReaction sickness/I-AdverseReaction ,/O urticaria/B-AdverseReaction ,/O soft/B-AdverseReaction tissue/I-AdverseReaction edema/I-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction )/O ./O
If/O serious/O and/or/O immediate/O hypersensitivity/O reactions/O occur/O further/O injection/O of/O XEOMIN/O should/O be/O discontinued/O and/O appropriate/O medical/O therapy/O immediately/O instituted/O ./O
5.4/O Dysphagia/O and/O Breathing/O Difficulties/O in/O Treatment/O of/O Cervical/O Dystonia/O Treatment/O with/O XEOMIN/O and/O other/O botulinum/O toxin/O products/O can/B-Factor result/O in/O swallowing/O or/O breathing/B-AdverseReaction difficulties/I-AdverseReaction ./O
Patients/O with/O pre/O -/O existing/O swallowing/O or/O breathing/O difficulties/O may/O be/O more/O susceptible/O to/O these/O complications/O ./O
In/O most/O cases/O ,/O this/O is/O a/O consequence/O of/O weakening/O of/O muscles/O in/O the/O area/O of/O injection/O that/O are/O involved/O in/O breathing/O or/O swallowing/O ./O
When/O distant/O effects/O occur/O ,/O additional/O respiratory/O muscles/O may/O be/O involved/O [/O See/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Deaths/B-AdverseReaction as/O a/O complication/O of/O severe/B-Severity dysphagia/B-AdverseReaction have/O been/O reported/O after/O treatment/O with/O botulinum/B-DrugClass toxin/I-DrugClass ./O
Dysphagia/B-AdverseReaction may/O persist/O for/O several/O months/O ,/O and/O require/O use/O of/O a/O feeding/O tube/O to/O maintain/O adequate/O nutrition/O and/O hydration/O ./O
Aspiration/B-AdverseReaction may/B-Factor result/O from/O severe/B-Severity dysphagia/B-AdverseReaction and/O is/O a/O particular/O risk/O when/O treating/O patients/O in/O whom/O swallowing/O or/O respiratory/O function/O is/O already/O compromised/O ./O
Treatment/O of/O cervical/O dystonia/O with/O botulinum/B-DrugClass toxins/I-DrugClass may/O weaken/B-AdverseReaction neck/I-AdverseReaction muscles/I-AdverseReaction that/O serve/O as/O accessory/O muscles/O of/O ventilation/O ./O
This/O may/B-Factor result/O in/O critical/B-Severity loss/B-AdverseReaction of/I-AdverseReaction breathing/I-AdverseReaction capacity/I-AdverseReaction in/O patients/O with/O respiratory/O disorders/O who/O may/O have/O become/O dependent/O upon/O these/O accessory/O muscles/O ./O
There/O have/O been/O post/O -/O marketing/O reports/O of/O serious/B-Severity breathing/B-AdverseReaction difficulties/I-AdverseReaction ,/O including/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O in/O patients/O with/O cervical/O dystonia/O treated/O with/O botulinum/B-DrugClass toxin/I-DrugClass products/I-DrugClass ./O
Patients/O with/O smaller/O neck/O muscle/O mass/O and/O patients/O who/O require/O bilateral/O injections/O into/O the/O sternocleidomastoid/O muscles/O have/O been/O reported/O to/O be/O at/O greater/O risk/B-Factor of/O dysphagia/B-AdverseReaction ./O
In/O general/O ,/O limiting/O the/O dose/O injected/O into/O the/O sternocleidomastoid/O muscle/O may/O decrease/O the/O occurrence/O of/O dysphagia/O ./O
Patients/O treated/O with/O botulinum/O toxin/O may/O require/O immediate/O medical/O attention/O should/O they/O develop/O problems/O with/O swallowing/O ,/O speech/O or/O respiratory/O disorders/O ./O
These/O reactions/O can/O occur/O within/O hours/O to/O weeks/O after/O injection/O with/O botulinum/O toxin/O [/O See/O Warnings/O and/O Precautions/O (/O 5.1/O )/O and/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.5/O Pre/O -/O existing/O Neuromuscular/O Disorders/O and/O other/O Special/O Populations/O Individuals/O with/O peripheral/O motor/O neuropathic/O diseases/O ,/O amyotrophic/O lateral/O sclerosis/O ,/O or/O neuromuscular/O junctional/O disorders/O (/O e.g./O ,/O myasthenia/O gravis/O or/O Lambert/O -/O Eaton/O syndrome/O )/O should/O be/O monitored/O particularly/O closely/O when/O given/O botulinum/O toxin/O ./O
Patients/O with/O neuromuscular/O disorders/O may/O be/O at/O increased/O risk/B-Factor of/O clinically/O significant/O effects/O including/O severe/B-Severity dysphagia/B-AdverseReaction and/O respiratory/B-AdverseReaction compromise/I-AdverseReaction from/O typical/O doses/O of/O XEOMIN/O [/O See/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
5.6/O Corneal/O Exposure/O ,/O Corneal/O Ulceration/O ,/O and/O Ectropion/O in/O Patients/O Treated/O with/O XEOMIN/O for/O Blepharospasm/O Reduced/B-AdverseReaction blinking/I-AdverseReaction from/O injection/O of/O botulinum/B-DrugClass toxin/I-DrugClass products/I-DrugClass in/O the/O orbicularis/O muscle/O can/O lead/O to/O corneal/B-AdverseReaction exposure/I-AdverseReaction ,/O persistent/O epithelial/O defect/O and/O corneal/B-AdverseReaction ulceration/I-AdverseReaction ,/O especially/O in/O patients/O with/O VII/O nerve/O disorders/O ./O
Careful/O testing/O of/O corneal/O sensation/O in/O eyes/O previously/O operated/O upon/O ,/O avoidance/O of/O injection/O into/O the/O lower/O lid/O area/O to/O avoid/O ectropion/O ,/O and/O vigorous/O treatment/O of/O any/O epithelial/O defect/O should/O be/O employed/O ./O
This/O may/O require/O protective/O drops/O ,/O ointment/O ,/O therapeutic/O soft/O contact/O lenses/O ,/O or/O closure/O of/O the/O eye/O by/O patching/O or/O other/O means/O ./O
Because/O of/O its/O anticholinergic/O effects/O ,/O XEOMIN/O should/O be/O used/O with/O caution/O in/O patients/O at/O risk/O of/O developing/O narrow/O angle/O glaucoma/O ./O
To/O prevent/O ectropion/O ,/O botulinum/O toxin/O products/O should/O not/O be/O injected/O into/O the/O medial/O lower/O eyelid/O area/O ./O
Ecchymosis/O easily/O occurs/O in/O the/O soft/O tissues/O of/O the/O eyelid/O ./O
Immediate/O gentle/O pressure/O at/O the/O injection/O site/O can/O limit/O that/O risk/O ./O
5.7/O Risk/O of/O Ptosis/O in/O Patients/O Treated/O with/O XEOMIN/O for/O Glabellar/O Lines/O Do/O not/O exceed/O the/O recommended/O dosage/O and/O frequency/O of/O administration/O of/O XEOMIN/O ./O
In/O order/O to/O reduce/O the/O complication/O of/O ptosis/O the/O following/O steps/O should/O be/O taken/O :/O Avoid/O injection/O near/O the/O levator/O palpebrae/O superioris/O ,/O particularly/O in/O patients/O with/O larger/O brow/O depressor/O complexes/O ./O
Corrugator/O injections/O should/O be/O placed/O at/O least/O 1/O cm/O above/O the/O bony/O supraorbital/O ridge/O ./O
5.8/O Human/O Albumin/O and/O Transmission/O of/O Viral/O Diseases/O This/O product/O contains/O albumin/O ,/O a/O derivative/O of/O human/O blood/O ./O
Based/O on/O effective/O donor/O screening/O and/O product/O manufacturing/O processes/O ,/O it/O carries/O an/O extremely/O remote/O risk/B-Factor for/O transmission/B-AdverseReaction of/I-AdverseReaction viral/I-AdverseReaction diseases/I-AdverseReaction ./O
A/O theoretical/O risk/B-Factor for/O transmission/O of/O Creutzfeldt/B-AdverseReaction -/I-AdverseReaction Jakob/O disease/O (/O CJD/B-AdverseReaction )/O is/O also/O considered/O extremely/O remote/O ./O
No/O cases/O of/O transmission/O of/O viral/O diseases/O or/O CJD/O have/O ever/O been/O reported/O for/O albumin/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O in/O patients/O with/O Dupuytren/O 's/O contracture/O are/O discussed/O in/O greater/O detail/O elsewhere/O in/O the/O labeling/O :/O Tendon/B-AdverseReaction ruptures/I-AdverseReaction or/O other/O serious/B-Severity injury/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction extremity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O The/O following/O serious/O adverse/O reactions/O in/O patients/O with/O Peyronie/O 's/O disease/O are/O discussed/O in/O greater/O detail/O elsewhere/O in/O the/O labeling/O :/O Corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O and/O severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O In/O other/O XIAFLEX/O -/O treated/O patients/O ,/O a/O combination/O of/O penile/B-AdverseReaction ecchymoses/I-AdverseReaction or/O hematoma/O ,/O sudden/O penile/B-AdverseReaction detumescence/I-AdverseReaction ,/O and/or/O a/O penile/B-AdverseReaction "/I-AdverseReaction popping/I-AdverseReaction "/O sound/O or/O sensation/O was/O reported/O ,/O and/O in/O these/O cases/O ,/O a/O diagnosis/O of/O corporal/B-AdverseReaction rupture/I-AdverseReaction can/B-Factor not/I-Factor be/I-Factor excluded/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O EXCERPT/O :/O Dupuytren/O 's/O Contracture/O (/O 6.1/O )/O The/O most/O common/O adverse/O reactions/O reported/O in/O 25/O %/O of/O patients/O treated/O with/O XIAFLEX/O and/O at/O an/O incidence/O greater/O than/O placebo/O were/O edema/B-AdverseReaction peripheral/I-AdverseReaction (/O e.g./O ,/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction hand/I-AdverseReaction )/O ,/O contusion/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O and/O pain/B-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction extremity/I-AdverseReaction ./O
Peyronie/O 's/O Disease/O (/O 6.2/O )/O The/O most/O frequently/O reported/O adverse/O drug/O reactions/O reported/O with/O 25/O %/O of/O patients/O treated/O with/O XIAFLEX/O and/O at/O an/O incidence/O greater/O than/O placebo/O were/O penile/B-AdverseReaction hematoma/I-AdverseReaction ,/O penile/B-AdverseReaction swelling/I-AdverseReaction and/O penile/B-AdverseReaction pain/I-AdverseReaction ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Auxilium/O Pharmaceuticals/O ,/O Inc./O at/O 1/O -/O 877/O -/O 663/O -/O 0412/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Studies/O Experience/O in/O Patients/O with/O Dupuytren/O 's/O Contracture/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Out/O of/O 1082/O patients/O who/O received/O 0.58/O mg/O of/O XIAFLEX/O in/O the/O controlled/O and/O uncontrolled/O portions/O of/O the/O XIAFLEX/O studies/O (/O 2630/O XIAFLEX/O injections/O )/O ,/O 3/O (/O 0.3/O %/O )/O patients/O had/O a/O flexor/O tendon/O rupture/O of/O the/O treated/O finger/O within/O 7/O days/O of/O the/O injection/O ./O
The/O data/O described/O below/O are/O based/O on/O two/O pooled/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O trials/O through/O Day/O 90/O in/O patients/O with/O Dupuytren/O 's/O contracture/O (/O Studies/O 1/O and/O 2/O )/O ./O
In/O these/O trials/O ,/O patients/O were/O treated/O with/O up/O to/O 3/O injections/O of/O 0.58/O mg/O of/O XIAFLEX/O or/O placebo/O with/O approximately/O 4-week/O intervals/O between/O injections/O and/O the/O patients/O had/O finger/O extension/O procedures/O the/O day/O after/O injection/O ,/O if/O needed/O ,/O to/O facilitate/O disruption/O of/O the/O cord/O [/O see/O Clinical/O Studies/O (/O 14/O )/O ]/O ./O
These/O trials/O were/O comprised/O of/O 374/O patients/O of/O whom/O 249/O and/O 125/O received/O 0.58/O mg/O of/O XIAFLEX/O and/O placebo/O ,/O respectively/O ./O
The/O mean/O age/O was/O 63/O years/O ,/O 80/O %/O were/O male/O and/O 20/O %/O were/O female/O ,/O and/O 100/O %/O were/O white/O ./O
In/O the/O placebo/O -/O controlled/O portions/O of/O Studies/O 1/O and/O 2/O through/O Day/O 90/O ,/O 98/O %/O and/O 51/O %/O of/O XIAFLEX/O -/O treated/O and/O placebo/O -/O treated/O patients/O had/O an/O adverse/O reaction/O after/O up/O to/O 3/O injections/O ,/O respectively/O ./O
Over/O 95/O %/O of/O XIAFLEX/O -/O treated/O patients/O had/O an/O adverse/B-AdverseReaction reaction/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction extremity/I-AdverseReaction after/O up/O to/O 3/O injections/O ./O
Approximately/O 81/O %/O of/O these/O local/O reactions/O resolved/O without/O intervention/O within/O 4/O weeks/O of/O XIAFLEX/O injections/O ./O
The/O adverse/O reaction/O profile/O was/O similar/O for/O each/O injection/O ,/O regardless/O of/O the/O number/O of/O injections/O administered/O ./O
However/O ,/O the/O incidence/O of/O pruritus/B-AdverseReaction increased/O with/O more/O injections/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
The/O most/O frequently/O reported/O adverse/O drug/O reactions/O (/O 25/O %/O )/O in/O the/O XIAFLEX/O clinical/O trials/O in/O patients/O with/O Dupuytren/O 's/O contracture/O included/O edema/B-AdverseReaction peripheral/I-AdverseReaction (/O mostly/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction hand/I-AdverseReaction )/O ,/O contusion/B-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O and/O pain/B-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction treated/I-AdverseReaction extremity/I-AdverseReaction ./O
Table/O 3/O shows/O the/O incidence/O of/O adverse/O reactions/O that/O were/O reported/O in/O greater/O than/O or/O equal/O to/O 5/O %/O of/O XIAFLEX/O -/O treated/O patients/O and/O at/O a/O frequency/O greater/O than/O placebo/O -/O treated/O patients/O after/O up/O to/O 3/O injections/O in/O the/O pooled/O placebo/O -/O controlled/O trials/O through/O Day/O 90/O (/O Studies/O 1/O and/O 2/O )/O ./O
Table/O 3/O ./O
Adverse/O Reactions/O Occurring/O in/O 5/O %/O of/O XIAFLEX/O -/O Treated/O Patients/O with/O Dupuytren/O 's/O Contracture/O and/O at/O a/O Greater/O Incidence/O than/O Placebo/O in/O the/O Placebo/O -/O Controlled/O Trials/O Through/O Day/O 90/O After/O Up/O to/O 3/O Injections/O a/O Most/O of/O these/O events/O were/O swelling/B-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction hand/I-AdverseReaction ./O
b/O Includes/O the/O terms/O :/O contusion/B-AdverseReaction (/O any/O body/O system/O )/O and/O ecchymosis/B-AdverseReaction c/O Includes/O the/O terms/O :/O injection/B-AdverseReaction site/I-AdverseReaction reaction/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction erythema/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction inflammation/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction irritation/I-AdverseReaction ,/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction warmth/I-AdverseReaction d/O Includes/O the/O terms/O :/O injection/B-AdverseReaction site/I-AdverseReaction swelling/I-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction edema/I-AdverseReaction e/O Includes/O the/O terms/O :/O pruritus/B-AdverseReaction and/O injection/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction f/O Includes/O the/O terms/O :/O lymphadenopathy/B-AdverseReaction and/O axillary/B-AdverseReaction mass/I-AdverseReaction Adverse/O Reaction/O XIAFLEXN=249/O PlaceboN=125/O All/O Adverse/O Reactions/O 98/O %/O 51/O %/O Edema/B-AdverseReaction Peripheral/I-AdverseReaction a/O 73/O %/O 5/O %/O Contusion/B-AdverseReaction b/O 70/O %/O 3/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Hemorrhage/I-AdverseReaction 38/O %/O 3/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Reaction/I-AdverseReaction c/O 35/O %/O 6/O %/O Pain/B-AdverseReaction in/I-AdverseReaction Extremity/I-AdverseReaction 35/O %/O 4/O %/O Tenderness/B-AdverseReaction 24/O %/O 0/O %/O Injection/B-AdverseReaction Site/I-AdverseReaction Swelling/I-AdverseReaction d/O 24/O %/O 6/O %/O Pruritus/B-AdverseReaction e/O 15/O %/O 1/O %/O Lymphadenopathy/B-AdverseReaction f/O 13/O %/O 0/O %/O Skin/B-AdverseReaction Laceration/I-AdverseReaction 9/O %/O 0/O %/O Lymph/B-AdverseReaction Node/I-AdverseReaction Pain/I-AdverseReaction 8/O %/O 0/O %/O Erythema/B-AdverseReaction 6/O %/O 0/O %/O Axillary/B-AdverseReaction Pain/I-AdverseReaction 6/O %/O 0/O %/O Some/O patients/O developed/O vasovagal/B-AdverseReaction syncope/I-AdverseReaction after/O finger/O extension/O procedures/O ./O
The/O safety/O of/O two/O concurrent/O injections/O of/O XIAFLEX/O 0.58/O mg/O into/O Dupuytren/O 's/O cords/O in/O the/O same/O hand/O was/O evaluated/O in/O a/O historically/O -/O controlled/O ,/O open/O -/O label/O multi/O -/O center/O trial/O in/O 715/O adult/O subjects/O with/O Dupuytren/O 's/O contracture/O (/O Study/O 3/O )/O ./O
In/O Study/O 3/O ,/O finger/O extension/O procedures/O were/O performed/O approximately/O 24/O to/O 72/O hours/O after/O injection/O ./O
The/O patient/O demographics/O were/O similar/O to/O Studies/O 1/O and/O 2/O ./O
Out/O of/O 715/O patients/O who/O received/O two/O concurrent/O injections/O of/O XIAFLEX/O 0.58/O mg/O in/O the/O same/O hand/O (/O 1450/O XIAFLEX/O injections/O )/O in/O Study/O 3/O ,/O one/O (/O 0.1/O %/O )/O patient/O experienced/O a/O tendon/O rupture/O of/O the/O treated/O finger/O within/O 3/O days/O of/O the/O injection/O ./O
Table/O 4/O shows/O the/O incidence/O of/O adverse/O reactions/O that/O were/O reported/O in/O greater/O than/O or/O equal/O to/O 5/O %/O of/O XIAFLEX/O -/O treated/O patients/O after/O two/O concurrent/O injections/O of/O XIAFLEX/O in/O the/O same/O hand/O through/O Day/O 60/O in/O Study/O 3/O ./O
Table/O 4/O ./O
Adverse/O Reactions/O Occurring/O in/O 5.0/O %/O of/O Subjects/O Who/O Received/O Two/O Concurrent/O Injections/O of/O XIAFLEX/O in/O Study/O 3/O Adverse/O Reaction/O XIAFLEXN=715/O Subjects/O with/O 1/O adverse/O reaction/O 95/O %/O Edema/B-AdverseReaction peripheral/I-AdverseReaction 77/O %/O Contusion/B-AdverseReaction 59/O %/O Pain/B-AdverseReaction in/I-AdverseReaction extremity/I-AdverseReaction 51/O %/O Laceration/B-AdverseReaction 22/O %/O Pruritus/B-AdverseReaction 15/O %/O Injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction 14/O %/O Lymphadenopathy/B-AdverseReaction 13/O %/O Blood/B-AdverseReaction blister/I-AdverseReaction 12/O %/O Injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction 8/O %/O Axillary/B-AdverseReaction pain/I-AdverseReaction 7/O %/O Injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction 6/O %/O Injection/B-AdverseReaction site/I-AdverseReaction swelling/I-AdverseReaction 5/O %/O Ecchymosis/B-AdverseReaction 5/O %/O Safety/O of/O Retreatment/O of/O Recurrent/O Contractures/O An/O observational/O ,/O open/O label/O study/O was/O conducted/O in/O subjects/O who/O had/O participated/O in/O XIAFLEX/O clinical/O trials/O for/O Dupuytren/O 's/O contracture/O (/O Study/O 4/O )/O ./O
A/O subset/O of/O patients/O who/O had/O recurrence/O of/O contracture/O in/O a/O joint/O that/O was/O previously/O successfully/O treated/O with/O XIAFLEX/O in/O Study/O 4/O were/O retreated/O (/O Study/O 5/O )/O ./O
No/O new/O safety/O signals/O were/O identified/O among/O subjects/O who/O were/O retreated/O with/O XIAFLEX/O ./O
6.2/O Clinical/O Studies/O Experience/O in/O Patients/O with/O Peyronie/O 's/O Disease/O Because/O clinical/O studies/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O studies/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O studies/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
In/O the/O controlled/O and/O uncontrolled/O clinical/O studies/O of/O XIAFLEX/O in/O Peyronie/O 's/O disease/O ,/O 1044/O patients/O received/O a/O total/O of/O 7466/O XIAFLEX/O injections/O ./O
Corporal/O Rupture/O and/O Other/O Serious/O Penile/O Injury/O Corporal/B-AdverseReaction rupture/I-AdverseReaction was/O reported/O as/O an/O adverse/O reaction/O after/O XIAFLEX/O injections/O in/O 5/O of/O 1044/O (/O 0.5/O %/O )/O XIAFLEX/O treated/O patients/O ./O
In/O other/O XIAFLEX/O -/O treated/O patients/O (/O 9/O of/O 1044/O ;/O 0.9/O %/O )/O ,/O a/O combination/O of/O penile/B-AdverseReaction ecchymoses/I-AdverseReaction or/O hematoma/O ,/O sudden/O penile/B-AdverseReaction detumescence/I-AdverseReaction ,/O and/or/O a/O penile/B-AdverseReaction "/I-AdverseReaction popping/I-AdverseReaction "/O sound/O or/O sensation/O was/O reported/O ,/O and/O in/O these/O cases/O ,/O a/O diagnosis/O of/O corporal/B-AdverseReaction rupture/I-AdverseReaction can/B-Factor not/I-Factor be/I-Factor excluded/O ./O
These/O patients/O were/O managed/O without/O surgical/O intervention/O ,/O but/O the/O long/O -/O term/O consequences/O are/O unknown/O ./O
Severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction was/O also/O reported/O as/O an/O adverse/O reaction/O in/O 39/O of/O 1044/O patients/O (/O 3.7/O %/O )/O in/O the/O controlled/O and/O uncontrolled/O clinical/O trials/O in/O Peyronie/O 's/O disease/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
The/O data/O described/O below/O are/O based/O on/O two/O identical/O ,/O pooled/O ,/O randomized/O ,/O double/O -/O blind/O ,/O placebo/O -/O controlled/O ,/O multi/O -/O center/O trials/O through/O Day/O 365/O in/O patients/O with/O Peyronie/O 's/O disease/O (/O Studies/O 1/O and/O 2/O )/O ./O
These/O trials/O included/O 832/O patients/O of/O whom/O 551/O and/O 281/O received/O XIAFLEX/O and/O placebo/O ,/O respectively/O ./O
In/O these/O trials/O ,/O patients/O were/O given/O up/O to/O 4/O treatment/O cycles/O of/O XIAFLEX/O or/O placebo/O ./O
In/O each/O cycle/O ,/O two/O injections/O of/O XIAFLEX/O or/O two/O injections/O of/O placebo/O were/O administered/O 1/O to/O 3/O days/O apart/O ./O
A/O penile/O modeling/O procedure/O was/O performed/O at/O the/O study/O site/O on/O patients/O 1/O to/O 3/O days/O after/O the/O second/O injection/O of/O the/O cycle/O ./O
The/O treatment/O cycle/O was/O repeated/O at/O approximately/O 6-week/O intervals/O up/O to/O three/O additional/O times/O ,/O for/O a/O maximum/O of/O 8/O total/O injection/O procedures/O and/O 4/O total/O modeling/O procedures/O [/O see/O Clinical/O Studies/O (/O 14.2/O )/O ]/O ./O
The/O majority/O of/O Peyronie/O 's/O patients/O experienced/O at/O least/O one/O adverse/O reaction/O (/O 92/O %/O XIAFLEX/O -/O treated/O patients/O ,/O 61/O %/O placebo/O -/O treated/O )/O ./O
Most/O adverse/O reactions/O were/O local/O events/O of/O the/O penis/O and/O groin/O and/O the/O majority/O of/O these/O events/O were/O of/O mild/B-Severity or/O moderate/B-Severity severity/O ,/O and/O most/O (/O 79/O %/O )/O resolved/O within/O 14/O days/O of/O the/O injection/O ./O
The/O adverse/O reaction/O profile/O was/O similar/O after/O each/O injection/O ,/O regardless/O of/O the/O number/O of/O injections/O administered/O ./O
The/O most/O frequently/O reported/O adverse/O drug/O reactions/O (/O 25/O %/O )/O in/O the/O XIAFLEX/O clinical/O trials/O in/O patients/O with/O Peyronie/O 's/O disease/O were/O penile/B-AdverseReaction hematoma/I-AdverseReaction ,/O penile/B-AdverseReaction swelling/I-AdverseReaction ,/O and/O penile/B-AdverseReaction pain/I-AdverseReaction ./O
Table/O 5/O shows/O the/O incidence/O of/O adverse/O reactions/O that/O were/O reported/O in/O greater/O than/O or/O equal/O to/O 1/O %/O of/O XIAFLEX/O -/O treated/O patients/O and/O at/O a/O frequency/O greater/O than/O placebo/O -/O treated/O patients/O after/O up/O to/O 8/O injections/O in/O the/O pooled/O placebo/O -/O controlled/O trials/O through/O Day/O 365/O ./O
Table/O 5/O ./O
Adverse/O Reactions/O Occurring/O in/O 1/O %/O of/O XIAFLEX/O -/O Treated/O Patients/O with/O Peyronie/O 's/O disease/O and/O at/O a/O Greater/O Incidence/O than/O Placebo/O After/O Up/O to/O Four/O Treatment/O Cycles/O in/O Studies/O 1/O and/O 2/O Combined/O a/O Includes/O :/O injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction and/O penile/B-AdverseReaction hematoma/I-AdverseReaction were/O reported/O with/O the/O verbatim/O term/O of/O penile/B-AdverseReaction bruising/I-AdverseReaction or/O injection/B-AdverseReaction site/I-AdverseReaction bruising/I-AdverseReaction in/O 87/O %/O of/O subjects/O ./O
b/O Includes/O :/O injection/B-AdverseReaction site/I-AdverseReaction swelling/I-AdverseReaction ,/O penile/B-AdverseReaction edema/I-AdverseReaction ,/O penile/B-AdverseReaction swelling/I-AdverseReaction ,/O local/B-AdverseReaction swelling/I-AdverseReaction ,/O scrotal/B-AdverseReaction swelling/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction edema/I-AdverseReaction ./O
c/O Includes/O :/O injection/B-AdverseReaction site/I-AdverseReaction pain/I-AdverseReaction ,/O penile/B-AdverseReaction pain/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction discomfort/I-AdverseReaction ./O
d/O Includes/O :/O contusion/B-AdverseReaction ,/O ecchymoses/B-AdverseReaction ,/O penile/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O and/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ./O
Adverse/O Reaction/O XIAFLEXN=551/O PlaceboN=281/O All/O Adverse/O Reactions/O 84.2/O %/O 36.3/O %/O Penile/B-AdverseReaction hematoma/I-AdverseReaction a/O 65.5/O %/O 19.2/O %/O Penile/B-AdverseReaction swelling/I-AdverseReaction b/O 55.0/O %/O 3.2/O %/O Penile/B-AdverseReaction pain/I-AdverseReaction c/O 45.4/O %/O 9.3/O %/O Penile/B-AdverseReaction ecchymoses/I-AdverseReaction d/O 14.5/O %/O 6.8/O %/O Blood/B-AdverseReaction blister/I-AdverseReaction 4.5/O %/O 0/O Penile/B-AdverseReaction blister/I-AdverseReaction 3.3/O %/O 0/O Pruritus/B-AdverseReaction genital/I-AdverseReaction 3.1/O %/O 0/O Painful/B-AdverseReaction erection/I-AdverseReaction 2.9/O %/O 0/O Erectile/B-AdverseReaction dysfunction/I-AdverseReaction 1.8/O %/O 0.4/O %/O Skin/B-AdverseReaction discoloration/I-AdverseReaction 1.8/O %/O 0/O Procedural/B-AdverseReaction pain/I-AdverseReaction 1.6/O %/O 0.7/O %/O Injection/B-AdverseReaction site/I-AdverseReaction vesicles/I-AdverseReaction 1.3/O %/O 0/O Localized/B-AdverseReaction edema/I-AdverseReaction 1.3/O %/O 0/O Dyspareunia/B-AdverseReaction 1.1/O %/O 0/O Injection/B-AdverseReaction site/I-AdverseReaction pruritus/I-AdverseReaction 1.1/O %/O 0/O Nodule/B-AdverseReaction 1.1/O %/O 0/O Suprapubic/B-AdverseReaction pain/I-AdverseReaction 1.1/O %/O 0/O Severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction or/O severe/B-Severity injection/B-AdverseReaction site/I-AdverseReaction hematoma/I-AdverseReaction were/O reported/O in/O 33/551/O (/O 6.0/O %/O )/O of/O XIAFLEX/O -/O treated/O patients/O and/O 0/281/O (/O 0/O %/O )/O of/O placebo/O -/O treated/O patients/O ,/O in/O Studies/O 1/O and/O 2/O combined/O ./O
Reports/O of/O penile/O "/O popping/O "/O sounds/O or/O sensations/O A/O popping/O noise/O or/O popping/B-AdverseReaction sensation/I-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction penis/I-AdverseReaction ,/O sometimes/O described/O as/O "/O snapping/O "/O or/O "/O cracking/O "/O ,/O and/O sometimes/O accompanied/O by/O detumescence/B-AdverseReaction ,/O hematoma/B-AdverseReaction and/or/O pain/B-AdverseReaction ,/O were/O reported/O in/O 73/551/O (/O 13.2/O %/O )/O XIAFLEX/O -/O treated/O patients/O and/O 1/281/O (/O 0.3/O %/O )/O placebo/O -/O treated/O patients/O ./O
There/O were/O no/O clinically/O meaningful/O differences/O in/O the/O incidence/O of/O adverse/O events/O following/O treatment/O with/O XIAFLEX/O based/O on/O the/O severity/O of/O baseline/O erectile/O dysfunction/O or/O concomitant/O phosphodiesterase/O type/O 5/O (/O PDE5/O )/O inhibitor/O use/O ./O
XIAFLEX/O was/O not/B-Negation associated/O with/O shortening/B-AdverseReaction of/I-AdverseReaction penile/I-AdverseReaction length/I-AdverseReaction in/O clinical/O trials/O in/O the/O treatment/O of/O Peyronie/O 's/O disease/O ./O
6.3/O Immunogenicity/O During/O clinical/O studies/O in/O Dupuytren/O 's/O contracture/O and/O Peyronie/O 's/O disease/O ,/O patients/O were/O tested/O at/O multiple/O time/O points/O for/O antibodies/O to/O the/O protein/O components/O of/O XIAFLEX/O (/O AUX/O -/O I/O and/O AUX/O -/O II/O )/O ./O
In/O the/O Dupuytren/O 's/O contracture/O clinical/O studies/O (/O Studies/O 1/O and/O 2/O )/O ,/O at/O 30/O days/O post/O the/O first/O injection/O of/O XIAFLEX/O 0.58/O mg/O ,/O 92/O %/O of/O patients/O had/O antibodies/O against/O AUX/O -/O I/O detected/O and/O 86/O %/O of/O patients/O had/O antibodies/O against/O AUX/O -/O II/O detected/O ./O
After/O the/O fourth/O injection/O of/O XIAFLEX/O ,/O every/O XIAFLEX/O -/O treated/O patient/O developed/O high/O titers/O of/O antibodies/O to/O both/O AUX/O -/O I/O and/O AUX/O -/O II/O ./O
After/O five/O years/O more/O than/O 90/O percent/O of/O patients/O remained/O seropositive/O for/O anti/O -/O AUX/O -/O I/O and/O anti/O -/O AUX/O -/O II/O antibody/O (/O Study/O 4/O )/O ./O
Neutralizing/O antibodies/O were/O assayed/O for/O all/O patients/O (/O 204/O )/O in/O Study/O 1/O ./O
Neutralizing/O antibodies/O to/O AUX/O -/O I/O or/O AUX/O -/O II/O ,/O were/O detected/O in/O 10/O %/O and/O 21/O %/O ,/O respectively/O ,/O of/O patients/O treated/O with/O XIAFLEX/O ./O
Among/O patients/O in/O Study/O 3/O who/O reported/O no/O prior/O exposure/O to/O XIAFLEX/O ,/O 97/O %/O of/O patients/O had/O antibodies/O against/O AUX/O -/O I/O and/O AUX/O -/O II/O after/O two/O concurrent/O doses/O of/O XIAFLEX/O 0.58/O mg/O (/O total/O dose/O of/O 1.16/O mg/O )/O in/O the/O same/O hand/O ./O
In/O Study/O 5/O ,/O treatment/O of/O recurrent/O contractures/O with/O XIAFLEX/O resulted/O in/O similar/O immunogenicity/O results/O as/O seen/O in/O Studies/O 1/O and/O 2/O ./O
In/O the/O Peyronie/O 's/O disease/O clinical/O studies/O ,/O at/O 6/O weeks/O after/O the/O first/O treatment/O cycle/O of/O XIAFLEX/O 0.58/O mg/O ,/O approximately/O 75/O %/O of/O patients/O had/O antibodies/O against/O AUX/O -/O I/O and/O approximately/O 55/O %/O of/O patients/O had/O antibodies/O against/O AUX/O -/O II/O ./O
Six/O weeks/O after/O the/O eighth/O injection/O (/O fourth/O treatment/O cycle/O )/O of/O XIAFLEX/O ,/O 99/O %/O of/O XIAFLEX/O -/O treated/O patients/O developed/O high/O titers/O of/O antibodies/O to/O both/O AUX/O -/O I/O and/O AUX/O -/O II/O ./O
Neutralizing/O antibodies/O were/O assayed/O for/O a/O subset/O of/O 70/O samples/O selected/O to/O be/O representative/O of/O high/O and/O low/O titer/O binding/O antibody/O responses/O at/O week/O 12/O of/O treatment/O ./O
For/O each/O subject/O in/O whom/O a/O Week/O 12/O sample/O was/O selected/O ,/O the/O corresponding/O Week/O 6/O ,/O 18/O ,/O 24/O ,/O and/O 52/O samples/O were/O assayed/O if/O they/O were/O also/O binding/O antibody/O positive/O ./O
Neutralizing/O antibodies/O to/O AUX/O -/O I/O or/O AUX/O -/O II/O ,/O were/O detected/O in/O 60/O %/O and/O 51.8/O %/O ,/O respectively/O ,/O of/O patients/O tested/O ./O
In/O patients/O treated/O for/O these/O two/O indications/O ,/O there/O was/O no/O apparent/O correlation/O of/O antibody/O frequency/O ,/O antibody/O titers/O ,/O or/O neutralizing/O status/O to/O clinical/O response/O or/O adverse/O reactions/O ./O
Since/O the/O protein/O components/O in/O XIAFLEX/O (/O AUX/O -/O I/O and/O AUX/O -/O II/O )/O have/O some/O sequence/O homology/O with/O human/O matrix/O metalloproteinases/O (/O MMPs/O )/O ,/O anti/O -/O product/O antibodies/O could/O theoretically/O interfere/O with/O human/O MMPs/O ./O
In/O vitro/O studies/O showed/O no/O evidence/O of/O cross/O -/O reactivity/O between/O anti/O -/O drug/O -/O antibody/O positive/O patient/O sera/O and/O a/O series/O of/O relevant/O MMPs/O ./O
In/O addition/O ,/O no/O clinical/O safety/O concerns/O related/O to/O the/O inhibition/O of/O endogenous/O MMPs/O have/O been/O observed/O ./O
Immunogenicity/O assay/O results/O are/O highly/O dependent/O on/O the/O sensitivity/O and/O specificity/O of/O the/O assay/O used/O in/O detection/O and/O may/O be/O influenced/O by/O several/O factors/O ,/O including/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O incidence/O of/O antibodies/O to/O collagenase/O clostridium/O histolyticum/O with/O the/O incidence/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O CORPORAL/B-AdverseReaction RUPTURE/I-AdverseReaction (/O PENILE/B-AdverseReaction FRACTURE/I-AdverseReaction )/O OR/O OTHER/O SERIOUS/B-Severity PENILE/B-AdverseReaction INJURY/I-AdverseReaction IN/O THE/O TREATMENT/O OF/O PEYRONIE/O 'S/O DISEASE/O WARNING/O :/O CORPORAL/B-AdverseReaction RUPTURE/I-AdverseReaction (/O PENILE/B-AdverseReaction FRACTURE/I-AdverseReaction )/O OR/O OTHER/O SERIOUS/B-Severity PENILE/B-AdverseReaction INJURY/I-AdverseReaction IN/O THE/O TREATMENT/O OF/O PEYRONIE/O 'S/O DISEASE/O Corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O was/O reported/O as/O an/O adverse/O reaction/O in/O 5/O of/O 1044/O (/O 0.5/O %/O )/O XIAFLEX/O -/O treated/O patients/O in/O clinical/O studies/O ./O
In/O other/O XIAFLEX/O -/O treated/O patients/O (/O 9/O of/O 1044/O ;/O 0.9/O %/O )/O ,/O a/O combination/O of/O penile/B-AdverseReaction ecchymoses/I-AdverseReaction or/O hematoma/O ,/O sudden/O penile/B-AdverseReaction detumescence/I-AdverseReaction ,/O and/or/O a/O penile/B-AdverseReaction "/I-AdverseReaction popping/I-AdverseReaction "/O sound/O or/O sensation/O was/O reported/O ,/O and/O in/O these/O cases/O ,/O a/O diagnosis/O of/O corporal/B-AdverseReaction rupture/I-AdverseReaction can/B-Factor not/I-Factor be/I-Factor excluded/O ./O
Severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction was/O also/O reported/O as/O an/O adverse/O reaction/O in/O 39/O of/O 1044/O (/O 3.7/O %/O )/O XIAFLEX/O -/O treated/O patients/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Signs/O or/O symptoms/O that/O may/O reflect/O serious/O penile/O injury/O should/O be/O promptly/O evaluated/O to/O assess/O for/O corporal/O rupture/O or/O severe/O penile/O hematoma/O which/O may/O require/O surgical/O intervention/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Because/O of/O the/O risks/B-Factor of/O corporal/B-AdverseReaction rupture/I-AdverseReaction or/O other/O serious/B-Severity penile/B-AdverseReaction injury/I-AdverseReaction ,/O XIAFLEX/O is/O available/O for/O the/O treatment/O of/O Peyronie/O 's/O disease/O only/O through/O a/O restricted/O program/O under/O a/O Risk/O Evaluation/O and/O Mitigation/O Strategy/O (/O REMS/O )/O called/O the/O XIAFLEX/O REMS/O Program/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O CORPORAL/B-AdverseReaction RUPTURE/I-AdverseReaction (/O PENILE/B-AdverseReaction FRACTURE/I-AdverseReaction )/O OR/O OTHER/O SERIOUS/B-Severity PENILE/B-AdverseReaction INJURY/I-AdverseReaction IN/O THE/O TREATMENT/O OF/O PEYRONIE/O 'S/O DISEASE/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O Corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O was/O reported/O as/O an/O adverse/O reaction/O in/O 5/O of/O 1044/O (/O 0.5/O %/O )/O XIAFLEX/O -/O treated/O patients/O in/O clinical/O studies/O ./O
In/O other/O XIAFLEX/O -/O treated/O patients/O (/O 9/O of/O 1044/O ;/O 0.9/O %/O )/O ,/O a/O diagnosis/O of/O corporal/B-AdverseReaction rupture/I-AdverseReaction can/B-Factor not/I-Factor be/I-Factor excluded/O ./O
Severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction was/O also/O reported/O as/O an/O adverse/O reaction/O in/O 39/O of/O 1044/O (/O 3.7/O %/O )/O XIAFLEX/O -/O treated/O patients/O (/O 5.2/O )/O ./O
XIAFLEX/O is/O available/O for/O the/O treatment/O of/O Peyronie/O 's/O disease/O only/O through/O a/O restricted/O program/O called/O the/O XIAFLEX/O REMS/O Program/O (/O 5.3/O )/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Tendon/B-AdverseReaction rupture/I-AdverseReaction or/O serious/B-Severity injury/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction injected/I-AdverseReaction finger/I-AdverseReaction hand/O :/O Avoid/O injecting/O XIAFLEX/O into/O tendons/O ,/O nerves/O ,/O blood/O vessels/O ,/O or/O other/O collagen/O -/O containing/O structure/O of/O the/O hand/O ./O
Injection/O into/O these/O structures/O may/O result/O in/O possible/O permanent/O injury/O ,/O such/O as/O tendon/O rupture/O or/O ligament/O damage/O ,/O or/O skin/O laceration/O ./O
(/O 5.1/O )/O Corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O or/O other/O serious/B-Severity injury/B-AdverseReaction to/I-AdverseReaction the/I-AdverseReaction penis/I-AdverseReaction :/O Avoid/O injecting/O into/O the/O urethra/O ,/O nerves/O ,/O blood/O vessels/O ,/O corpora/O cavernosa/O or/O other/O collagen/O -/O containing/O structures/O of/O the/O penis/O ./O
Injection/O into/O these/O structures/O may/B-Factor result/O in/O possible/O permanent/B-AdverseReaction injury/I-AdverseReaction such/O as/O corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O ./O
(/O 5.2/O )/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction :/O Healthcare/O providers/O should/O be/O prepared/O to/O address/O hypersensitivity/O reactions/O ,/O including/O anaphylaxis/O ,/O following/O XIAFLEX/O injections/O ./O
(/O 5.4/O )/O Patients/O with/O abnormal/O coagulation/O :/O Use/O with/O caution/O ,/O including/O in/O patients/O who/O have/O received/O anticoagulant/O medications/O other/O than/O low/O -/O dose/O aspirin/O within/O 7/O days/O of/O the/O injection/O ./O
(/O 5.5/O )/O 5.1/O Tendon/O Rupture/O or/O Other/O Serious/O Injury/O to/O the/O Injected/O Finger/O Hand/O in/O the/O Treatment/O of/O Dupuytren/O 's/O Contracture/O In/O the/O controlled/O and/O uncontrolled/O portions/O of/O clinical/O trials/O in/O Dupuytren/O 's/O contracture/O ,/O flexor/B-AdverseReaction tendon/I-AdverseReaction ruptures/I-AdverseReaction occurred/O after/O XIAFLEX/O injection/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Injection/O of/O XIAFLEX/O into/O collagen/O -/O containing/O structures/O such/O as/O tendons/O or/O ligaments/O of/O the/O hand/O may/B-Factor result/O in/O damage/O to/O those/O structures/O and/O possible/B-Factor permanent/B-AdverseReaction injury/I-AdverseReaction such/O as/O tendon/B-AdverseReaction rupture/I-AdverseReaction or/O ligament/B-AdverseReaction damage/I-AdverseReaction ./O
Therefore/O ,/O XIAFLEX/O should/O be/O injected/O only/O into/O the/O collagen/O cord/O with/O a/O MP/O or/O PIP/O joint/O contracture/O ,/O and/O care/O should/O be/O taken/O to/O avoid/O injecting/O into/O tendons/O ,/O nerves/O ,/O blood/O vessels/O ,/O or/O other/O collagen/O -/O containing/O structures/O of/O the/O hand/O ./O
When/O injecting/O a/O cord/O affecting/O a/O PIP/O joint/O of/O the/O fifth/O finger/O ,/O the/O needle/O insertion/O should/O not/O be/O more/O than/O 2/O to/O 3/O mm/O in/O depth/O and/O avoid/O injecting/O more/O than/O 4/O mm/O distal/O to/O the/O palmar/O digital/O crease/O [/O see/O Dosage/O and/O Administration/O (/O 2.1/O )/O ]/O ./O
Other/O XIAFLEX/O -/O associated/O serious/O local/O adverse/O reactions/O included/O pulley/B-AdverseReaction rupture/I-AdverseReaction ,/O ligament/B-AdverseReaction injury/I-AdverseReaction ,/O complex/B-AdverseReaction regional/I-AdverseReaction pain/I-AdverseReaction syndrome/I-AdverseReaction (/O CRPS/B-AdverseReaction )/O ,/O sensory/B-AdverseReaction abnormality/I-AdverseReaction of/I-AdverseReaction the/I-AdverseReaction hand/I-AdverseReaction ,/O and/O skin/B-AdverseReaction laceration/I-AdverseReaction (/O tear/O )/O ./O
In/O a/O historically/O controlled/O post/O -/O marketing/O trial/O ,/O the/O incidence/O of/O skin/B-AdverseReaction laceration/I-AdverseReaction (/O 22/O %/O )/O was/O higher/O for/O subjects/O treated/O with/O two/O concurrent/O injections/O of/O XIAFLEX/O compared/O with/O subjects/O treated/O with/O up/O to/O three/O single/O injections/O in/O the/O placebo/O -/O controlled/O premarketing/O trials/O (/O 9/O %/O )/O ./O
Cases/O of/O skin/B-AdverseReaction laceration/I-AdverseReaction requiring/O skin/O graft/O after/O finger/O extension/O procedures/O have/O been/O reported/O post/O -/O marketing/O ./O
Signs/O or/O symptoms/O that/O may/O reflect/O serious/O injury/O to/O the/O injected/O finger/O hand/O should/O be/O promptly/O evaluated/O because/O surgical/O intervention/O may/O be/O required/O ./O
5.2/O Corporal/O Rupture/O (/O Penile/O Fracture/O )/O or/O Other/O Serious/O Injury/O to/O the/O Penis/O in/O the/O Treatment/O of/O Peyronie/O 's/O Disease/O Corporal/B-AdverseReaction rupture/I-AdverseReaction was/O reported/O as/O an/O adverse/O reaction/O after/O XIAFLEX/O injections/O in/O 5/O of/O 1044/O (/O 0.5/O %/O )/O XIAFLEX/O treated/O patients/O in/O the/O controlled/O and/O uncontrolled/O clinical/O trials/O in/O Peyronie/O 's/O disease/O ./O
In/O other/O XIAFLEX/O -/O treated/O patients/O (/O 9/O of/O 1044/O ;/O 0.9/O %/O )/O ,/O a/O combination/O of/O penile/B-AdverseReaction ecchymoses/I-AdverseReaction or/O hematoma/O ,/O sudden/O penile/B-AdverseReaction detumescence/I-AdverseReaction ,/O and/or/O a/O penile/B-AdverseReaction "/I-AdverseReaction popping/I-AdverseReaction "/O sound/O or/O sensation/O was/O reported/O ,/O and/O in/O these/O cases/O ,/O a/O diagnosis/O of/O corporal/B-AdverseReaction rupture/I-AdverseReaction can/B-Factor not/I-Factor be/I-Factor excluded/I-Factor ./O
These/O patients/O were/O managed/O without/O surgical/O intervention/O ,/O but/O the/O long/O -/O term/O consequences/O are/O unknown/O ./O
Severe/B-Severity penile/B-AdverseReaction hematoma/I-AdverseReaction was/O also/O reported/O as/O an/O adverse/O reaction/O in/O 39/O of/O 1044/O patients/O (/O 3.7/O %/O )/O in/O the/O controlled/O and/O uncontrolled/O clinical/O trials/O in/O Peyronie/O 's/O disease/O [/O see/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
Signs/O or/O symptoms/O that/O may/O reflect/O serious/O injury/O to/O the/O penis/O should/O be/O promptly/O evaluated/O in/O order/O to/O assess/O for/O corporal/O rupture/O or/O severe/O penile/O hematoma/O ,/O which/O may/O require/O surgical/O intervention/O ./O
Injection/O of/O XIAFLEX/O into/O collagen/O -/O containing/O structures/O such/O as/O the/O corpora/O cavernosa/O of/O the/O penis/O may/B-Factor result/O in/O damage/O to/O those/O structures/O and/O possible/B-Factor injury/O such/O as/O corporal/B-AdverseReaction rupture/I-AdverseReaction (/O penile/B-AdverseReaction fracture/I-AdverseReaction )/O ./O
Therefore/O ,/O XIAFLEX/O should/O be/O injected/O only/O into/O the/O Peyronie/O 's/O plaque/O and/O care/O should/O be/O taken/O to/O avoid/O injecting/O into/O the/O urethra/O ,/O nerves/O ,/O blood/O vessels/O ,/O corpora/O cavernosa/O or/O other/O collagen/O -/O containing/O structures/O of/O the/O penis/O ./O
5.3/O XIAFLEX/O REMS/O Program/O Because/O of/O the/O risks/O of/O corporal/O rupture/O (/O penile/O fracture/O )/O or/O other/O serious/O penile/O injury/O in/O the/O treatment/O of/O Peyronie/O 's/O disease/O ,/O XIAFLEX/O is/O available/O only/O through/O the/O XIAFLEX/O REMS/O Program/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Required/O components/O of/O the/O XIAFLEX/O REMS/O Program/O include/O the/O following/O :/O Prescribers/O must/O be/O certified/O with/O the/O program/O by/O enrolling/O and/O completing/O training/O in/O the/O administration/O of/O XIAFLEX/O treatment/O for/O Peyronie/O 's/O disease/O ./O
Healthcare/O sites/O must/O be/O certified/O with/O the/O program/O and/O ensure/O that/O XIAFLEX/O is/O only/O dispensed/O for/O use/O by/O certified/O prescribers/O ./O
Further/O information/O is/O available/O at/O www.XIAFLEXREMS.com/O or/O 1/O -/O 877/O -/O 313/O -/O 1235/O ./O
5.4/O Hypersensitivity/O Reactions/O ,/O Including/O Anaphylaxis/O In/O the/O controlled/O portions/O of/O the/O clinical/O trials/O in/O Dupuytren/O 's/O contracture/O (/O Studies/O 1/O and/O 2/O )/O ,/O a/O greater/O proportion/O of/O XIAFLEX/O -/O treated/O patients/O (/O 15/O %/O )/O compared/O to/O placebo/O -/O treated/O patients/O (/O 1/O %/O )/O had/O mild/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction (/O pruritus/B-AdverseReaction )/O after/O up/O to/O 3/O injections/O ./O
The/O incidence/O of/O XIAFLEX/O -/O associated/O pruritus/B-AdverseReaction increased/O after/O more/O XIAFLEX/O injections/O in/O patients/O with/O Dupuytren/O 's/O contracture/O ./O
In/O the/O double/O -/O blind/O ,/O placebo/O -/O controlled/O portions/O of/O the/O clinical/O trials/O in/O Peyronie/O 's/O disease/O (/O Studies/O 1/O and/O 2/O )/O ,/O a/O greater/O proportion/O of/O XIAFLEX/O -/O treated/O patients/O (/O 4/O %/O )/O compared/O to/O placebo/O -/O treated/O patients/O (/O 1/O %/O )/O had/O localized/B-AdverseReaction pruritus/I-AdverseReaction after/O up/O to/O 4/O treatment/O cycles/O (/O involving/O up/O to/O 8/O XIAFLEX/O injection/O procedures/O )/O ./O
The/O incidence/O of/O XIAFLEX/O -/O associated/O pruritus/B-AdverseReaction was/O similar/O after/O each/O injection/O regardless/O of/O the/O number/O of/O injections/O administered/O ./O
Because/O XIAFLEX/O contains/O foreign/O proteins/O ,/O severe/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction to/O XIAFLEX/O can/B-Factor occur/O ./O
Anaphylaxis/B-AdverseReaction was/O reported/O in/O a/O post/O -/O marketing/O clinical/O trial/O (/O Study/O 3/O )/O in/O one/O patient/O who/O had/O previous/O exposure/O to/O XIAFLEX/O for/O the/O treatment/O of/O Dupuytren/O 's/O contracture/O ./O
Some/O patients/O with/O Dupuytren/O 's/O contracture/O developed/O IgE/O -/O anti/O -/O drug/O antibodies/O in/O greater/O proportions/O and/O higher/O titers/O with/O successive/O XIAFLEX/O injections/O ./O
Healthcare/O providers/O should/O be/O prepared/O to/O address/O severe/O allergic/O reactions/O following/O XIAFLEX/O injections/O ./O
5.5/O Risk/O of/O bleeding/O in/O Patients/O with/O Abnormal/O Coagulation/O In/O the/O XIAFLEX/O trials/O in/O Dupuytren/O 's/O contracture/O (/O Studies/O 1/O and/O 2/O )/O ,/O 70/O %/O and/O 38/O %/O of/O XIAFLEX/O -/O treated/O patients/O developed/O an/O ecchymosis/B-AdverseReaction contusion/B-AdverseReaction or/O an/O injection/B-AdverseReaction site/I-AdverseReaction hemorrhage/I-AdverseReaction ,/O respectively/O (/O see/O Table/O 3/O )/O ./O
In/O the/O XIAFLEX/O controlled/O trials/O in/O Peyronie/O 's/O disease/O (/O Studies/O 1/O and/O 2/O )/O ,/O 65.5/O %/O of/O XIAFLEX/O -/O treated/O patients/O developed/O penile/B-AdverseReaction hematoma/I-AdverseReaction ,/O and/O 14.5/O %/O developed/O penile/B-AdverseReaction ecchymosis/I-AdverseReaction (/O see/O Table/O 4/O )/O ./O
Patients/O with/O abnormal/O coagulation/O (/O except/O for/O patients/O taking/O low/O -/O dose/O aspirin/O ,/O e.g./O ,/O up/O to/O 150/O mg/O per/O day/O )/O were/O excluded/O from/O participating/O in/O these/O studies/O ./O
Therefore/O ,/O the/O efficacy/O and/O safety/O of/O XIAFLEX/O in/O patients/O receiving/O anticoagulant/O medications/O (/O other/O than/O low/O -/O dose/O aspirin/O ,/O e.g./O ,/O up/O to/O 150/O mg/O per/O day/O )/O within/O 7/O days/O prior/O to/O XIAFLEX/O administration/O is/O not/O known/O ./O
In/O addition/O ,/O it/O is/O recommended/O to/O avoid/O use/O of/O XIAFLEX/O in/O patients/O with/O coagulation/O disorders/O ,/O including/O patients/O receiving/O concomitant/O anticoagulants/O (/O except/O for/O low/O -/O dose/O aspirin/O )/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O is/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Seizure/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O are/O asthenia/B-AdverseReaction fatigue/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O weight/B-AdverseReaction decreased/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O and/O dizziness/B-AdverseReaction vertigo/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Astellas/O Pharma/O US/O ,/O Inc./O at/O 1/O -/O 800/O -/O 727/O -/O 7003/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Two/O randomized/O clinical/O trials/O enrolled/O patients/O with/O metastatic/O prostate/O cancer/O that/O has/O progressed/O on/O androgen/O deprivation/O therapy/O (/O GnRH/O therapy/O or/O bilateral/O orchiectomy/O )/O ,/O a/O disease/O setting/O that/O is/O also/O defined/O as/O metastatic/O CRPC/O ./O
In/O both/O studies/O ,/O patients/O received/O XTANDI/O 160/O mg/O orally/O once/O daily/O in/O the/O active/O treatment/O arm/O or/O placebo/O in/O the/O control/O arm/O ./O
All/O patients/O continued/O androgen/O deprivation/O therapy/O ./O
Patients/O were/O allowed/O ,/O but/O not/O required/O ,/O to/O take/O glucocorticoids/O ./O
The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O that/O occurred/O more/O commonly/O (/O 2/O %/O over/O placebo/O )/O in/O the/O XTANDI/O -/O treated/O patients/O from/O the/O two/O randomized/O clinical/O trials/O were/O asthenia/B-AdverseReaction fatigue/B-AdverseReaction ,/O back/B-AdverseReaction pain/I-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O constipation/B-AdverseReaction ,/O arthralgia/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O peripheral/B-AdverseReaction edema/I-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O musculoskeletal/B-AdverseReaction pain/I-AdverseReaction ,/O weight/B-AdverseReaction decreased/I-AdverseReaction ,/O headache/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O and/O dizziness/B-AdverseReaction vertigo/B-AdverseReaction ./O
Study/O 1/O :/O Metastatic/O Castration/O -/O Resistant/O Prostate/O Cancer/O Following/O Chemotherapy/O Study/O 1/O enrolled/O 1199/O patients/O with/O metastatic/O CRPC/O who/O had/O previously/O received/O docetaxel/O ./O
The/O median/O duration/O of/O treatment/O was/O 8.3/O months/O with/O XTANDI/O and/O 3.0/O months/O with/O placebo/O ./O
During/O the/O trial/O ,/O 48/O %/O of/O patients/O on/O the/O XTANDI/O arm/O and/O 46/O %/O of/O patients/O on/O the/O placebo/O arm/O received/O glucocorticoids/O ./O
Grade/O 3/O and/O higher/O adverse/O reactions/O were/O reported/O among/O 47/O %/O of/O XTANDI/O -/O treated/O patients/O and/O 53/O %/O of/O placebo/O -/O treated/O patients/O ./O
Discontinuations/O due/O to/O adverse/O events/O were/O reported/O for/O 16/O %/O of/O XTANDI/O -/O treated/O patients/O and/O 18/O %/O of/O placebo/O -/O treated/O patients/O ./O
The/O most/O common/O adverse/O reaction/O leading/O to/O treatment/O discontinuation/O was/O seizure/B-AdverseReaction ,/O which/O occurred/O in/O 0.9/O %/O of/O the/O XTANDI/O -/O treated/O patients/O compared/O to/O none/O (/O 0/O %/O )/O of/O the/O placebo/O -/O treated/O patients/O ./O
Table/O 1/O shows/O adverse/O reactions/O reported/O in/O Study/O 1/O that/O occurred/O at/O a/O 2/O %/O higher/O frequency/O in/O the/O XTANDI/O arm/O compared/O to/O the/O placebo/O arm/O ./O
Table/O 1/O ./O
Adverse/O Reactions/O in/O Study/O 1/O XTANDI/O N/O 800/O Placebo/O N/O 399/O Grade/O 1/O -/O 4a/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O Grade/O 1/O -/O 4/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O General/O Disorders/O Asthenic/B-AdverseReaction Conditionsb/I-AdverseReaction 50.6/O 9.0/O 44.4/O 9.3/O Peripheral/B-AdverseReaction Edema/I-AdverseReaction 15.4/O 1.0/O 13.3/O 0.8/O Musculoskeletal/O And/O Connective/O Tissue/O Disorders/O Back/B-AdverseReaction Pain/I-AdverseReaction 26.4/O 5.3/O 24.3/O 4.0/O Arthralgia/B-AdverseReaction 20.5/O 2.5/O 17.3/O 1.8/O Musculoskeletal/B-AdverseReaction Pain/I-AdverseReaction 15.0/O 1.3/O 11.5/O 0.3/O Muscular/B-AdverseReaction Weakness/I-AdverseReaction 9.8/O 1.5/O 6.8/O 1.8/O Musculoskeletal/B-AdverseReaction Stiffness/I-AdverseReaction 2.6/O 0.3/O 0.3/O 0.0/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 21.8/O 1.1/O 17.5/O 0.3/O Vascular/O Disorders/O Hot/B-AdverseReaction Flush/I-AdverseReaction 20.3/O 0.0/O 10.3/O 0.0/O Hypertension/B-AdverseReaction 6.4/O 2.1/O 2.8/O 1.3/O Nervous/O System/O Disorders/O Headache/B-AdverseReaction 12.1/O 0.9/O 5.5/O 0.0/O Dizzinessc/B-AdverseReaction 9.5/O 0.5/O 7.5/O 0.5/O Spinal/B-AdverseReaction Cord/I-AdverseReaction Compression/I-AdverseReaction and/O Cauda/B-AdverseReaction Equina/I-AdverseReaction Syndrome/I-AdverseReaction 7.4/O 6.6/O 4.5/O 3.8/O Paresthesia/B-AdverseReaction 6.6/O 0.0/O 4.5/O 0.0/O Mental/B-AdverseReaction Impairment/I-AdverseReaction Disordersd/I-AdverseReaction 4.3/O 0.3/O 1.8/O 0.0/O Hypoesthesia/B-AdverseReaction 4.0/O 0.3/O 1.8/O 0.0/O Infections/O And/O Infestations/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infectione/O 10.9/O 0.0/O 6.5/O 0.3/O Lower/O Respiratory/O Tract/O And/O Lung/B-AdverseReaction Infectionf/I-AdverseReaction 8.5/O 2.4/O 4.8/O 1.3/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 8.8/O 0.0/O 6.0/O 0.5/O Anxiety/B-AdverseReaction 6.5/O 0.3/O 4.0/O 0.0/O Renal/O And/O Urinary/O Disorders/O Hematuria/B-AdverseReaction 6.9/O 1.8/O 4.5/O 1.0/O Pollakiuria/B-AdverseReaction 4.8/O 0.0/O 2.5/O 0.0/O Injury/O ,/O Poisoning/O And/O Procedural/O Complications/O Fall/B-AdverseReaction 4.6/O 0.3/O 1.3/O 0.0/O Non/B-AdverseReaction -/I-AdverseReaction pathologic/O Fractures/O 4.0/O 1.4/O 0.8/O 0.3/O Skin/O And/O Subcutaneous/O Tissue/O Disorders/O Pruritus/B-AdverseReaction 3.8/O 0.0/O 1.3/O 0.0/O Dry/B-AdverseReaction Skin/I-AdverseReaction 3.5/O 0.0/O 1.3/O 0.0/O Respiratory/O Disorders/O Epistaxis/B-AdverseReaction 3.3/O 0.1/O 1.3/O 0.3/O a/O CTCAE/O v4b/O Includes/O asthenia/B-AdverseReaction and/O fatigue.c/B-AdverseReaction Includes/O dizziness/B-AdverseReaction and/O vertigo.d/B-AdverseReaction Includes/O amnesia/B-AdverseReaction ,/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O cognitive/B-AdverseReaction disorder/I-AdverseReaction ,/O and/O disturbance/B-AdverseReaction in/I-AdverseReaction attention.e/I-AdverseReaction Includes/O nasopharyngitis/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O rhinitis/B-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O and/O laryngitis.f/B-AdverseReaction Includes/O pneumonia/B-AdverseReaction ,/O lower/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O and/O lung/B-AdverseReaction infection/I-AdverseReaction ./O
Study/O 2/O :/O Chemotherapy/O -/O naive/O Metastatic/O Castration/O -/O Resistant/O Prostate/O Cancer/O Study/O 2/O enrolled/O 1717/O patients/O with/O metastatic/O CRPC/O who/O had/O not/O received/O prior/O cytotoxic/O chemotherapy/O ,/O of/O whom/O 1715/O received/O at/O least/O one/O dose/O of/O study/O drug/O ./O
The/O median/O duration/O of/O treatment/O was/O 17.5/O months/O with/O XTANDI/O and/O 4.6/O months/O with/O placebo/O ./O
Grade/O 3/O -/O 4/O adverse/O reactions/O were/O reported/O in/O 44/O %/O of/O XTANDI/O -/O treated/O patients/O and/O 37/O %/O of/O placebo/O -/O treated/O patients/O ./O
Discontinuations/O due/O to/O adverse/O events/O were/O reported/O for/O 6/O %/O of/O XTANDI/O -/O treated/O patients/O and/O 6/O %/O of/O placebo/O -/O treated/O patients/O ./O
The/O most/O common/O adverse/O reaction/O leading/O to/O treatment/O discontinuation/O was/O fatigue/B-AdverseReaction asthenia/B-AdverseReaction ,/O which/O occurred/O in/O 1/O %/O of/O patients/O on/O each/O treatment/O arm/O ./O
Table/O 2/O includes/O adverse/O reactions/O reported/O in/O Study/O 2/O that/O occurred/O at/O a/O 2/O %/O higher/O frequency/O in/O the/O XTANDI/O arm/O compared/O to/O the/O placebo/O arm/O ./O
Table/O 2/O ./O
Adverse/O Reactions/O in/O Study/O 2/O XTANDI/O N/O 871/O Placebo/O N/O 844/O Grade/O 1/O -/O 4/O a/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O Grade/O 1/O -/O 4/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O General/O Disorders/O Asthenic/B-AdverseReaction Conditionsb/I-AdverseReaction 46.9/O 3.4/O 33.0/O 2.8/O Peripheral/B-AdverseReaction Edema/I-AdverseReaction 11.5/O 0.2/O 8.2/O 0.4/O Musculoskeletal/O And/O Connective/O Tissue/O Disorders/O Back/B-AdverseReaction Pain/I-AdverseReaction 28.6/O 2.5/O 22.4/O 3.0/O Arthralgia/B-AdverseReaction 21.4/O 1.6/O 16.1/O 1.1/O Gastrointestinal/O Disorders/O Constipation/B-AdverseReaction 23.2/O 0.7/O 17.3/O 0.4/O Diarrhea/B-AdverseReaction 16.8/O 0.3/O 14.3/O 0.4/O Vascular/O Disorders/O Hot/B-AdverseReaction Flush/I-AdverseReaction 18.0/O 0.1/O 7.8/O 0.0/O Hypertension/B-AdverseReaction 14.2/O 7.2/O 4.1/O 2.3/O Nervous/O System/O Disorders/O Dizzinessc/B-AdverseReaction 11.3/O 0.3/O 7.1/O 0.0/O Headache/B-AdverseReaction 11.0/O 0.2/O 7.0/O 0.4/O Dysgeusia/B-AdverseReaction 7.6/O 0.1/O 3.7/O 0.0/O Mental/B-AdverseReaction Impairment/I-AdverseReaction Disordersd/I-AdverseReaction 5.7/O 0.0/O 1.3/O 0.1/O Restless/B-AdverseReaction Legs/I-AdverseReaction Syndrome/I-AdverseReaction 2.1/O 0.1/O 0.4/O 0.0/O Respiratory/O Disorders/O Dyspneae/B-AdverseReaction 11.0/O 0.6/O 8.5/O 0.6/O Infections/O And/O Infestations/O Upper/B-AdverseReaction Respiratory/I-AdverseReaction Tract/I-AdverseReaction Infectionf/O 16.4/O 0.0/O 10.5/O 0.0/O Lower/O Respiratory/O Tract/O And/O Lung/B-AdverseReaction Infectiong/I-AdverseReaction 7.9/O 1.5/O 4.7/O 1.1/O Psychiatric/O Disorders/O Insomnia/B-AdverseReaction 8.2/O 0.1/O 5.7/O 0.0/O Renal/O And/O Urinary/O Disorders/O Hematuria/B-AdverseReaction 8.8/O 1.3/O 5.8/O 1.3/O Injury/O ,/O Poisoning/O And/O Procedural/O Complications/O Fall/B-AdverseReaction 12.7/O 1.6/O 5.3/O 0.7/O Non/B-AdverseReaction -/I-AdverseReaction Pathological/O Fracture/O 8.8/O 2.1/O 3.0/O 1.1/O Metabolism/O and/O Nutrition/O Disorders/O Decreased/B-AdverseReaction Appetite/I-AdverseReaction 18.9/O 0.3/O 16.4/O 0.7/O Investigations/O Weight/B-AdverseReaction Decreased/I-AdverseReaction 12.4/O 0.8/O 8.5/O 0.2/O Reproductive/O System/O and/O Breast/O disorders/O Gynecomastia/B-AdverseReaction 3.4/O 0.0/O 1.4/O 0.0/O a/O CTCAE/O v4b/O Includes/O asthenia/B-AdverseReaction and/O fatigue.c/B-AdverseReaction Includes/O dizziness/B-AdverseReaction and/O vertigo.d/B-AdverseReaction Includes/O amnesia/B-AdverseReaction ,/O memory/B-AdverseReaction impairment/I-AdverseReaction ,/O cognitive/B-AdverseReaction disorder/I-AdverseReaction ,/O and/O disturbance/B-AdverseReaction in/I-AdverseReaction attention.e/I-AdverseReaction Includes/O dyspnea/B-AdverseReaction ,/O exertional/B-AdverseReaction dyspnea/I-AdverseReaction ,/O and/O dyspnea/B-AdverseReaction at/I-AdverseReaction rest.f/I-AdverseReaction Includes/O nasopharyngitis/B-AdverseReaction ,/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O sinusitis/B-AdverseReaction ,/O rhinitis/B-AdverseReaction ,/O pharyngitis/B-AdverseReaction ,/O and/O laryngitis.g/B-AdverseReaction Includes/O pneumonia/B-AdverseReaction ,/O lower/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction ,/O bronchitis/B-AdverseReaction ,/O and/O lung/B-AdverseReaction infection/I-AdverseReaction ./O
Laboratory/O Abnormalities/O In/O the/O two/O randomized/O clinical/O trials/O ,/O Grade/B-Severity 1/I-Severity -/O 4/O neutropenia/B-AdverseReaction occurred/O in/O 15/O %/O of/O patients/O treated/O with/O XTANDI/O (/O 1/O %/O Grade/O 3/O -/O 4/O )/O and/O in/O 6/O %/O of/O patients/O treated/O with/O placebo/O (/O 0.5/O %/O Grade/O 3/O -/O 4/O )/O ./O
The/O incidence/O of/O Grade/B-Severity 1/I-Severity -/O 4/O thrombocytopenia/B-AdverseReaction was/O 6/O %/O of/O patients/O treated/O with/O XTANDI/O (/O 0.3/O %/O Grade/O 3/O -/O 4/O )/O and/O 5/O %/O of/O patients/O treated/O with/O placebo/O (/O 0.5/O %/O Grade/O 3/O -/O 4/O )/O ./O
Grade/B-Severity 1/I-Severity -/O 4/O elevations/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction occurred/O in/O 10/O %/O of/O patients/O treated/O with/O XTANDI/O (/O 0.2/O %/O Grade/O 3/O -/O 4/O )/O and/O 16/O %/O of/O patients/O treated/O with/O placebo/O (/O 0.2/O %/O Grade/O 3/O -/O 4/O )/O ./O
Grade/B-Severity 1/I-Severity -/O 4/O elevations/B-AdverseReaction in/I-AdverseReaction bilirubin/I-AdverseReaction occurred/O in/O 3/O %/O of/O patients/O treated/O with/O XTANDI/O (/O 0.1/O %/O Grade/O 3/O -/O 4/O )/O and/O 2/O %/O of/O patients/O treated/O with/O placebo/O (/O no/O Grade/O 3/O -/O 4/O )/O ./O
Infections/O In/O Study/O 1/O ,/O 1/O %/O of/O patients/O treated/O with/O XTANDI/O compared/O to/O 0.3/O %/O of/O patients/O treated/O with/O placebo/O died/B-AdverseReaction from/O infections/B-AdverseReaction or/O sepsis/B-AdverseReaction ./O
In/O Study/O 2/O ,/O 1/O patient/O in/O each/O treatment/O group/O (/O 0.1/O %/O )/O had/O an/O infection/B-AdverseReaction resulting/O in/O death/B-AdverseReaction ./O
Falls/O and/O Fall/O -/O related/O Injuries/O In/O the/O two/O randomized/O clinical/O trials/O ,/O falls/B-AdverseReaction including/O fall/B-AdverseReaction -/I-AdverseReaction related/O injuries/O ,/O occurred/O in/O 9/O %/O of/O patients/O treated/O with/O XTANDI/O compared/O to/O 4/O %/O of/O patients/O treated/O with/O placebo/O ./O
Falls/B-AdverseReaction were/O not/B-Negation associated/O with/O loss/B-AdverseReaction of/I-AdverseReaction consciousness/I-AdverseReaction or/O seizure/B-AdverseReaction ./O
Fall/B-AdverseReaction -/I-AdverseReaction related/O injuries/O were/O more/O severe/O in/O patients/O treated/O with/O XTANDI/O and/O included/O non/B-AdverseReaction -/I-AdverseReaction pathologic/O fractures/O ,/O joint/B-AdverseReaction injuries/I-AdverseReaction ,/O and/O hematomas/B-AdverseReaction ./O
Hypertension/B-AdverseReaction In/O the/O two/O randomized/O trials/O ,/O hypertension/B-AdverseReaction was/O reported/O in/O 11/O %/O of/O patients/O receiving/O XTANDI/O and/O 4/O %/O of/O patients/O receiving/O placebo/O ./O
No/B-Negation patients/O experienced/O hypertensive/B-AdverseReaction crisis/I-AdverseReaction ./O
Medical/O history/O of/O hypertension/O was/O balanced/O between/O arms/O ./O
Hypertension/B-AdverseReaction led/O to/O study/O discontinuation/O in/O 1/O %/O of/O patients/O in/O each/O arm/O ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Seizure/B-AdverseReaction occurred/O in/O 0.9/O %/O of/O patients/O receiving/O XTANDI/O who/O previously/O received/O docetaxel/O and/O in/O 0.1/O %/O of/O patients/O who/O were/O chemotherapy/O -/O naive/O ./O
There/O is/O no/O clinical/O trial/O experience/O with/O XTANDI/O in/O patients/O who/O have/O had/O a/O seizure/O ./O
Permanently/O discontinue/O XTANDI/O in/O patients/O who/O develop/O a/O seizure/O during/O treatment/O ./O
(/O 5.1/O )/O 5.1/O Seizure/O In/O Study/O 1/O ,/O which/O enrolled/O patients/O who/O previously/O received/O docetaxel/O ,/O 7/O of/O 800/O (/O 0.9/O %/O )/O patients/O treated/O with/O XTANDI/O experienced/O a/O seizure/B-AdverseReaction and/O no/B-Negation patients/O treated/O with/O placebo/O experienced/O a/O seizure/B-AdverseReaction ./O
Seizure/B-AdverseReaction occurred/O from/O 31/O to/O 603/O days/O after/O initiation/O of/O XTANDI/O ./O
In/O Study/O 2/O ,/O 1/O of/O 871/O (/O 0.1/O %/O )/O chemotherapy/O -/O naive/O patients/O treated/O with/O XTANDI/O and/O 1/O of/O 844/O (/O 0.1/O %/O )/O patients/O treated/O with/O placebo/O experienced/O a/O seizure/B-AdverseReaction ./O
Patients/O experiencing/O seizure/B-AdverseReaction were/O permanently/O discontinued/O from/O therapy/O and/O all/O seizure/O events/O resolved/O ./O
There/O is/O no/O clinical/O trial/O experience/O re/O -/O administering/O XTANDI/O to/O patients/O who/O experienced/O seizure/O ./O
Limited/O safety/O data/O are/O available/O in/O patients/O with/O predisposing/O factors/O for/O seizure/O because/O these/O patients/O were/O generally/O excluded/O from/O the/O trials/O ./O
These/O exclusion/O criteria/O included/O a/O history/O of/O seizure/O ,/O underlying/O brain/O injury/O with/O loss/O of/O consciousness/O ,/O transient/O ischemic/O attack/O within/O the/O past/O 12/O months/O ,/O cerebral/O vascular/O accident/O ,/O brain/O metastases/O ,/O and/O brain/O arteriovenous/O malformation/O ./O
Study/O 1/O excluded/O the/O use/O of/O concomitant/O medications/O that/O may/O lower/O the/O seizure/O threshold/O ,/O whereas/O Study/O 2/O permitted/O the/O use/O of/O these/O medications/O ./O
Because/O of/O the/O risk/O of/O seizure/O associated/O with/O XTANDI/O use/O ,/O patients/O should/O be/O advised/O of/O the/O risk/O of/O engaging/O in/O any/O activity/O where/O sudden/O loss/O of/O consciousness/O could/O cause/O serious/O harm/O to/O themselves/O or/O others/O ./O
Permanently/O discontinue/O XTANDI/O in/O patients/O who/O develop/O a/O seizure/O during/O treatment/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O ./O
?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O enterocolitis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O hepatitis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O dermatitis/O [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O neuropathies/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O endocrinopathies/O [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O ./O
?/O Other/O immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O ,/O including/O ocular/B-AdverseReaction manifestations/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O ./O
EXCERPT/O :/O Most/O common/O adverse/O reactions/O (/O 5/O %/O )/O are/O fatigue/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O colitis/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Bristol/O -/O Myers/O Squibb/O at/O 1/O -/O 800/O -/O 721/O -/O 5072/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O the/O adverse/O reaction/O rates/O observed/O can/O not/O be/O directly/O compared/O with/O rates/O in/O other/O clinical/O trials/O or/O experience/O with/O therapeutics/O in/O the/O same/O class/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
The/O clinical/O development/O program/O excluded/O patients/O with/O active/O autoimmune/O disease/O or/O those/O receiving/O systemic/O immunosuppression/O for/O organ/O transplantation/O ./O
Exposure/O to/O YERVOY/O 3/O mg/O kg/O for/O 4/O doses/O given/O by/O intravenous/O infusion/O in/O previously/O treated/O patients/O with/O unresectable/O or/O metastatic/O melanoma/O was/O assessed/O in/O a/O randomized/O ,/O double/O -/O blind/O clinical/O study/O (/O Study/O 1/O )/O ./O
[/O See/O Clinical/O Studies/O (/O 14/O )/O ./O
]/O One/O hundred/O thirty/O -/O one/O patients/O (/O median/O age/O 57/O years/O ,/O 60/O %/O male/O )/O received/O YERVOY/O as/O a/O single/O agent/O ,/O 380/O patients/O (/O median/O age/O 56/O years/O ,/O 61/O %/O male/O )/O received/O YERVOY/O with/O an/O investigational/O gp100/O peptide/O vaccine/O (/O gp100/O )/O ,/O and/O 132/O patients/O (/O median/O age/O 57/O years/O ,/O 54/O %/O male/O )/O received/O gp100/O peptide/O vaccine/O alone/O ./O
Patients/O in/O the/O study/O received/O a/O median/O of/O 4/O doses/O (/O range/O :/O 1/O -/O 4/O doses/O )/O ./O
YERVOY/O was/O discontinued/O for/O adverse/O reactions/O in/O 10/O %/O of/O patients/O ./O
The/O most/O common/O adverse/O reactions/O (/O 5/O %/O )/O in/O patients/O who/O received/O YERVOY/O at/O 3/O mg/O kg/O were/O fatigue/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O pruritus/B-AdverseReaction ,/O rash/B-AdverseReaction ,/O and/O colitis/B-AdverseReaction ./O
Table/O 1/O presents/O selected/O adverse/O reactions/O from/O Study/O 1/O ,/O which/O occurred/O in/O at/O least/O 5/O %/O of/O patients/O in/O the/O YERVOY/O -/O containing/O arms/O and/O with/O at/O least/O 5/O %/O increased/O incidence/O over/O the/O control/O gp100/O arm/O for/O all/O -/O grade/O events/O and/O at/O least/O 1/O %/O incidence/O over/O the/O control/O group/O for/O Grade/O 3/O -/O 5/O events/O ./O
Table/O 1/O :/O Selected/O Adverse/O Reactions/O in/O Study/O 1/O a/O Incidences/O presented/O in/O this/O table/O are/O based/O on/O reports/O of/O adverse/O events/O regardless/O of/O causality/O ./O
Percentage/O (/O %/O )/O of/O Patientsa/O YERVOY3/O mg/O kgn=131/O YERVOY3/O mg/O kg+gp100n=380/O gp100n=132/O System/O Organ/O Class/O Preferred/O Term/O AnyGrade/O Grade3/O -/O 5/O AnyGrade/O Grade3/O -/O 5/O AnyGrade/O Grade3/O -/O 5/O Gastrointestinal/O Disorders/O Diarrhea/B-AdverseReaction 32/O 5/O 37/O 4/O 20/O 1/O Colitis/B-AdverseReaction 8/O 5/O 5/O 3/O 2/O 0/O Skin/O and/O Subcutaneous/O Tissue/O Disorders/O Pruritus/B-AdverseReaction 31/O 0/O 21/O 1/O 11/O 0/O Rash/B-AdverseReaction 29/O 2/O 25/O 2/O 8/O 0/O General/O Disorders/O and/O Administration/O Site/O Conditions/O Fatigue/B-AdverseReaction 41/O 7/O 34/O 5/O 31/O 3/O Table/O 2/O presents/O the/O per/O -/O patient/O incidence/O of/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O from/O Study/O 1/O ./O
Table/O 2/O :/O Severe/B-Severity to/O Fatal/B-AdverseReaction Immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction Adverse/O Reactions/O in/O Study/O 1/O a/O Including/O fatal/B-AdverseReaction outcome/O ./O
b/O Including/O intestinal/B-AdverseReaction perforation/I-AdverseReaction ./O
c/O Underlying/O etiology/O not/O established/O ./O
Percentage/O (/O %/O )/O of/O Patients/O YERVOY3/O mg/O kgn=131/O YERVOY3/O mg/O kg+gp100n=380/O Any/O Immune/O -/O mediated/O Adverse/O Reaction/O 15/O 12/O Enterocolitisa/B-AdverseReaction ,/O b/O 7/O 7/O Hepatotoxicitya/B-AdverseReaction 1/O 2/O Dermatitisa/B-AdverseReaction 2/O 3/O Neuropathya/B-AdverseReaction 1/O 1/O Endocrinopathy/B-AdverseReaction 4/O 1/O Hypopituitarism/B-AdverseReaction 4/O 1/O Adrenal/B-AdverseReaction insufficiency/I-AdverseReaction 0/O 1/O Other/O Pneumonitis/B-AdverseReaction 0/O 1/O Meningitis/B-AdverseReaction 0/O 1/O Nephritis/B-AdverseReaction 1/O 0/O Eosinophiliac/B-AdverseReaction 1/O 0/O Pericarditisa/B-AdverseReaction ,/O c/O 0/O 1/O Across/O clinical/O studies/O that/O utilized/O YERVOY/O doses/O ranging/O from/O 0.3/O to/O 10/O mg/O kg/O ,/O the/O following/O adverse/O reactions/O were/O also/O reported/O (/O incidence/O less/O than/O 1/O %/O unless/O otherwise/O noted/O )/O :/O urticaria/B-AdverseReaction (/O 2/O %/O )/O ,/O large/B-AdverseReaction intestinal/I-AdverseReaction ulcer/I-AdverseReaction ,/O esophagitis/B-AdverseReaction ,/O acute/B-AdverseReaction respiratory/I-AdverseReaction distress/I-AdverseReaction syndrome/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O and/O infusion/B-AdverseReaction reaction/I-AdverseReaction ./O
Based/O on/O the/O experience/O in/O the/O entire/O clinical/O program/O for/O melanoma/O ,/O the/O incidence/O and/O severity/O of/O enterocolitis/B-AdverseReaction and/O hepatitis/B-AdverseReaction appear/O to/O be/O dose/O dependent/O ./O
6.2/O Postmarketing/O Experience/O The/O following/O adverse/O reactions/O have/O been/O identified/O during/O postapproval/O use/O of/O YERVOY/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Skin/O and/O Subcutaneous/O Tissue/O Disorders/O :/O Drug/B-AdverseReaction reaction/I-AdverseReaction with/I-AdverseReaction eosinophilia/I-AdverseReaction and/I-AdverseReaction systemic/I-AdverseReaction symptoms/I-AdverseReaction (/O DRESS/B-AdverseReaction syndrome/I-AdverseReaction )/O 6.3/O Immunogenicity/O In/O clinical/O studies/O ,/O 1.1/O %/O of/O 1024/O evaluable/O patients/O tested/O positive/O for/O binding/O antibodies/O against/O ipilimumab/O in/O an/O electrochemiluminescent/O (/O ECL/O )/O based/O assay/O ./O
This/O assay/O has/O substantial/O limitations/O in/O detecting/O anti/O -/O ipilimumab/O antibodies/O in/O the/O presence/O of/O ipilimumab/O ./O
Infusion/O -/O related/O or/O peri/B-AdverseReaction -/I-AdverseReaction infusional/O reactions/O consistent/O with/O hypersensitivity/B-AdverseReaction or/O anaphylaxis/B-AdverseReaction were/O not/B-Negation reported/O in/O these/O 11/O patients/O nor/O were/O neutralizing/O antibodies/O against/O ipilimumab/O detected/O ./O
Because/O trough/O levels/O of/O ipilimumab/O interfere/O with/O the/O ECL/O assay/O results/O ,/O a/O subset/O analysis/O was/O performed/O in/O the/O dose/O cohort/O with/O the/O lowest/O trough/O levels/O ./O
In/O this/O analysis/O ,/O 6.9/O %/O of/O 58/O evaluable/O patients/O ,/O who/O were/O treated/O with/O 0.3/O mg/O kg/O dose/O ,/O tested/O positive/O for/O binding/O antibodies/O against/O ipilimumab/O ./O
Immunogenicity/O assay/O results/O are/O highly/O dependent/O on/O several/O factors/O including/O assay/O sensitivity/O and/O specificity/O ,/O assay/O methodology/O ,/O sample/O handling/O ,/O timing/O of/O sample/O collection/O ,/O concomitant/O medications/O ,/O and/O underlying/O disease/O ./O
For/O these/O reasons/O ,/O comparison/O of/O incidence/O of/O antibodies/O to/O YERVOY/O with/O the/O incidences/O of/O antibodies/O to/O other/O products/O may/O be/O misleading/O ./O
BOXED/O WARNING/O :/O WARNING/O :/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/I-AdverseReaction ADVERSE/O REACTIONS/O WARNING/O :/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/I-AdverseReaction ADVERSE/O REACTIONS/O YERVOY/O can/B-Factor result/O in/O severe/B-Severity and/O fatal/B-AdverseReaction immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O due/O to/O T/O -/O cell/O activation/O and/O proliferation/O ./O
These/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O reactions/O may/B-Factor involve/O any/O organ/O system/O ;/O however/O ,/O the/O most/O common/O severe/B-Severity immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O are/O enterocolitis/B-AdverseReaction ,/O hepatitis/B-AdverseReaction ,/O dermatitis/B-AdverseReaction (/O including/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction )/O ,/O neuropathy/B-AdverseReaction ,/O and/O endocrinopathy/B-AdverseReaction ./O
The/O majority/O of/O these/O immune/O -/O mediated/O reactions/O initially/O manifested/O during/O treatment/O ;/O however/O ,/O a/O minority/O occurred/O weeks/O to/O months/O after/O discontinuation/O of/O YERVOY/O ./O
Permanently/O discontinue/O YERVOY/O and/O initiate/O systemic/O high/O -/O dose/O corticosteroid/O therapy/O for/O severe/O immune/O -/O mediated/O reactions/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O Assess/O patients/O for/O signs/O and/O symptoms/O of/O enterocolitis/O ,/O dermatitis/O ,/O neuropathy/O ,/O and/O endocrinopathy/O and/O evaluate/O clinical/O chemistries/O including/O liver/O function/O tests/O and/O thyroid/O function/O tests/O at/O baseline/O and/O before/O each/O dose/O ./O
[/O See/O Warnings/O and/O Precautions/O (/O 5.1/O ,/O 5.2/O ,/O 5.3/O ,/O 5.4/O ,/O 5.5/O )/O ./O
]/O EXCERPT/O :/O WARNING/O :/O IMMUNE/B-AdverseReaction -/I-AdverseReaction MEDIATED/I-AdverseReaction ADVERSE/O REACTIONS/O See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
YERVOY/O can/B-Factor result/O in/O severe/B-Severity and/O fatal/B-AdverseReaction immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O due/O to/O T/O -/O cell/O activation/O and/O proliferation/O ./O
These/O immune/O -/O mediated/O reactions/O may/B-Factor involve/O any/O organ/O system/O ;/O however/O ,/O the/O most/O common/O severe/B-Severity immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O are/O enterocolitis/B-AdverseReaction ,/O hepatitis/B-AdverseReaction ,/O dermatitis/B-AdverseReaction (/O including/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction )/O ,/O neuropathy/B-AdverseReaction ,/O and/O endocrinopathy/B-AdverseReaction ./O
The/O majority/O of/O these/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O reactions/O initially/O manifested/O during/O treatment/O ;/O however/O ,/O a/O minority/O occurred/O weeks/O to/O months/O after/O discontinuation/O of/O YERVOY/O ./O
Permanently/O discontinue/O YERVOY/O and/O initiate/O systemic/O high/O -/O dose/O corticosteroid/O therapy/O for/O severe/O immune/O -/O mediated/O reactions/O ./O
(/O 2.2/O )/O Assess/O patients/O for/O signs/O and/O symptoms/O of/O enterocolitis/O ,/O dermatitis/O ,/O neuropathy/O ,/O and/O endocrinopathy/O and/O evaluate/O clinical/O chemistries/O including/O liver/O function/O tests/O and/O thyroid/O function/O tests/O at/O baseline/O and/O before/O each/O dose/O ./O
(/O 5.1/O ,/O 5.2/O ,/O 5.3/O ,/O 5.4/O ,/O 5.5/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O YERVOY/O can/B-Factor result/O in/O severe/B-Severity and/O fatal/B-AdverseReaction immune/B-AdverseReaction -/I-AdverseReaction mediated/O reactions/O due/O to/O T/O -/O cell/O activation/O and/O proliferation/O ./O
[/O See/O Boxed/O Warning/O ./O
]/O EXCERPT/O :/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O :/O Permanently/O discontinue/O for/O severe/O reactions/O ./O
Withhold/O dose/O for/O moderate/O immune/O -/O mediated/O adverse/O reactions/O until/O return/O to/O baseline/O ,/O improvement/O to/O mild/O severity/O ,/O or/O complete/O resolution/O ,/O and/O patient/O is/O receiving/O less/O than/O 7.5/O mg/O prednisone/O or/O equivalent/O per/O day/O ./O
Administer/O systemic/O high/O -/O dose/O corticosteroids/O for/O severe/O ,/O persistent/O ,/O or/O recurring/O immune/O -/O mediated/O reactions/O ./O
(/O 5.1/O ,/O 5.2/O ,/O 5.3/O ,/O 5.4/O ,/O 5.5/O )/O ?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O hepatitis/O :/O Evaluate/O liver/O function/O tests/O before/O each/O dose/O of/O YERVOY/O ./O
(/O 5.2/O )/O ?/O Immune/B-AdverseReaction -/I-AdverseReaction mediated/O endocrinopathies/O :/O Monitor/O thyroid/O function/O tests/O and/O clinical/O chemistries/O prior/O to/O each/O dose/O ./O
Evaluate/O at/O each/O visit/O for/O signs/O and/O symptoms/O of/O endocrinopathy/O ./O
Institute/O hormone/O replacement/O therapy/O as/O needed/O ./O
(/O 5.5/O )/O 5.1/O Immune/O -/O mediated/O Enterocolitis/O In/O Study/O 1/O ,/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction (/O diarrhea/B-AdverseReaction of/O 7/B-Severity or/I-Severity more/I-Severity stools/I-Severity above/I-Severity baseline/I-Severity ,/O fever/B-AdverseReaction ,/O ileus/B-AdverseReaction ,/O peritoneal/B-AdverseReaction signs/I-AdverseReaction ;/O Grade/B-Severity 3/I-Severity -/O 5/O )/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O enterocolitis/O occurred/O in/O 34/O (/O 7/O %/O )/O YERVOY/O -/O treated/O patients/O ,/O and/O moderate/B-Severity (/O diarrhea/B-AdverseReaction with/O up/B-Severity to/I-Severity 6/I-Severity stools/I-Severity above/I-Severity baseline/I-Severity ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O mucus/O or/O blood/B-AdverseReaction in/I-AdverseReaction stool/I-AdverseReaction ;/O Grade/B-Severity 2/I-Severity )/O enterocolitis/B-AdverseReaction occurred/O in/O 28/O (/O 5/O %/O )/O YERVOY/O -/O treated/O patients/O ./O
Across/O all/O YERVOY/O -/O treated/O patients/O (/O n=511/O )/O ,/O 5/O (/O 1/O %/O )/O patients/O developed/O intestinal/B-AdverseReaction perforation/I-AdverseReaction ,/O 4/O (/O 0.8/O %/O )/O patients/O died/B-AdverseReaction as/O a/O result/O of/O complications/O ,/O and/O 26/O (/O 5/O %/O )/O patients/O were/O hospitalized/O for/O severe/B-Severity enterocolitis/B-AdverseReaction ./O
The/O median/O time/O to/O onset/O was/O 7.4/O weeks/O (/O range/O :/O 1.6/O -/O 13.4/O )/O and/O 6.3/O weeks/O (/O range/O :/O 0.3/O -/O 18.9/O )/O after/O the/O initiation/O of/O YERVOY/O for/O patients/O with/O Grade/B-Severity 3/I-Severity -/O 5/O enterocolitis/B-AdverseReaction and/O with/O Grade/B-Severity 2/I-Severity enterocolitis/B-AdverseReaction ,/O respectively/O ./O
Twenty/O -/O nine/O patients/O (/O 85/O %/O )/O with/O Grade/B-Severity 3/I-Severity -/O 5/O enterocolitis/B-AdverseReaction were/O treated/O with/O high/O -/O dose/O (/O 40/O mg/O prednisone/O equivalent/O per/O day/O )/O corticosteroids/O ,/O with/O a/O median/O dose/O of/O 80/O mg/O day/O of/O prednisone/O or/O equivalent/O ;/O the/O median/O duration/O of/O treatment/O was/O 2.3/O weeks/O (/O ranging/O up/O to/O 13.9/O weeks/O )/O followed/O by/O corticosteroid/O taper/O ./O
Of/O the/O 28/O patients/O with/O moderate/B-Severity enterocolitis/B-AdverseReaction ,/O 46/O %/O were/O not/O treated/O with/O systemic/O corticosteroids/O ,/O 29/O %/O were/O treated/O with/O 40/O mg/O prednisone/O or/O equivalent/O per/O day/O for/O a/O median/O duration/O of/O 5.1/O weeks/O ,/O and/O 25/O %/O were/O treated/O with/O high/O -/O dose/O corticosteroids/O for/O a/O median/O duration/O of/O 10/O days/O prior/O to/O corticosteroid/O taper/O ./O
Infliximab/O was/O administered/O to/O 5/O of/O the/O 62/O patients/O (/O 8/O %/O )/O with/O moderate/B-Severity ,/O severe/B-Severity ,/O or/O life/B-Severity -/O threatening/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O enterocolitis/O following/O inadequate/O response/O to/O corticosteroids/O ./O
Of/O the/O 34/O patients/O with/O Grade/B-Severity 3/I-Severity -/O 5/O enterocolitis/B-AdverseReaction ,/O 74/O %/O experienced/O complete/O resolution/O ,/O 3/O %/O experienced/O improvement/O to/O Grade/O 2/O severity/O ,/O and/O 24/O %/O did/O not/O improve/O ./O
Among/O the/O 28/O patients/O with/O Grade/B-Severity 2/I-Severity enterocolitis/B-AdverseReaction ,/O 79/O %/O experienced/O complete/O resolution/O ,/O 11/O %/O improved/O ,/O and/O 11/O %/O did/O not/O improve/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O enterocolitis/O (/O such/O as/O diarrhea/O ,/O abdominal/O pain/O ,/O mucus/O or/O blood/O in/O stool/O ,/O with/O or/O without/O fever/O )/O and/O of/O bowel/O perforation/O (/O such/O as/O peritoneal/O signs/O and/O ileus/O )/O ./O
In/O symptomatic/O patients/O ,/O rule/O out/O infectious/O etiologies/O and/O consider/O endoscopic/O evaluation/O for/O persistent/O or/O severe/O symptoms/O ./O
Permanently/O discontinue/O YERVOY/O in/O patients/O with/O severe/O enterocolitis/O and/O initiate/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O of/O prednisone/O or/O equivalent/O ./O
Upon/O improvement/O to/O Grade/O 1/O or/O less/O ,/O initiate/O corticosteroid/O taper/O and/O continue/O to/O taper/O over/O at/O least/O 1/O month/O ./O
In/O clinical/O trials/O ,/O rapid/O corticosteroid/O tapering/O resulted/O in/O recurrence/O or/O worsening/O symptoms/O of/O enterocolitis/O in/O some/O patients/O ./O
Withhold/O YERVOY/O dosing/O for/O moderate/O enterocolitis/O ;/O administer/O anti/O -/O diarrheal/O treatment/O and/O ,/O if/O persistent/O for/O more/O than/O 1/O week/O ,/O initiate/O systemic/O corticosteroids/O at/O a/O dose/O of/O 0.5/O mg/O kg/O day/O prednisone/O or/O equivalent/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O 5.2/O Immune/O -/O mediated/O Hepatitis/O In/O Study/O 1/O ,/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction hepatotoxicity/B-AdverseReaction (/O AST/O or/O ALT/B-AdverseReaction elevations/I-AdverseReaction of/O more/O than/O 5/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity or/O total/B-AdverseReaction bilirubin/I-AdverseReaction elevations/I-AdverseReaction more/O than/O 3/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity ;/O Grade/B-Severity 3/I-Severity -/O 5/O )/O occurred/O in/O 8/O (/O 2/O %/O )/O YERVOY/O -/O treated/O patients/O ,/O with/O fatal/B-AdverseReaction hepatic/B-AdverseReaction failure/I-AdverseReaction in/O 0.2/O %/O and/O hospitalization/O in/O 0.4/O %/O of/O YERVOY/O -/O treated/O patients/O ./O
An/O additional/O 13/O (/O 2.5/O %/O )/O patients/O experienced/O moderate/B-Severity hepatotoxicity/B-AdverseReaction manifested/O by/O liver/B-AdverseReaction function/I-AdverseReaction test/I-AdverseReaction abnormalities/I-AdverseReaction (/O AST/O or/O ALT/B-AdverseReaction elevations/I-AdverseReaction of/O more/O than/O 2.5/B-Severity times/I-Severity but/I-Severity not/I-Severity more/I-Severity than/I-Severity 5/I-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity or/O total/B-AdverseReaction bilirubin/I-AdverseReaction elevation/I-AdverseReaction of/O more/O than/O 1.5/B-Severity times/I-Severity but/I-Severity not/I-Severity more/I-Severity than/I-Severity 3/I-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity ;/O Grade/B-Severity 2/I-Severity )/O ./O
The/O underlying/O pathology/O was/O not/O ascertained/O in/O all/O patients/O but/O in/O some/O instances/O included/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O hepatitis/O ./O
There/O were/O insufficient/O numbers/O of/O patients/O with/O biopsy/O -/O proven/O hepatitis/O to/O characterize/O the/O clinical/O course/O of/O this/O event/O ./O
Monitor/O liver/O function/O tests/O (/O hepatic/O transaminase/O and/O bilirubin/O levels/O )/O and/O assess/O patients/O for/O signs/O and/O symptoms/O of/O hepatotoxicity/O before/O each/O dose/O of/O YERVOY/O ./O
In/O patients/O with/O hepatotoxicity/O ,/O rule/O out/O infectious/O or/O malignant/O causes/O and/O increase/O frequency/O of/O liver/O function/O test/O monitoring/O until/O resolution/O ./O
Permanently/O discontinue/O YERVOY/O in/O patients/O with/O Grade/O 3/O -/O 5/O hepatotoxicity/O and/O administer/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O of/O prednisone/O or/O equivalent/O ./O
When/O liver/O function/O tests/O show/O sustained/O improvement/O or/O return/O to/O baseline/O ,/O initiate/O corticosteroid/O tapering/O and/O continue/O to/O taper/O over/O 1/O month/O ./O
Across/O the/O clinical/O development/O program/O for/O YERVOY/O ,/O mycophenolate/O treatment/O has/O been/O administered/O in/O patients/O who/O have/O persistent/O severe/O hepatitis/O despite/O high/O -/O dose/O corticosteroids/O ./O
Withhold/O YERVOY/O in/O patients/O with/O Grade/O 2/O hepatotoxicity/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O Concurrent/O Administration/O with/O Vemurafenib/O In/O a/O dose/O -/O finding/O trial/O ,/O Grade/B-Severity 3/I-Severity increases/B-AdverseReaction in/I-AdverseReaction transaminases/I-AdverseReaction with/O or/O without/O concomitant/O increases/B-AdverseReaction in/I-AdverseReaction total/I-AdverseReaction bilirubin/I-AdverseReaction occurred/O in/O 6/O of/O 10/O patients/O who/O received/O concurrent/O YERVOY/O (/O 3/O mg/O kg/O )/O and/O vemurafenib/O (/O 960/O mg/O BID/O or/O 720/O mg/O BID/O )/O ./O
5.3/O Immune/O -/O mediated/O Dermatitis/O In/O Study/O 1/O ,/O severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction immune/B-AdverseReaction -/I-AdverseReaction mediated/O dermatitis/O (/O eg/O ,/O Stevens/B-AdverseReaction -/I-AdverseReaction Johnson/O syndrome/O ,/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction ,/O or/O rash/B-AdverseReaction complicated/O by/O full/O thickness/O dermal/B-AdverseReaction ulceration/I-AdverseReaction ,/O or/O necrotic/O ,/O bullous/O ,/O or/O hemorrhagic/O manifestations/O ;/O Grade/B-Severity 3/I-Severity -/O 5/O )/O occurred/O in/O 13/O (/O 2.5/O %/O )/O YERVOY/O -/O treated/O patients/O ./O
One/O (/O 0.2/O %/O )/O patient/O died/B-AdverseReaction as/O a/O result/O of/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction and/O one/O additional/O patient/O required/O hospitalization/O for/O severe/B-Severity dermatitis/B-AdverseReaction ./O
There/O were/O 63/O (/O 12/O %/O )/O patients/O with/O moderate/B-Severity (/O Grade/B-Severity 2/I-Severity )/O dermatitis/B-AdverseReaction ./O
The/O median/O time/O to/O onset/O of/O moderate/B-Severity ,/O severe/B-Severity ,/O or/O life/B-Severity -/O threatening/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O dermatitis/O was/O 3.1/O weeks/O and/O ranged/O up/O to/O 17.3/O weeks/O from/O the/O initiation/O of/O YERVOY/O ./O
Seven/O (/O 54/O %/O )/O YERVOY/O -/O treated/O patients/O with/O severe/B-Severity dermatitis/B-AdverseReaction received/O high/O -/O dose/O corticosteroids/O (/O median/O dose/O 60/O mg/O prednisone/O day/O or/O equivalent/O )/O for/O up/O to/O 14.9/O weeks/O followed/O by/O corticosteroid/O taper/O ./O
Of/O these/O 7/O patients/O ,/O 6/O had/O complete/O resolution/O ;/O time/O to/O resolution/O ranged/O up/O to/O 15.6/O weeks/O ./O
Of/O the/O 63/O patients/O with/O moderate/B-Severity dermatitis/B-AdverseReaction ,/O 25/O (/O 40/O %/O )/O were/O treated/O with/O systemic/O corticosteroids/O (/O median/O of/O 60/O mg/O day/O of/O prednisone/O or/O equivalent/O )/O for/O a/O median/O of/O 2.1/O weeks/O ,/O 7/O (/O 11/O %/O )/O were/O treated/O with/O only/O topical/O corticosteroids/O ,/O and/O 31/O (/O 49/O %/O )/O did/O not/O receive/O systemic/O or/O topical/O corticosteroids/O ./O
Forty/O -/O four/O (/O 70/O %/O )/O patients/O with/O moderate/B-Severity dermatitis/B-AdverseReaction were/O reported/O to/O have/O complete/O resolution/O ,/O 7/O (/O 11/O %/O )/O improved/O to/O mild/O (/O Grade/O 1/O )/O severity/O ,/O and/O 12/O (/O 19/O %/O )/O had/O no/O reported/O improvement/O ./O
Monitor/O patients/O for/O signs/O and/O symptoms/O of/O dermatitis/O such/O as/O rash/O and/O pruritus/O ./O
Unless/O an/O alternate/O etiology/O has/O been/O identified/O ,/O signs/O or/O symptoms/O of/O dermatitis/O should/O be/O considered/O immune/O -/O mediated/O ./O
Permanently/O discontinue/O YERVOY/O in/O patients/O with/O Stevens/O -/O Johnson/O syndrome/O ,/O toxic/O epidermal/O necrolysis/O ,/O or/O rash/O complicated/O by/O full/O thickness/O dermal/O ulceration/O ,/O or/O necrotic/O ,/O bullous/O ,/O or/O hemorrhagic/O manifestations/O ./O
Administer/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O of/O prednisone/O or/O equivalent/O ./O
When/O dermatitis/O is/O controlled/O ,/O corticosteroid/O tapering/O should/O occur/O over/O a/O period/O of/O at/O least/O 1/O month/O ./O
Withhold/O YERVOY/O dosing/O in/O patients/O with/O moderate/O to/O severe/O signs/O and/O symptoms/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O For/O mild/O to/O moderate/O dermatitis/O ,/O such/O as/O localized/O rash/O and/O pruritus/O ,/O treat/O symptomatically/O ./O
Administer/O topical/O or/O systemic/O corticosteroids/O if/O there/O is/O no/O improvement/O of/O symptoms/O within/O 1/O week/O ./O
5.4/O Immune/O -/O mediated/O Neuropathies/O In/O Study/O 1/O ,/O 1/O case/O of/O fatal/B-AdverseReaction Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O and/O 1/O case/O of/O severe/B-Severity (/O Grade/B-Severity 3/I-Severity )/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction were/O reported/O ./O
Across/O the/O clinical/O development/O program/O of/O YERVOY/O ,/O myasthenia/B-AdverseReaction gravis/I-AdverseReaction and/O additional/O cases/O of/O Guillain/B-AdverseReaction -/I-AdverseReaction Barre/O syndrome/O have/O been/O reported/O ./O
Monitor/O for/O symptoms/O of/O motor/O or/O sensory/O neuropathy/O such/O as/O unilateral/O or/O bilateral/O weakness/O ,/O sensory/O alterations/O ,/O or/O paresthesia/O ./O
Permanently/O discontinue/O YERVOY/O in/O patients/O with/O severe/O neuropathy/O (/O interfering/O with/O daily/O activities/O )/O such/O as/O Guillain/O -/O Barre/O -/O like/O syndromes/O ./O
Institute/O medical/O intervention/O as/O appropriate/O for/O management/O of/O severe/O neuropathy/O ./O
Consider/O initiation/O of/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O prednisone/O or/O equivalent/O for/O severe/O neuropathies/O ./O
Withhold/O YERVOY/O dosing/O in/O patients/O with/O moderate/O neuropathy/O (/O not/O interfering/O with/O daily/O activities/O )/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O 5.5/O Immune/O -/O mediated/O Endocrinopathies/O In/O Study/O 1/O ,/O severe/B-Severity to/O life/B-Severity -/O threatening/O immune/B-AdverseReaction -/I-AdverseReaction mediated/O endocrinopathies/O (/O requiring/O hospitalization/O ,/O urgent/O medical/O intervention/O ,/O or/O interfering/O with/O activities/O of/O daily/O living/O ;/O Grade/B-Severity 3/I-Severity -/O 4/O )/O occurred/O in/O 9/O (/O 1.8/O %/O )/O YERVOY/O -/O treated/O patients/O ./O
All/O 9/O patients/O had/O hypopituitarism/B-AdverseReaction and/O some/O had/O additional/O concomitant/O endocrinopathies/B-AdverseReaction such/O as/O adrenal/B-AdverseReaction insufficiency/I-AdverseReaction ,/O hypogonadism/B-AdverseReaction ,/O and/O hypothyroidism/B-AdverseReaction ./O
Six/O of/O the/O 9/O patients/O were/O hospitalized/O for/O severe/B-Severity endocrinopathies/B-AdverseReaction ./O
Moderate/B-Severity endocrinopathy/B-AdverseReaction (/O requiring/O hormone/O replacement/O or/O medical/O intervention/O ;/O Grade/B-Severity 2/I-Severity )/O occurred/O in/O 12/O (/O 2.3/O %/O )/O patients/O and/O consisted/O of/O hypothyroidism/B-AdverseReaction ,/O adrenal/B-AdverseReaction insufficiency/I-AdverseReaction ,/O hypopituitarism/B-AdverseReaction ,/O and/O 1/O case/O each/O of/O hyperthyroidism/B-AdverseReaction and/O Cushing/B-AdverseReaction 's/I-AdverseReaction syndrome/O ./O
The/O median/O time/O to/O onset/O of/O moderate/B-Severity to/O severe/B-Severity immune/B-AdverseReaction -/I-AdverseReaction mediated/O endocrinopathy/O was/O 11/O weeks/O and/O ranged/O up/O to/O 19.3/O weeks/O after/O the/O initiation/O of/O YERVOY/O ./O
Of/O the/O 21/O patients/O with/O moderate/B-Severity to/O life/B-Severity -/O threatening/O endocrinopathy/B-AdverseReaction ,/O 17/O patients/O required/O long/O -/O term/O hormone/O replacement/O therapy/O including/O ,/O most/O commonly/O ,/O adrenal/O hormones/O (/O n=10/O )/O and/O thyroid/O hormones/O (/O n=13/O )/O ./O
Monitor/O patients/O for/O clinical/O signs/O and/O symptoms/O of/O hypophysitis/O ,/O adrenal/O insufficiency/O (/O including/O adrenal/O crisis/O )/O ,/O and/O hyper-/O or/O hypothyroidism/O ./O
Patients/O may/O present/O with/O fatigue/O ,/O headache/O ,/O mental/O status/O changes/O ,/O abdominal/O pain/O ,/O unusual/O bowel/O habits/O ,/O and/O hypotension/O ,/O or/O nonspecific/O symptoms/O which/O may/O resemble/O other/O causes/O such/O as/O brain/O metastasis/O or/O underlying/O disease/O ./O
Unless/O an/O alternate/O etiology/O has/O been/O identified/O ,/O signs/O or/O symptoms/O of/O endocrinopathies/O should/O be/O considered/O immune/O -/O mediated/O ./O
Monitor/O thyroid/O function/O tests/O and/O clinical/O chemistries/O at/O the/O start/O of/O treatment/O ,/O before/O each/O dose/O ,/O and/O as/O clinically/O indicated/O based/O on/O symptoms/O ./O
In/O a/O limited/O number/O of/O patients/O ,/O hypophysitis/B-AdverseReaction was/O diagnosed/O by/O imaging/O studies/O through/O enlargement/O of/O the/O pituitary/O gland/O ./O
Withhold/O YERVOY/O dosing/O in/O symptomatic/O patients/O ./O
Initiate/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O of/O prednisone/O or/O equivalent/O ,/O and/O initiate/O appropriate/O hormone/O replacement/O therapy/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O 5.6/O Other/O Immune/O -/O mediated/O Adverse/O Reactions/O ,/O Including/O Ocular/O Manifestations/O The/O following/O clinically/O significant/O immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O were/O seen/O in/O less/O than/O 1/O %/O of/O YERVOY/O -/O treated/O patients/O in/O Study/O 1/O :/O nephritis/B-AdverseReaction ,/O pneumonitis/B-AdverseReaction ,/O meningitis/B-AdverseReaction ,/O pericarditis/B-AdverseReaction ,/O uveitis/B-AdverseReaction ,/O iritis/B-AdverseReaction ,/O and/O hemolytic/B-AdverseReaction anemia/I-AdverseReaction ./O
Across/O the/O clinical/O development/O program/O for/O YERVOY/O ,/O the/O following/O likely/O immune/B-AdverseReaction -/I-AdverseReaction mediated/I-AdverseReaction adverse/O reactions/O were/O also/O reported/O with/O less/O than/O 1/O %/O incidence/O :/O myocarditis/B-AdverseReaction ,/O angiopathy/B-AdverseReaction ,/O temporal/B-AdverseReaction arteritis/I-AdverseReaction ,/O vasculitis/B-AdverseReaction ,/O polymyalgia/B-AdverseReaction rheumatica/I-AdverseReaction ,/O conjunctivitis/B-AdverseReaction ,/O blepharitis/B-AdverseReaction ,/O episcleritis/B-AdverseReaction ,/O scleritis/B-AdverseReaction ,/O leukocytoclastic/B-AdverseReaction vasculitis/I-AdverseReaction ,/O erythema/B-AdverseReaction multiforme/I-AdverseReaction ,/O psoriasis/B-AdverseReaction ,/O pancreatitis/B-AdverseReaction ,/O arthritis/B-AdverseReaction ,/O autoimmune/B-AdverseReaction thyroiditis/I-AdverseReaction ,/O sarcoidosis/B-AdverseReaction ,/O neurosensory/B-AdverseReaction hypoacusis/I-AdverseReaction ,/O autoimmune/B-AdverseReaction central/I-AdverseReaction neuropathy/I-AdverseReaction (/O encephalitis/B-AdverseReaction )/O ,/O myositis/B-AdverseReaction ,/O polymyositis/B-AdverseReaction ,/O and/O ocular/B-AdverseReaction myositis/I-AdverseReaction ./O
Permanently/O discontinue/O YERVOY/O for/O clinically/O significant/O or/O severe/O immune/O -/O mediated/O adverse/O reactions/O ./O
Initiate/O systemic/O corticosteroids/O at/O a/O dose/O of/O 1/O to/O 2/O mg/O kg/O day/O prednisone/O or/O equivalent/O for/O severe/O immune/O -/O mediated/O adverse/O reactions/O ./O
Administer/O corticosteroid/O eye/O drops/O to/O patients/O who/O develop/O uveitis/O ,/O iritis/O ,/O or/O episcleritis/O ./O
Permanently/O discontinue/O YERVOY/O for/O immune/O -/O mediated/O ocular/O disease/O that/O is/O unresponsive/O to/O local/O immunosuppressive/O therapy/O ./O
[/O See/O Dosage/O and/O Administration/O (/O 2.2/O )/O ./O
]/O 6/O ADVERSE/O REACTIONS/O The/O following/O serious/O reactions/O are/O described/O in/O greater/O detail/O in/O the/O Warnings/O and/O Precautions/O section/O :/O Hypersensitivity/B-AdverseReaction reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 5/O %/O in/O either/O indication/O )/O are/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O headache/B-AdverseReaction and/O pyrexia/B-AdverseReaction ./O
(/O 6.1/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Merck/O Sharp/O &/O Dohme/O Corp./O ,/O a/O subsidiary/O of/O Merck/O &/O Co./O ,/O Inc./O ,/O at/O 1/O -/O 877/O -/O 888/O -/O 4231/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O also/O may/O not/O reflect/O rates/O observed/O in/O practice/O ./O
ZERBAXA/O was/O evaluated/O in/O Phase/O 3/O comparator/O -/O controlled/O clinical/O trials/O of/O cIAI/O and/O cUTI/O ,/O which/O included/O a/O total/O of/O 1015/O patients/O treated/O with/O ZERBAXA/O and/O 1032/O patients/O treated/O with/O comparator/O (/O levofloxacin/O 750/O mg/O daily/O in/O cUTI/O or/O meropenem/O 1/O g/O every/O 8/O hours/O in/O cIAI/O )/O for/O up/O to/O 14/O days/O ./O
The/O mean/O age/O of/O treated/O patients/O was/O 48/O to/O 50/O years/O (/O range/O 18/O to/O 92/O years/O )/O ,/O across/O treatment/O arms/O and/O indications/O ./O
In/O both/O indications/O ,/O about/O 25/O %/O of/O the/O subjects/O were/O 65/O years/O of/O age/O or/O older/O ./O
Most/O patients/O (/O 75/O %/O )/O enrolled/O in/O the/O cUTI/O trial/O were/O female/O ,/O and/O most/O patients/O (/O 58/O %/O )/O enrolled/O in/O the/O cIAI/O trial/O were/O male/O ./O
Most/O patients/O (/O 70/O %/O )/O in/O both/O trials/O were/O enrolled/O in/O Eastern/O Europe/O and/O were/O White/O ./O
The/O most/O common/O adverse/O reactions/O (/O 5/O %/O or/O greater/O in/O either/O indication/O )/O occurring/O in/O patients/O receiving/O ZERBAXA/O were/O nausea/B-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O headache/B-AdverseReaction ,/O and/O pyrexia/B-AdverseReaction ./O
Table/O 5/O lists/O adverse/O reactions/O occurring/O in/O 1/O %/O or/O greater/O of/O patients/O receiving/O ZERBAXA/O in/O Phase/O 3/O clinical/O trials/O ./O
Table/O 5/O :/O Adverse/O Reactions/O Occurring/O in/O 1/O %/O or/O Greater/O of/O Patients/O Receiving/O ZERBAXA/O in/O Phase/O 3/O Clinical/O Trials/O Preferred/O Term/O Complicated/O Intra/O -/O abdominal/O Infections/O Complicated/O Urinary/O Tract/O Infections/O ,/O Including/O Pyelonephritis/O ZERBAXA(N=482/O )/O Meropenem(N=497/O )/O ZERBAXA(N=533/O )/O Levofloxacin(N=535/O )/O Nausea/B-AdverseReaction 38/O (/O 7.9/O )/O 29/O (/O 5.8/O )/O 15/O (/O 2.8/O )/O 9/O (/O 1.7/O )/O Headache/B-AdverseReaction 12/O (/O 2.5/O )/O 9/O (/O 1.8/O )/O 31/O (/O 5.8/O )/O 26/O (/O 4.9/O )/O Diarrhea/B-AdverseReaction 30/O (/O 6.2/O )/O 25/O (/O 5/O )/O 10/O (/O 1.9/O )/O 23/O (/O 4.3/O )/O Pyrexia/B-AdverseReaction 27/O (/O 5.6/O )/O 20/O (/O 4/O )/O 9/O (/O 1.7/O )/O 5/O (/O 0.9/O )/O Constipation/B-AdverseReaction 9/O (/O 1.9/O )/O 6/O (/O 1.2/O )/O 21/O (/O 3.9/O )/O 17/O (/O 3.2/O )/O Insomnia/B-AdverseReaction 17/O (/O 3.5/O )/O 11/O (/O 2.2/O )/O 7/O (/O 1.3/O )/O 14/O (/O 2.6/O )/O Vomiting/B-AdverseReaction 16/O (/O 3.3/O )/O 20/O (/O 4/O )/O 6/O (/O 1.1/O )/O 6/O (/O 1.1/O )/O Hypokalemia/B-AdverseReaction 16/O (/O 3.3/O )/O 10/O (/O 2/O )/O 4/O (/O 0.8/O )/O 2/O (/O 0.4/O )/O ALT/B-AdverseReaction increased/I-AdverseReaction 7/O (/O 1.5/O )/O 5/O (/O 1/O )/O 9/O (/O 1.7/O )/O 5/O (/O 0.9/O )/O AST/B-AdverseReaction increased/I-AdverseReaction 5/O (/O 1/O )/O 3/O (/O 0.6/O )/O 9/O (/O 1.7/O )/O 5/O (/O 0.9/O )/O Anemia/B-AdverseReaction 7/O (/O 1.5/O )/O 5/O (/O 1/O )/O 2/O (/O 0.4/O )/O 5/O (/O 0.9/O )/O Thrombocytosis/B-AdverseReaction 9/O (/O 1.9/O )/O 5/O (/O 1/O )/O 2/O (/O 0.4/O )/O 2/O (/O 0.4/O )/O Abdominal/B-AdverseReaction pain/I-AdverseReaction 6/O (/O 1.2/O )/O 2/O (/O 0.4/O )/O 4/O (/O 0.8/O )/O 2/O (/O 0.4/O )/O Anxiety/B-AdverseReaction 9/O (/O 1.9/O )/O 7/O (/O 1.4/O )/O 1/O (/O 0.2/O )/O 4/O (/O 0.7/O )/O Dizziness/B-AdverseReaction 4/O (/O 0.8/O )/O 5/O (/O 1/O )/O 6/O (/O 1.1/O )/O 1/O (/O 0.2/O )/O Hypotension/B-AdverseReaction 8/O (/O 1.7/O )/O 4/O (/O 0.8/O )/O 2/O (/O 0.4/O )/O 1/O (/O 0.2/O )/O Atrial/B-AdverseReaction fibrillation/I-AdverseReaction 6/O (/O 1.2/O )/O 3/O (/O 0.6/O )/O 1/O (/O 0.2/O )/O 0/O Rash/B-AdverseReaction 8/O (/O 1.7/O )/O 7/O (/O 1.4/O )/O 5/O (/O 0.9/O )/O 2/O (/O 0.4/O )/O Treatment/O discontinuation/O due/O to/O adverse/O events/O occurred/O in/O 2.0/O %/O (/O 20/1015/O )/O of/O patients/O receiving/O ZERBAXA/O and/O 1.9/O %/O (/O 20/1032/O )/O of/O patients/O receiving/O comparator/O drugs/O ./O
Renal/B-AdverseReaction impairment/I-AdverseReaction (/O including/O the/O terms/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction ,/O and/O renal/B-AdverseReaction failure/I-AdverseReaction acute/I-AdverseReaction )/O led/O to/O discontinuation/O of/O treatment/O in/O 5/1015/O (/O 0.5/O %/O )/O subjects/O receiving/O ZERBAXA/O and/O none/O in/O the/O comparator/O arms/O ./O
Increased/O Mortality/O In/O the/O cIAI/O trials/O (/O Phase/O 2/O and/O 3/O )/O ,/O death/B-AdverseReaction occurred/O in/O 2.5/O %/O (/O 14/564/O )/O of/O patients/O receiving/O ZERBAXA/O and/O in/O 1.5/O %/O (/O 8/536/O )/O of/O patients/O receiving/O meropenem/O ./O
The/O causes/O of/O death/B-AdverseReaction varied/O and/O included/O worsening/O and/or/O complications/B-AdverseReaction of/I-AdverseReaction infection/I-AdverseReaction ,/O surgery/O and/O underlying/O conditions/O ./O
Less/O Common/O Adverse/O Reactions/O The/O following/O selected/O adverse/O reactions/O were/O reported/O in/O ZERBAXA/O -/O treated/O subjects/O at/O a/O rate/O of/O less/O than/O 1/O %/O :/O Cardiac/O disorders/O :/O tachycardia/B-AdverseReaction ,/O angina/B-AdverseReaction pectoris/I-AdverseReaction Gastrointestinal/O disorders/O :/O ileus/B-AdverseReaction ,/O gastritis/B-AdverseReaction ,/O abdominal/B-AdverseReaction distension/I-AdverseReaction ,/O dyspepsia/B-AdverseReaction ,/O flatulence/B-AdverseReaction ,/O ileus/B-AdverseReaction paralytic/I-AdverseReaction General/O disorders/O and/O administration/O site/O conditions/O :/O infusion/B-AdverseReaction site/I-AdverseReaction reactions/I-AdverseReaction Infections/O and/O infestations/O :/O candidiasis/B-AdverseReaction ,/O oropharyngeal/O ,/O fungal/B-AdverseReaction urinary/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction Investigations/O :/O increased/B-AdverseReaction serum/I-AdverseReaction gamma/I-AdverseReaction -/I-AdverseReaction glutamyl/O transpeptidase/O (/O GGT/O )/O ,/O increased/B-AdverseReaction serum/I-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O positive/B-AdverseReaction Coombs/I-AdverseReaction test/I-AdverseReaction Metabolism/O and/O nutrition/O disorders/O :/O hyperglycemia/B-AdverseReaction ,/O hypomagnesemia/B-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction Nervous/O system/O disorders/O :/O ischemic/B-AdverseReaction stroke/I-AdverseReaction Renal/O and/O urinary/O system/O :/O renal/B-AdverseReaction impairment/I-AdverseReaction ,/O renal/B-AdverseReaction failure/I-AdverseReaction Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O :/O dyspnea/B-AdverseReaction Skin/O and/O subcutaneous/O tissue/O disorders/O :/O urticaria/B-AdverseReaction Vascular/O disorders/O :/O venous/B-AdverseReaction thrombosis/I-AdverseReaction 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Decreased/O efficacy/O in/O patients/O with/O baseline/O CrCl/O of/O 30/O to/O 50/O mL/O min/O ./O
Monitor/O CrCl/O at/O least/O daily/O in/O patients/O with/O changing/O renal/O function/O and/O adjust/O the/O dose/O of/O ZERBAXA/O accordingly/O ./O
(/O 5.1/O )/O Serious/B-Severity hypersensitivity/O (/O anaphylactic/O )/O reactions/O have/O been/O reported/O with/O beta/B-DrugClass -/I-DrugClass lactam/I-DrugClass antibacterial/O drugs/O ./O
Exercise/O caution/O in/O patients/O with/O known/O hypersensitivity/O to/O beta/O -/O lactam/O antibacterial/O drugs/O ./O
(/O 5.2/O )/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/I-AdverseReaction (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O with/O nearly/O all/O systemic/O antibacterial/O agents/O ,/O including/O ZERBAXA/O ./O
Evaluate/O if/O diarrhea/O occurs/O ./O
(/O 5.3/O )/O 5.1/O Decreased/O Efficacy/O in/O Patients/O with/O Baseline/O Creatinine/O Clearance/O of/O 30/O to/O 50/O mL/O min/O In/O a/O subgroup/O analysis/O of/O a/O Phase/O 3/O cIAI/O trial/O ,/O clinical/O cure/O rates/O were/O lower/O in/O patients/O with/O baseline/O creatinine/O clearance/O (/O CrCl/O )/O of/O 30/O to/O 50/O mL/O min/O compared/O to/O those/O with/O CrCl/O 50/O mL/O min/O (/O Table/O 4/O )/O ./O
The/O reduction/O in/O clinical/O cure/O rates/O was/O more/O marked/O in/O the/O ZERBAXA/O plus/O metronidazole/O arm/O compared/O to/O the/O meropenem/O arm/O ./O
A/O similar/O trend/O was/O also/O seen/O in/O the/O cUTI/O trial/O ./O
Monitor/O CrCl/O at/O least/O daily/O in/O patients/O with/O changing/O renal/O function/O and/O adjust/O the/O dosage/O of/O ZERBAXA/O accordingly/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
Table/O 4/O :/O Clinical/O Cure/O Rates/O in/O a/O Phase/O 3/O Trial/O of/O cIAI/O by/O Baseline/O Renal/O Function/O (/O MITT/O Population/O )/O Baseline/O Renal/O Function/O ZERBAXA/O plus/O metronidazolen/O N/O (/O %/O )/O Meropenemn/O N/O (/O %/O )/O Normal/O mild/O impairment(CrCl/O 50/O mL/O min/O )/O 312/366/O (/O 85.2/O )/O 355/404/O (/O 87.9/O )/O Moderate/O impairment(CrCl/O 30/O to/O 50/O mL/O min/O )/O 11/23/O (/O 47.8/O )/O 9/13/O (/O 69.2/O )/O 5.2/O Hypersensitivity/O Reactions/O Serious/B-Severity and/O occasionally/O fatal/B-AdverseReaction hypersensitivity/O (/O anaphylactic/O )/O reactions/O have/O been/O reported/O in/O patients/O receiving/O beta/B-DrugClass -/I-DrugClass lactam/I-DrugClass antibacterial/O drugs/O ./O
Before/O initiating/O therapy/O with/O ZERBAXA/O ,/O make/O careful/O inquiry/O about/O previous/O hypersensitivity/O reactions/O to/O other/O cephalosporins/O ,/O penicillins/O ,/O or/O other/O beta/O -/O lactams/O ./O
If/O this/O product/O is/O to/O be/O given/O to/O a/O patient/O with/O a/O cephalosporin/O ,/O penicillin/O ,/O or/O other/O beta/O -/O lactam/O allergy/O ,/O exercise/O caution/O because/O cross/O sensitivity/O has/O been/O established/O ./O
If/O an/O anaphylactic/O reaction/O to/O ZERBAXA/O occurs/O ,/O discontinue/O the/O drug/O and/O institute/O appropriate/O therapy/O ./O
5.3/O Clostridium/O difficile/O -associated/O Diarrhea/O Clostridium/B-AdverseReaction difficile/I-AdverseReaction -associated/I-AdverseReaction diarrhea/O (/O CDAD/B-AdverseReaction )/O has/O been/O reported/O for/O nearly/O all/O systemic/O antibacterial/O agents/O ,/O including/O ZERBAXA/O ,/O and/O may/O range/O in/O severity/O from/O mild/B-Severity diarrhea/B-AdverseReaction to/O fatal/B-AdverseReaction colitis/B-AdverseReaction ./O
Treatment/O with/O antibacterial/O agents/O alters/O the/O normal/O flora/O of/O the/O colon/O and/O may/O permit/O overgrowth/O of/O C/O ./O
difficile/O ./O
C./O difficile/O produces/O toxins/O A/O and/O B/O which/O contribute/O to/O the/O development/O of/O CDAD/O ./O
CDAD/O must/O be/O considered/O in/O all/O patients/O who/O present/O with/O diarrhea/O following/O antibacterial/O use/O ./O
Careful/O medical/O history/O is/O necessary/O because/O CDAD/O has/O been/O reported/O to/O occur/O more/O than/O 2/O months/O after/O the/O administration/O of/O antibacterial/O agents/O ./O
If/O CDAD/O is/O confirmed/O ,/O discontinue/O antibacterials/O not/O directed/O against/O C./O difficile/O ,/O if/O possible/O ./O
Manage/O fluid/O and/O electrolyte/O levels/O as/O appropriate/O ,/O supplement/O protein/O intake/O ,/O monitor/O antibacterial/O treatment/O of/O C./O difficile/O ,/O and/O institute/O surgical/O evaluation/O as/O clinically/O indicated/O ./O
5.4/O Development/O of/O Drug/O -/O Resistant/O Bacteria/O Prescribing/O ZERBAXA/O in/O the/O absence/O of/O a/O proven/O or/O strongly/O suspected/O bacterial/O infection/O is/O unlikely/O to/O provide/O benefit/O to/O the/O patient/O and/O risks/O the/O development/O of/O drug/O -/O resistant/O bacteria/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O serious/O adverse/O reactions/O have/O been/O associated/O with/O Zydelig/O in/O clinical/O trials/O and/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O prescribing/O information/O ./O
Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Severe/B-Severity Diarrhea/B-AdverseReaction or/O Colitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Pneumonitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O Intestinal/B-AdverseReaction Perforation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O Severe/B-Severity Cutaneous/B-AdverseReaction Reactions/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Anaphylaxis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O ]/O Neutropenia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O incidence/O 20/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O pyrexia/B-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O chills/B-AdverseReaction ,/O and/O rash/B-AdverseReaction (/O 6.1/O )/O ./O
The/O most/O common/O laboratory/O abnormalities/O (/O incidence/O 30/O %/O )/O are/O neutropenia/B-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O ALT/B-AdverseReaction elevations/I-AdverseReaction ,/O and/O AST/B-AdverseReaction elevations/I-AdverseReaction (/O 6.1/O )/O ./O
To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Gilead/O Sciences/O ,/O Inc./O at/O 1/O -/O 800-GILEAD-5/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O 6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
Summary/O of/O Clinical/O Trials/O in/O Chronic/O Lymphocytic/O Leukemia/O The/O safety/O data/O reflect/O subject/O exposure/O to/O Zydelig/O from/O Study/O 1/O ,/O in/O which/O 218/O subjects/O with/O relapsed/O CLL/O received/O up/O to/O 8/O doses/O of/O rituximab/O with/O or/O without/O Zydelig/O 150/O mg/O twice/O daily/O ./O
The/O median/O duration/O of/O exposure/O to/O Zydelig/O was/O 5/O months/O ./O
Serious/O adverse/O reactions/O were/O reported/O in/O 54/O (/O 49/O %/O )/O subjects/O treated/O with/O Zydelig/O +/O rituximab/O ./O
The/O most/O frequent/O (/O 2/O %/O )/O serious/O adverse/O reactions/O reported/O for/O subjects/O treated/O with/O Zydelig/O were/O pneumonia/B-AdverseReaction (/O 17/O %/O )/O ,/O pyrexia/B-AdverseReaction (/O 9/O %/O )/O ,/O sepsis/B-AdverseReaction (/O 8/O %/O )/O ,/O febrile/B-AdverseReaction neutropenia/I-AdverseReaction (/O 5/O %/O )/O and/O diarrhea/B-AdverseReaction (/O 5/O %/O )/O ./O
Adverse/O reactions/O that/O led/O to/O discontinuation/O of/O Zydelig/O occurred/O in/O 11/O (/O 10/O %/O )/O subjects/O ./O
The/O most/O common/O adverse/O reactions/O that/O led/O to/O treatment/O discontinuations/O were/O hepatotoxicity/B-AdverseReaction and/O diarrhea/B-AdverseReaction colitis/B-AdverseReaction ./O
Thirty/O -/O nine/O subjects/O (/O 35/O %/O )/O had/O dose/O interruptions/O and/O sixteen/O subjects/O (/O 15/O %/O )/O had/O dose/O reductions/O due/O to/O adverse/O reactions/O or/O laboratory/O abnormalities/O ./O
The/O most/O common/O reasons/O for/O dose/O reductions/O were/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O diarrhea/B-AdverseReaction or/O colitis/B-AdverseReaction ,/O and/O rash/B-AdverseReaction ./O
Table/O 2/O and/O Table/O 3/O summarize/O common/O adverse/O reactions/O and/O laboratory/O abnormalities/O reported/O for/O Zydelig/O +/O rituximab/O and/O placebo/O +/O rituximab/O arms/O ./O
Table/O 2/O Adverse/O Reactions/O Reported/O in/O 5/O %/O of/O CLL/O Patients/O and/O Occurred/O at/O 2/O %/O Higher/O Incidence/O in/O Subjects/O Receiving/O Zydelig/O Zydelig/O +/O RN=110/O (/O %/O )/O Placebo/O +/O RN=108/O (/O %/O )/O Adverse/O Reaction/O Any/O Grade/O Grade/O =3/O Any/O Grade/O Grade/O =3/O R/O :/O rituximab/O Gastrointestinal/O disorders/O nausea/B-AdverseReaction 28/O (/O 25/O )/O 0/O 23/O (/O 21/O )/O 0/O vomiting/B-AdverseReaction 14/O (/O 13/O )/O 0/O 9/O (/O 8)/O 0/O diarrhea/B-AdverseReaction 23/O (/O 21/O )/O 6/O (/O 5/O )/O 17/O (/O 16/O )/O 0/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction 7/O (/O 6/O )/O 0/O 1/O (/O 1/O )/O 0/O stomatitis/B-AdverseReaction 7/O (/O 6/O )/O 2/O (/O 2/O )/O 2/O (/O 2/O )/O 0/O Nervous/O system/O disorders/O headache/B-AdverseReaction 11/O (/O 10/O )/O 1/O (/O 1/O )/O 5/O (/O 5/O )/O 0/O General/O disorders/O and/O administration/O site/O conditions/O pyrexia/B-AdverseReaction 38/O (/O 35/O )/O 3/O (/O 3/O )/O 18/O (/O 17/O )/O 1/O (/O 1/O )/O chills/B-AdverseReaction 23/O (/O 21/O )/O 2/O (/O 2/O )/O 17/O (/O 16/O )/O 0/O pain/B-AdverseReaction 8/O (/O 7/O )/O 0/O 2/O (/O 2/O )/O 0/O Skin/O and/O subcutaneous/O tissue/O disorders/O rash/B-AdverseReaction 20/O (/O 18/O )/O 4/O (/O 4/O )/O 7/O (/O 6/O )/O 1/O (/O 1/O )/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O pneumonia/B-AdverseReaction 25/O (/O 23/O )/O 18/O (/O 16/O )/O 19/O (/O 18/O )/O 14/O (/O 13/O )/O nasal/B-AdverseReaction congestion/I-AdverseReaction 6/O (/O 5/O )/O 0/O 2/O (/O 2/O )/O 0/O Infections/O and/O infestations/O sepsis/B-AdverseReaction 9/O (/O 8)/O 8/O (/O 7/O )/O 4/O (/O 4/O )/O 4/O (/O 4/O )/O bronchitis/B-AdverseReaction 7/O (/O 6/O )/O 1/O (/O 1/O )/O 3/O (/O 3/O )/O 1/O (/O 1/O )/O sinusitis/B-AdverseReaction 9/O (/O 8)/O 0/O 4/O (/O 4/O )/O 0/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 6/O (/O 5/O )/O 0/O 3/O (/O 3/O )/O 2/O (/O 2/O )/O Musculoskeletal/O and/O connective/O tissue/O disorders/O arthralgia/B-AdverseReaction 8/O (/O 7/O )/O 1/O (/O 1/O )/O 4/O (/O 4/O )/O 1/O (/O 1/O )/O Table/O 3/O Treatment/O -/O emergent/O Laboratory/O Abnormalities/O Reported/O in/O 10/O %/O of/O CLL/O Patients/O Occurring/O at/O a/O 5/O %/O Higher/O Incidence/O in/O Subjects/O Receiving/O Zydelig/O Zydelig/O +/O RN=110/O (/O %/O )/O Placebo/O +/O RN=108/O (/O %/O )/O Laboratory/O Parameter/O Any/O Grade/O Grade/O 3/O -/O 4/O Any/O Grade/O Grade/O 3/O -/O 4/O Grades/O were/O obtained/O per/O CTCAE/O version/O 4.03.R/O :/O rituximab/O Hematology/O abnormalities/O neutrophil/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction 66/O (/O 60/O )/O 41/O (/O 37/O )/O 55/O (/O 51/O )/O 29/O (/O 27/O )/O lymphocyte/B-AdverseReaction count/I-AdverseReaction decreased/I-AdverseReaction 22/O (/O 20/O )/O 10/O (/O 9/O )/O 13/O (/O 12/O )/O 4/O (/O 4/O )/O lymphocyte/B-AdverseReaction count/I-AdverseReaction increased/I-AdverseReaction 27/O (/O 25/O )/O 20/O (/O 18/O )/O 10/O (/O 9/O )/O 5/O (/O 5/O )/O Serum/O chemistry/O abnormalities/O ALT/B-AdverseReaction increased/I-AdverseReaction 38/O (/O 35/O )/O 9/O (/O 8)/O 11/O (/O 10/O )/O 1/O (/O 1/O )/O AST/B-AdverseReaction increased/I-AdverseReaction 27/O (/O 25/O )/O 6/O (/O 5/O )/O 15/O (/O 14/O )/O 0/O GGT/B-AdverseReaction increased/I-AdverseReaction 29/O (/O 26/O )/O 2/O (/O 2/O )/O 15/O (/O 14/O )/O 3/O (/O 3/O )/O triglycerides/O (/O hypertriglyceridemia/B-AdverseReaction )/O 62/O (/O 56/O )/O 3/O (/O 3/O )/O 37/O (/O 34/O )/O 0/O hyperglycemia/B-AdverseReaction 59/O (/O 54/O )/O 8/O (/O 7/O )/O 50/O (/O 46/O )/O 2/O (/O 2/O )/O hypoglycemia/B-AdverseReaction 12/O (/O 11/O )/O 0/O 5/O (/O 5/O )/O 0/O hyponatremia/B-AdverseReaction 22/O (/O 20/O )/O 2/O (/O 2/O )/O 16/O (/O 15/O )/O 7/O (/O 6/O )/O Summary/O of/O Clinical/O Trials/O in/O Indolent/O Non/O -/O Hodgkin/O Lymphoma/O The/O safety/O data/O reflect/O exposure/O to/O Zydelig/O in/O 146/O adults/O with/O indolent/O non/O -/O Hodgkin/O lymphoma/O treated/O with/O Zydelig/O 150/O mg/O twice/O daily/O in/O clinical/O trials/O ./O
The/O median/O duration/O of/O exposure/O was/O 6.1/O months/O (/O range/O 0.3/O to/O 26.4/O months/O )/O ./O
Serious/O adverse/O reactions/O were/O reported/O in/O 73/O (/O 50/O %/O )/O subjects/O ./O
The/O most/O frequent/O serious/O adverse/O reactions/O that/O occurred/O were/O pneumonia/B-AdverseReaction (/O 15/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 11/O %/O )/O ,/O and/O pyrexia/B-AdverseReaction (/O 9/O %/O )/O ./O
Adverse/O reactions/O resulted/O in/O interruption/O or/O discontinuation/O for/O 78/O (/O 53/O %/O )/O subjects/O ./O
The/O most/O common/O reasons/O for/O interruption/O or/O discontinuations/O were/O diarrhea/B-AdverseReaction (/O 11/O %/O )/O ,/O pneumonia/B-AdverseReaction (/O 11/O %/O )/O ,/O and/O elevated/B-AdverseReaction transaminases/I-AdverseReaction (/O 10/O %/O )/O ./O
Table/O 4/O provides/O the/O adverse/O reactions/O occurring/O in/O at/O least/O 10/O %/O of/O subjects/O receiving/O Zydelig/O monotherapy/O ,/O and/O Table/O 5/O provides/O the/O treatment/O -/O emergent/O laboratory/O abnormalities/O ./O
Table/O 4/O Adverse/O Reactions/O (/O 10/O %/O of/O Subjects/O )/O in/O Patients/O with/O Indolent/O non/O -/O Hodgkin/O Lymphoma/O Treated/O with/O Zydelig/O 150/O mg/O BID/O Zydelig/O MonotherapyN=146/O (/O %/O )/O Adverse/O Reaction/O Any/O Grade/O Grade/O =3/O Gastrointestinal/O disorders/O diarrhea/B-AdverseReaction 68/O (/O 47/O )/O 20/O (/O 14/O )/O nausea/B-AdverseReaction 42/O (/O 29/O )/O 2/O (/O 1/O )/O abdominal/B-AdverseReaction pain/I-AdverseReaction 38/O (/O 26/O )/O 3/O (/O 2/O )/O vomiting/B-AdverseReaction 22/O (/O 15/O )/O 2/O (/O 1/O )/O General/O disorders/O and/O administration/O site/O conditions/O fatigue/B-AdverseReaction 44/O (/O 30/O )/O 2/O (/O 1/O )/O pyrexia/B-AdverseReaction 41/O (/O 28/O )/O 3/O (/O 2/O )/O asthenia/B-AdverseReaction 17/O (/O 12/O )/O 3/O (/O 2/O )/O peripheral/B-AdverseReaction edema/I-AdverseReaction 15/O (/O 10/O )/O 3/O (/O 2/O )/O Infections/O and/O infestations/O upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 18/O (/O 12/O )/O 0/O Respiratory/O ,/O thoracic/O ,/O and/O mediastinal/O disorders/O pneumonia/B-AdverseReaction 37/O (/O 25/O )/O 23/O (/O 16/O )/O cough/B-AdverseReaction 42/O (/O 29/O )/O 1/O (/O 1/O )/O dyspnea/B-AdverseReaction 25/O (/O 17/O )/O 6/O (/O 4/O )/O Skin/O and/O subcutaneous/O disorders/O rash/B-AdverseReaction 31/O (/O 21/O )/O 4/O (/O 3/O )/O night/B-AdverseReaction sweats/I-AdverseReaction 18/O (/O 12/O )/O 0/O Nervous/O system/O disorders/O headache/B-AdverseReaction 16/O (/O 11/O )/O 1/O (/O 1/O )/O Metabolism/O and/O nutrition/O disorders/O decreased/B-AdverseReaction appetite/I-AdverseReaction 24/O (/O 16/O )/O 1/O (/O 1/O )/O Psychiatric/O disorders/O insomnia/B-AdverseReaction 17/O (/O 12/O )/O 0/O Table/O 5/O Treatment/O -/O emergent/O Laboratory/O Abnormalities/O in/O Patients/O with/O Indolent/O non/O -/O Hodgkin/O Lymphoma/O Treated/O with/O Zydelig/O 150/O mg/O BID/O Zydelig/O MonotherapyN=146/O (/O %/O )/O Laboratory/O Abnormality/O Any/O Grade/O Grade/O 3/O Grade/O 4/O Grades/O were/O obtained/O per/O CTCAE/O version/O 4.03/O ./O
Serum/O chemistry/O abnormalities/O ALT/B-AdverseReaction increased/I-AdverseReaction 73/O (/O 50/O )/O 20/O (/O 14/O )/O 7/O (/O 5/O )/O AST/B-AdverseReaction increased/I-AdverseReaction 60/O (/O 41/O )/O 12/O (/O 8)/O 6/O (/O 4/O )/O Hematology/O abnormalities/O neutrophils/B-AdverseReaction decreased/I-AdverseReaction 78/O (/O 53/O )/O 20/O (/O 14/O )/O 16/O (/O 11/O )/O hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 41/O (/O 28/O )/O 3/O (/O 2/O )/O 0/O platelets/B-AdverseReaction decreased/I-AdverseReaction 38/O (/O 26/O )/O 4/O (/O 3/O )/O 5/O (/O 3/O )/O BOXED/O WARNING/O :/O WARNING/O :/O FATAL/B-AdverseReaction AND/O SERIOUS/B-Severity TOXICITIES/B-AdverseReaction :/O HEPATIC/O ,/O SEVERE/B-Severity DIARRHEA/B-AdverseReaction ,/O COLITIS/B-AdverseReaction ,/O PNEUMONITIS/B-AdverseReaction ,/O and/O INTESTINAL/B-AdverseReaction PERFORATION/I-AdverseReaction WARNING/O :/O FATAL/B-AdverseReaction AND/O SERIOUS/B-Severity TOXICITIES/B-AdverseReaction :/O HEPATIC/O ,/O SEVERE/B-Severity DIARRHEA/B-AdverseReaction ,/O COLITIS/B-AdverseReaction ,/O PNEUMONITIS/B-AdverseReaction ,/O and/O INTESTINAL/B-AdverseReaction PERFORATION/I-AdverseReaction Fatal/B-AdverseReaction and/or/O serious/B-Severity hepatotoxicity/B-AdverseReaction occurred/O in/O 14/O %/O of/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O hepatic/O function/O prior/O to/O and/O during/O treatment/O ./O
Interrupt/O and/O then/O reduce/O or/O discontinue/O Zydelig/O as/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Fatal/B-AdverseReaction and/or/O serious/B-Severity and/O severe/B-Severity diarrhea/B-AdverseReaction or/O colitis/B-AdverseReaction occurred/O in/O 14/O %/O of/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O for/O the/O development/O of/O severe/O diarrhea/O or/O colitis/O ./O
Interrupt/O and/O then/O reduce/O or/O discontinue/O Zydelig/O as/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Fatal/B-AdverseReaction and/O serious/B-Severity pneumonitis/B-AdverseReaction can/O occur/O in/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O for/O pulmonary/O symptoms/O and/O bilateral/O interstitial/O infiltrates/O ./O
Interrupt/O or/O discontinue/O Zydelig/O as/O recommended/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ,/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
Fatal/B-AdverseReaction and/O serious/B-Severity intestinal/B-AdverseReaction perforation/I-AdverseReaction can/O occur/O in/O Zydelig/O -/O treated/O patients/O across/O clinical/O trials/O ./O
Discontinue/O Zydelig/O for/O intestinal/O perforation/O [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O ]/O ./O
EXCERPT/O :/O WARNING/O :/O FATAL/B-AdverseReaction AND/O SERIOUS/B-Severity TOXICITIES/B-AdverseReaction :/O HEPATIC/O ,/O SEVERE/B-Severity DIARRHEA/B-AdverseReaction ,/O COLITIS/B-AdverseReaction ,/O PNEUMONITIS/B-AdverseReaction ,/O and/O INTESTINAL/B-AdverseReaction PERFORATION/I-AdverseReaction See/O full/O prescribing/O information/O for/O complete/O boxed/O warning/O ./O
Fatal/B-AdverseReaction and/or/O serious/B-Severity hepatotoxicity/B-AdverseReaction occurred/O in/O 14/O %/O of/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O hepatic/O function/O prior/O to/O and/O during/O treatment/O ./O
Interrupt/O and/O then/O reduce/O or/O discontinue/O Zydelig/O ./O
(/O 5.1/O )/O Fatal/B-AdverseReaction and/or/O serious/B-Severity and/O severe/B-Severity diarrhea/B-AdverseReaction or/O colitis/B-AdverseReaction occurred/O in/O 14/O %/O of/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O for/O the/O development/O of/O severe/O diarrhea/O or/O colitis/O ./O
Interrupt/O and/O then/O reduce/O or/O discontinue/O Zydelig/O ./O
(/O 5.2/O )/O Fatal/B-AdverseReaction and/O serious/B-Severity pneumonitis/B-AdverseReaction can/O occur/O in/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O for/O pulmonary/O symptoms/O and/O bilateral/O interstitial/O infiltrates/O ./O
Interrupt/O or/O discontinue/O Zydelig/O ./O
(/O 5.3/O )/O Fatal/B-AdverseReaction and/O serious/B-Severity intestinal/B-AdverseReaction perforation/I-AdverseReaction can/O occur/O in/O Zydelig/O -/O treated/O patients/O across/O clinical/O trials/O ./O
Discontinue/O Zydelig/O if/O intestinal/O perforation/O is/O suspected/O ./O
(/O 5.4/O )/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Severe/B-Severity cutaneous/B-AdverseReaction reactions/I-AdverseReaction :/O Monitor/O patients/O for/O the/O development/O of/O severe/O cutaneous/O reactions/O and/O discontinue/O Zydelig/O ./O
(/O 5.5/O )/O Anaphylaxis/B-AdverseReaction :/O Monitor/O patients/O for/O anaphylaxis/O and/O discontinue/O Zydelig/O ./O
(/O 5.6/O )/O Neutropenia/B-AdverseReaction :/O monitor/O blood/O counts/O ./O
(/O 5.7/O )/O Embryo/B-AdverseReaction -/I-AdverseReaction fetal/O toxicity/O :/O may/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O women/O of/O potential/O risk/O to/O a/O fetus/O and/O to/O avoid/O pregnancy/O while/O taking/O Zydelig/O ./O
(/O 5.8/O )/O 5.1/O Hepatotoxicity/O Fatal/B-AdverseReaction and/or/O serious/B-Severity hepatotoxicity/B-AdverseReaction occurred/O in/O 14/O %/O of/O patients/O treated/O with/O Zydelig/O ./O
Elevations/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction or/O AST/O greater/O than/O 5/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity have/O occurred/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
These/O findings/O were/O generally/O observed/O within/O the/O first/O 12/O weeks/O of/O treatment/O and/O were/O reversible/O with/O dose/O interruption/O ./O
After/O resumption/O of/O treatment/O at/O a/O lower/O dose/O ,/O 26/O %/O of/O patients/O had/O recurrence/O of/O ALT/O and/O AST/O elevations/O ./O
Discontinue/O Zydelig/O for/O recurrent/O hepatotoxicity/O ./O
Avoid/O concurrent/O use/O of/O Zydelig/O with/O other/O drugs/O that/O may/O cause/O liver/O toxicity/O ./O
Monitor/O ALT/O and/O AST/O in/O all/O patients/O every/O 2/O weeks/O for/O the/O first/O 3/O months/O of/O treatment/O ,/O every/O 4/O weeks/O for/O the/O next/O 3/O months/O ,/O then/O every/O 1/O to/O 3/O months/O thereafter/O ./O
Monitor/O weekly/O for/O liver/O toxicity/O if/O the/O ALT/O or/O AST/O rises/O above/O 3/O times/O the/O upper/O limit/O of/O normal/O until/O resolved/O ./O
Withhold/O Zydelig/O if/O the/O ALT/O or/O AST/O is/O greater/O than/O 5/O times/O the/O upper/O limit/O of/O normal/O ,/O and/O continue/O to/O monitor/O AST/O ,/O ALT/O and/O total/O bilirubin/O weekly/O until/O the/O abnormality/O is/O resolved/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.2/O Severe/O Diarrhea/O or/O Colitis/O Severe/B-Severity diarrhea/B-AdverseReaction or/O colitis/B-AdverseReaction (/O Grade/B-Severity 3/I-Severity or/O higher/O )/O occurred/O in/O 14/O %/O of/O Zydelig/O -/O treated/O patients/O across/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Diarrhea/B-AdverseReaction can/B-Factor occur/O at/O any/O time/O ./O
Avoid/O concurrent/O use/O of/O Zydelig/O and/O other/O drugs/O that/O cause/O diarrhea/O ./O
Diarrhea/B-AdverseReaction due/O to/O Zydelig/O responds/O poorly/O to/O antimotility/O agents/O ./O
Median/O time/O to/O resolution/O ranged/O between/O 1/O week/O and/O 1/O month/O across/O trials/O ,/O following/O interruption/O of/O Zydelig/O therapy/O and/O in/O some/O instances/O ,/O use/O of/O corticosteroids/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.3/O Pneumonitis/O Fatal/B-AdverseReaction and/O serious/B-Severity pneumonitis/B-AdverseReaction occurred/O in/O patients/O treated/O with/O Zydelig/O ./O
Patients/O taking/O Zydelig/O who/O present/O with/O pulmonary/O symptoms/O such/O as/O cough/O ,/O dyspnea/O ,/O hypoxia/O ,/O interstitial/O infiltrates/O on/O a/O radiologic/O exam/O ,/O or/O a/O decline/O by/O more/O than/O 5/O %/O in/O oxygen/O saturation/O should/O be/O evaluated/O for/O pneumonitis/O ./O
If/O pneumonitis/O is/O suspected/O ,/O interrupt/O Zydelig/O until/O the/O etiology/O of/O the/O pulmonary/O symptoms/O has/O been/O determined/O ./O
Patients/O with/O pneumonitis/O thought/O to/O be/O caused/O by/O Zydelig/O have/O been/O treated/O with/O discontinuation/O of/O Zydelig/O and/O administration/O of/O corticosteroids/O ./O
5.4/O Intestinal/O Perforation/O Fatal/B-AdverseReaction and/O serious/B-Severity intestinal/B-AdverseReaction perforation/I-AdverseReaction occurred/O in/O Zydelig/O -/O treated/O patients/O ./O
At/O the/O time/O of/O perforation/O ,/O some/O patients/O had/O moderate/B-Severity to/O severe/B-Severity diarrhea/B-AdverseReaction ./O
Advise/O patients/O to/O promptly/O report/O any/O new/O or/O worsening/O abdominal/O pain/O ,/O chills/O ,/O fever/O ,/O nausea/O ,/O or/O vomiting/O ./O
Discontinue/O Zydelig/O permanently/O in/O patients/O who/O experience/O intestinal/O perforation/O ./O
5.5/O Severe/O Cutaneous/O Reactions/O One/O case/O of/O toxic/B-AdverseReaction epidermal/I-AdverseReaction necrolysis/I-AdverseReaction (/O TEN/B-AdverseReaction )/O occurred/O in/O a/O study/O of/O Zydelig/O in/O combination/O with/O rituximab/O and/O bendamustine/O ./O
Other/O severe/B-Severity or/O life/B-Severity -/O threatening/O (/O Grade/O =3/O )/O cutaneous/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O dermatitis/B-AdverseReaction exfoliative/I-AdverseReaction ,/O rash/B-AdverseReaction ,/O rash/B-AdverseReaction erythematous/I-AdverseReaction ,/O rash/B-AdverseReaction generalized/I-AdverseReaction ,/O rash/B-AdverseReaction macular/I-AdverseReaction ,/O rash/B-AdverseReaction maculo/I-AdverseReaction -/O papular/O ,/O rash/B-AdverseReaction papular/I-AdverseReaction ,/O rash/B-AdverseReaction pruritic/I-AdverseReaction ,/O exfoliative/B-AdverseReaction rash/I-AdverseReaction ,/O and/O skin/B-AdverseReaction disorder/I-AdverseReaction ,/O have/O been/O reported/O in/O Zydelig/O -/O treated/O patients/O ./O
Monitor/O patients/O for/O the/O development/O of/O severe/O cutaneous/O reactions/O and/O discontinue/O Zydelig/O ./O
5.6/O Anaphylaxis/O Serious/B-Severity allergic/B-AdverseReaction reactions/I-AdverseReaction ,/O including/O anaphylaxis/B-AdverseReaction ,/O have/O been/O reported/O in/O patients/O on/O Zydelig/O ./O
In/O patients/O who/O develop/O serious/O allergic/O reactions/O ,/O discontinue/O Zydelig/O permanently/O and/O institute/O appropriate/O supportive/O measures/O ./O
5.7/O Neutropenia/O Treatment/O -/O emergent/O Grade/B-Severity 3/I-Severity or/O 4/O neutropenia/B-AdverseReaction occurred/O in/O 31/O %/O of/O Zydelig/O -/O treated/O patients/O across/O clinical/O trials/O [/O see/O Adverse/O Reactions/O (/O 6.1/O )/O ]/O ./O
Monitor/O blood/O counts/O at/O least/O every/O two/O weeks/O for/O the/O first/O 3/O months/O of/O therapy/O ,/O and/O at/O least/O weekly/O in/O patients/O while/O neutrophil/O counts/O are/O less/O than/O 1.0/O Gi/O L/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
5.8/O Embryo/O -/O fetal/O Toxicity/O Based/O on/O findings/O in/O animals/B-Animal ,/O Zydelig/O may/O cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
Idelalisib/O is/O teratogenic/B-AdverseReaction in/O rats/B-Animal ,/O at/O systemic/O exposures/O 12/O times/O those/O reported/O in/O patients/O at/O the/O recommended/O dose/O of/O 150/O mg/O twice/O daily/O ./O
If/O this/O drug/O is/O used/O during/O pregnancy/O ,/O or/O if/O the/O patient/O becomes/O pregnant/O while/O taking/O this/O drug/O ,/O the/O patient/O should/O be/O apprised/O of/O the/O potential/O hazard/O to/O a/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
Advise/O females/O of/O reproductive/O potential/O to/O avoid/O becoming/O pregnant/O while/O taking/O Zydelig/O ./O
If/O contraceptive/O methods/O are/O being/O considered/O ,/O use/O effective/O contraception/O during/O treatment/O ,/O and/O for/O at/O least/O 1/O month/O after/O the/O last/O dose/O of/O Zydelig/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.6/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O adverse/O reactions/O are/O discussed/O in/O greater/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Severe/B-Severity or/O Persistent/B-Severity Gastrointestinal/B-AdverseReaction Toxicity/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.1/O )/O ]/O Hepatotoxicity/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.2/O )/O ]/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction Pneumonitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.3/O )/O ]/O QT/B-AdverseReaction Interval/I-AdverseReaction Prolongation/I-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.4/O )/O and/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O Hyperglycemia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.5/O )/O ]/O Bradycardia/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.6/O )/O and/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O Pancreatitis/B-AdverseReaction [/O see/O Warnings/O and/O Precautions/O (/O 5.7/O )/O ]/O EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O incidence/O of/O at/O least/O 25/O %/O )/O are/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O fatigue/B-AdverseReaction ,/O decreased/B-AdverseReaction appetite/I-AdverseReaction ,/O and/O constipation/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Novartis/O Pharmaceuticals/O Corporation/O at/O 1/O -/O 888/O -/O 669/O -/O 6682/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trials/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O practice/O ./O
The/O safety/O evaluation/O of/O ZYKADIA/O is/O based/O on/O 255/O ALK/O -/O positive/O patients/O in/O Study/O 1/O (/O 246/O patients/O with/O NSCLC/O and/O 9/O patients/O with/O other/O cancers/O who/O received/O ZYKADIA/O at/O a/O dose/O of/O 750/O mg/O daily/O )/O ./O
The/O median/O duration/O of/O exposure/O to/O ZYKADIA/O was/O 6/O months/O ./O
The/O study/O population/O characteristics/O were/O :/O median/O age/O 53/O years/O ,/O age/O less/O than/O 65/O (/O 84/O %/O )/O ,/O female/O (/O 53/O %/O )/O ,/O Caucasian/O (/O 63/O %/O )/O ,/O Asian/O (/O 34/O %/O )/O ,/O NSCLC/O adenocarcinoma/O histology/O (/O 90/O %/O )/O ,/O never/O or/O former/O smoker/O (/O 97/O %/O )/O ,/O ECOG/O PS/O 0/O or/O 1/O (/O 89/O %/O )/O ,/O brain/O metastasis/O (/O 49/O %/O )/O ,/O and/O number/O of/O prior/O therapies/O 2/O or/O more/O (/O 67/O %/O )/O ./O
Dose/O reductions/O due/O to/O adverse/O reactions/O occurred/O in/O 59/O %/O of/O patients/O treated/O with/O ZYKADIA/O ./O
The/O most/O frequent/O adverse/O reactions/O ,/O reported/O in/O at/O least/O 10/O %/O of/O patients/O ,/O that/O led/O to/O dose/O reductions/O or/O interruptions/O were/O :/O increased/B-AdverseReaction ALT/I-AdverseReaction (/O 29/O %/O )/O ,/O nausea/B-AdverseReaction (/O 20/O %/O )/O ,/O increased/B-AdverseReaction AST/I-AdverseReaction (/O 16/O %/O )/O ,/O diarrhea/B-AdverseReaction (/O 16/O %/O )/O ,/O and/O vomiting/B-AdverseReaction (/O 16/O %/O )/O ./O
Serious/O adverse/O drug/O reactions/O reported/O in/O 2/O %/O or/O more/O of/O patients/O in/O Study/O 1/O were/O convulsion/B-AdverseReaction ,/O pneumonia/B-AdverseReaction ,/O ILD/B-AdverseReaction pneumonitis/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O dehydration/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O and/O nausea/B-AdverseReaction ./O
Fatal/B-AdverseReaction adverse/O reactions/O in/O patients/O treated/O with/O ZYKADIA/O occurred/O in/O 5/O %/O of/O patients/O ,/O consisting/O of/O :/O pneumonia/B-AdverseReaction (/O 4/O patients/O )/O ,/O respiratory/B-AdverseReaction failure/I-AdverseReaction ,/O ILD/B-AdverseReaction pneumonitis/B-AdverseReaction ,/O pneumothorax/B-AdverseReaction ,/O gastric/B-AdverseReaction hemorrhage/I-AdverseReaction ,/O general/B-AdverseReaction physical/I-AdverseReaction health/I-AdverseReaction deterioration/I-AdverseReaction ,/O pulmonary/B-AdverseReaction tuberculosis/I-AdverseReaction ,/O cardiac/B-AdverseReaction tamponade/I-AdverseReaction ,/O and/O sepsis/B-AdverseReaction (/O 1/O patient/O each/O )/O ./O
Discontinuation/O of/O therapy/O due/O to/O adverse/O reactions/O occurred/O in/O 10/O %/O of/O patients/O treated/O with/O ZYKADIA/O ./O
The/O most/O frequent/O adverse/O drug/O reactions/O that/O led/O to/O discontinuation/O in/O 1/O %/O or/O more/O of/O patients/O in/O Study/O 1/O were/O pneumonia/B-AdverseReaction ,/O ILD/B-AdverseReaction pneumonitis/B-AdverseReaction ,/O and/O decreased/B-AdverseReaction appetite/I-AdverseReaction ./O
Tables/O 2/O and/O 3/O summarize/O the/O common/O adverse/O reactions/O and/O laboratory/O abnormalities/O observed/O in/O ZYKADIA/O -/O treated/O patients/O ./O
Table/O 2/O :/O Adverse/O Reactions/O (/O 10/O %/O for/O All/O NCI/O CTCAE/O Grades/O or/O 2/O %/O for/O Grades/O 3/O -/O 4/O )/O in/O ALK/O -/O Positive/O Patients/O Treated/O with/O ZYKADIA/O in/O Study/O 1/O National/O Cancer/O Institute/O Common/O Terminology/O Criteria/O for/O Adverse/O Events/O (/O version/O 4.03/O )/O a/O Abdominal/B-AdverseReaction pain/I-AdverseReaction (/O abdominal/B-AdverseReaction pain/I-AdverseReaction ,/O upper/B-AdverseReaction abdominal/I-AdverseReaction pain/I-AdverseReaction ,/O abdominal/B-AdverseReaction discomfort/I-AdverseReaction ,/O epigastric/B-AdverseReaction discomfort/I-AdverseReaction )/O b/O Esophageal/B-AdverseReaction disorder/I-AdverseReaction (/O dyspepsia/B-AdverseReaction ,/O gastroesophageal/B-AdverseReaction reflux/I-AdverseReaction disease/I-AdverseReaction ,/O dysphagia/B-AdverseReaction )/O c/O Fatigue/B-AdverseReaction (/O fatigue/B-AdverseReaction ,/O asthenia/B-AdverseReaction )/O d/O Rash/B-AdverseReaction (/O rash/B-AdverseReaction ,/O maculopapular/B-AdverseReaction rash/I-AdverseReaction ,/O acneiform/B-AdverseReaction dermatitis/I-AdverseReaction )/O ZYKADIAN=255/O All/O Grades/O Grade/O 3/O -/O 4/O %/O %/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 86/O 6/O Nausea/B-AdverseReaction 80/O 4/O Vomiting/B-AdverseReaction 60/O 4/O Abdominal/B-AdverseReaction pain/I-AdverseReaction a/O 54/O 2/O Constipation/B-AdverseReaction 29/O 0/O Esophageal/B-AdverseReaction disorder/I-AdverseReaction b/O 16/O 1/O General/O disorders/O and/O administration/O site/O conditions/O Fatigue/B-AdverseReaction c/O 52/O 5/O Metabolism/O and/O nutrition/O disorders/O Decreased/B-AdverseReaction appetite/I-AdverseReaction 34/O 1/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction d/O 16/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Interstitial/B-AdverseReaction lung/I-AdverseReaction disease/I-AdverseReaction pneumonitis/B-AdverseReaction 4/O 3/O Additional/O clinically/O significant/O adverse/O reactions/O occurring/O in/O 2/O %/O or/O more/O of/O patients/O treated/O with/O ZYKADIA/O included/O neuropathy/B-AdverseReaction (/O 17/O %/O ;/O comprised/O of/O paresthesia/B-AdverseReaction ,/O muscular/B-AdverseReaction weakness/I-AdverseReaction ,/O gait/B-AdverseReaction disturbance/I-AdverseReaction ,/O peripheral/B-AdverseReaction neuropathy/I-AdverseReaction ,/O hypoesthesia/B-AdverseReaction ,/O peripheral/B-AdverseReaction sensory/I-AdverseReaction neuropathy/I-AdverseReaction ,/O dysesthesia/B-AdverseReaction ,/O neuralgia/B-AdverseReaction ,/O peripheral/B-AdverseReaction motor/I-AdverseReaction neuropathy/I-AdverseReaction ,/O hypotonia/B-AdverseReaction ,/O or/O polyneuropathy/B-AdverseReaction )/O ,/O vision/B-AdverseReaction disorder/I-AdverseReaction (/O 9/O %/O ;/O comprised/O of/O vision/B-AdverseReaction impairment/I-AdverseReaction ,/O blurred/B-AdverseReaction vision/I-AdverseReaction ,/O photopsia/B-AdverseReaction ,/O accommodation/B-AdverseReaction disorder/I-AdverseReaction ,/O presbyopia/B-AdverseReaction ,/O or/O reduced/B-AdverseReaction visual/I-AdverseReaction acuity/I-AdverseReaction )/O ,/O prolonged/B-AdverseReaction QT/I-AdverseReaction interval/I-AdverseReaction (/O 4/O %/O )/O ,/O and/O bradycardia/B-AdverseReaction (/O 3/O %/O )/O ./O
Table/O 3/O :/O Key/O Laboratory/O Abnormalities/O Occurring/O in/O 10/O %/O (/O All/O NCI/O CTCAE/O Grades/O )/O of/O ALK/O -/O Positive/O Patients/O Treated/O with/O ZYKADIA/O in/O Study/O 1/O ZYKADIAN=255/O All/O Grades/O Grade/O 3/O -/O 4/O %/O %/O Hemoglobin/B-AdverseReaction decreased/I-AdverseReaction 84/O 5/O Alanine/O transaminase/O (/O ALT/O )/O increased/O 80/O 27/O Aspartate/O transaminase/O (/O AST/O )/O increased/O 75/O 13/O Creatinine/B-AdverseReaction increased/I-AdverseReaction 58/O 2/O Glucose/B-AdverseReaction increased/I-AdverseReaction 49/O 13/O Phosphate/B-AdverseReaction decreased/I-AdverseReaction 36/O 7/O Lipase/B-AdverseReaction increased/I-AdverseReaction 28/O 10/O Bilirubin/O (/O total/O )/O increased/O 15/O 1/O 5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Severe/O or/O Persistent/O Gastrointestinal/O Toxicity/O :/O Dose/O modification/O due/O to/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction or/O abdominal/B-AdverseReaction pain/I-AdverseReaction occurred/O in/O 38/O %/O of/O patients/O ./O
Withhold/O if/O not/O responsive/O to/O anti/O -/O emetics/O or/O anti/O -/O diarrheals/O ,/O then/O dose/O reduce/O ZYKADIA/O ./O
(/O 2.2/O ,/O 5.1/O )/O Hepatotoxicity/B-AdverseReaction :/O ZYKADIA/O can/B-Factor cause/O hepatotoxicity/B-AdverseReaction ./O
Monitor/O liver/O laboratory/O tests/O at/O least/O monthly/O ./O
Withhold/O then/O dose/O reduce/O ,/O or/O permanently/O discontinue/O ZYKADIA/O ./O
(/O 2.2/O ,/O 5.2/O )/O Interstitial/B-AdverseReaction Lung/I-AdverseReaction Disease/I-AdverseReaction (/O ILD)/Pneumonitis/B-AdverseReaction :/O Occurred/O in/O 4/O %/O of/O patients/O ./O
Permanently/O discontinue/O ZYKADIA/O in/O patients/O diagnosed/O with/O treatment/O -/O related/O ILD/O pneumonitis/O ./O
(/O 2.2/O ,/O 5.3/O )/O QT/B-AdverseReaction Interval/I-AdverseReaction Prolongation/I-AdverseReaction :/O ZYKADIA/O can/B-Factor cause/O QTc/B-AdverseReaction interval/I-AdverseReaction prolongation/I-AdverseReaction ./O
Monitor/O electrocardiograms/O and/O electrolytes/O in/O patients/O with/O congestive/O heart/O failure/O ,/O bradyarrhythmias/O ,/O electrolyte/O abnormalities/O ,/O or/O those/O who/O are/O taking/O medications/O that/O are/O known/O to/O prolong/O the/O QTc/O interval/O ./O
Withhold/O then/O dose/O reduce/O ,/O or/O permanently/O discontinue/O ZYKADIA/O ./O
(/O 2.2/O ,/O 5.4/O )/O Hyperglycemia/B-AdverseReaction :/O ZYKADIA/O can/B-Factor cause/O hyperglycemia/B-AdverseReaction ./O
Monitor/O fasting/O glucose/O prior/O to/O treatment/O and/O periodically/O thereafter/O as/O clinically/O indicated/O ./O
Initiate/O or/O optimize/O anti/O -/O hyperglycemic/O medications/O as/O indicated/O ./O
Withhold/O then/O dose/O reduce/O ,/O or/O permanently/O discontinue/O ZYKADIA/O ./O
(/O 2.2/O ,/O 5.5/O )/O Bradycardia/B-AdverseReaction :/O ZYKADIA/O can/B-Factor cause/O bradycardia/B-AdverseReaction ./O
Monitor/O heart/O rate/O and/O blood/O pressure/O regularly/O ./O
Withhold/O then/O dose/O reduce/O ,/O or/O permanently/O discontinue/O ZYKADIA/O ./O
(/O 2.2/O ,/O 5.6/O )/O Pancreatitis/B-AdverseReaction :/O Elevations/B-AdverseReaction of/I-AdverseReaction lipase/I-AdverseReaction and/or/O amylase/O and/O pancreatitis/B-AdverseReaction can/B-Factor occur/O ./O
Monitor/O lipase/O and/O amylase/O prior/O to/O treatment/O and/O periodically/O thereafter/O as/O clinically/O indicated/O ./O
(/O 2.2/O ,/O 5.7/O )/O Embryofetal/B-AdverseReaction Toxicity/I-AdverseReaction :/O ZYKADIA/O may/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction ./O
Advise/O females/O of/O reproductive/O potential/O of/O the/O potential/O risk/O to/O a/O fetus/O ./O
(/O 5.8/O ,/O 8.1/O ,/O 8.7/O )/O 5.1/O Severe/O or/O Persistent/O Gastrointestinal/O Toxicity/O Diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O or/O abdominal/B-AdverseReaction pain/I-AdverseReaction occurred/O in/O 96/O %/O of/O 255/O patients/O including/O severe/B-Severity cases/O in/O 14/O %/O of/O patients/O treated/O with/O ZYKADIA/O in/O Study/O 1/O ./O
Dose/O modification/O due/O to/O diarrhea/B-AdverseReaction ,/O nausea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O or/O abdominal/B-AdverseReaction pain/I-AdverseReaction occurred/O in/O 38/O %/O of/O patients/O ./O
Monitor/O and/O manage/O patients/O using/O standards/O of/O care/O ,/O including/O anti/O -/O diarrheals/O ,/O anti/O -/O emetics/O ,/O or/O fluid/O replacement/O ,/O as/O indicated/O ./O
Based/O on/O the/O severity/O of/O the/O adverse/O drug/O reaction/O ,/O withhold/O ZYKADIA/O with/O resumption/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 1/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.2/O Hepatotoxicity/O Drug/O -/O induced/O hepatotoxicity/B-AdverseReaction occurred/O in/O patients/O treated/O with/O ZYKADIA/O ./O
Elevations/B-AdverseReaction in/I-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction (/O ALT/O )/O greater/O than/O 5/B-Severity times/I-Severity the/I-Severity upper/I-Severity limit/I-Severity of/I-Severity normal/I-Severity (/O ULN/O )/O occurred/O in/O 27/O %/O of/O 255/O patients/O in/O Study/O 1/O ./O
One/O patient/O (/O 0.4/O %/O )/O required/O permanent/O discontinuation/O due/O to/O elevated/B-AdverseReaction transaminases/I-AdverseReaction ,/O and/O jaundice/B-AdverseReaction ./O
Concurrent/O elevations/B-AdverseReaction in/I-AdverseReaction ALT/I-AdverseReaction greater/O than/O 3/B-Severity times/I-Severity the/I-Severity ULN/I-Severity and/O total/O bilirubin/O greater/O than/O 2/O times/O the/O ULN/O ,/O with/O normal/O alkaline/O phosphatase/O ,/O occurred/O in/O less/O than/O 1/O %/O of/O patients/O in/O clinical/O studies/O ./O
Monitor/O with/O liver/O laboratory/O tests/O including/O ALT/O ,/O aspartate/O aminotransferase/O (/O AST/O )/O ,/O and/O total/O bilirubin/O once/O a/O month/O and/O as/O clinically/O indicated/O ,/O with/O more/O frequent/O testing/O in/O patients/O who/O develop/O transaminase/O elevations/O ./O
Based/O on/O the/O severity/O of/O the/O adverse/O drug/O reaction/O ,/O withhold/O ZYKADIA/O with/O resumption/O at/O a/O reduced/O dose/O ,/O or/O permanently/O discontinue/O ZYKADIA/O as/O described/O in/O Table/O 1/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.3/O Interstitial/O Lung/O Disease/O (/O ILD)/Pneumonitis/O Severe/B-Severity ,/O life/B-Severity -/O threatening/O ,/O or/O fatal/B-AdverseReaction ILD/B-AdverseReaction pneumonitis/B-AdverseReaction can/B-Factor occur/O in/O patients/O treated/O with/O ZYKADIA/O ./O
In/O Study/O 1/O ,/O pneumonitis/B-AdverseReaction was/O reported/O in/O 4/O %/O of/O 255/O patients/O treated/O with/O ZYKADIA/O ./O
CTCAE/O Grade/B-Severity 3/I-Severity or/O 4/O ILD/B-AdverseReaction pneumonitis/B-AdverseReaction was/O reported/O in/O 3/O %/O of/O patients/O ,/O and/O fatal/B-AdverseReaction ILD/B-AdverseReaction pneumonitis/B-AdverseReaction was/O reported/O in/O 1/O patient/O (/O 0.4/O %/O )/O in/O Study/O 1/O ./O
One/O percent/O (/O 1/O %/O )/O of/O patients/O discontinued/O ZYKADIA/O in/O Study/O 1/O due/O to/O ILD/B-AdverseReaction pneumonitis/B-AdverseReaction ./O
Monitor/O patients/O for/O pulmonary/O symptoms/O indicative/O of/O ILD/O pneumonitis/O ./O
Exclude/O other/O potential/O causes/O of/O ILD/O pneumonitis/O ,/O and/O permanently/O discontinue/O ZYKADIA/O in/O patients/O diagnosed/O with/O treatment/O -/O related/O ILD/O pneumonitis/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.4/O QT/O Interval/O Prolongation/O QTc/B-AdverseReaction interval/I-AdverseReaction prolongation/I-AdverseReaction ,/O which/O may/O lead/O to/O an/O increased/O risk/B-Factor for/O ventricular/B-AdverseReaction tachyarrhythmias/I-AdverseReaction (/O e.g./O ,/O Torsade/B-AdverseReaction de/I-AdverseReaction pointes/I-AdverseReaction )/O or/O sudden/B-AdverseReaction death/I-AdverseReaction ,/O occurred/O in/O patients/O treated/O with/O ZYKADIA/O in/O clinical/O trials/O ./O
Three/O percent/O (/O 3/O %/O )/O of/O 255/O patients/O experienced/O a/O QTc/B-AdverseReaction interval/I-AdverseReaction increase/I-AdverseReaction over/O baseline/O greater/O than/O 60/B-Severity msec/I-Severity in/O Study/O 1/O ./O
Across/O the/O development/O program/O of/O ZYKADIA/O ,/O one/O of/O 304/O patients/O (/O less/O than/O 1/O %/O )/O treated/O with/O ZYKADIA/O doses/O ranging/O from/O 50/O to/O 750/O mg/O was/O found/O to/O have/O a/O QTc/B-AdverseReaction greater/I-AdverseReaction than/I-AdverseReaction 500/I-AdverseReaction msec/I-AdverseReaction and/O 3/O %/O of/O patients/O had/O an/O increase/B-AdverseReaction from/I-AdverseReaction baseline/I-AdverseReaction QTc/I-AdverseReaction greater/O than/O 60/B-Severity msec/I-Severity ./O
A/O pharmacokinetic/O analysis/O suggested/B-Factor that/O ZYKADIA/O causes/O concentration/O -/O dependent/O increases/B-AdverseReaction in/I-AdverseReaction the/I-AdverseReaction QTc/I-AdverseReaction interval/I-AdverseReaction ./O
When/O possible/O ,/O avoid/O use/O of/O ZYKADIA/O in/O patients/O with/O congenital/O long/O QT/O syndrome/O ./O
Conduct/O periodic/O monitoring/O with/O electrocardiograms/O (/O ECGs/O )/O and/O electrolytes/O in/O patients/O with/O congestive/O heart/O failure/O ,/O bradyarrhythmias/O ,/O electrolyte/O abnormalities/O ,/O or/O those/O who/O are/O taking/O medications/O that/O are/O known/O to/O prolong/O the/O QTc/O interval/O ./O
Withhold/O ZYKADIA/O in/O patients/O who/O develop/O a/O QTc/O interval/O greater/O than/O 500/O msec/O on/O at/O least/O 2/O separate/O ECGs/O until/O the/O QTc/O interval/O is/O less/O than/O 481/O msec/O or/O recovery/O to/O baseline/O if/O the/O QTc/O interval/O is/O greater/O than/O or/O equal/O to/O 481/O msec/O ,/O then/O resume/O ZYKADIA/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 1/O ./O
Permanently/O discontinue/O ZYKADIA/O in/O patients/O who/O develop/O QTc/O interval/O prolongation/O in/O combination/O with/O Torsade/O de/O pointes/O or/O polymorphic/O ventricular/O tachycardia/O or/O signs/O symptoms/O of/O serious/O arrhythmia/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Clinical/O Pharmacology/O (/O 12.2/O )/O ]/O ./O
5.5/O Hyperglycemia/O Hyperglycemia/B-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O ZYKADIA/O ./O
In/O Study/O 1/O ,/O CTCAE/O Grade/B-Severity 3/I-Severity -/O 4/O hyperglycemia/B-AdverseReaction ,/O based/O on/O laboratory/O values/O ,/O occurred/O in/O 13/O %/O of/O 255/O patients/O ./O
There/O was/O a/O 6-fold/O increase/O in/O the/O risk/B-Factor of/O CTCAE/O Grade/B-Severity 3/I-Severity -/O 4/O hyperglycemia/B-AdverseReaction in/O patients/O with/O diabetes/O or/O glucose/O intolerance/O and/O a/O 2-fold/O increase/O in/O patients/O taking/O corticosteroids/O ./O
Monitor/O fasting/O serum/O glucose/O prior/O to/O the/O start/O of/O ZYKADIA/O treatment/O and/O periodically/O thereafter/O as/O clinically/O indicated/O ./O
Initiate/O or/O optimize/O anti/O -/O hyperglycemic/O medications/O as/O indicated/O ./O
Based/O on/O the/O severity/O of/O the/O adverse/O drug/O reaction/O ,/O withhold/O ZYKADIA/O until/O hyperglycemia/O is/O adequately/O controlled/O ,/O then/O resume/O ZYKADIA/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 1/O ./O
If/O adequate/O hyperglycemic/O control/O can/O not/O be/O achieved/O with/O optimal/O medical/O management/O ,/O permanently/O discontinue/O ZYKADIA/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.6/O Bradycardia/O Bradycardia/B-AdverseReaction can/B-Factor occur/O in/O patients/O receiving/O ZYKADIA/O ./O
In/O Study/O 1/O ,/O sinus/B-AdverseReaction bradycardia/I-AdverseReaction ,/O defined/O as/O a/O heart/B-AdverseReaction rate/I-AdverseReaction of/I-AdverseReaction less/I-AdverseReaction than/I-AdverseReaction 50/I-AdverseReaction beats/I-AdverseReaction per/I-AdverseReaction minute/I-AdverseReaction ,/O was/O noted/O as/O a/O new/O finding/O in/O 1/O %/O of/O 255/O patients/O ./O
Bradycardia/B-AdverseReaction was/O reported/O as/O an/O adverse/O drug/O reaction/O in/O 3/O %/O of/O patients/O in/O Study/O 1/O ./O
Avoid/O using/O ZYKADIA/O in/O combination/O with/O other/O agents/O known/O to/O cause/O bradycardia/O (/O e.g./O ,/O beta/O -/O blockers/O ,/O non/O -/O dihydropyridine/O calcium/O channel/O blockers/O ,/O clonidine/O ,/O and/O digoxin/O )/O to/O the/O extent/O possible/O ./O
Monitor/O heart/O rate/O and/O blood/O pressure/O regularly/O ./O
In/O cases/O of/O symptomatic/O bradycardia/O that/O is/O not/O life/O -/O threatening/O ,/O withhold/O ZYKADIA/O until/O recovery/O to/O asymptomatic/O bradycardia/O or/O to/O a/O heart/O rate/O of/O 60/O bpm/O or/O above/O ,/O evaluate/O the/O use/O of/O concomitant/O medications/O ,/O and/O adjust/O the/O dose/O of/O ZYKADIA/O ./O
Permanently/O discontinue/O ZYKADIA/O for/O life/O -/O threatening/O bradycardia/O if/O no/O contributing/O concomitant/O medication/O is/O identified/O ;/O however/O ,/O if/O associated/O with/O a/O concomitant/O medication/O known/O to/O cause/O bradycardia/O or/O hypotension/O ,/O withhold/O ZYKADIA/O until/O recovery/O to/O asymptomatic/O bradycardia/O or/O to/O a/O heart/O rate/O of/O 60/O bpm/O or/O above/O ,/O and/O if/O the/O concomitant/O medication/O can/O be/O adjusted/O or/O discontinued/O ,/O resume/O ZYKADIA/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 1/O upon/O recovery/O to/O asymptomatic/O bradycardia/O or/O to/O a/O heart/O rate/O of/O 60/O bpm/O or/O above/O ,/O with/O frequent/O monitoring/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.7/O Pancreatitis/O Pancreatitis/B-AdverseReaction ,/O including/O one/O fatality/B-AdverseReaction ,/O has/O been/O reported/O in/O less/O than/O 1/O %/O of/O patients/O receiving/O ZYKADIA/O in/O clinical/O trials/O ./O
CTCAE/O Grade/B-Severity 3/I-Severity -/O 4/O elevations/B-AdverseReaction of/I-AdverseReaction lipase/I-AdverseReaction and/or/O amylase/O occurred/O in/O 15/O %/O of/O patients/O receiving/O ZYKADIA/O in/O Study/O 1/O ./O
Monitor/O lipase/O and/O amylase/O prior/O to/O the/O start/O of/O ZYKADIA/O treatment/O and/O periodically/O thereafter/O as/O clinically/O indicated/O ./O
Based/O on/O the/O severity/O of/O the/O laboratory/O abnormalities/O ,/O withhold/O ZYKADIA/O with/O resumption/O at/O a/O reduced/O dose/O as/O described/O in/O Table/O 1/O [/O see/O Dosage/O and/O Administration/O (/O 2.2/O )/O and/O Adverse/O Reactions/O (/O 6/O )/O ]/O ./O
5.8/O Embryofetal/O Toxicity/O Based/O on/O its/O mechanism/O of/O action/O ,/O ZYKADIA/O may/B-Factor cause/O fetal/B-AdverseReaction harm/I-AdverseReaction when/O administered/O to/O a/O pregnant/O woman/O ./O
In/O animal/O studies/O ,/O administration/O of/O ceritinib/O to/O rats/O and/O rabbits/O during/O organogenesis/O at/O maternal/O plasma/O exposures/O below/O the/O recommended/O human/O dose/O of/O 750/O mg/O daily/O caused/O increases/B-AdverseReaction in/I-AdverseReaction skeletal/I-AdverseReaction anomalies/I-AdverseReaction in/O rats/B-Animal and/O rabbits/B-Animal ./O
Apprise/O women/O of/O reproductive/O potential/O of/O the/O potential/O hazard/O to/O a/O fetus/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.1/O )/O ]/O ./O
Advise/O females/O of/O reproductive/O potential/O to/O use/O effective/O contraception/O during/O treatment/O with/O ZYKADIA/O and/O for/O at/O least/O 2/O weeks/O following/O completion/O of/O therapy/O [/O see/O Use/O in/O Specific/O Populations/O (/O 8.7/O )/O ]/O ./O
6/O ADVERSE/O REACTIONS/O The/O following/O are/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Hypertension/B-AdverseReaction ,/O Hypokalemia/B-AdverseReaction ,/O and/O Fluid/B-AdverseReaction Retention/I-AdverseReaction due/O to/O Mineralocorticoid/B-AdverseReaction Excess/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Adrenocortical/B-AdverseReaction Insufficiency/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Hepatotoxicity/B-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O are/O fatigue/B-AdverseReaction ,/O joint/B-AdverseReaction swelling/I-AdverseReaction or/O discomfort/O ,/O edema/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction and/O contusion/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 20/O %/O )/O are/O anemia/B-AdverseReaction ,/O elevated/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O elevated/B-AdverseReaction AST/I-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O elevated/B-AdverseReaction ALT/I-AdverseReaction and/O hypokalemia/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Janssen/O Biotech/O ,/O Inc./O at/O 1/O -/O 800/O -/O 526/O -/O 7736/O (/O 1/O -/O 800-JANSSEN/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Two/O randomized/O placebo/O -/O controlled/O ,/O multicenter/O clinical/O trials/O enrolled/O patients/O who/O had/O metastatic/O castration/O -/O resistant/O prostate/O cancer/O who/O were/O using/O a/O gonadotropin/O -/O releasing/O hormone/O (/O GnRH/O )/O agonist/O or/O were/O previously/O treated/O with/O orchiectomy/O ./O
In/O both/O Study/O 1/O and/O Study/O 2/O ZYTIGA/O was/O administered/O at/O a/O dose/O of/O 1,000/O mg/O daily/O in/O combination/O with/O prednisone/O 5/O mg/O twice/O daily/O in/O the/O active/O treatment/O arms/O ./O
Placebo/O plus/O prednisone/O 5/O mg/O twice/O daily/O was/O given/O to/O control/O patients/O ./O
The/O most/O common/O adverse/O drug/O reactions/O (/O 10/O %/O )/O reported/O in/O the/O two/O randomized/O clinical/O trials/O that/O occurred/O more/O commonly/O (/O 2/O %/O )/O in/O the/O abiraterone/O acetate/O arm/O were/O fatigue/B-AdverseReaction ,/O joint/B-AdverseReaction swelling/I-AdverseReaction or/O discomfort/O ,/O edema/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction and/O contusion/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 20/O %/O )/O reported/O in/O the/O two/O randomized/O clinical/O trials/O that/O occurred/O more/O commonly/O (/O 2/O %/O )/O in/O the/O abiraterone/O acetate/O arm/O were/O anemia/B-AdverseReaction ,/O elevated/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O elevated/B-AdverseReaction AST/I-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O elevated/B-AdverseReaction ALT/I-AdverseReaction and/O hypokalemia/B-AdverseReaction ./O
Study/O 1/O :/O Metastatic/O CRPC/O Following/O Chemotherapy/O Study/O 1/O enrolled/O 1195/O patients/O with/O metastatic/O CRPC/O who/O had/O received/O prior/O docetaxel/O chemotherapy/O ./O
Patients/O were/O not/O eligible/O if/O AST/O and/or/O ALT/O 2.5/O ULN/O in/O the/O absence/O of/O liver/O metastases/O ./O
Patients/O with/O liver/O metastases/O were/O excluded/O if/O AST/O and/or/O ALT/O 5/O ULN/O ./O
Table/O 1/O shows/O adverse/O reactions/O on/O the/O ZYTIGA/O arm/O in/O Study/O 1/O that/O occurred/O with/O a/O 2/O %/O absolute/O increase/O in/O frequency/O compared/O to/O placebo/O or/O were/O events/O of/O special/O interest/O ./O
The/O median/O duration/O of/O treatment/O with/O ZYTIGA/O was/O 8/O months/O ./O
Table/O 1/O :/O Adverse/O Reactions/O due/O to/O ZYTIGA/O in/O Study/O 1/O ZYTIGA/O with/O Prednisone(N=791/O )/O Placebo/O with/O Prednisone(N=394/O )/O System/O Organ/O Class/O Adverse/O reaction/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Joint/B-AdverseReaction swelling/I-AdverseReaction discomfort/O 29.5/O 4.2/O 23.4/O 4.1/O Muscle/B-AdverseReaction discomfort/I-AdverseReaction 26.2/O 3.0/O 23.1/O 2.3/O General/O disorders/O Edema/B-AdverseReaction 26.7/O 1.9/O 18.3/O 0.8/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 19.0/O 0.3/O 16.8/O 0.3/O Hypertension/B-AdverseReaction 8.5/O 1.3/O 6.9/O 0.3/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 17.6/O 0.6/O 13.5/O 1.3/O Dyspepsia/B-AdverseReaction 6.1/O 0/O 3.3/O 0/O Infections/O and/O infestations/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 11.5/O 2.1/O 7.1/O 0.5/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 5.4/O 0/O 2.5/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 10.6/O 0/O 7.6/O 0/O Renal/O and/O urinary/O disorders/O Urinary/B-AdverseReaction frequency/I-AdverseReaction 7.2/O 0.3/O 5.1/O 0.3/O Nocturia/B-AdverseReaction 6.2/O 0/O 4.1/O 0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Fractures/B-AdverseReaction 5.9/O 1.4/O 2.3/O 0/O Cardiac/O disorders/O Arrhythmia/B-AdverseReaction 7.2/O 1.1/O 4.6/O 1.0/O Chest/B-AdverseReaction pain/I-AdverseReaction or/O chest/B-AdverseReaction discomfort/I-AdverseReaction 3.8/O 0.5/O 2.8/O 0/O Cardiac/B-AdverseReaction failure/I-AdverseReaction 2.3/O 1.9/O 1.0/O 0.3/O Table/O 2/O shows/O laboratory/O abnormalities/O of/O interest/O from/O Study/O 1/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O low/B-AdverseReaction serum/I-AdverseReaction phosphorus/I-AdverseReaction (/O 7/O %/O )/O and/O low/B-AdverseReaction potassium/I-AdverseReaction (/O 5/O %/O )/O occurred/O at/O a/O greater/O than/O or/O equal/O to/O 5/O %/O rate/O in/O the/O ZYTIGA/O arm/O ./O
Table/O 2/O :/O Laboratory/O Abnormalities/O of/O Interest/O in/O Study/O 1/O Abiraterone/O (/O N=791/O )/O Placebo/O (/O N=394/O )/O Laboratory/O Abnormality/O All/O Grades/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O Hypertriglyceridemia/B-AdverseReaction 62.5/O 0.4/O 53.0/O 0/O High/B-AdverseReaction AST/I-AdverseReaction 30.6/O 2.1/O 36.3/O 1.5/O Hypokalemia/B-AdverseReaction 28.3/O 5.3/O 19.8/O 1.0/O Hypophosphatemia/B-AdverseReaction 23.8/O 7.2/O 15.7/O 5.8/O High/B-AdverseReaction ALT/I-AdverseReaction 11.1/O 1.4/O 10.4/O 0.8/O High/B-AdverseReaction Total/I-AdverseReaction Bilirubin/I-AdverseReaction 6.6/O 0.1/O 4.6/O 0/O Study/O 2/O :/O Metastatic/O CRPC/O Prior/O to/O Chemotherapy/O Study/O 2/O enrolled/O 1088/O patients/O with/O metastatic/O CRPC/O who/O had/O not/O received/O prior/O cytotoxic/O chemotherapy/O ./O
Patients/O were/O ineligible/O if/O AST/O and/or/O ALT/O 2.5/O ULN/O and/O patients/O were/O excluded/O if/O they/O had/O liver/O metastases/O ./O
Table/O 3/O shows/O adverse/O reactions/O on/O the/O ZYTIGA/O arm/O in/O Study/O 2/O that/O occurred/O with/O a/O 2/O %/O absolute/O increase/O in/O frequency/O compared/O to/O placebo/O ./O
The/O median/O duration/O of/O treatment/O with/O ZYTIGA/O was/O 13.8/O months/O ./O
Table/O 3/O :/O Adverse/O Reactions/O in/O 5/O %/O of/O Patients/O on/O the/O ZYTIGA/O Arm/O in/O Study/O 2/O ZYTIGA/O with/O Prednisone/O (/O N=542/O )/O Placebo/O with/O Prednisone/O (/O N=540/O )/O System/O Organ/O Class/O Adverse/O reaction/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O General/O disorders/O Fatigue/B-AdverseReaction 39.1/O 2.2/O 34.3/O 1.7/O Edema/B-AdverseReaction 25.1/O 0.4/O 20.7/O 1.1/O Pyrexia/B-AdverseReaction 8.7/O 0.6/O 5.9/O 0.2/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Joint/B-AdverseReaction swelling/I-AdverseReaction discomfort/O 30.3/O 2.0/O 25.2/O 2.0/O Groin/B-AdverseReaction pain/I-AdverseReaction 6.6/O 0.4/O 4.1/O 0.7/O Gastrointestinal/O disorders/O Constipation/B-AdverseReaction 23.1/O 0.4/O 19.1/O 0.6/O Diarrhea/B-AdverseReaction 21.6/O 0.9/O 17.8/O 0.9/O Dyspepsia/B-AdverseReaction 11.1/O 0.0/O 5.0/O 0.2/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 22.3/O 0.2/O 18.1/O 0.0/O Hypertension/B-AdverseReaction 21.6/O 3.9/O 13.1/O 3.0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 17.3/O 0.0/O 13.5/O 0.2/O Dyspnea/B-AdverseReaction 11.8/O 2.4/O 9.6/O 0.9/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 13.5/O 0.2/O 11.3/O 0.0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Contusion/B-AdverseReaction 13.3/O 0.0/O 9.1/O 0.0/O Falls/B-AdverseReaction 5.9/O 0.0/O 3.3/O 0.0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 12.7/O 0.0/O 8.0/O 0.0/O Nasopharyngitis/B-AdverseReaction 10.7/O 0.0/O 8.1/O 0.0/O Renal/O and/O urinary/O disorders/O Hematuria/B-AdverseReaction 10.3/O 1.3/O 5.6/O 0.6/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 8.1/O 0.0/O 3.7/O 0.0/O Table/O 4/O shows/O laboratory/O abnormalities/O that/O occurred/O in/O greater/O than/O 15/O %/O of/O patients/O ,/O and/O more/O frequently/O (/O 5/O %/O )/O in/O the/O ZYTIGA/O arm/O compared/O to/O placebo/O in/O Study/O 2/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O lymphopenia/B-AdverseReaction (/O 9/O %/O )/O ,/O hyperglycemia/B-AdverseReaction (/O 7/O %/O )/O and/O high/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction (/O 6/O %/O )/O occurred/O at/O a/O greater/O than/O 5/O %/O rate/O in/O the/O ZYTIGA/O arm/O ./O
Table/O 4/O :/O Laboratory/O Abnormalities/O in/O 15/O %/O of/O Patients/O in/O the/O ZYTIGA/O Arm/O of/O Study/O 2/O Abiraterone/O (/O N=542/O )/O Placebo/O (/O N=540/O )/O Laboratory/O Abnormality/O Grade/O 1/O -/O 4/O %/O Grade/O 3/O -/O 4/O %/O Grade/O 1/O -/O 4/O %/O Grade/O 3/O -/O 4/O %/O Hematology/O Lymphopenia/B-AdverseReaction 38.2/O 8.7/O 31.7/O 7.4/O Chemistry/O Hyperglycemia/B-AdverseReaction 56.6/O 6.5/O 50.9/O 5.2/O High/B-AdverseReaction ALT/I-AdverseReaction 41.9/O 6.1/O 29.1/O 0.7/O High/B-AdverseReaction AST/I-AdverseReaction 37.3/O 3.1/O 28.7/O 1.1/O Hypernatremia/B-AdverseReaction 32.8/O 0.4/O 25.0/O 0.2/O Hypokalemia/B-AdverseReaction 17.2/O 2.8/O 10.2/O 1.7/O Cardiovascular/O Adverse/O Reactions/O :/O In/O the/O combined/O data/O for/O studies/O 1/O and/O 2/O ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O more/O commonly/O in/O patients/O treated/O with/O ZYTIGA/O compared/O to/O patients/O on/O the/O placebo/O arm/O (/O 2.1/O %/O versus/O 0.7/O %/O )/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O in/O 1.6/O %/O of/O patients/O taking/O ZYTIGA/O and/O led/O to/O 5/O treatment/O discontinuations/O and/O 2/O deaths/B-AdverseReaction ./O
Grade/B-Severity 3/I-Severity -/O 4/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O in/O 0.2/O %/O of/O patients/O taking/O placebo/B-Factor ./O
There/O were/O no/O treatment/O discontinuations/O and/O one/O death/B-AdverseReaction due/O to/O cardiac/B-AdverseReaction failure/I-AdverseReaction in/O the/O placebo/B-Factor group/O ./O
In/O Study/O 1/O and/O 2/O ,/O the/O majority/O of/O arrhythmias/B-AdverseReaction were/O grade/B-Severity 1/I-Severity or/O 2/O ./O
There/O was/O one/O death/B-AdverseReaction associated/O with/O arrhythmia/B-AdverseReaction and/O one/O patient/O with/O sudden/B-AdverseReaction death/I-AdverseReaction in/O the/O ZYTIGA/O arms/O and/O no/B-Negation deaths/B-AdverseReaction in/O the/O placebo/B-Factor arms/O ./O
There/O were/O 7/O (/O 0.5/O %/O )/O deaths/B-AdverseReaction due/O to/O cardiorespiratory/B-AdverseReaction arrest/I-AdverseReaction in/O the/O ZYTIGA/O arms/O and/O 3/O (/O 0.3/O %/O )/O deaths/B-AdverseReaction in/O the/O placebo/B-Factor arms/O ./O
Myocardial/B-AdverseReaction ischemia/I-AdverseReaction or/O myocardial/B-AdverseReaction infarction/I-AdverseReaction led/O to/O death/B-AdverseReaction in/O 3/O patients/O in/O the/O placebo/B-Factor arms/O and/O 2/O deaths/B-AdverseReaction in/O the/O ZYTIGA/O arms/O ./O
6.2/O Post/O Marketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O ZYTIGA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O myopathy/B-AdverseReaction ,/O including/O rhabdomyolysis/B-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Mineralocorticoid/B-AdverseReaction excess/I-AdverseReaction :/O Use/O ZYTIGA/O with/O caution/O in/O patients/O with/O a/O history/O of/O cardiovascular/O disease/O ./O
The/O safety/O of/O ZYTIGA/O in/O patients/O with/O LVEF/O 50/O %/O or/O NYHA/O Class/O III/O or/O IV/O heart/O failure/O in/O Study/O 1/O or/O LVEF/O 50/O %/O or/O NYHA/O Class/O II/O to/O IV/O heart/O failure/O in/O Study/O 2/O was/O not/O established/O ./O
Control/O hypertension/O and/O correct/O hypokalemia/O before/O treatment/O ./O
Monitor/O blood/O pressure/O ,/O serum/O potassium/O and/O symptoms/O of/O fluid/O retention/O at/O least/O monthly/O ./O
(/O 5.1/O )/O Adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction :/O Monitor/O for/O symptoms/O and/O signs/O of/O adrenocortical/O insufficiency/O ./O
Increased/O dosage/O of/O corticosteroids/O may/O be/O indicated/O before/O ,/O during/O and/O after/O stressful/O situations/O ./O
(/O 5.2/O )/O Hepatotoxicity/B-AdverseReaction :/O Increases/B-AdverseReaction in/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction have/O led/O to/O drug/O interruption/O ,/O dose/O modification/O and/or/O discontinuation/O ./O
Monitor/O liver/O function/O and/O modify/O ,/O interrupt/O ,/O or/O discontinue/O ZYTIGA/O dosing/O as/O recommended/O ./O
(/O 5.3/O )/O 5.1/O Hypertension/O ,/O Hypokalemia/O and/O Fluid/O Retention/O Due/O to/O Mineralocorticoid/O Excess/O ZYTIGA/O may/B-Factor cause/O hypertension/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O and/O fluid/B-AdverseReaction retention/I-AdverseReaction as/O a/O consequence/O of/O increased/B-AdverseReaction mineralocorticoid/I-AdverseReaction levels/I-AdverseReaction resulting/O from/O CYP17/O inhibition/O [/O seeClinical/O Pharmacology/O (/O 12.1/O )/O ]/O ./O
In/O the/O two/O randomized/O clinical/O trials/O ,/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity hypertension/B-AdverseReaction occurred/O in/O 2/O %/O of/O patients/O ,/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity hypokalemia/B-AdverseReaction in/O 4/O %/O of/O patients/O ,/O and/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity edema/B-AdverseReaction in/O 1/O %/O of/O patients/O treated/O with/O ZYTIGA/O [/O seeAdverse/O Reactions/O (/O 6/O )/O ]/O ./O
Co/O -/O administration/O of/O a/O corticosteroid/O suppresses/O adrenocorticotropic/O hormone/O (/O ACTH/O )/O drive/O ,/O resulting/O in/O a/O reduction/O in/O the/O incidence/O and/O severity/O of/O these/O adverse/O reactions/O ./O
Use/O caution/O when/O treating/O patients/O whose/O underlying/O medical/O conditions/O might/O be/O compromised/O by/O increases/O in/O blood/O pressure/O ,/O hypokalemia/O or/O fluid/O retention/O ,/O e.g./O ,/O those/O with/O heart/O failure/O ,/O recent/O myocardial/O infarction/O or/O ventricular/O arrhythmia/O ./O
Use/O ZYTIGA/O with/O caution/O in/O patients/O with/O a/O history/O of/O cardiovascular/O disease/O ./O
The/O safety/O of/O ZYTIGA/O in/O patients/O with/O left/O ventricular/O ejection/O fraction/O 50/O %/O or/O New/O York/O Heart/O Association/O (/O NYHA/O )/O Class/O III/O or/O IV/O heart/O failure/O (/O in/O Study/O 1/O )/O or/O NYHA/O Class/O II/O to/O IV/O heart/O failure/O (/O in/O Study/O 2/O )/O was/O not/O established/O because/O these/O patients/O were/O excluded/O from/O these/O randomized/O clinical/O trials/O [/O seeClinical/O Studies/O (/O 14/O )/O ]/O ./O
Monitor/O patients/O for/O hypertension/O ,/O hypokalemia/O ,/O and/O fluid/O retention/O at/O least/O once/O a/O month/O ./O
Control/O hypertension/O and/O correct/O hypokalemia/O before/O and/O during/O treatment/O with/O ZYTIGA/O ./O
5.2/O Adrenocortical/O Insufficiency/O Adrenal/B-AdverseReaction insufficiency/I-AdverseReaction occurred/O in/O the/O two/O randomized/O clinical/O studies/O in/O 0.5/O %/O of/O patients/O taking/O ZYTIGA/O and/O in/O 0.2/O %/O of/O patients/O taking/O placebo/O ./O
Adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction was/O reported/O in/O patients/O receiving/O ZYTIGA/O in/O combination/O with/O prednisone/O ,/O following/O interruption/O of/O daily/O steroids/O and/or/O with/O concurrent/O infection/O or/O stress/O ./O
Use/O caution/O and/O monitor/O for/O symptoms/O and/O signs/O of/O adrenocortical/O insufficiency/O ,/O particularly/O if/O patients/O are/O withdrawn/O from/O prednisone/O ,/O have/O prednisone/O dose/O reductions/O ,/O or/O experience/O unusual/O stress/O ./O
Symptoms/O and/O signs/O of/O adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction may/O be/O masked/O by/O adverse/O reactions/O associated/O with/O mineralocorticoid/B-AdverseReaction excess/I-AdverseReaction seen/O in/O patients/O treated/O with/O ZYTIGA/O ./O
If/O clinically/O indicated/O ,/O perform/O appropriate/O tests/O to/O confirm/O the/O diagnosis/O of/O adrenocortical/O insufficiency/O ./O
Increased/O dosage/O of/O corticosteroids/O may/O be/O indicated/O before/O ,/O during/O and/O after/O stressful/O situations/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5.3/O Hepatotoxicity/O In/O the/O two/O randomized/O clinical/O trials/O ,/O grade/B-Severity 3/I-Severity or/O 4/O ALT/O or/O AST/B-AdverseReaction increases/I-AdverseReaction (/O at/O least/O 5/O ULN/O )/O were/O reported/O in/O 4/O %/O of/O patients/O who/O received/O ZYTIGA/O ,/O typically/O during/O the/O first/O 3/O months/O after/O starting/O treatment/O ./O
Patients/O whose/O baseline/O ALT/O or/O AST/O were/O elevated/O were/O more/O likely/O to/O experience/O liver/B-AdverseReaction test/I-AdverseReaction elevation/I-AdverseReaction than/O those/O beginning/O with/O normal/O values/O ./O
Treatment/O discontinuation/O due/O to/O liver/B-AdverseReaction enzyme/I-AdverseReaction increases/I-AdverseReaction occurred/O in/O 1/O %/O of/O patients/O taking/O ZYTIGA/O ./O
No/B-Negation deaths/B-AdverseReaction clearly/O related/O to/O ZYTIGA/O were/O reported/O due/O to/O hepatotoxicity/B-AdverseReaction events/O ./O
Measure/O serum/O transaminases/O (/O ALT/O and/O AST/O )/O and/O bilirubin/O levels/O prior/O to/O starting/O treatment/O with/O ZYTIGA/O ,/O every/O two/O weeks/O for/O the/O first/O three/O months/O of/O treatment/O and/O monthly/O thereafter/O ./O
In/O patients/O with/O baseline/O moderate/O hepatic/O impairment/O receiving/O a/O reduced/O ZYTIGA/O dose/O of/O 250/O mg/O ,/O measure/O ALT/O ,/O AST/O ,/O and/O bilirubin/O prior/O to/O the/O start/O of/O treatment/O ,/O every/O week/O for/O the/O first/O month/O ,/O every/O two/O weeks/O for/O the/O following/O two/O months/O of/O treatment/O and/O monthly/O thereafter/O ./O
Promptly/O measure/O serum/O total/O bilirubin/O ,/O AST/O ,/O and/O ALT/O if/O clinical/O symptoms/O or/O signs/O suggestive/O of/O hepatotoxicity/O develop/O ./O
Elevations/O of/O AST/O ,/O ALT/O ,/O or/O bilirubin/O from/O the/O patient/O 's/O baseline/O should/O prompt/O more/O frequent/O monitoring/O ./O
If/O at/O any/O time/O AST/O or/O ALT/O rise/O above/O five/O times/O the/O ULN/O ,/O or/O the/O bilirubin/O rises/O above/O three/O times/O the/O ULN/O ,/O interrupt/O ZYTIGA/O treatment/O and/O closely/O monitor/O liver/O function/O ./O
Re/O -/O treatment/O with/O ZYTIGA/O at/O a/O reduced/O dose/O level/O may/O take/O place/O only/O after/O return/O of/O liver/O function/O tests/O to/O the/O patient/O 's/O baseline/O or/O to/O AST/O and/O ALT/O less/O than/O or/O equal/O to/O 2.5/O ULN/O and/O total/O bilirubin/O less/O than/O or/O equal/O to/O 1.5/O ULN/O [/O seeDosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
The/O safety/O of/O ZYTIGA/O re/O -/O treatment/O of/O patients/O who/O develop/O AST/O or/O ALT/O greater/O than/O or/O equal/O to/O 20/O ULN/O and/or/O bilirubin/O greater/O than/O or/O equal/O to/O 10/O ULN/O is/O unknown/O ./O
